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ABSTRACT 
Colonic inflammation in C. difficile infection is mediated by released toxins A 
and B. I have investigated responses to C. difficile toxin A and B by primary 
human colonic myofibroblasts, which represent a distinct subpopulation of 
mucosal cells that are normally located below the intestinal epithelium and 
epithelial cell lines, Caco-2 and HT29. Myofibroblasts, isolated from normal 
human colonic mucosal specimens, Caco-2 and HT29 cells incubated with 
purified toxin A or B displayed a dose dependent response. Myofibroblast 
morphology changed to a stellate shaped cell, with processes that were 
immunoreactive for alpha smooth muscle actin. Most of the myofibroblasts 
remained viable, with persistent stellate morphology, despite exposure to high 
concentrations (up to 10 pg/ml) of toxin A for 72 h. In contrast, a majority of 
the toxin B exposed myofibroblasts lost their processes prior to cell death over 
24-72 h. Investigating toxin A+B on myofibroblasts, at low concentrations, 
toxin A provided protection against toxin B-induced cell death. Most of the 
intestinal epithelial, HT29 cells remained viable despite exposure to high 
concentrations of either toxin (up to 10 pg/mi). By contrast, a significant loss 
in cell viability was observed in Caco-2 cells exposed to either toxin. Within 4 
h, myofibroblast and epithelial cell types exposed to either toxin A or B lost 
expression of the non-glucosylated form of Racl, but total intracellular RhoA 
remained unchanged in myofibroblasts and Caco-2 cells. A time-dependent 
reduction in RhoA expression was seen in HT29 in response to toxin A or B. 
Active RhoA expression was lost within 4h in myofibroblasts exposed to either 
toxin. Despite pre-exposure to high concentrations of toxin A for 3 h, colonic 
myofibroblasts were able to recover their morphology and proliferative 
capacity during prolonged culture in medium. This was also shown when pre- 
exposure to toxin A was extended to 48 h. However, toxin B-pre-exposed 
myofibroblasts were not able to recover. In conclusion, primary human colonic 
mucosal myofibroblasts are resistant to toxin A (but not toxin B)-induced cell 
death. Responses by colonic myoflbroblasts may play an important role in 
mucosal protection, repair, and regeneration in colitis due to C. difficile 
infection. Investigation into the apparent resilience of HT29 cells has 
highlighted the importance of cell specific substrate specificity by C. difficile 
toxins. 
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CHAPTER 1 
1 Introduction 
1.1 Clostridium difficile Infection 
- 
the clinical significance 
C. difficile infection (CDI) leads to a spectrum of disease ranging from the 
asymptomatic carrier, mild diarrhoea, colitis, pseudomembranous colitis (PMC) 
and fulminant colitis (Borriello 1998). 
The asymptomatic carrier state is often the end result for many patients; 
however these patients may act as silent reservoirs perpetuating 
contamination within the hospital environment (Lawrence, Puzniak et al. 
2007). Treatment of asymptomatic carriers has not been found to eradicate 
the carrier state and will therefore not reduce the spread of nocosomial 
transmission (Kelly and LaMont 1998). 
Accounting for 20% of all antibiotic associated cases of diarrhoea, most 
patients do not progress to pseudomembranous colitis and fulminant colitis. 
With a speedy diagnosis and cessation of contributing antibiotic therapy, 
diarrhoea is self limiting (Hookman and Barkin 2009). Some individuals will 
develop colitis without pseudomembrane formation and may present with a 
fever, malaise, abdominal pain, nausea and watery diarrhea (Schroeder 
2005). Endoscopic examination may reveal patchy non-specific redness 
without pseudomembranes (Kawamoto, Horton et al. 1999). 
The presence of pseudomembrane plagues (raised yellow plaques ranging 
from 2mm to 10mm in diameter) on the colorectal mucosa (Kawamoto, 
Horton et al. 1999) signal full-blown C. difficile colitis and a more serious 
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disease. Approximately 3% of patients will develop fulminant colitis from C. 
difficile infection (Hookman and Barkin 2009). Patients with fulminant colitis 
may present with severe diarrhoea and abdominal pain, high fevers and 
marked peripheral leukocytosis (Bennett, Allen et al. 1984; Schroeder 2005). 
PMC can be complicated by dehydration, shock, septicaemia, toxic megacolon 
and peritonitis (Borriello 1998) and can result in death. 
1.1.1 Acquisition 
Clostridium difficile infection generally occurs as a result of ingesting the heat 
resistant spores released by the bacterium, the vegetative cells are unable to 
survive in an aerobic environment (Larson, Price et al. 1978). Transmission 
can occur by fecal-oral; person to person or; fomite/instrument to patient 
routes (McFee and Abdelsayed 2009). On ingestion the spores migrate to the 
colon and mature into vegetative cells. Whilst C. diffcile is found the gut of 3- 
5% of the population (Bartlett 2002), the gut flora of the healthy individual is 
able to control the over-growth of C. difcile preventing colonisation and 
subsequent clinical manifestation (Bartlett, Chang et al. 1978). 
The acquisition of Clostridium difficile is linked primarily to hospitalisation 
(Bartlett 2002; Dallal, Harbrecht et al. 2002), the rate of which rises from 
13% in stays of up to 2 weeks to 50% in those staying longer than four weeks 
(Clabots, Johnson et al. 1992). Although the risk of acquiring a Clostridium 
difficle infection in the community is low current figures suggest that 
community CDI rates in the United States have been reported as 7.7 cases 
per 100,000 person years (Hirschhorn, Tmka et al. 1994). Of those cases 
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35% received no antibiotics within 42 days of detected infection (! bid, 1994) 
More recent investigations completed by the Centers for Disease Control 
report similar rates of infection but increased disease severity (Chernak 
2005). What remains apparent is that community associated CDI without 
previous direct or indirect contact with a hospital environment is rare when 
compared with hospital acquired attrition (Rupnik, Wilcox et al. 2009). The 
hypervirulent strain B1/Napl/027 has been reported in community acquired 
cases however community presence has been strongly correlated with its 
presence in local healthcare facilities (! bid, 2009). 
Other potential community sources of CDI include soil, water, pets, animals 
used for food, meat and vegetables (al Saif and Brazier 1996). At this stage 
there is no evidence to suggest that food contaminated with C. difficile has 
resulted in clinical disease in humans (Rupnik, Wilcox et at. 2009), however 
should the dramatic increase in infection rates be attributed to the presence of 
more virulent strains or could it be an unknown vehicle for transmission 
contributing to the increase. 
1.1.2 Risk factors 
The disruption of the gut flora by antibiotic therapy and advanced age are the 
commonest pre-disposing factors to Clostridium di ficile infection but a 
number of other factors can be related to whether a person remains 
asymptomatic, develops fulminant colitis and PMC or experience recurrent 
bouts of infection. 
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Immune-suppression using chemotherapeutic or immunosuppressant agents 
(Anand and Glatt 1993; Blot, Escande et al. 2003; Svenungsson, Burman et 
al. 2003), patients having undergone gastrointestinal surgery or manipulation 
(Zerey, Paton et al. 2007) and patients with IBD (Issa, Vijayapal et al. 2007) 
are at greater risk of CDI, see Table 1-1. In addition, an association between 
the use of proton-pump inhibitors and H2 receptor antagonists to suppress 
acid production has also been reported. Further studies are required to 
establish any causal relationship but a potential mechanism could be the 
survival of vegetative forms in the gastric content caused by the increased pH 
(Jump, Pultz et al. 2007; Leonard, Marshall et al. 2007). 
Table 1-1 Populations at increased risk of C. difficile infection 
Adapted from (Bookman and Barkin 2009) 
Patients who take the following drugs: 
" 
Antibiotics 
" Proton Pump Inhibitors (Dial, Delaney et at. 2005; Yearsley, Gilby et at. 2006) 
" 
Valacyclovir (De Andres, Ferreiro et al. 2004) 
Patient characteristics 
" 
IBD (Issa, Vijayapal et at. 2007) 
" 
Serious underlying illnesses / co-morbidities 
" 
Gastrointestinal surgery / manipulations (Zerey, Paton et al. 2007) 
" 
Advanced age 
" Immune-compromising conditions (post transplantation) (Munoz, Giannella et 
at. 2007) 
" 
Peri-partum (Rouphael, O'Donnell et al. 2008) 
Environment 
" Prolonged stay in health care settings (Clabots, Johnson et at. 1992) 
Laboratory factors 
" 
Hypoalbuminemia (Dansinger, Johnson et at. 1996) 
" Low levels of anti toxin A and B antibodies 
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1.1.3 Diagnosis 
The suspicion of Clostridium difcile infection is often based on foul smelling 
diarrhoea, this is however not sufficient for an accurate diagnosis but can be 
used to the isolate suspected cases (Bartlett and Gerding 2008). The 
traditional gold standard for diagnosis of C. difcile infection is a cytotoxin 
assay that detects cell cytotoxicity of toxin B and in some cases toxin A and 
the subsequent neutralisation of the cytotoxic effect using anti toxin 
antibodies (Fekety 1997; Bartlett 2006). As an alternative, cytotoxigenic 
culture detects strains capable of producing toxin rather than actual toxin 
production are used but care should be taken as capacity to produce the toxin 
does not confirm that it actual produces it (Monaghan, Boswell et al. 2008). 
Several commercial kits are available with variable accuracy, a recent 
systematic review of six toxin detections kits found that positive predictive 
value (PPV) was unacceptably low and as the PPV reduces as the prevalence 
of CDI decreases (Planche, Aghaizu et al. 2008). New molecular methods 
identifying genes encoding the toxins may provide a rapid and sensitive 
alternative but face the similar limitations discussed for the cytotoxigenic 
culture (Rupnik, Wilcox et al. 2009). Any test that fails to test the activity of 
the toxins produced will have limited accuracy and will need to be compared 
against patient records and clinical treatment outcomes for confirmation of 
accuracy. 
1.1.4 Treatment 
Clostridium difficile is resistant to a wide range of antibiotics allowing the 
bacterium to colonize and infect in the presence of antibiotics (Pituch, vavn 
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Belkum et al. 2003). Individuals remain resistant to C. difficile if their normal 
gut flora is not disrupted by antibiotics. The introduction of antibiotic therapy 
gradually destroys the gut flora and the bacteria colonise, releases toxins and 
cause clinical manifestation. The treatment of CDI has not changed 
dramatically since 1981 when oral Vancomycin was found to be highly 
effective (Silva, Batts et al. 1981). The replacement of Clindamycin, with 
Metronidazole has been effective in treating Clindamycin-resistant strains 
(Teasley, Gerding et al. 1983). The management of recurrent CDI Is a major 
challenge and whilst patients with multiple recurrences typically respond to 
Metronidazole or Vancomycin, the diarrhoea returns when treatment is 
stopped (Rupnik, Wilcox et al. 2009). Strategies for multiple recurrent 
infections include prolonged tapering of antibiotic treatment, pulse dosage 
(giving antibiotic treatment every other day or every three days) in the hope 
that the inhibitory levels will keep the bacteria under control whilst allowing 
the gut flora to establish (ibid, 2009). Recent research has found that the 
most effective treatment in recurrent infections is the replenishment of the 
normal bacterial flora by faecal transplant (Aas, Gessert et at. 2003). An 
effective treatment for severe complicated CDI has not been found, and if 
after management with intravenous fluids, vasopressors, oral and intravenous 
antibiotic use then removal of the colon may be the only life-saving option 
remaining (Lamontagne, Labbe et al. 2007). 
1.2 Epidemiology 
In the United Kingdom, the Health Protection Agency has been monitoring the 
increasing incidence of C. difcile infection since the early 1990's (Djuretic, 
Wall et al. 1996; HPA 2006). Whilst reporting was initially voluntary, 
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mandatory reporting was introduced in January 2004 for all cases in persons 
aged 65 years and over. Whilst it has be speculated that the 26.2% increase 
in cases of infection between 2004 and 2006 (HPA 2007) can be linked to 
more stringent monitoring it is generally accepted that the marked increase 
can only be explained in part by the mandatory reporting. Since April 2007 
this mandatory reporting was extended to NHS Trusts reporting cases of CDI 
in patients aged 2 years and over (HPA 2007). 
More recent figures of infection rates in the UK have shown a marked 
decrease in the number of cases in England after years of steady increases. 
This marked decrease has been championed by the Department of Health's 
target to reduce C. diffcile infections by 30% by 2011. In June 2009, data 
published by the Health Protection Agency confirmed the early achievement of 
this target (HPA 2010). Despite this apparent success the Department of 
Health reports a wide variation between the best and worst performers in 
reducing rates of infection and some 30,000 cases are still recorded annually 
(HPA 2010). 
During the year following the introduction of enhanced surveillance for CDI 
there were over 55,000 reports of CDI, representing a baseline quarterly 
average of approximately 14,000 reports. For the most recent quarter, July- 
September 2010 just under 6,000 reports of CDI were recorded, 
corresponding to a 58% reduction on the baseline year's quarterly average. 
This is a decrease of 1.5% on the previous quarter (HPA 2010). 
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Figure 1-1 Counts of all Clostridium dif icile infection reports. July 
- 
September 2007 to July September 2010. Taken from (HPA 2010) 
In contrast to the 1.5% decrease in all reports since April-June 2010 a 9.5% increase in cases 
reported from April-June 2010 to July-September 2010 (2,988 to 3,272, respectively) is reported 
in non-trust (not hospital linked) figures. By comparison there was a 12.5% decrease in Trust 
patients (in-patient, day-patients, emergency assessment patients who have had a specimen 
taken and the specimen was taken 4 or more days after admission) reports of CDI over the same 
period (2,995 to 2,622). The decrease in the number of Trust reports was also observed during 
the second and third quarters of 2009 and 2008. Despite the seasonal spikes observed the overall 
trend appears to be flattening. 
The trend observed in the number of CDI reports is also seen in the rates of 
infection with the population rate of infection for all CDI reports increasing 
very slightly in the present quarter (July-September 2010) compared to the 
last quarter. However, the rate for all CDI reports has remained between 4.7 
reports/10,000 population and 5.5 reports/10,000 population since April-June 
2009 (HPA 2010). 
Although a decrease in the number of reported cases is being observed in the 
United Kingdom, the number of Clostridium difficile infections is on the rise 
across Canada, America and other areas of Europe (Monaghan, Boswell et al. 
2008). In the United States, it is estimated that there are 
-500,000 cases of 
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CDI per year in hospitals and care facilities (Rupnik, Wilcox et al. 2009). This 
is a marked increase on the 150,000 cases reported in 2000 and the 300,000 
cases in 2006. Of these cases, it is estimated that 15,000-20,000 patients die 
from CDI in the US each year (ibid, 2009). In Europe, few countries have the 
necessary systems to monitor CDI and the rates of death linked to C. difficile 
and in some countries even the facilities to test for CDI are poor (ibid, 2009). 
What is evident is the incidence of CDI in on the increase across Europe; 
Spain reported a threefold increase in CDI between 1997-2005 (Soler, 
Nogareda et al. 2008) and Germany reported an increase between 2002 and 
2006 (Burckhardt, Friedrich et al. 2008). 
In addition, a dramatic increase in the number of cases of severe CDI was 
being reported and molecular analysis of C. difficile isolates from a number of 
healthcare facilities across North America during 2005 led to the identification 
of the strain responsible for the increase in infection rates, B1/NAP1/027 (Loo, 
Poirier et at. 2005; McDonald, Killgore et at. 2005). This strain has now been 
isolated in hospitals all over America, in all provinces of Canada and in most 
European countries (Loo, Poirier et at. 2005; McDonald, Killgore et al. 2005; 
Muto, Pokrywka et al. 2005; Pepin, Saheb et al. 2005; Hubert, Loo et al. 
2007; Kuijper, Barbut et at. 2008). The increased infection rates and severity 
are not all attributed to this strain as in some countries, other strains have 
also been linked to increasing rates of infection and or disease severity 
(Borgmann, Kist et al. 2008; Goorhuis, Bakker et at. 2008; Rupnik, Widmer et 
al. 2008). 
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1.3 Prevention and Control 
Reducing the incidence of Clostridium difficile infections is a significant 
challenge and three main strategies are used to meet this challenge; prudent 
use of antimicrobials; prevention of cross infection, and; active 
surveillance/reporting. 
1.3.1 Prudent use of antimicrobials 
The principle risk factor for CDI is the use of antimicrobial therapy and some 
drugs gave been identified as having a higher propensity to cause disease 
than others, see Table 1-2. 
Table 1-2 Risk of Clostridium diffic le for different antibiotics. 
Adapted from (Monaghan, Boswell et al. 2008) 
Low Risk Medium Risk High Risk 
Aminoglycosides Co-amoxiclav Second/third generation 
cephalosporins 
Vancomycin Macrolides Clindamycin 
Trimethroprim Amoxicillin/ampicillin Fluoroquinolones 
Tetracyclins 
Piptazobactam 
Benzylpenicillin 
It is expected that over time this will change, the appearance of 
fluoroquinolone resistant strains have changed the previously low risk choice 
11 
to that of medium risk choice when compared with cephaisporins (Monaghan, 
Boswell et at. 2008). it is now accepted that prudent antimicrobial use is an 
essential control measure, particularly within high risk health care areas, see 
Table 1-3. 
Table 1-3 Reported success in the control of C. diddle infection by restriction 
of high risk broad spectrum antibiotics 
Adapted from (Monaghan, Boswell et al. 2008) 
Setting Antibiotics reduced Antibiotics increased 
Elderly care Cephalosporins Benzylpenicillin, 
trimethoprin, 
gentamycin 
Elderly care Co-amoxiclav Benzylpenicillin, 
amoxicillin, 
trimethropin 
Elderly care Cefotaxime Ciprofloxacin 
Medicine surgery Ceftriaxone, oral Levofloxacin 
cephalosporins 
Elderly care Cefotaxime Piptazobactum 
Medicine, elderly Ceftriaxone, Moxifloxicin, 
care cefuroxime piptazobactam 
Hospital wide Clindamycin Various 
1.3.2 Prevention of cross-infection 
The infection prevention and control measures for patients with CDI are well 
established. Disease is spread via the faecal-oral route and the biggest 
challenge in the healthcare setting is the heat-resistant spores produced by 
the bacteria which remain viable on surfaces for extended periods of time 
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(Jump, Puitz et al. 2007). Patients suspected of CDI should be isolated as 
soon as possible into a room with an en-suite bathroom preferably, or a 
patient designated commode (Monaghan, Boswell et al. 2008). If an outbreak 
is suspected then patients should be grouped into specific areas and 
designated nurses assigned (Schroeder 2005). The failure to rapidly isolate 
symptomatic patients was one of the main contributory factors in the 
outbreaks at Stoke Mandeville Hospital, UK (CHAI 2006). Enhanced 
environmental and equipment cleaning is essential and care taken to ensure 
disinfectants being used possess some sporicidal activity, as most commonly 
used disinfectants are ineffective against C. difficile spores (Monaghan, 
Boswell et al. 2008). Vaporised hydrogen peroxide is suggested for 
environmental disinfection but this cannot be completed with staff or patients 
in the room (ibid, 2008). For those staff treating patients with CDI protective 
clothing should be worn and a rigorous hand washing routine with soap and 
water after treating each patient (Gerding, Muto et al. 2008). 
1.3.3 Surveillance 
Surveillance should be conducted at a local, regional and national level to 
ensure timely feedback to clinicians and other healthcare professionals 
(Schroeder 2005; Monaghan, Boswell et al. 2008). Although this is routinely 
completed in the United Kingdom, other countries have poorly defined 
surveillance systems meaning potential outbreaks are not effectively 
monitored and early interventions not employed. In the UK, our effective 
surveillance has resulted in current treatment practices being reviewed and 
modified to meet changing the epidemiology. 
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1.4 Mucosal Immunity 
1.4.1 The intestine 
The intestine with its large surface area is the subject of constant antigenic 
challenge and therefore in a high state of activity (MacDonald 2003). These 
challenges can come from a plethora of origins but can be categorised into 
three broad groups, food; normal bacterial flora and; pathogens. The main 
function of the gut is the digestion of nutrients from food and the absorption 
of water and electrolytes. 
The intestine can be split into two regions, the small intestine comprising the 
duodenum, jejunum and the proximal ileum and the large intestine comprising 
distal ileum and colon. Each area can be characterised by their specific 
histology and function, see'Table 
-1-4. 
Table 
-1-4 Differences in the large and small intestine 
The main differences are outlined below; however a number of histological differences are also 
present including the absence of Taeniae coli, Haustra and presence of Plicae in the small intestine 
with the opposite being observed in the large intestine. 
Small intestine 
I 
Large intestine 
Three sections 
Long 4.5 to 6 metres 
Digestion completed 
Secretes hormones 
Absorbs the digested nutrients 
Villi present 
Peyers Patches present 
Two sections 
Shorter 1.5 metres 
No role in digestion 
No hormone secretion 
Absorbs water 
No villi 
No Peyers Patches 
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Lining the huge surface area of the gut is a single layer of epithelial cells 
which are replaced every 2-5 days from pluripotent stem cells in the base of 
the crypts (Bach, Renehan et al. 2000). Six different lineages have been 
identified and each cell is joined to its neighbouring cell by desmosomes, 
adherens and tight junctions (Maldonado-Contreras and McCormick). The role 
of this single cell layer in sensing and promoting a host immune response and 
its ability to distinguish between self and non-self, food, commensals and 
pathogens is vital. The single layer of epithelial cells is attached to the 
basement membrane and immediately subjacent to this are the colonic sub- 
epithelial myofibroblasts. Together with interstitial fibroblasts the 
myofibroblasts form a network of interconnected cells throughout the lamina 
propria (Adegboyega, Mifflin et al. 2002). The closeness of these cells to the 
epithelium has lead to research considering the role of myofibroblasts in the 
regulation of epithelial cell function and extracellular matrix metabolism 
(Powell, Mifflin et al. 1999). It may also be that myofibroblasts are among the 
first cells to interact with pathogens and their products, presenting them to T- 
lymphocytes (Saada, Pinchuk et al. 2006). 
The many facets of the mucosal defence mechanism can be split between 
those of innate immunity and those of adaptive immunity and by working in 
synergy we have mucosal immunity. 
1.4.2 Innate Immunity 
- 
mucus and epithelial barrier 
The obvious starting point is the barrier function provided by the single layer 
of cells lining that separates the intestinal lumen (mucosal) from the sub- 
epithelial lamina propria or basolateral domain (serosal) where the mucosal 
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immune cells reside (Maldonado-Contreras and McCormick). However, this 
layer of epithelial cells are also protected, a mucus layer covers the cells 
restricting contact by microorganisms. This mucus layer is produced by goblet 
cells located in both the crypt and villus epithelium throughout the intestinal 
tract and is made up of mucin glycoproteins and trefoil peptides, of which 
MUC2 and TFF3 predominate (ibid, 2010). The absence or thinning of this 
mucus barrier has been reported in patients with Irritable Bowel Syndrome 
(IBS) and Crohns disease (CrD) and highlights the importance of this in the 
protection of the epithelium (Fyderek, Strus et al. 2009). 
1.4.2.1 Immunoglobulin A 
The epithelial cell also has its own protective mechanism in the form of 
immunoglobulin A (IgA), the most abundant immunoglobulin found in the gut 
(Maldonado-Contreras and McCormick). Within the cell IgA can deactivate 
bacterial lipoproteins and IgA secreted into the lumen by undifferentiated 
crypt enterocytes (Mostov 1994) bind to the mucus layer, prevent infiltration 
and neutralize bacteria (Apodaca, Bomsel et al. 1991). 
1.4.2.2 Antimicrobial Peptides 
Another important group of secreted proteins are the antimicrobial peptides 
(AMPS) which disrupt the microbial cell membrane (Ganz 1999). Secreted by 
the Paneth cells, three primary AMP's are expressed in the gut: defensins, 
lyzozymes and cathelicidins. Of these, defensins are the predominant AMP 
and two different types have been identified, a and ß defensins, based on 
their molecular structure (Maldonado-Contreras and McCormick). 
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1.4.2.2.1 Alpha-defensins 
Alpha-defensins are mainly expressed by neutrophils and natural killer cells 
(NK) but have also been found in Paneth cells within the small intestine 
(Ouellette and Selsted 1996). Interestingly this AMP has also been reported 
in the distal colon suggesting this protein does not undergo degradation or 
proteolysis on its journey through the GI tract (Mastroianni and Ouellette 
2009). Defects in a-defensin expression have been linked to chronic 
inflammation and in an extensive study by Salzman and colleagues comparing 
the intestinal microbiota in homozygous and heterozygous strains of 
transgenic mice encoding o-defensin 5 (DEFA5), a significant increase in 
Firmicutes and a decrease in Bacteroides was found in mice over expressing 
DEFA-5 (Salzman, Hung et al. ). This suggests a-defensins, specifically DEFA5 
plays a fundamental role in microbiota composition (ibid, 2010). 
1.4.2.2.2 Beta-defensins 
Beta-defensins are produced by epithelial (Fehlbaum, Rao et al. 2000) and 
non-epithelial cells (Garcia, Krause et al. 2001) and are found at the epithelial 
surface throughout the gastrointestinal tract. As with a-defensins, this group 
also play a role in controlling the microbial population and are linked to the 
host response towards bacteria and fungi (Maldonado-Contreras and 
McCormick). HBD1 is effective in eradicating E-co/i and S. typhimurium 
(Zhao, Wang et al. 1996). HBD2 and HBD3 have antimicrobial activity against 
Gram-negative bacteria, several Gram-positive bacteria and some yeast (Jia, 
Schutte et at. 2001). Using histamine and prostaglandin D2, ß defensins also 
trigger the activation and degranulation of mast cells (Bensch, Raida et at. 
1995). Linking the increased levels of histamine to CrD and ulcerative colitis 
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it is possible that the activation and degranulation of mast cells is responsible 
(Raithel, Matek et al. 1995). 
1.4.2.3 Lysozymes 
Lysozymes are another AMP produced by Paneth cells which provide 
protection against Gram-positive infections by catalyzing the hydrolysis of 
murein on the bacterial cell wall (Fleming, 1922 cited by (Maldonado- 
Contreras and McCormick). The human cathelicidin, LL37 expressed by 
epithelial cells is also involved in microbial homeostasis (Hase, Eckmann et al. 
2002). 
1.4.3 Adaptive Immunity 
This first line of defense maintains boundaries and homeostasis, however 
many microbes have evolved mechanisms to counter this barrier and gain 
access to the basolateral epithelial domain where the Immune cells reside 
(MacDonald 2003). The intimate relationship between the mucosa, 
particularly the epithelial cell layer; the inductor and effector sites of adaptive 
immunity are pivotal to the organized immune response seen in the 
gastrointestinal tract (Maldonado-Contreras and McCormick). 
1.4.3.1 Peyers Patches and Microfold (M) cells 
One of the major histological differences in the small and large intestine is the 
presence of Peyers Patches (PP), known as the inductive site of the mucosal 
immune response (MacDonald 2003). This organized lymphoid tissue can only 
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be found in the mucosa of the small bowel and is overlaid with specialized 
epithelium, microfold cells (M cells) (Neutra, Phillips et at. 1987). The follicles 
of the PP are covered with a layer of cubiodal epithelium containing few goblet 
cells and the most prominent feature of the PP is the follicle centre (Owen and 
Jones 1974). The follicle centre contains centrocytes and centroblasts 
surrounded by small lymphocytes which join together with plasma cells, 
dendritic cells, small B cells (centrocyte-like cells) and macrophages to form 
the mixed cell dome which infiltrate the overlying epithelium (Spencer, Finn et 
at. 1986). B cells are not found in the villus or crypt epithelium. The 
lymphoid tissues are capable of sampling antigens in the luminal space 
(Neutra, Phillips et at. 1987) and also acting as an entry point for many 
pathogens (Wolf, Rubin et at. 1981; Neutra, Pringault et al. 1996). Although 
the transcytotic function of M cells has been established, it is not clear 
whether the cells present the antigen directly to B and T cells or whether it 
uses the Major Histocompatibility Complex (MHC)-II to present antigen 
peptides (Neutra, Phillips et at. 1987). Sampling the luminal content, the 
microfold cell take antigens and microorganisms from the lumen into the 
underlying gut associated lymphoid tissue (GALT). The invaginated 
basolateral surface provides a large intra-epithelial pocket where T and B 
lymphocytes and macrophages reside and the translocation of bacteria across 
the M cell triggers IgA release and the proliferation of B lymphocytes (Corr, 
Gahan et at. 2008). The adaptive secretory IgA response is mostly generated 
in the PP, the products of which migrating to the lamina propria (Craig and 
Cebra 1971; Guy-Grand, Griscelli et al. 1974). PP are the major route for 
lymphocyte recirculation (Gowans and Knight 1964). Naive T cells enter the 
PP and bind to L-selectin (Boursier, Farstad et al. 2002), if these cells 
subsequently become activated in the PP they lose the L-selectin and the co- 
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expression of a407 integrin and L-selectin by CD54RO+ cells signal that the T 
cells are on their way to the lamina propria via the blood (Farstad, Norstein et 
al. 1997). 
1.4.3,2 Induction, Activation and effector sites for B and T cells 
The B cells (Pierce and Gowans 1975) and T cells (Guy-Grand, Griscelli et al. 
1978) leave the PP following induction and travel from the follicles of the PP 
through lymphatic's and pass via the mesenteric lymph nodes and the thoracic 
duct to recirculate in the peripheral blood and then travel to the effector site, 
the mucosal lamina propria. The effector site of the intestinal mucosal 
immune system is made up of lymphocytes and plasma cells of the lamina 
propria and the epithelium (MacDonald 2003). Interspersed between the 
epithelial cells of the intestinal villi and colonic crypts are the intraepithelial 
lymphocytes (IEL's). 
1.4.3.3 Intraepithelial lymphocytes 
The IEL's are a highly unusual population of T cells with many features distinct 
from T cells populations of the lamina propria and systemic lymphoid tissues 
(MacDonald 2003). This heterogeneous collection of T cell populations consist 
predominantly of CD8+ cells expressing a/ß or y/ö with fewer CD4+ cells and 
even fewer CD3+ cells (Lefrancois 1991). Whilst systemic T cells express 
CD8+ as a heterodimer consisting of two (CD8o and CD80) polypeptide 
chains, most of the y/a and many of the a/ß express a homodimer of CD8aa 
(ibid, 1991). 
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The expression of these specific molecules on the cell surface, which bind to 
respective ligands on the intestinal epithelium, promote adhesion and 
trafficking. The IEL's located in the intestinal epithelium express the integrin 
a4ß7, as well as other binding molecules and this particular integrin 
recognizes the ligand E-cadherin, expressed by epithelial cells (Cepek, Shaw 
et al. 1994; Blikslager and Roberts 1997). Adhesion of the IEL has also been 
shown to be associated with the extracellular matrix (ECM), with IEL's binding 
to collagen type I and IV (Roberts, Brolin et al. 1999). Colonic IEL's have 
been shown to express L-selectin and it is postulated that the localized 
expression may be regulated by the MMP, sheddase (Seibold, Seibold-Schmid 
et al. 1998). The homing and activation receptor, L-selectin, binds to a 
carbohydrate domain of MAdCAM-1 and is subsequently transported to the 
mucosal region (ibid, 1998). Another molecule expressed by IEL's, LFA-1 
binds to Intercellular Adhesion Molecule-1 (ICAM-1), may also play an 
important role in cell localization (Smart, Calabrese et al. 1991). These 
surface molecules allow cells to enter the gut associated lymphoid tissue 
(GALT) and more specifically the Peyers patches and other antigen priming 
sites (Mahida 2001). 
More recently, research has established chemokine receptors on the cell 
surface of IEL's suggesting they may play a role in chemotaxis to mucosa and 
surface epithelium (Ebert 1995). Indeed IEL's have been reported to migrate 
towards IL-8, macrophage inflammatory protein 
-1 (MIP-1) and monocyte 
chemoattractant protein (MCP) and an increased migratory activity has been 
observed in response to TNF-a (Roberts, Bilenker et al. 1997). 
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Essential to the growth and development of T cells, cytokines are also needed 
for their functional activity and whilst a number of cytokines have been 
associated with IEL's most of their roles are still to be elucidated (Mahida 
2001). To further complicate this, it has been suggested that intestinal 
location, which may reflect different IEL populations, may also reflect the 
cytokines expressed (Beagley, Fujihashi et al. 1995). Of particular interest, 
IEL proliferation and survival of the activated form have been observed in 
response to IL-15 and given that IL-15 is produced by intestinal epithelial cells 
(IEC), it may conceivable that IEC are capable of local IEL stimulation 
(Reinecker, MacDermott et al. 1996). This has been supported by the down 
regulation of isolated IEL's by IEC membrane fractions irrespective of E- 
cadherin, TGF-ß, CD1 or MHC Class I or II (Yamamoto, Fujihashi et al. 1998). 
It is also reported that bacteria and their by-products are capable of IEL 
activation and cytokine production (Beagley, Fujihashi et al. 1993; Sperber, 
Silverstein et al. 1995). 
IEL's are in a unique state of activation and upon activation they rapidly 
upregulate Fas-ligand and CD66a (bilary glycoprotein) (Chott, Gerdes et al. 
1997). It is suggested that the upregulation of Fas may provide inhibitory 
signals to IEL's once activated (Morales, Christ et at. 1999). Co-stimulation of 
the intraepithelial lymphocyte by CD28 has been studied and debated in great 
detail, however its role remains unclear (Mahida 2001). Another molecule, 
BY-55 has also been reported to play a similar co-stimulatory role in IEL 
activation and it has been demonstrated to be present on all IEL's as well as a 
subset of NK cells and CD8+ CD28 negative peripheral blood T cells 
(Anumanthan, Bensussan et al. 1998). The investigation of cytolytic activity 
in IEL's have provided mixed results, with suggestions that IEL immediately 
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possess cytolytic activity, ex-vivo (Lundqvist, Melgar et al. 1996), but others 
report no activity (Russell, Nagler-Anderson et al. 1993). Investigating in-situ 
cells has revealed that IEL's are at rest and do not display the cytolytic 
phenotype until activated (Chott, Gerdes et al. 1997). 
The function of this population of T cells remains unclear and despite being 
exposed to a plethora of antigenic stimulants they appear restricted in their T 
cell receptor usage being in a unique state of activation. It is postulated that 
the role of this population in mucosal immunity is in immuno-survelliance and 
activity in immuno-regulation (Mahida 2001). 
The lamina propria (LP) is home to mainly IgA secreting plasma cells, induced 
in the PP's and transported to the LP as described previously, and CD4+ T 
cells (Mahida 2001). The secreting dimeric IgA binds to the polymeric Ig 
receptor expressed on the intestinal epithelial cell and the entire complex is 
endocytosed (Stokes, Soothill et al. 1975). Once inside the cell the complex is 
transported to the apical surface where proteolysis removes the receptor and 
the IgA is released into the intestinal lumen where it can bind to luminal 
antigens and prevent epithelial cell penetration (`immune exclusion') (ibid, 
1975). Antigens that manage to penetrate the epithelial cell layer can be 
transported back to the lumen or neutralized intracellularly by being bound to 
IgA (immune elimination') (Mazanec, Coudret et al. 1995). 
The lamina propria T cells are of the aß TCR, CD4+ subset, having similar 
characteristics to activated memory cells (Mahida 2001). In comparison to 
systemic lymphocytes, the T cells of the lamina propria are slow to proliferate 
and crosslink surface CD3 molecules following stimulation, however they do 
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produce a vast array of cytokines which may increase IgA secretion by plasma 
cells (ibid, 2001). 
The M cell however represents are very small percentage of the total surface 
area and bacteria have devised methods of penetrating this surface 
(Maldonado-Contreras and McCormick). A number of structures connect the 
epithelial cell to its neighbor, the most of apical of which is the tight junction 
complex (TJC). The TJC is the target of a number of bacterial products 
including the enterotoxin of Clostridium perfingens (Sonoda, Furuse et at. 
1999), the cytotoxic necrotizing factor 1 from E. coil (Oswald, Sugai et al. 
1994) and toxins A and B from Clostridium difficile (Nusrat, Giry et at. 1995; 
Nusrat, von Eichel-Streiber et at. 2001). 
Upon penetration of this barrier the pathogen or pathogen associated 
molecular pattern (PAMP) will be recognized by specialized receptors 
(Maldonado-Contreras and McCormick). The extracellular Toll-like receptors 
(TLR's) of which at least 11 TLR homologs have been identified (Kawai and 
Akira 2006) and intracellular Nod-like receptors (NLR's) recognize conserved 
microbial elements such as flagellin, lipopolysaccharide (LPS), formylated 
peptides and peptidoglycan (Maldonado-Contreras and McCormick). The 
identification of a specific microbe results in the recruitment of an adaptor 
protein which brings about a signaling cascade that controls the expression of 
nuclear factor kappa-ß (NF-KO), mitogen activated protein kinases (MAPK) or 
caspase-dependent signaling pathways (ibid, 2010). The activation of these 
specialized receptors also triggers the expression of interleukin (IL)-6, TNF-a 
and IL-10 (Kawai and Akira 2006). The TLR's have the remarkable ability of 
recognizing self from non self and therefore are able to induce the production 
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of inflammatory cytokines, chemotactic factors and antimicrobial factors in 
response to specific cues (Takeda, Kaisho et al. 2003). The location of each 
TLR on the extracellular surface determines ligand specificity and accessibility, 
for example TLR 4, the most studied receptor is located at the apical pole of 
differentiated intestinal epithelial cells (Maldonado-Contreras and McCormick). 
In-vitro challenge of epithelial cells with LPS has been shown to cause TLR4 
redistribution (Cario, Brown et al. 2002) and although its role as a 
basolaterally placed TLR4 receptor is not known, the TLR4 receptor has been 
found on the basolateral domain during active ulcerative colitis (Carlo and 
Podolsky 2000). 
The intracellular recognition of PAMP's is orchestrated by NLR's and the best 
known are NOD1 and NOD2 which recognize different structural motifs from 
peptidoglycan, a protein which makes up the cell wall (Maldonado-Contreras 
and McCormick). NOD1 is ubiquitously expressed by epithelial cells and NOD2 
is only expressed by monocytes, macrophages, dendritic cells and intestinal 
Paneth cells (ibid, 2010). The activated NOD1/NOD2 recruits an adaptor 
protein Rip2 which results in the signaling to NF-Kß and Mitogen activated 
protein kinase (MAPK) pathways (Girardin, Tournebize et at, 2001; Pauleau 
and Murray 2003). NOD2 also known as a CARD receptor 15 (CARD15) is 
highly expressed in Paneth cells and stimulation leads to the activation of NF- 
KO and a-defensin production (Hisamatsu, Suzuki et al. 2003). A significant 
reduction in HD5 and HD6 has been linked to CrD (Wehkamp, Salzman et al. 
2005) and chronic inflammation in IBS (Arijs, De Hertogh et at. 2009), have 
been linked to a mutation of NOD2. In fact, Cho et al have reported that 
mutations in NOD2 alter the mucosal host microbial interactions through the 
modulation of a-defensins (Cho 2008) and others have revealed the 
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importance of NOD2 in homeostasis of the gut microbiota (Petnicki-Ocwieja, 
Hrncir et al. 2009). Therefore functional NOD2 not only restricts chronic 
inflammation but also by using a feedback mechanism, NOW together with 
other commensals maintains the balance in the intestine (Maldonado- 
Contreras and McCormick). 
The interplay of innate and adaptive mechanisms maintains the delicate 
balance between responsiveness to pathogens and tolerance to a vast array of 
harmless antigens. 
1.5 Clostridium spp. 
The genus Clostridium was originally described by Prazmowski in 1880 and 
included gram positive rods that were obligate anaerobes metabolically and 
produced heat resistant spores that swell inside the cell. Bergey expanded on 
this definition in 1923 and in 1986 Cato describe in Bergey's Manual of 
Systematic Bacteriology, Volume 2 the inclusion criteria for the genus 
Clostridium, the species must be an anaerobic or micro-aerophillic spore- 
forming rods that do not sporulate in the presence of air and do not complete 
dissimilatory sulphate reduction (Sneath, Mair et al. 1986). The genus 
Clostridium contains approximately 100 species and in 1994 the heterogeneity 
of the species was confirmed by 16S rRNA gene sequencing. As a result five 
new genera and eleven new species have been proposed (Collins, Lawson et 
al. 1994), none of which have been linked to human disease (Winn, Allen et 
al. 1997). 
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Criteria essential for inclusion in the genus are principally morphological and 
some flexibility has been observed when considering the inclusion of a 
species, with morphological differences significantly dependent on culture age 
and medium used. Likewise, the early requirement that clostridia be gram- 
positive was challenged as some species are only gram positive when viewed 
as very young cultures, and in other species only gram-negative cells are ever 
seen (De Vos P. 2009). 
This flexibility has also been observed in the degree of anaerobiosis required 
for inclusion in the genus Clostridium. Some species are strict anaerobes 
(Clostridium Noyvi Type A and C. heamolytium), conversely others species are 
aero-tolerant growing aerobically with the addition of 5-10% COz (Clostridium 
tertium, Clostridium histolyticum and Clostridium carnis) (Winn, Allen et al. 
1997). 
The single requirement of spore formation has grouped together species of 
wide diversity, both phenotypically and genetically into one genus. Most 
species have straight or curved rods but spirals are described in two species 
and in one species the cells are round to oval. The cells can vary in length 
and width and have blunt rounded or pointed ends. The species may produce 
motile or non-motile spores that may or may not swell the cell and they may 
be terminal, central or subterminal (De Vos P. 2009). 
The first criteria used for classification to species and identification within the 
genus Clostridium is metabolic activity. Sub groups within the genus are 
based on biochemical substrate utilisation producing a mixture of organic 
acids and alcohols from carbohydrates (e. g. Clostridium butyricum, C. 
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acetobutylicum) or peptones (Clostridium pasteurisnum). Clostridia are 
ubiquitous and species have been identified from soil (Sanada and Nishida 
1965; Warnick, Methe et al. 2002), marine and freshwater sediment 
(Segner, Schmidt et al. 1971; Finne and Matches 1974), human faeces 
(Drasar, Goddard et al, 1976) and the intestinal tracts of mammal (Savage 
1977), poultry (Mead and Impey 1970), and humans (Hall and O'Toole 1935). 
Nine species of Clostridium have been reported to cause human disease and 
the clinically significant species produce a variety of toxins (HPA 2008). The 
four most frequently isolated in the United Kingdom being, C. perfringens 
- 
responsible for food poisoning from poorly prepared meat and poultry; C. 
septicum 
- 
responsible for gas gangrene; C. tertium; and C. difficile (HPA 
2008) 
- 
the most identified bacterial agent to cause diarrhoea, second only to 
C. perfringens (Borriello 1995). The remaining species, C. novyii Type A, C. 
sordelli, C. tetani, C. histolyticum, C. botulinum whilst causing human disease 
are rarely isolated in the UK (HPA 2008). 
1.5.1 Clostridial toxins 
Three classes of clostridial toxins have been established; 1) neurotoxins; 2) 
binary toxins; and 3) 'large clostridial cytotoxins', so called due to their high 
molecular weights (Mr>200,000 Da) (Just and Gerhard 2004). 
The neurotoxins (produced by C. tetanus and C. botulinum) target the 
neuronal cells and inhibit the release of neurotransmitters (Montecucco and 
Schiavo 1995). With a distinctive heavy chain and light chain structure held 
together by a di-sulphide bond, the heavy chain is responsible for host 
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targeting. When bound to surface proteins of the host the toxin is 
endocytosed wherein the light chain can cleave endocytotic vesicles; enter the 
cytoplasm and protealytically degrade the target protein resulting in inhibition 
of neurotransmitters. 
The binary toxins secreted by C. perfringens, C. botulinum and others consist 
of two separate and independent proteins, labeled components A and B, that 
work synergistically to intoxicate the host cell, exerting a potent biological 
effect. Component A is described as enzymatic, whilst Component B is 
responsible for binding. Working together component A docks onto the 
extracellular binding component B and the A/B complex is translocated into 
the cytosol by acidified endosomes. Once inside the cell component A acting 
as an ADP-ribosyltranferase catalyses the transfer of an ADP-ribosyl group 
from nicotinamide adenine dinucleotide (NAD+) onto monomeric actin; 
inhibiting the polymerisation of actin filaments causing cytoskeletal 
disorganisation and ultimately cell death (Barth, Aktories et al. 2004). 
The final group to be described are the large clostridial toxins. As mentioned 
previously these toxins are named such due to their large molecular weight. 
With an A-B modular structure, the catalytic N-terminal can be found in the A 
domain and is responsible for the biological activity. The C-terminal receptor 
binding region and the central translocation region make up the B domain. 
This group includes toxin A and B from C. difficile, the a-toxin of C. noyvil and 
the lethal toxins of C. sorde//ii. The toxins bind to surface receptors on host 
cells and are internalised into endosomes by receptor mediated endocytosis. 
Upon endosomal activation catalytic domain is released into the cytoplasm 
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leading to inactivation of key molecular switches; cell rounding and death 
(Just and Gerhard 2004). 
1.6 Clostridium difficile 
- 
history and discovery 
Clostridium difficile, a spore forming Gram positive anaerobic bacillus was first 
isolated in 1935 under the name `Bacillus difficulus' from healthy infant faeces 
(Hall and O'Toole 1935). With infrequent reports of isolation and a lack of 
evidence supporting this organism as a pathogen it was initially labelled a 
commensal bacterium. By the early 1970's Pseudomembranous colitis (PMC) 
was a prevalent disease, thought to be caused by Staphylococcus aureus. 
Disproving this theory in 1974, Tedesco et al reported a link between the 
disease and the use of the antibiotic Clindamycin (Tedesco, Barton et al. 
1974). 
In 1978, Clostridium dffcile was identified as the primary causative agent of 
PMC following the discovery of toxigenic activity In the stool filtrates isolated 
from patients undergoing antibiotic therapy that could be neutralised by C. 
sordellii anti-toxin (Chang, Gorbach et al. 1978). Subsequent isolation of C. 
dif /clle from patient stool filtrates were found to exhibit the same 
characteristic cytotoxicity observed previously, confirming the role of C. 
difficile in pseudomembranous colitis disease (Bartlett, Moon et al. 1978; 
George, Symonds et al. 1978; Larson, Price et al. 1978; Rolfe and Finegold 
1979; Willey and Bartlett 1979). 
Initially, the cytotoxicity observed was thought to be caused by a singular 
'cytotoxin' produced by C. diffrcile (Rolfe and Finegold 1979; Taylor and 
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Bartlett 1979) however further purification of the cytotoxin revealed a second 
distinct cytotoxic activity, which was clearly implicated in the pathological 
changes being ascribed to C. difficile disease (Taylor, Thorne et al. 1981). 
Initially designated D1 and D2 (Banno, Kobayashi et al. 1984), the toxins 
were later renamed to toxin A (enterotoxin) and toxin B (cytotoxin) based on 
the elution profiles from anion-exchange resins (Sullivan, Pellett et al. 1982). 
In 1988, researchers identified a third toxin (48kDa), with similar mechanism 
of action to the C. botulinum C2 toxin and the C. perfringens iota toxin. The 
new toxin named after the strain CD196, was termed CDT (CD196- ADP- 
ribosyltransferase toxin) (Popoff, Rubin et al. 1988). Early findings reported 
the toxin as non-cytotoxic when tested in isolation on cultured cells and 
despite being linked with the hypervirulent NAP01/027 strain responsible for 
outbreaks across America and Northern Europe, research still suggests that 
that the toxin CDT is not capable of facilitating the biological response seen 
with toxins A and B but may play an adjunct role in C. difcile associated 
disease (Geric, Carman et al. 2006). 
Some thirty years have elapsed since C. difficile was identified as the cause of 
PMC, it is currently believed to be responsible for almost all cases of PMC 
(Monaghan, Boswell et al. 2008) and 150 PCR ribotypes and 24 toxinotypes 
have been characterised (Kuijper, Coignard et al. 2006) and the number of C. 
difflcile infections has increased with antibiotic resistant and hyper-virulent 
strains causing endemic infections worldwide (Johnson, Samore et al. 1999; 
Loo, Poirier et al. 2005; McDonald, Killgore et al. 2005; Muto, Pokrywka et al. 
2005). 
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1.7 Major virulence factors 
The major virulence factors in the pathogenesis of Clostridium difficile are the 
two high molecular weight enterotoxins, toxin A (TcdA) and toxin B (TcdB) 
(Borriello, Davies et al. 1990) secreted from the bacterium. In addition a 
number of other attributes of the bacteria assist in the pathogenesis either by 
facilitating colonization; including the ability of fimbriae to associate with the 
mucosal lining and capsule formation, and; the production of hydrolytic 
enzymes that contribute to tissue damage (Borriello 1998). 
Among the largest clostridial toxins, Toxin A (308kDa) and Toxin B (270kDa) 
are glucosyltransferases that inactivate Rho, Rac and Cdc42, modulating 
numerous physiological events in the cell (Just, Selzer et at. 1995; Just, Wilm 
et at. 1995). The toxins are encoded on the chromosomal pathogenicity region 
and are expressed efficiently during late log and stationary phases of growth 
in response to a variety of environmental stimuli. The precise environmental 
signals that modulate toxin expression remain unclear. In vitro studies 
indicate that toxin expression may be enhanced by stress, including 
antibiotics, and catabolic repression (Dupuy and Sonenshein 1998). Given the 
role of antibiotic therapy in PMC early studies focused on the effects of various 
antimicrobials on toxin production. It was found that sub-inhibitory levels of 
penicillin and vancomycin increased toxin production in cultures of C. dfff7cile 
(Onderdonk, Lowe et at. 1979; Adams, Riggs et at. 2007). Whilst evidence 
suggests that antibiotic therapy is a stressor, inducing toxin expression, other 
factors may also contribute. Limiting biotin, a water-soluble B-complex 
vitamin, in culture media has been reported to reduce growth of C. dif icile but 
enhance toxin production when grown In the presence of 0.05nM biotin. 
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(Yamakawa, Karasawa et at. 1996). In contrast, limiting amino acids did not 
enhance toxin production (Yamakawa, Kamiya et at. 1994). Research has 
also proposed links between toxin production and purine biosynthesis. 
Despite these findings, other studies have argued against stress and catabolic 
repression as a mechanism of regulating toxin production (Karisson, Burman 
et at. 1999; Maegawa, Karasawa et at. 2002) and further research is needed 
to clarify our understanding about the factors that facilitate and regulate toxin 
production. 
The toxins have provided one of the quickest areas to understanding the 
clinical disease with a number of studies establishing the role of these toxins 
in the pathogenesis of Clostridium difficile associated disease (CDAD). 
Early research established the presence of a cytotoxin in over 90% of patients 
suffering from C. difficile infection and the clinical manifestation, 
pseudomembranous colitis (Bartlett, Onderdonk et al. 1977; Bartlett, Chang 
et al. 1978; Keighley, Burdon et al. 1978). At this point in time scientists 
were of the opinion that C. difcile produced just one toxin (Taylor and 
Bartlett 1979). In 1981, Taylor and colleagues purified the cytotoxin further 
and revealed a second distinct cytotoxic activity which could also be linked to 
C. difci/e disease (Taylor, Thorne et al. 1981). In that same year, Burdon 
and colleagues demonstrated that the toxins caused clinical disease by 
showing a direct relationship between toxin levels and development of 
pseudomembranous colitis and duration of diarrhoea (Burdon, George et al. 
1981). 
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Direct evidence of the role of toxin A has been shown in animal studies, with 
the hallmarks of PMC; fluid accumulation, inflammation and cell damage 
reported (Libby, Jortner et al. 1982; Czuprynski, Johnson et al. 1983; 
Lonnroth and Lange 1983; Amon, Mills et al. 1984). Toxin A given 
intragastrically caused hemorrhage, fluid accumulation in the intestine, 
diarrhoea and death in hamsters (Lyerly, Saum et al. 1985). Kurtz et a/ have 
shown that C. difficile toxins can be neutralized with an anionic high molecular 
weight polymer, protecting 80% of experimental hamsters exposed to the 
organism (Kurtz, Cannon et al. 2001). In addition, levels of immunoglobulin 
G against toxin A correlate directly with protection from disease following 
colonisation, indicating that the antibody response to this toxin is sufficient for 
protection from CDAD. (Kyne, Warny et al. 2001). 
The role of TcdB in disease is not as well understood. Early research using 
crude supernatant containing both toxins suggested that the toxins worked 
synergistically to elicit disease (Lyerly, Saum et al. 1985). The isolation of 
numerous TcdA- TcdB+ strains capable of causing disease and in some cases 
extensive Pseudo membranous colitis and death challenged this belief (Alfa, 
Kabani et al. 2000) and these strains have been useful In characterising the 
role of TcdB in disease and confirming its cytotoxic presence. (Kato, Kato et 
al. 1998; Limaye, Turgeon et al. 2000; Sambol, Merrigan et al. 2000; Kuijper, 
de Weerdt et al. 2001; Pituch, van den Braak et al. 2001; Komatsu, Kato et 
al. 2003; Rupnik, Kato et al. 2003; Drudy, Harnedy et al. 2007). Alfa and 
colleagues characterized a TcdA- strain and demonstrated that whilst the 
strain was TcdA- TcdB+ was capable of eliciting the full clinical spectrum of 
disease, when Investigated on intestinal tissue the strain was unable to alter 
tight junctions, a response indicative of TcdA (Alfa, Kabani et al. 2000). 
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With the acceptance of TcdB as a potent cytotoxin consideration of earlier 
research demonstrating that monoclonal antibodies to TcdA were able to block 
disease progression in mice treated with both toxins questions the role of 
toxin A as a facilitator of toxin B cytotoxic effect (Corthier, Muller et al. 1991). 
In 1988, a new ADP-ribosyltransferase was identified in C. difficile strain 
(CD196) and was found to covalently modify cell actin (Popoff, Rubin et al. 
1988). This binary toxin (CDT) has now been identified in about 6-12.5% of 
clinical C. difficile isolates taken in the United States and Europe (Stubbs, 
Rupnik et al. 2000). The structure and function of CDT are similar to those 
found in other binary toxins (Gulke, Pfeifer et al. 2001). The binary toxin is 
encoded by two chromosomal genes (cdtA and cdtB), separate from the 
chromosomal pathogenicity locus. The cdtB gene arbitrates cell surface 
binding and translocation, whilst cdt4 ribosylates adenosine phosphate 
resulting in the disruption of actin filament and cell death (Barth, Aktories et 
al. 2004). The pathogenic role of CDT in Clostridium difficile associated 
diseases is not clear but it is a suspected virulence factor in strains that carry 
the toxin (Gulke, Pfeifer et al. 2001). 
1.7.1 Other toxins 
A small number of clinical isolates have also been found to produce binary 
toxins that display ADP-ribosyltransferase activity (Perelle, Gibert et al. 1997; 
Stubbs, Rupnik et al. 2000). CD196, a strain isolated from a patient with 
pseudomembranous colitis, was shown to produce a ss43 kDa protein capable 
of modifying the actin cytoskeleton via ADP-ribosyltransferase activity (Popoff, 
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Rubin et al. 1988). Early findings established the toxin not to be cytotoxic and 
was subsequently identified to be a two-component ADP-ribosyltranferase 
toxin encoded by the genes cdtA and cdtB (Perelle, Gibert et al. 1997). The 
more recent isolation of NAP1/027 (Bartlett 2002; McDonald, Kiligore et al. 
2005), this epidemic strain expresses all three toxins (Warny, Pepin et al. 
2005) and whilst the increased virulence is suggested to be attributable to a 
gene deletion in the TcdC regulatory region of the pathogenicity locus 
(Stabler, Dawson et al. 2008) the role of CDT still needs to be characterized. 
In addition to TcdA, TcdB and CDT, strains of C. difficile that contain variant 
toxin genes that produce hybrid toxins have been identified. The most 
characterised of which is produced by C. difcile strain 1470 (von Eichel- 
Streiber, Meyer zu Heringdorf et al. 1995; Chaves-Olarte, Low et al. 1999). 
TcdB-1470 is a hybrid toxin that is closely related to the non-hybrid toxin, 
TcdB, showing 99% homology in the C-terminus and middle domain. This 
hybrid toxin has the ability to modify Ras, Rac, Rap and Ral and is believed to 
be a unique hybrid between TcsL and TcdB (Chaves-Olarte, Low et al. 1999). 
1.8 Genetics of toxin A and toxin B 
1.8.1 Pathogenicity Locus (PaLoc) 
The genes encoding TcdA and TcdB have been identified, sequenced and are 
found in a single open reading frame located within a su19kb pathogenicity 
locus (Barroso, Wang et al. 1990; Dove, Wang et al. 1990), see Figure 1-2. 
The two toxins are closely situated with a 1,350 nucleotide intervening 
sequence. The toxin genes show similar sequence and functional homology 
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with low G+C content, comparable with the overall C. dif>icile genome. In 
addition to tcdA and tcd8, three other open reading frames are located on the 
pathogenicity locus and are believed to be involved in regulation of toxin 
production or release of the toxins from the cell (Hammond and Johnson 
1995). 
The gene, tcdC can be found downstream and unlike the other genes located 
on the pathogenicity locus, it is transcribed in the opposite direction. TcdC is 
highly expressed in the early exponential phase of bacterial growth but later 
declines in the stationary phase (Hundsberger, Braun et al. 1997). The 
decrease in TcdC expression corresponds with an increase in toxin A and B 
secretion suggesting that TcdC may function as a negative regulator of toxin 
production (Hundsberger, Braun et al. 1997). tcdR (formerly tcdD) is encoded 
upstream of TcdB and expressed at the same time as TcdA and TcdB. TcdR 
(formerly TcdD) shows homology with TetR and BotR positive regulators of 
tetanus and botulinum toxin production. It has also been reported that TcdR 
can auto-regulate its own expression in response to environmental conditions 
such as growth phase and local surroundings. Thus TcdR may serve as a 
major positive regulator of toxin synthesis in C. diffcile (Hundsberger, Braun 
et al. 1997; Mani and Dupuy 2001; Mani, Lyras et al. 2002). 
The gene encoding TcdE is located between TcdA and TcdB and shows 
homology with holin proteins and has been speculated to facilitate the release 
of TcdA and TcdB through the permeabilization of the C. difficile cell wall (Tan, 
Wee et al. 2001). It can therefore be postulated that toxin expression 
appears to be dependent on decreases in TcdC, enhanced expression of TcdR 
and TcdE mediated release from the cell. 
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PaLoc(19kb) 
tcdR tcdB tcdE tcdA tcdC 
Figure 1-2 Pathogenicity Locus (PaLoc) 
Contains five genes tcdB and tcdA encode for the major virulence factors Toxin A and B. tcdR, 
formerly tcdD is involved in positive transcriptional regulation and tcdC encodes a negative 
regulator. lcdE codes a protein similar to phage holins. Adapted from (Rupnik, Wilcox et al. 2009). 
It has been proposed that the two toxin genes may have arisen from a gene 
duplication event (von Eichel-Streiber, Laufenberg-Feldmann et al. 1992). 
Supporting this idea, both toxins use a highly conserved N-terminal domain 
with 74% homology to modify identical substrates (von Eichel-Streiber, 
Laufenberg-Feldmann et al. 1992). The major areas of homology between 
toxin A and B fall within the enzymatic and receptor binding domains of the 
two toxins (von Eichel-Streiber, Laufenberg-Feldmann et al. 1990). The C- 
terminal domains show a number of short homologous regions termed 
combined repetitive oligopeptides (CROPS) (von Eichel-Streiber, Laufenberg- 
Feldmann et al. 1992). Both toxins encode five groups of CROPs ranging in 
size from 21-50 residues and can be repeated throughout the C terminus of 
the protein, four of the CROPs in toxin B show homology to four of the CROPS 
in toxin A but the CROPs found in toxin B display more divergence and appear 
less frequent than those found in toxin A. Whilst the CROPs appear to play a 
role in initial target cell interaction and receptor binding the need for these 
repeats in cell binding remains unclear (Voth and Ballard 2005). 
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1.8.2 Functional domains of toxin A and B 
TcdA and TcdB are predicted to have three domains, enzymatic, translocation 
and receptor binding, see Figure 1-3. Each domain serves a specific function 
during cellular intoxication. 
i 
. 
J: Jciu Uanavi 
NH, 
Sul»Late 
W I02 k D\D Sp-fwy 
Gu syaaß.. rnvm. 
[-i--TI H 
CROP. 
Figure 1-3 Three domain structure of toxin A and B 
Diagrammatic representation of C. dijcile toxin A and B protein structure. Both toxins are single 
chain proteins with three functional domains. Adapted from (Voth and Ballard 2005). 
1.8.2.1 The enzymatic domain 
The enzymatic domain of TcdB contains a 546-residue region responsible for 
glucosylation activities (Hofmann, Busch et al. 1997). This region has been 
shown to effectively glucosylate substrates in vitro but lacks any cytotoxic 
activity. Recent research conducted by Rupnik and co-workers has shown 
that a fragment of the enzymatic domain was in fact cytotoxic when 
microinjected into cells (Rupnik, Pabst et al. 2005). Spyres and colleagues 
report any deletion in the enzymatic region of the PaLoc results in a complete 
loss of enzymatic activity and micro-injection of TcdB mutants are capable of 
inhibiting wild-type TcdB enzymatic activity (Spyres, Qa'Dan et al. 2001; 
Spyres, Daniel et al. 2003). Challenging these findings, another group 
reportedly reduced the enzymatically active portion substantially whilst 
retaining the ability of the region to glucosylate Rho Rac and Cdc42 in vitro 
(Wagenknecht-Wiesner, Weidmann et al. 1997). Using chimeric hybrids 
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between TcdB and TcsL, the substrate recognition region of TcdB has been 
reduced to residues 364 to 516 (Hofmann, Busch et al. 1998). In addition to 
finding this site Busch and colleagues also found that glucosyltransferase 
activity is dependent on a DXD motif in the enzymatic domain and mutations 
in this vital motif lead to the production of toxins unable to modify GTPases 
via glucosylation in vitro (Busch, Hofmann et al. 1998). Another critical region 
involved in TcdB glucosylation is Trp102, Busch and colleagues report that 
Trp102 is involved in UDP-glucose binding and mutants lacking this residue 
were no longer cytotoxic to cells (Busch, Hofmann et al. 2000). 
1.8.2.2 The receptor binding domain 
Making up approximately one third of the toxin the receptor binding domain 
contains up to 38 repeating CROP modules. The hemagglutinating activity of 
TcdA may be explained by the high degree of repetition within these CROP 
modules (Wren 1991). It has also been suggested that the CROP region of 
toxin A contains isolate-specific repeats and deletions demonstrating that this 
region may have originated from multiple duplication and recombination 
events (Rupnik, Avesani et al. 1998). The CROP sequences vary in length but 
all contain a consensus triad YYF and an overall hydrophilic stretch indicative 
of a solvent exposed area of the protein (Wren, Russell et al. 1991). 
Supporting the role of the C-terminal as the binding domain, specific 
monoclonal antibodies capable of neutralizing the enterotoxic activity of toxin 
A were found to bind to two epitobes in this region (Frey and Wilkins 1992) 
and recombinant protein produced from the C terminal region neutralized the 
effect of TcdA by competitive inhibition of receptor binding (Sauerborn, Leukel 
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et al. 1997). The same fragment was also found to immunize mice against 
toxin A (Ward, Douce et al. 1999). More recently Frisch and colleagues have 
shown that the entire C terminal receptor domain is required for both receptor 
binding the endocytosis of the holotoxin (Frisch, Gerhard et al. 2003). 
Toxins A and B also share a high degree of similarity to the other large 
clostridial toxins. Toxin B shows the most homology with the cytotoxin TscL, 
produced by Clostridium sordellii which glucosylates Ras, Rac, Rap and Rai 
(Chang, Gorbach et al. 1978). The main differences in these proteins are 
found in the N-termini and are responsible for the difference in substrate 
specificity (Hofmann, Busch et al. 1998). Toxin A is thought to be most similar 
to the enterotoxin TcsH, produced by C. sordellii (Chang, Gorbach et al. 
1978). The close homology between these large clostridial toxins is further 
demonstrated by antiserum to toxin A recognising TcsH; and antiserum to 
toxin B recognising TscL; and vice versa (Martinez and Wilkins 1988). 
Showing the least homology, Tcna, produced by C. novyi also glycosylates 
Rho, Rac and Cdc42 and differs only in the co-substrate used (Voth and 
Ballard 2005). 
1.8.3 Toxinotypes of C. difficile isolates 
Variations in the PaLoc sequence determine which toxinotype the isolate 
belongs to. In non-toxigenic TcdA negative TcdB positive strains the PaLoc 
region is replaced by a 115bp of non-coding sequence (Rupnik, Avesani et al. 
1998). Rupnik established a typing system to distinguish the various 
toxinotypes and there are at 22 toxinotypes of C. difficile established, twenty 
one are pathogenic and one non-pathogenic (toxinotype XI). Toxinotypes I- 
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VII, IX, XII-XV, and XVIII-XXII produce toxins A and B. Toxinotype VIII, X, 
XVI and XVII only produce toxin B (Rupnik, Avesani et al. 1998; Rupnik, Kato 
et al. 2003). 
Research investigating the role of TcdA and TcdB in the pathogenesis of 
Clostridium difficile associated disease (CDAD) has been completed using the 
reference strain VP110463, however several genetic variants of these toxins 
have been isolated from clinical samples. Some of which are hybrids 
occurring as a result of genetic exchange between large clostridial toxin 
producing Clostridia. More commonly subtle sequence variations, deletion and 
duplication within the pathogenicity locus account for the various toxinotypes. 
This typing has proved very useful in categorising new strains based on major 
virulence factors. Serotyping has also been established to distinguish between 
different strains of C. difficile. Currently 14 different serotype groups have 
been recorded. 
1.8.3.1 TcdA-negative strains in disease 
Although TcdA is thought to play an important role in Clostridium difficile 
associated disease, an increasing number of TcdA-negative, TcdB-positive 
strains have been reported in clinical isolates (al-Barrak, Embil et al. 1999; 
Brazier, Stubbs et al. 1999; Alfa, Kabani et al. 2000; Wilcox and Fawley 2001; 
Barbut, Lalande et al. 2002; Johnson, Sambol et al. 2003; Komatsu, Kato et 
al. 2003; Pituch, vavn Belkum et al. 2003). The TcdA-negative strains 
produce TcdB but contain deletions In tcdA gene and encode shortened forms 
of the protein (Rupnik, Avesani et al. 1998; Soehn, Wagenknecht-Wiesner et 
al. 1998; Rupnik, Kato et al. 2003). Over 20 toxinotypes of C. difficile have 
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been identified, nine of which contain deletions in the 3' end of the tcdA gene 
(Rupnik, Avesani et al. 1998; Rupnik, Kato et al. 2003). Absence of the CROP 
region not only reduces cytopathic activity but also prevents the recognition of 
TcdA-negative strains by most detection systems as they use the presence of 
toxin A to confirm C. difficile infection (Voth and Ballard 2005). 
TcdA-negative, TcdB-positive strains have been isolated in a variety of 
different patients, spanning from the elderly to children (Johnson, Kent et al. 
2001; Rupnik, Kato et at. 2003). Early reports suggest TcdA-negative, TcdB- 
positive strains occurred at a low frequency (Sambol, Merrigan et at. 2000; 
Pituch, van den Braak et al. 2001; Geric, Rupnik et al. 2004), however a study 
of individuals suffering severe disease reported over 55% of stool specimens 
analysed were TcdA-negative, TcdB-positive strains (Samra, Talmor et al. 
2002). The reported increase in TcdA-negative, TcdB-positive strains over 
recent years may also reflect our increased understanding of C. difficile 
epidemiology and the typing systems put in place over the same period. 
The ability of TcdA-negative, TcdB-positive strains to cause disease has 
caused some confusion. Early research argued that TcdB was ineffective 
unless TcdA was administered first suggesting that TcdB not only lacked the 
ability to cause disease but also needed TcdA to gain access to target cells 
(Lyerly, Saum et at. 1985). This finding was supported by limited evidence to 
suggest that TcdB had any impact on the cells in the gastrointestinal tract 
(Riegler, Sedivy et al. 1995; Fiorentini, Fabbri et at. 1998; Savidge, Pan et at. 
2003). 
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Interestingly, the clinical presentation is remarkably similar between TcdA- 
negative (TcdB-positive) and TcdA-positive strains (Johnson, Kent et al. 
2001). The identification of more TcdA- strains from clinical isolates of C. 
diffcile may highlight a more prominent role of TcdB in CDAD. In fact Savidge 
et al reported that TcdB functions as a potent enterotoxin (Savidge, Pan et al. 
2003). TcdB interactions with other C. difficile factors may explain why the 
toxin is cytopathic in the absence of TcdA. 
It has also been suggested that the increasing number of TcdA-negative, 
TcdB-positive strains may also highlight a selection event within the host. 
Most of the tcdA deletions occur in the CROP region and given the repeat 
sequences, this area would be susceptible to deletion by recombination. It 
has been suggested therefore that the disease is in fact initiated by a TcdA 
strain but there is selection for strains that have lost their ability to produce 
toxin (Voth and Ballard 2005). This idea has been refuted by Sambol and co- 
workers who argue that TcdA-negative, TcdB-positive isolates are able to 
cause disease in hamster models (Sambol, Merrigan et al. 2000; Sambol, 
Tang et al. 2001). Until recently, the absence of an isogenic strain lacking 
TcdA or select deletions in tcdA this argument could not be resolved. In a 
recent publication Kuehne and fellow workers report C. difficile isogenic 
mutants capable producing toxin A or toxin B can cause fulminant disease and 
the construction of a double-mutant strain completely attenuated disease 
(Kuehne, Cartman et al. ). These findings re-establish the importance of both 
toxins when studying the pathogenesis of Clostridium difficile associated 
disease (CDAD). 
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Figure 1-4 Pathogenesis of Clostridium difficile associated disease 
Ingested spores are transported down the intestinal tract and the spores mature into vegetative cells 
and release toxin A and toxin B into the lumen. Toxins bind to surface receptors located on 
colonic epithelial cells and upon internalisation the toxins inactivate key intracellular signals. The 
epithelial cells round and undergo apoptosis, tight junctions open. The simultaneous release of 
TNF-a and pro-inflammatory interleukins increase vascular permeability and neutrophils and 
monocytes are recruited to the site of injury. Production of hydrolytic enzymes leads to tissue 
degradation and pseudomembrane formation. Illustration adapted from UK Clostridium docile. 
1.9 Pathophysiological response 
1.9.1 Cell death 
- 
apoptosis 
Cell death is the most obvious impact of TcdA and TcdB on cell physiology but 
our understanding of the mechanisms that precede this are still being 
elucidated. 
Cell rounding caused by the inactivation of Rho, Rac and Cdc42; the 
subsequent cytoskeletal rearrangement; cell rounding; and basement 
membrane detachment have been suggested as temporally distinct events to 
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cell death (Voth and Ballard 2005). This is supported by research conducted 
by Qa'Dan and colleagues indicating cell rounding and cell death may be 
temporally distinct events in toxin B exposed cells as cell rounding was visible 
in less than 2 hours and cell death did not occur until at least 24 hours. 
(Qa'Dan, Ramsey et al. 2002). The mechanism of cell death in cells exposed 
to TcdA and TcdB is apoptosis and a number of studies have been conducted 
providing evidence to suggest that inactivation of Rho causes cell death 
(Fiorentini, Fabbri et al. 1998). Inactivation of Rho in an endothelial cell line 
resulted in the activation of caspase-3 and caspase-9 (Hippenstiel, Schmeck 
et al. 2002). In a similar study, Brito and colleagues report that toxin A 
induced the apoptotic pathway in T84 cells via the release of caspase-3, 
-6, - 
8, 
-9 and Bid activation (Brito, Fujji et al. 2002). Further delineating the 
apoptosis-signalling cascade induced by toxin A in T84 cells, Carneiro and 
colleagues found that toxin A induced caspases 6,8 and 9 prior to caspase 3 
activation and induced Bid cleavage using a caspase independent mechanism. 
(Carneiro, Fujii et al. 2006) 
Purporting toxin A to induce apoptosis independently of Rho protein 
inactivation, He Hagen et al reported the intoxication of cells with toxin A 
results in an accumulation of toxin at the mitochondria prior to any detectable 
glucosylation of Rho proteins (He, Hagen et al. 2000). It may be therefore 
toxin A causes apoptosis by disrupting the mitochondria and promoting 
proapoptotic events. 
In contrast and implicating in-activation of Rho proteins and caspase 
dependent apoptosis Qa'Dan and co-workers demonstrated that the 
intoxication of HeLa cells with toxin B resulted in caspase-3 dependent 
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apoptosis with a simultaneous loss of host cell vimentin and apoptosis induced 
by substrate inactivation (Qa'Dan, Ramsey et al. 2002). In a recent study, 
Nottrott and colleagues report cultured human adenocarcinoma cells (HT29) 
undergo TcdA induced apoptosis following the glucosylation of Rho GTPases 
leading to the activation of cathespins and caspase-3 (Nottrott, Schoentaube 
et al. 2007). This paper also reported that whilst TcdA induced mitochondrial 
damage and cytochrome c release, p53 was not activated. 
Intoxication of cells with TcdA and TcdB at relatively low concentrations has 
been shown to induce distinct morphological alterations (Donta, Sullivan et al. 
1982). TcdB has been identified as a more potent cytotoxin (Chaves-Olarte, 
Weidmann et al. 1997; Riegler, Sedivy et al. 1997), able to intoxicate a 
variety of cell lines, and depending on cell type exert a cell specific effect 
ranging from 4-fold to 200-fold increase in cytotoxic activity than TcdA 
(Donta, Sullivan et al. 1982). Supporting the cell-specific effect mouse 
teratocarcinoma cells were more sensitive than Chinese Hamster Ovary (CHO) 
cells when exposed to TcdA and it was proposed that increased expression of 
TcdA specific carbohydrate receptors may be responsible (Tucker, 1990 #96). 
Research conducted by Chaves-Olarte and co-workers sought to establish why 
TcdA and TcdB displayed different cytotoxic potency despite intoxicating 
target cells by the same mechanism. Using Don and T84 cells, two main 
differences were identified, with differing enzymatic activities highlighted as 
the main determinant and receptor binding difference contributed less 
(Chaves-Olarte, Weidmann et at. 1997). 
The substrate targets Rho, Rac and Cdc42 also regulate other cellular events 
outside of the actin cytoskeleton (Prepens, Just et al. 1996; Schmidt, 
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Rumenapp et al. 1996; Caron and Hall 1998; Brito, Fujji et al. 2002; 
Hippenstiel, Schmeck et al. 2002). Given the temporal differences between 
cell rounding and cell death reported by Qa'Dan and colleagues and the many 
other pathways linked to the small GTPases it would be pertinent to conclude 
that other events downstream of actin condensation may also contribute to 
cell death. 
1.9.2 Increased epithelial cell permeability 
The first and most obvious impact on cell physiology is loss of structural 
integrity caused by the disruption of the actin cytoskeleton in cells exposed to 
toxins A and B. Chang et al reported alterations in cell surface projections and 
rearranged microvilli (Chang, Lin et al. 1979) and in a later paper reported 
that toxin A altered the ultrastructure of CHO cells, with clear actinomorphic 
changes and marginalization of the nucleus seen using electron microscopy 
(Fiorentini, Malorni et al. 1990). Similar observations were viewed in TcdB 
exposed cells (Feltis, Wiesner et al. 2000). Exposure of cultured human 
intestinal epithelial (T84) cell monolayers to TcdA and TcdB reduced 
transepithelial resistance and increased epithelial cell permeability, with flux 
studies identifying that the permeability failing occurred at the intercellular 
tight junction (Hecht, Pothoulakis et al. 1988; Hecht, Koutsouris et al. 1992). 
The disruption of epithelial tight junctions of the epithelium is considered to be 
directly attributable to the toxins (Feltis, Wiesner et al. 2000). Supporting 
these early studies, 7ohal and co-workers investigated barrier function of 
cultured human intestinal epithelial cells (T84) in response to varying 
concentrations of TcdA and demonstrated that after pre-exposure to >10 
ng/ml a complete and irreversible loss of epithelial resistance was observed, 
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exposure to lower concentrations resulted in loss of resistance followed by 
recovery, enhanced by recombinant isoforms of TGF-ß (]ohal, Solomon et al. 
2004). Transforming growth factor (TGF)-ß has previously been shown to 
regulate paracellular permeability of epithelial cells via their effects on tight 
junctions (McKay and Baird 1999). 
The loss of structural integrity is however expected since Rho, Rac and Cdc42 
each regulate structural processes dependent on actin polymerization and this 
was supported by Nusrat and colleagues who presented strong evidence that 
the Rho protein regulates tight junctions and the organization of actin 
microfilament in polarized T84 colonic cell monolayers (Nusrat, Giry et al. 
1995). 
This disruption is likely due to the inactivation of Rho proteins, small GTPases 
known to be important in tight junction maintenance (Nusrat, Giry et al. 
1995). A reduction in epithelial monolayer resistance in <3 hrs following toxin 
A intoxication was report by Johal and colleagues (Johal, Solomon et al. 
2004), by contrast Hecht et al, reported. Loss of resistance appeared to occur 
prior to loss of confluence suggesting that cell to cell contact was disrupted 
before contraction of the cell. Toxin B has also been found to disrupt 
epithelial integrity through the decline in F-actin and disruption of the 
perijunctional actomyosin ring (Hecht, Koutsouris et al. 1992). 
Further definition has been provided by Nusrat and co-workers who 
demonstrated the loss of apical and basal F-actin, is associated with loss of 
intact occiudin and ZO- in the tight junction membrane (Nusrat, von Eichel- 
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Streiber et al. 2001). Collectively these studies suggest that the loss of 
epithelial barrier integrity may be due to direct interactions with the cell. 
1.9.3 Inflammatory Response 
Many of the symptoms described in patients with C. difficile disease can be 
ascribed to inflammatory events and TcdA and TcdB would appear to be, given 
the wealth of evidence, implicated as likely modulators of these events. 
TcdA and TcdB are capable of imitating the physiological events occurring in 
Clostridium difcile disease and pseudomembranous colitis (Savidge, Pan et 
al. 2003). The inflammatory response seen in PMC can be triggered in rabbit 
or rat ileal loop models by toxin A (Lima, Lyerly et al. 1988). The pathologies 
observe in PMC have been attributed to inflammation caused by increased 
epithelial permeability (Feltis, Wiesner et al. 2000), production of cytokines 
and chemokines (Castagliuolo, Keates et al. 1998; He, Sougioultzis et al. 
2002), neutrophil infiltration (Kelly, Becker et al. 1994), activation of 
submucosal neurons (Neunlist, Barouk et al. 2003), construction of reactive 
oxygen intermediates (He, Sougioultzis et al. 2002), mast cell activation 
(Wershil, Castagliuolo et al. 1998), substance P production (Pothoulakis, 
Castagliuolo et al. 1994) and direct damage to the intestinal mucosa (Mantyh, 
Pappas et al. 1996). 
The contribution of other toxin activities in causing inflammation remains a 
target for research. Whilst PMC associated inflammation can be induced with 
toxin alone, isogenic strains lacking both toxins have been suggested as a 
possible route of future research. In addition, direct links between 
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inactivation of Rho proteins and the induction of inflammation have not been 
reported and therefore consideration should be directed toward other toxin 
activities contributing to inflammation. 
Early studies found that the rat intestinal response to TcdA could be 
attenuated by a substance P antagonist (Mantyh, Pappas et al. 1996). 
Substance P is an 11-amino acid polypeptide associated with sensory neurons 
that line the submucosal regions of the intestinal epithelium and has been 
shown to be involved in inflammatory diarrhea (Pothoulakis, Castagliuolo et al. 
1994). Treatment of rat ileal loops with TcdA has resulted in an increase in 
substance P production (Mantyh, Maggio et al. 1996). Amplifying the 
inflammatory response substance P has been shown to activate lamina propria 
macrophages to release tumour necrosis factor 
- 
alpha (TNFa) (Castagliuolo, 
Keates et al. 1998). As a result of this substance P mechanism, neutrophil 
recruitment and inflammation is increased. 
Later research has shown that removal of neural endopeptidase, an important 
protein in substance P synthesis, amplifies the inflammatory response 
(Kirkwood, Bunnett et al. 2001). Together these studies highlight the 
contributions of neuronal signalling to inflammatory pseudomembranous 
colitis. 
Toxin A has been shown to stimulate cytokine production. TcdA triggers 
interleukin-8 (IL-8) secretion and the production of reactive oxygen 
intermediates by human colonocytes (Mahida, Makh et al. 1996; He, 
Sougioultzis et al. 2002). Jefferson and colleagues have demonstrated that 
IL-8 activation is dependent on TcdA entering the cell and activating nuclear 
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factor kappa beta (NK-Kß) and activating protein-1 (AP-1) (Jefferson, Smith et 
al. 1999). Along the same theme, Castagluiolo found that interleukin-11 (IL- 
11) inhibits TcdA related damage by blocking the release of TNF-a and 
macrophage inflammatory-protein 2 (MIP-2) (Castagliuolo, Kelly et al. 1997). 
Causing further inflammation, macrophages have been shown to release 
intestinal secretory factor following exposure to TcdA (Rocha, Soares et al. 
1998). 
In addition to the many direct interactions of TcdA, it has also been suggested 
that products of these initial interactions may also exacerbate the 
inflammatory response. This is true in neutrophils; responding neutrophils 
release reactive oxygen metabolites (Qiu, Pothoulakis et al. 1999). TcdA also 
induces responses in macrophages and mast cells furthering the inflammatory 
response through the release of TNFo (Calderon, Torres-Lopez et al. 1998). 
Mast cell deficient mice have reduced neutrophil recruitment and exhibit 
reduced levels of fluid accumulation following TcdA intoxication (Wershil, 
Castagliuolo et al. 1998). 
Whilst early research into mast cell activation by TcdA and TcdB was 
conducted on rat basophilic leukaemia cells and murine peritoneal mast cells 
(Calderon, Torres-Lopez et al. 1998), a recent study used a novel model 
system to investigate mast cell-mediated processes. Using human mast cells 
(HMC-1), Meyer and colleagues demonstrated the activation of human mast 
cells by TcdA and TcdB resulted in degranulation and IL-8 release (Meyer, 
Neetz et al. 2007). 
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1.9.4 Toxin cell surface receptors 
Receptor binding is the first step in cell entry. Understood to be non- 
proteinaceous the receptor for toxin A displays the disaccharide Galß1- 
4GIcNac. This disaccharide is found on blood antigens I, X and Y on a variety 
of cells and these antigens have been shown to act as receptors for toxin A 
(Tucker and Wilkins 1991). Recent analyses of the C-terminal crystal 
structure of TcdA have provided insights into the interaction of the toxins with 
carbohydrate receptor structures (Ho, Greco et al. 2005) and our knowledge 
extended with the construction of a high resolution co-crystal structure 
(Greco, Ho et al. 2006). 
Animal studies have identified many species susceptible to TcdA but receptors 
are not identical and in one particular study the receptor Gala-1-3Galß1-4 
GlcNac is reported to bind TcdA but it does not appear to be present in human 
cells (Krivan, Clark et al. 1986). Supporting these studies, treatment of cells 
or tissues with galactosidase reduces binding of toxin A (Krivan, Clark et at. 
1986; Clark, Krivan et al. 1987; Smith, Cooke et at. 1997; Cooke and Borriello 
1998). The receptor for toxin B whilst undefined is ubiquitous with TcdB 
capable of intoxicating a broad range of cell types. 
1.9.5 Receptor-mediated endocytosis and membrane translocation 
As mentioned previously, Toxin A&B enter the cell by receptor mediated 
endocytosis and require an acidified endosome for translocation into the 
cytosol (Florin and Thelestam 1983; Fiorentini, Malorni et al. 1990). In 
support, it has been demonstrated that lysomotropic inhibitors such as 
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bafilomycin A and ammonium chloride can directly inhibit cytotoxic effects of 
large clostridial toxins (Florin and Thelestam 1983). In addition, preventing 
lysosome fusion with the endosome weakens toxin B activity (Florin and 
Thelestam 1986). 
it would appear that a low pH is essential for conformational changes within 
the toxin, leading to the exposure of the hydrophobic domain and subsequent 
insertion into the target membrane (Qa'Dan, Spyres et al. 2000). This idea 
was supported by Barth and colleagues, who observed the formation of 
channels in the lipid bilayers by toxin B through an acid pH-dependent process 
(Barth, Pfeifer et al. 2001). 
With the toxin packaged inside the acidified endosome, researchers found that 
following proteolytic cleavage only the N-terminal domain exits the endosome 
and gains access to the substrates (Pfeifer, Schirmer et al. 2003) and the 
cleavage of TcdB occurs after residue 543 (Rupnik, Pabst et at. 2005). These 
finding are supported by the rapid cytotoxicity demonstrated when 
microinjection of the N-terminal fragment was compared with the cytotoxicity 
of the microinjected holotoxin into the host cell (Rupnik, Pabst et at. 2005). 
Once internalized the N-terminal fragment targets intracellular proteins 
- 
small GTPases. 
1.10 Small GTPases and the Ras Super-family 
Before delineating specific protein interactions and subsequent modification 
discussion will begin small GTPases; the Ras Super family and highlight the 
cellular importance of these proteins. 
54 
Found in all eukaryotic organisms, small GTPases are small monomeric 
guanine triphosphate (GTP) binding proteins with molecular masses ranging 
from 20-25kDa. These monomers act as molecular switches, facilitating 
intracellular signalling and controlling a variety of cellular functions. Members 
share approximately 30% amino acid homology across the super-family and 
this identity is derived from the highly conserved domains needed for guanine 
diphosphate (GDP), GTP and GTPase activity. 
The members of this super family of small GTPases can be divided into five 
distinct sub-families: Ras; Rho/Rac; Rab; Arf/Sarl and Ran. Each sub-family 
shares in the order >_40% amino acid homology and conserved motifs identify 
specific classes of downstream effectors. 
The molecular switch has two states; the inactive 
- 
GDP-bound, and; the 
active 
- 
GTP bound. The process of GDP/GTP cycling is illustrated in Figure 
1-5. Intracellular signalling occurs only when the small GTPase is in its active 
form (Schmidt and Hall 2002). In response to extra-cellular signals, the 
dissociation of GDP inhibitors from the GDP-bound protein is carried out and 
the monomer localises to the cell membrane where guanine nucleotide 
exchange factors (GEF's) catalyze the removal of GDP and GTP binds (Schmidt 
and Hall 2002). The inherent hydrolysis of GTP by the activated Rho and 
enhanced by GTPase activating proteins (GAP'S) removes the y-phosphate 
group thereby returning the complex to the inactive GDP-bound state 
(Bernards and Settleman 2004). 
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The GDP dissociation inhibitors provide extra regulation by blocking nucleotide 
exchange and maintain GDP-bound form in its inactive state. This prevents 
any association with the membrane and interactions with guanine exchange 
factors (Fukumoto, Kaibuchi et al. 1990; Mizuno, Kaibuchi et al. 1991; Bishop 
and Hall 2000). 
1.10.1 The Rho Family 
Rho proteins, small GTPases present in three isoforms (A, B, and C) are found 
in mammalian cells. These proteins are primary regulators of the actin 
cytoskeleton found ubiquitously in eukaryotic cells (Bishop and Hall 2000). As 
discussed previously, following expression, the small GTPase Rho is subject to 
posttranscriptional modification that aids localization to the cytoplasmic side of 
the plasma membrane where exchange of GTP and GDP occur (Adamson, 
Marshall et al. 1992; Marshall 1993; Schmidt and Hall 2002). The 
mechanisms of regulation in Rac and Cdc42 are relatively identical to the 
mechanism discussed for Rho (Etienne-Manneville and Hall 2002). 
Rho plays a major role in regulation and localisation of stress fibre at focal 
adhesion sites, cell motility and the formation of perijunctonal rings at the 
apical side of epithelial cells (Ridley 2001). Rho interacts with and activates a 
diverse range of effector proteins including Rho-kinase (Fujisawa, Madaule et 
al. 1998), citron K (Madaule, Eda et al. 1998) and phosphotidylinositol 4- 
phosphate 5 kinase (Chong, Traynor-Kaplan et al. 1994). Rac and Cdc42 are 
specifically involved with lamellipodium and filopodium formation and are 
essential to cellular movement and sensing the external environment 
(Wennerberg and Der 2004). 
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Transduction of cell signalling 
The ligand (L) binds to its receptor (R) initiating the activation of membrane bound G protein. The 
G protein has two domains; Switch I (S I) and Switch 2 (S2), (C) and (N) represent the C-terminal 
and N-terminal, respectively. In its non-activated GDP-bound state SI and S2 are off. The 
interaction of Si with guanine exchange factor (GEF) facilitates the removal of GDP allowing 
GTP to bind. The bound GTP induces conformational changes in the G protein which allows 
interaction with downstream effectors (DE) initiating a cascade of downstream events. 
Stimulation continues until GTP is hydrolysed to GDP by the endogenous GTPase activity of G 
protein. The rate of endogenous hydrolysis is increased by interaction of GAP (GTPase-activating 
protein) with S2. The G-protein is reduced to it inactive state once more. Adapted from (Mims C 
A 2000) 
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1.10.2 Modification of intracellular proteins 
- 
small GTPases 
Early studies into the effects of TcdB on cell structure indicated cells 
underwent marked changes in the organization of their actin cytoskeleton 
(Thelestam and Bronnegard 1980; Wedel, Toselli et al. 1983; Mitchell, 
Laughon et al. 1987). This effect has since become the hallmark of the 
intoxication of cells by TcdA and TcdB and is believed to preface cell death in a 
variety of cell types. The Rho proteins are known regulators of the 
cytoskeleton. 
Supporting these early observations, Just and co-workers found that the small 
GTPase Rho was no longer subject to ADP-ribosylation by C. botulinum C3 co- 
enzyme, indicating that toxin B altered Rho within the cell (Sekine, Fujiwara et 
al. 1989; Just, Fritz et al. 1994). Over-expression of Rho protected cells from 
TcdB induced rounding, further linking this protein as a target of TcdB. TcdA 
was subsequently found to exercise a comparable effect on Rho (Just, Selzer 
et al. 1995). 
With Rho identified as the putative target of TcdA and TcdB, it was 
demonstrated by Just et al that TcdB giucosylated RhoA via the transfer of a 
sugar moiety to Thr-37 of the GTPase using UDP-glucose as the co-substrate 
(Just, Fritz et al. 1994; Just, Selzer et al. 1995) (see Figure 1-7). This 
seminal study also reported TcdB giucosylated two further GTPases, Rac and 
Cdc42 (Just, Selzer et al. 1995). This group also observed TcdA modify RhoA 
with the same mechanism previously observed in TcdB (Just, Selzer et al. 
1995; Just, Wilm et al. 1995). The modification of Rac and Cdc42 however, 
resulted from the addition of the sugar moiety to Thr-35 and not Thr-37 (see 
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Figure 1-7) (Just, Selzer et al. 1995; Just, Selzer et al. 1995; Just, Wilm et al. 
1995). In line with these observations, cells with reduced levels of UDP- 
glucose have been reported to be less sensitive to the toxins (Chaves-Olarte, 
Florin et al. 1996). 
TcdA and TcdB target isoforms of Rho, Rac and Cdc42, leading to actin 
condensation, rounding of cells, and membrane swelling and eventual 
apoptosis of the target cell. These toxins exert their activities on a wide range 
of cell types; however TcdB has been shown to exhibit a higher rate of 
enzymatic activity than TcdA, proving more cytopathic in some cell types 
(Chaves-Olarte, Weidmann et al. 1997). Another group have reported that 
UDP glucose hydrolysis by TcdB occurs at a rate z5 fold greater than that by 
TcdA (Ciesla and Bobak 1998). TcdA and TcdB appear to promote neutrophil 
migration whilst at the same time inactivate the primary cellular proteins 
needed to facilitate this process (Pothoulakis, Sullivan et al. 1988; Souza, 
Melo-Filho et al. 1997). 
Supporting earlier observations, the elucidation of crystal structures clarifying 
the RhoA/GDP and RhoA/GTP complex has provided vital information 
regarding the effects of glucosylation on these small GTPases and enabled a 
number of predictions to be cast (Wei, Zhang et al. 1997; Ihara, Muraguchi et 
al. 1998). Examination of the structure suggested glucosylation prevented 
Thr-37 forming a complex with the y phosphate on the bound GTP molecule. 
These findings support research shown previously, in particular the ability of 
TcdA and TcdB to glucosylate both the GDP-bound and GTP bound forms of 
Rho, with easier modification of GDP bound Rho (Just, Selzer et al. 1995). 
The group also observed TcdA modifying RhoA with the same mechanism as 
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TcdB (Just, Selzer et al. 1995; Just, Selzer et al. 1995; Just, Wilm et al. 
1995). In line with these observations, cells with reduced levels of UDP- 
glucose are less sensitive to the toxins (Chaves-Olarte, Florin et al. 1996). 
Collectively these studies defined TcdA and TcdB as glucosyltransferases 
- 
glucosylating Thr-37 in Rho and Thr-35 in Rac and Cdc42, preventing binding 
of GTP and subsequently blocking activation. 
The inactivation of Rho by TcdA and TcdB may result in any of the following 
steps being blocked; membrane localisation; guanine exchange factor 
interactions; or contact with downstream signalling proteins. 
As mentioned earlier, TcdA and TcdB are unable to elicit their cytotoxic effects 
extracellularly and therefore must be internalised into the host cell. Entry into 
the host cell is via receptor mediated endocytosis and requires an acidic 
endosome for access to the cytosol (Florin and Thelestam 1986; Henriques, 
Florin et at. 1987; Mitchell, Laughon et at. 1987). Frisch and colleagues later 
demonstrated that the complete receptor-binding domain is necessary for 
binding-induced endocytosis (Frisch, Gerhard et at. 2003). 
1.11 The cell cycle 
In its simplest form the cell cycle can be described as a process by which cells 
copy their content and then divide into two identical cells. However this 
description fails to capture the complex series of events and chemical signals 
that are needed for the cell to grow, replicate its DNA and divide. A number 
of mechanisms monitor the progression to ensure errors are corrected or bring 
about cell death if errors remain. The malfunctioning of this regulatory 
60 
function caused by genetic mutations is seen in cancer, where the genetic 
mutations result in uncontrolled cell proliferation (Bury and Cross 2003). 
1.11.1 The cell cycle phases 
The eukaryote cell cycle progresses through four distinct phases, G1, S, G2 
and M, see Figure 1-6 
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Figure 1-6 The Cell Cycle 
In the first phase (G1) the cell grows. When it has reached a certain size it enters the phase of 
DNA-synthesis (S) where the chromosomes are duplicated. During the next phase (G2) the cell 
prepares itself for division. During mitosis (M) the chromosomes are separated and segregated to 
the daughter cells, which thereby get exactly the same chromosome set up. The cells are then back 
in G1 and the cell cycle is completed. Image taken from (Anon 2001) 
G1 or gap phase represents a critical period where the cell cycle can proceed 
with cell growth or decide the cell will enter GO (quiescence). Cell metabolism 
is at its highest level to prepare for the synthesis of DNA (Bury and Cross 
2003). The period of time a cell takes to progress through G1 is particularly 
variable and is the main determinant of the overall length of the cell cycle. 
The rapidly proliferating cells of intestinal epithelium spend around 11 hours of 
their total 24 hour cycle in the G1 phase (Bury and Cross 2003). 
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In S (synthesis) phase DNA replication occurs and usually takes around 8 
hours, however any damage to the DNA will extend this time (Howard 1953). 
During G2 or gap 2 phase, the cell will complete the DNA replication process 
by packaging the chromosomes and sister chromatids. The cell continues to 
grow and essentials proteins are synthesized for mitosis. 
Taking the shortest period of time, M phase makes up only 5% of time taken 
to complete a cycle (Bury and Cross 2003). The M phase can be split into 
mitosis, referring to the nuclear division and cytokinesis the subsequent 
formation of the daughter cells. Mitosis can further be split into five stages; 
prophase, prometaphase, metaphase, anaphase and telophase, each 
completing specific roles in nuclear division. 
1.11.2 Cell cycle control 
The cell cycle relies on signals from growth factors and other external stimuli 
and in the absence of suitable stimuli, cells in GO will not re-enter the cell 
cycle and daughter cells produced after cell division will enter GO and not 
undergo further division (Bury and Cross 2003). Once stimulated the cell 
cycle is completed in full, even if the initiating stimuli is removed. The ability 
of the cell to ignore external stimuli after initiation ensures the cell will not 
leave the cycle early, avoiding unfavourable outcomes (Blagosklonny and 
Pardee 2002). 
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The timepoint at which a cell becomes committed to division independent of 
further stimulation occurs 2-3 hour before the G1/S transition and it is termed 
the 'restriction point' (Pardee 1974). The 'restriction point' determines that 
fate of daughter cells resulting from mitosis and the mechanism controlling 
the balance between cell differentiation and proliferation (! bid, 1974). Once 
the cell has successfully passed this point a combination of intrinsic links and 
checkpoint pathways operate at key timepoints to halt progress until 
particular conditions have been achieved. 
The second checkpoint `replication checkpoint' operates during S-phase to 
ensure mitosis is halted until DNA replication is complete (Samuel, Weber et 
al. 2002). These specific checkpoint pathways monitor intracellular 
conditions and by recruiting three families of molecules; the cyclin dependent 
kinases (CDKs) and their regulators, the cyclins and the cyclin dependent 
inhibitors (CKIs) key transitions between phases in the cell cycle occur (Bury 
and Cross 2003). 
Four CDK molecules are known to effect cell cycle progression in humans; 
CDK 1,2,4 and 6 and different cyclins are responsible for activation and 
similarly are inhibited by different families of CDK inhibitors (ibld, 2003), see 
Table 1-5. 
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Table 1-5 Cyclin dependent kinases (CDKs) their activating cyclins and 
inhibitory cyclin dependent kinases (CKIs) 
Adapted from (Burn and Cross 2003) 
CDK Activating cyclin (s) Inhibitory CDKI family 
CDK 1 Cyclin-B 
CDK 2 Cyclin-A, Cyclin-E Cip/Kip 
CDK 4 Cyclin-D Cip/Kip, INK4 
CDK 6 Cyctin-D Cip/Kip 
Whilst CDK's are present throughout the cell cycle, they are unable to exert an 
effect until bound to their regulatory subunit, the cyclin. As with CDKs there 
are four different cyclins known to influence cell cycle control, cyclins 
-A, 
-B, - 
D and 
-E and as shown in Table 1-5, binding between cyclins and CDK's is 
type specific. It is also necessary for this signal to be inhibited and this is 
achieved using cyclin dependent kinase inhibitors (CDKI's). These inhibitors 
can be split into two main classes based on their structure and function and 
unlike the invariant nature of the CDK and cyclin, CDKI's are cell and tissue 
specific (Pardee 1974). 
The INK4 (`Inhibitor of CDK 4') family of proteins comprises p15, p16, p18 
and p19 and three proteins are found In the Cip/Kip ('CDK interacting protein' 
or 'kinases inhibitory protein') family, p21, p57 and p27 (Roussel 1999). As 
the name suggests, INK4 proteins compete with cyclin D for the regulatory 
subunit CDK4 and serve to negatively regulate cell cycle progression (ibid, 
1999). In fact, active CDK4/cyclin-D is required for progression past the 
restriction point and entry into the cell cycle. The Cip/Kip proteins are linked 
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to a diverse range of pathways including the involvement of p21 in cell cycle 
arrest when DNA is damaged via the p53 pathway and p27 is increased in 
response to a anti-mitotic signals and TGFß (Yue and Mulder 2001). 
The homeostatic balance of cyclins and CDKI's is dependent upon accurate 
transcription and timely proteolytic degradation (Clarke 2002). The correct 
functioning of these two processes ensures the smooth functioning and the 
avoidance of'mixed messages' throughout cell cycle progression. 
CDK 1 is responsible for the initiating mitosis and CDK 2,4 and 6 are involved 
in the progression of the cell through the restriction point in G1 and initiation 
of S phase(Bury and Cross 2003). 
1.11.3 The role of Rho GTPases in cell cycle progression 
As discussed previously the cell cycle moves through four successive phases. 
The transition from one phase to the next is controlled by cyclin- Cdk (cyclin 
dependent kinase) complexes which ensure timely and accurate progression 
by phosphorylating a set of substrates which includes members of the 
retinoblastoma (RB) proteins (Coleman, Marshall et al. 2004). GTPases are 
essential at all points in the cell cycle affecting key components via numerous 
mechanisms (ibid, 2004). 
Rho GTPases have been shown to influence the cell cycle at two specific 
phases: G1 progression and; the organisation of the microtubule and actin 
cytoskeletons during M phase (Jaffe and Hall 2005). 
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1.11.3.1 G1 progression 
Gi progression is ultimately controlled by the cellular levels of two types of 
cyclin-CDK complex, cyclin D/Cdk6 and cyclin E/Cdk2 and subsequently 
inhibited by binding to one of the Cip/Kip (`CDK interacting proteins' or 
`kinases inhibitory protein') p21, p27 and p57(Bury and Cross 2003). The 
cyclin D/Cdk4 complex can be inhibited by binding to the INK4A ('Inhibitor of 
CDK4'), p15, p16, p18 and p19 and Cip/Kip, p21, p27 and p57 (ibid, 2003). 
The largest body of research investigating the role of Rho GTPases on cell 
cycle progression has focused on the progression through G1. Whilst it is 
evident that inhibition of Rho, Rac or Cdc42 blocks G1 progression and 
microinjection of active Rho A, Rac1 or Cdc42 into quiescent cells induced G1- 
S phase progression (Olson, Ashworth et al. 1995), the mechanism appears to 
be cell-type dependent and establishing the pathways leading to this end have 
been difficult (Jaffe and Hall 2005). As mentioned earlier the cellular levels of 
cyclins and CDK inhibitors are key to G1 progression and the best understood 
pathway is the transcription of cyclin-Di by the Ras/ERK (extracellular signal- 
regulated kinases) pathway (Coleman, Marshall et al. 2004). Cyclin-D1 is 
usually the first cyclin to be expressed and levels increase during G1 (Klein, 
Campbell et al. 2008). To achieve the correct levels of cyclin-D at mid G1 
sustained ERK/MAPK activation is needed and therefore additional signals from 
adhesion to the ECM are essential (Assoian and Schwartz 2001). It is thought 
that many of the Rho GTPase effects on G1 progression are linked to the 
adhesion/anchorage dependent proliferation. Indeed, epithelial cell 
proliferation requires signals from integrins but is also strongly influenced by 
the cell-cell adhesion protein, E-cadherin (Fournier, Campbell et al. 2008). 
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It has been shown that whilst both Rac and ERK signaling induce cyclin D1, 
the timing of cyclin D1 gene expression is different (Klein, Campbell et al. 
2008). The Rac signal results in an early G1 phase expression of cyclin D1, 
however the ERK signaling resulted in mid G1 phase induction (Welsh, 
Roovers et al. 2001). Very little is known of the interplay between ERK and 
Rac activation of cyclin D1 as research has focused on different cell types or 
used different methods (Klein, Campbell et al. 2008). 
Active RhoA was found to be necessary for sustained ERK/MAPK activation 
(Welsh, Roovers et al. 2001) and ERK activity can regulate cip/kip family of 
cdk inhibitors (Yang, Klein et al. 2008). Inhibition of ERK activity blocks S- 
phase entry and increases p21 levels, however knocking down p21 using 
siRNA did not result in cell cycle progression (Klein, Campbell et al. 2008). 
Rho has also been shown to regulate Cdk2 inhibitors by attenuating high 
levels of p21 triggered by Ras (Jaffe and Hall 2005). At high levels, p21 and 
p27 inhibit cyclin E resulting in cell cycle arrest (Weber, Hu et al. 1997; Olson, 
Paterson et al. 1998). RhoA induced p21 transcription is mediated by cell 
type dependent signaling pathways (Roovers and Assoian 2003). Rac has also 
been linked to the induction of cyclin-Di (Klein, Yung et al. 2007), however in 
fibroblasts Rac-dependent induction of cyclin D1 is not seen unless Rho 
signaling is inactive (Welsh, Roovers et al. 2001). Rho inhibition blocks stress 
fiber formation and in cells without a need for intracellular tension the Rac- 
dependent gene expression of cyclin D1 is detectable (Fournier, Campbell et 
al. 2008). Rac-dependent expression of cyclin D1 early in G1 is not sufficient 
to support Rb phosphorylation and S phase entry and joint Rac/ERK 
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expression of cyclin D1 throughout G1 is required (Coleman, Marshall et al. 
2004). 
1.11.3.2 Mitosis and cytokinesis 
During mitosis the spindle positioning is arranged following interaction of 
Cdc42 with Par6 (Gotta, Abraham et al. 2001). The conformational change in 
Par6 by Cdc42 led to activation of aPKC (atypical protein kinase C) (ibid, 
2001). Inactivation of Cdc42 has also been linked to mitotic arrest (Yasuda, 
Oceguera-Yanez et al. 2004). 
The assembly of a cleavage furrow and an actin/myosin contractile ring marks 
the beginning of cell division and the end of mitosis and Rho plays a crucial 
role in the formation of these structures via at least three known effector 
proteins; ROCK, Citron kinase and mDia (Glotzer 2004). 
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Figure 1-7 Glucosylation and downstream effects 
UDP 
Rho GTPases are glucosylated at Thr37 (e. g. RhoA) or at Thr35 (e. g. Rac. Cdc42). Glucosylation 
blocks the active conformation of Rho GTPases and inhibits downstream signalling events 
controlled by the GTPases. Adapted from (Nottrott, Schoentaube et al. 2007) 
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CHAPTER 2 
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2 Materials and methods 
2.1 Toxin A purification 
2.1.1 Introduction 
The unique structure and activity of C. difficile toxin A has made possible the 
efficient purification of this protein. A number of purification protocols have 
been formulated (Sullivan, Pellett et al. 1982; Kamiya, Reed et al. 1989; 
Meng, Kamiya et al. 1993) and are widely used. These protocols utilize the 
temperature dependent specific binding of toxin A to Gala 1-3Galß1-4GlcNAc 
carbohydrate residues found on the bovine thyroglobulin molecule. Toxin A 
was found to bind to this residue at low temperatures (4°C) and dissociate at 
high temperatures (37°C). Exploiting this temperature dependent binding and 
utilizing a thermal affinity chromatographic procedure toxin A was separated 
from toxin B and other contaminants. Further purification used the negative 
charge of the toxin A molecule and employed two sequential anion exchange 
chromatography steps to remove traces of toxin B and any other remaining 
contaminants. 
2.2 Bacterial Culture 
2.2.1 Bacterial strains 
C. difficile, VPI 10463 (Toxinotype 0), a widely used reference strain was 
chosen for this study as it expresses the genes tcdA and tcd8 and produces 
active forms of toxin A and toxin B proteins. 
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2.2.2 Recovery of viable bacteria 
Clostridium difficile spores were retrieved from long-term storage in cooked 
meat broth (Oxoid). 50 NI of broth supernatant was mixed with the same 
volume of 70 % ethanol and left for 1 hour to ensure vegetative bacteria were 
destroyed. 20 pl of the resultant solution was streaked asceptically onto blood 
agar plates (Oxoid) and incubated anaerobically for 4 days at 37°C. 
2.2.3 Bacterial growth and harvesting 
C. difficile colonies grown on blood agar plates were transferred to universals 
containing 10 ml of brain heart infusion (BHI) broth (see Solutions 
- 
Appendix 
1), and incubated anaerobically at 37°C for two days. The purity of the 
culture was checked by inoculation of an aliquot of the bacterial suspension 
onto a blood agar plate and streaking to single colonies. After the preparation 
of five, one litre spouted flasks with visking dialysis tubing (pore size <12,400 
MW) suspended in 1 litre of BHI broth as shown in Figure 2-1, Phosphate 
buffered saline (PBS) (Sigma) was dialysed into the sterile tubing and the 
flasks autoclaved at 121°C for 20 minutes. To straighten out any creases in 
the tubing, sterile PBS was inoculated asceptically and the flasks left overnight 
to equilibrate. 5 ml of the bacterial harvest was pipetted into the dialysis 
tubing and the flasks incubated anaerobically at 37°C for 3-4 days. 
The contents of the dialysis tubing were centrifuged at 4,000 rpm for 30 
minutes and the bacterial pellet removed. The remaining supernatant was 
syringe filtered using a 0.2 um filter and stored at 4°C. 
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Figure 2-1 Schematic diagram of flask assembly 
Clostridium difficile bacterial suspension is inoculated aseptically into the dialysis membrane and 
following 3-4 days of anaerobic incubation, the bacteria and toxins are retained in the dialysis 
tubing. 
2.3 Protein purification chromatography 
2.3.1 Bovine thyroglobulin affinity chromatography column 
2.3.1.1 Column preparation 
A bovine affinity gel was prepared by dissolving 1250 mg of bovine 
thyroglobulin (Sigma) in 250 ml of 0.1 M morpholinepropane-sulphonic acid 
buffer pH 7.0 (Sigma) before allowing it to bind with 50 mis of Affi-Gel 15 
beads (Bio-Rad Laboratories) by overnight rotation at 4°C. The remaining 
active sites on the beads were blocked by treatment with 100 pl of 0.1 M 
ethanolamine (Sigma) for 30 minutes at 4°C before the gel was poured into a 
50 ml column (Amersham Biosciences). 
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Previously stored in sodium azide solution at 4°C, the thyroglobulin column 
was washed with 100-200ml of Tris buffer solution (TBS), (see solutions 
- 
Appendix 1). The filtered supernatant of cultured C. difficile was then applied 
to thyroglobulin column overnight at 4°C. Any unbound supernatant was 
washed from the column with TBS at 4°C. The column was then transferred 
to 37°C and allowed to warm for an hour. Warm (37°C) TBS was then run 
through the column to elute the bound toxin A. A 40 ml fraction was 
collected, syringe filtered and stored at 4°C. The column was then washed 
with 100 mis of acidic buffer followed by 100 mis of basic buffer (see solutions 
- 
Appendix 1 for both) at 37°C. The three step cleaning process removes any 
protein and / or contaminants from the column prior to storage. The column 
was then returned to 4°C and washed with TBS. Finally, the column was 
stored in 0.02% sodium azide/TBS solution. 
Crude toxin A eluted from the thyroglobulin column was dialysed overnight at 
4°C, in 20 mM TBS to remove excess salt. 
2.3.2 Anion-exchange chromatography 
Anion exchange chromatography uses the positively charged beads inside the 
column to bind the negatively charged protein of choice. This ionic interaction 
is broken and the protein is eluted using a NaCl gradient, see Figure 2-2. 
Using AKTA Purifier P900 (GE Healthcare) two sequential anion exchange 
chromatography runs were completed using ready prepared DEAE Q- 
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Sepharose (Amersham Biosciences, Uppsala, Sweden) and Mono Q columns 
(Amersham Biosciences). 
2.3.2.1 DEAE-Sepharose anion exchange chromatography 
The supernatant was syringe filtered using a 0.2 pm filter and degassed using 
helium. The sample was then injected into the superloop and passed through 
the DEAE (diethylaminoethyl, a weak anionic exchanger) Sepharose-FF 
column. Toxin A binds to the coated beads and all other proteins and 
contaminants pass through into the waste. Unbound proteins are washed out 
of the column and a 0-1.0 M salt gradient is subsequently passed through the 
column to elute toxin A, which was collected in fractions. A representative 
graph profiling the elution of toxin A is shown in Figure 2-3. A dot blot of 
fractions was completed to confirm the presence of toxin A, details of which 
can be in Figure 2-4. Toxin A positive fractions were pooled and dialysed 
against 20 mM TBS overnight at 4°C. 
2.3.2.2 Mono-Q anion exchange chromatography 
The pooled DEAE fractions (B13-D1) as identified in Figure 2-3 were syringe 
filtered using a 0.2 Nm filter; degassed using helium and injected into the 
superloop and this time passed through a Mono-Q (quaternary amine, a 
strong anionic exchanger) column. Fractions were collected after the elution 
using 0-1M NaCl gradient. Figure 2-5 illustrates a representative graph 
profiling the elution of toxin A from the Mono-Q column, a single peaked graph 
was representative of pure toxin A. A dot blot of fractions was completed to 
confirm the presence of toxin A in A9-B2, see Figure 2-6. 
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Figure 2-2 Ion Exchange Chromatography 
Ion Exchange Chromatography relies on charge-charge interactions, negatively charged toxin A 
binds to the positively charged resin in the column. The ionic interaction is broken using a NaCI 
gradient and the toxin A is eluted. 
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J B13-D1 Figure 2-3 DEAE-Sepharose anion exchange chromatography profile 
X axis displays mAU values measured at 280 nm: Y axis details volume passing through the 
column and fractions eluted. The peak represents purified protein eluted between fraction B 13 and 
D1. The linear line crossing the peak represents the NaCI gradient used to elute the bound protein. 
The toxin A started to elute when the NaCI gradient reached 6% and measured 22% at the peak of 
concentration. 
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Figure 2-4 Dot blot of DEAE-Sepharose eluted fractions 
Using fractions B13-DI, a positive control of previously purified toxin A and a negative control (BHI) broth. All fractions were confirmed to be toxin A when compared with positive control. 
The representative membrane shows an increase in immune-reactivity correlating with the peak 
shown in the profile Figure 2-3 
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Figure 2-5 Mono-Q anion-exchange chromatography profile 
X axis displays mAU values measured at 280 nm; Y axis details volume passing through the 
column and fractions eluted. The peak represents purified protein eluted between fraction A9 and 
B2. The linear line crossing the peak represents the NaCl gradient used to elute the bound protein. 
The toxin A started to elute when the NaCl gradient reached 14% and measured 22% at the peak of 
concentration. 
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Figure 2-6 Dot blot of Mono-Q eluted fractions 
Using fractions A9-B2, a positive control sample of previously purified toxin A and a negative 
control (BHI). All fractions were confirmed to be toxin A when compared with positive control 
The representative membrane shows an increase in immune-reactivity correlating with the peak 
shown in the profile Figure 2-5 
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2.4 Characterisation of purified toxin A 
2.4.1 Dot blot (immunoperoxidase system) using specific PCG-4 antibody 
The presence of toxin A in eluted fractions can be confirmed by using the 
specific binding of mouse PCG-4 monoclonal antibody to C. difficile toxin A 
using Vectastain Universal Elite ABC kit (Vector) and VIP Substrate kit for 
peroxidase (Vector). A schematic diagram outlining the dot blot protocol is 
shown in Figure 2-7. 
Using nitrocellulose membrane (GE Healthcare) with a +ve charge, 5 NI of 
each fraction was placed on the membrane and allowed to dry. The 
membrane was covered with TBS blocking buffer (see solutions 
- 
Appendix 1) 
and placed on a rocking platform overnight at 4°C. Toxin A (-ve charge) 
binds to the membrane and the milk protein in the blocking buffer blocks all 
other areas. 
The membrane was washed thoroughly using TBS wash buffer (see solutions 
- 
Appendix 1). PCG-4 (125 pg/mi) antibody was diluted 1: 20 with TBS wash 
buffer, poured over the membrane and incubated on a rocking platform at 
room temperature for 1 hour. The PCG-4 antibody binds specifically to toxin 
A. 
The membrane was washed with TBS wash buffer and covered with 
biotinylated secondary antibody (containing blocking serum and biotinylated 
affinity purified anti-mouse immunoglobulin) and incubated on a rocking 
platform at room temperature for 30 minutes. The biotinylated secondary 
antibody binds to the PCG-4. 
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The preformed avidin/biotinylated horseradish peroxidase macromolecular 
complex was prepared and left to incubate for 30 minutes before use. After 
washing the membrane to remove the biotinylated secondary antibody the 
pre-prepared avidin/biotin complex was poured over the membrane and left to 
incubate on the rocking platform at room temperature for 30 minutes. 
The membrane was washed once more. The horseradish peroxidase is 
visualized using peroxidase substrate, when prepared the peroxidase 
substrate was poured over the membrane. As soon as the colour developed 
the membrane was rinsed with water to end the reaction. When dry the 
membrane was scanned for future reference. 
2.4.2 Determination of protein concentration 
Early purification of toxins used the Nanodrop to determine protein 
concentration, however later purification run employed the Bradford Assay to 
determine total protein concentration. 
2.4.2.1 Using the Nanodrop 
In brief, the Nanodrop was blanked with nuclease free water, 1 pi of each 
fraction was analysed for protein concentration at 280 nm. Values are 
reported as concentration in mg/ml. 
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Nitrocellulose membrane with a +ve charge 
OOOD Protein sample applied to membrane and allowed to dry 
toxin A= 
Nitrocellulose membrane blocked with skimmed milk OOOO 
Primary antibody PCG-4 binds to toxin AV 
Biotinylated secondary antibody binds to PCG-4 
Avidin/Biotin horseradish peroxidase 
complex binds to secondary antibody. 
The horseradish peroxidase was visualised using 
peroxidase substrate. 
Figure 2-7 Schematic diagram of dot blot for toxin A 
Specific binding of primary antibody PCG-4 to Clostridium dii facile toxin A and the subsequent 
secondary antibody avidin/biotin complex (Vectastain Universal ABC Kit, Vector) visualized 
using peroxidase substrate (VIP Substrate Kit, Vector). 
2.4.2.2 Using Bradford Assay 
The Bradford Assay is a standard colormetric assay that can, when used with 
a selection of known standards and standard curve prepared, calculate the 
concentration of protein in a solution. The assay is based on the observation 
that the absorbance maximum for an acidic solution of Coomassie Brilliant 
Blue G-250 (Sigma) shifts from 465 nm to 595 nm when binding to protein 
occurs. Both hydrophobic and ionic interactions stabilize the anionic form of 
the dye, causing a visible color change. 
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In brief, 10 pi of 25,125,250 and 500 pg/ml and the unknown samples were 
placed into a 96 well plate in duplicate and 300 pi of Coomassie Brilliant Blue 
added to each well. The absorbance was measured at 595 nm using Bench 
Mark Plus microplate spectrophotometer (Biorad, UK). and the standard curve 
plotted. The R2 value was checked and linear equation established. Using this 
equation 
- 
total protein concentration of the unknown samples was calculated 
using the absorbance measured at 595 nm. Dilutions were factored and the 
mean reported. 
2.4.3 Cytotoxicity Assay 
Fractions of purified toxin A were characterised by their ability to induce 
rounding in Vero cells (African Green Monkey (Cercopithecus aethiops) kidney 
cells]. Vero cells were obtained from American Type Culture Collection (ATCC) 
(Cat No. CCL-81) and used at passage 20-25. Using the method outlined in 
(Donta, Sullivan et al. 1982), a series of 10 fold dilutions in supplemented 
DMEM was applied to a confluent cell monolayer. The cells were visualized 
after 24 hours and the toxin titre determined, defined as the concentration of 
toxin able to induce 50% cell rounding (Donta, Sullivan et al. 1982). Cell 
culture methods start from page 84. 
2.4.4 Polyacrylamide gel electrophoresis 
2.4.4.1 Thegel 
The homogeneity of the purified product was identified by native 
polyacrylamide gel electrophoresis (PAGE). 
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A resolving gel was prepared (see solutions in Appendix 1) and poured into 
the assembled apparatus (BioRad), a comb inserted, layered with water and 
left for 30 minutes to polymerise. When set, the gel was placed into 
electrophoresis apparatus (BioRad) and the reservoirs filled with 1x running 
buffer (25 mM Trisma, 0.192 M glycine in dH2O). Each 10 ul sample was 
prepared by the addition of 10 ul of loading buffer (0.01% bromophenol blue 
in glycerol). A high molecular weight protein marker was also prepared and 
10ul of this marker and samples were added to each well. A constant voltage 
of 100 V was applied for 100 minutes. 
2.4.4.2 Coomassie Staining 
The gel was removed from the apparatus and stained by soaking in Coomassie 
staining solution (0.25 g Coomassie brilliant blue (Sigma), 90 ml methanol, 10 
ml acetic acid) for 1 hour. 
The gel was then destained by repeated washes with destaining solution: (10 
methanol & 10 % acetic acid in 500 mis distilled water) until the solution 
ran clear and the background staining was minimised. The gel was stored in 
distilled water until the image was scanned. 
2.4.4.3 Silver Staining 
- -- --- -------- - ------ ---------- - The gel was removed from the apparatus and using a silver staining kit 
(BioRad) the gel was immersed into the fixative (40% methanol/10% acetic 
acid v/v for 30 minutes). Whilst fixing the oxidizer and silver reagent were 
83 
made up using 5 ml of the oxidizer (10-fold solution containing potassium 
dichromate and nitric acid) and silver reagent (10 fold solution containing 
silver nitrate) stock solutions and 45 ml of dH20 and left at room temperature. 
In addition the developer (powder containing sodium carbonate and 
paraformaldehyde, 32 g dissolved in iL distilled water) was also prepared. 
The fixed gel was completely immersed in the oxidizer for 5 minutes followed 
by 3 water washes to remove yellow colouring from the gel and then 
immersed in the silver reagent for 20 minutes. The gel was rinsed and 
enough developer poured to immerse the gel for 30 seconds or until a smoky 
brown precipitate was visible. The developer was removed and replaced 
repeatedly until the desired intensity of banding was achieved and then the 
reaction was stopped by immersing the gel in a 5% acetic v/v solution for 15 
minutes. The gel was then scanned. 
2.4.5 Purified toxin A- Storage 
Toxin A was labelled with the eluted fraction reference and stored in 100 pl 
aliquots at 
-8011C. 
2.5 Cell Culture 
2.5.1 Mammalian cell lines 
Vero cells (African Green Monkey (Cercopithecus aethiops) kidney cells), HT29 
cells (human intestinal epithelial cells) and Caco-2 cells (human intestinal 
epithelial cells) were obtained from ATCC (Cat No. CCL-81; HTB-38 and HTB- 
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37) respectively. Vero cells were used at passage 20-25, HT29 cells at 
passage 145-150 and Caco-2 cells at passage 80-85. 
2.5.2 Primary human intestinal Myofibroblasts 
2.5.2.1 Isolation from intestinal tissue 
Fresh, histologically normal colonic mucosal were obtained (after informed 
consent) from patients undergoing resection of the large bowel, median age of 
tissue donors was 69 yrs (range 47-87 yrs; 6 female; 8 male). Ethical 
committee approval was provided by Nottingham Research Ethics Committee 
(REC Q1020310). Intestinal myofibroblasts were isolated and established in 
pure culture as previously described (Mahida, Beitinger et al. 1997). The 
myofibroblasts used in these experiments were isolated by Mrs J. Webb and 
immunohistochemistry performed by K. R. Hughes. The tissue was initially 
cleaned by washing three times in 20 ml Hanks Buffered Saline Solution 
(HBSS) w/o Mg+ & Ca+ (Gibco) and surface epithelial cells were detached 
from mucosal samples by three sequential treatments with 1 mmol 
Ethylenediaminetetraacetic acid (EDTA), with intermediate wash cycles using 
cold HBSS w/o Mg+ Ca+ (Gibco). The remaining tissue was washed five 
times with HBSS with Mg+ & Ca+ and plated into culture dishes in Roswell 
Park Memorial Institute media (RPMI) supplemented with 10% FCS. 
Myofibroblasts migrate via the basement membrane pores of the mucosal 
samples denuded of epithelial cells to form colonies in the culture dish 
(Mahida, Beltinger et al. 1997). The tissue was removed and the media 
changed to DMEM (Sigma) supplemented with 10% fetal calf serum (FCS) and 
1% non-essential amino acids (NEAA), (Gibco). The cells proliferate to 
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establish a monolayer in the culture dish and are then trypsinised with 0.1% 
trypsin and transferred to a normal cell culture flask. The isolated 
myofibroblasts can be maintained over many passages and for this research 
they have been studied at passages 3-7. To confirm the myofibroblast 
phenotype, immunohistochemical staining of cells fixed onto glass coverslips 
confirmed the presence of smooth muscle actin and vimentin and the absence 
of desmin, see Figure 1-2-8. 
2.5.2.2 Culture Medium 
All cells were cultured in Dulbecco Modified Eagle Medium 
- 
DMEM (Gibco) 
supplemented with 10% fetal calf serum (FCS), 200 mM L-Glutamine and 
antibiotics; penicillin (100 ng/ml), streptomycin (100 ng/ml) and gentamycin 
(50 ng/ml) (PSG). In addition to the above additions, Caco-2 cell medium 
was also supplemented with holotransferin (Sigma) and Myofibroblast medium 
supplemented with 1% non essential amino acids (NEAA). 
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Isolate: MF159/N/L 
Control 
Isolate: MF136/N/L 
a-SMA 
.. 
Desmin 
Control 
Figure 1-2-8 Immuno-histochemical staining of intestinal myofibroblasts 
Intestinal myofibroblast characterisation of two isolates indicate the presence of alpha-smooth 
muscle actin and vimentin and the absence of desmin, performed by K. R. Hughes. 
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2.5.2.3 Resurrection of cells 
Cells were removed from nitrogen storage, thawed rapidly in a 37°C 
waterbath. Cells were then transferred into a 75 cm2 flask (Nunc) containing 
15 ml of supplemented DMEM (Gibco) before incubation at 37°C, 5% CO2.24 
hours later the media in the flask was replaced and cells re-incubated at 37°C, 
5% CO2 until confluent. 
2.5.2.4 Cell passage 
Upon confluence, the used media was discarded from Caco-2, HT29 and Vero 
cells and the cells washed with 2 ml 0.25 % trypsin (x10 Trypsin (Gibco) and 
versine (0.02% EDTA in PBS pH7.2)), before incubation in the presence of 3 
ml trypsin at 37°C, 5% CO2 for 10 minutes. Detached cells were removed 
from the flask and together with 7 ml of new media pelleted by centrifugation 
at 1000 rpm for 5 minutes and the resultant supernatant discarded. The cell 
pellet was then resuspended in 15 ml of new media and 5 ml aliquots seeded 
into three 75 cm2 flasks containing 10 ml of fresh media. Cells were 
incubated at 37°C, 5% CO2 until confluent. Myofibroblast cell passage used a 
less concentrated solution of trypsin (0.1 %) and the cells were not 
centrifuged, the 3 ml of trypsin containing the cells was transferred into new 
flasks containing 19 mis of warmed media. Vero cells were split 1: 2 
- 
1: 7; 
Caco-2 cells split 1: 2 
- 
1: 4; HT29 cells spilt 1: 2 
- 
1: 5; and myofibroblasts 
split 1: 2 
- 
1: 3. A confluent 75 cm2 flask of Caco-2, HT29 and Vero cells held 
approx 4x 107,4 X 107,7 x 106 and 1x 106 cells, respectively. 
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2.5.2.5 Cell freezing 
Confluent cells were trypsinised as previously described and resuspended in 7 
ml of fresh, warm DMEM. The cells were pelleted by centrifugation at 1000 
rpm for 5 minutes and the supernatant discarded. The pellet was 
resuspended in the residual media and 1 ml of freezing media (100 pl 
Dimethyl Sulphoxide (DMSO, Sigma) in 900 pl FCS (Gibco). The cells were 
frozen immediately at 
-80°C overnight before transfer to long-term nitrogen 
storage. 
2.5.2.6 Culture in 24-well plates 
Confluent cells in a 75 cm2 flasks were trypsinised as previously described and 
a cell count conducted. Cells were subsequently resuspended in 25 ml of 
fresh media to achieve 1x 104 cells/ml and 1000 pl of the cell suspension 
aliquoted into each well of a 24-well plate (Costar, UK). Plates were incubated 
at 37°C, 5% CO2 until confluent. 
2.5.2.7 Culture in 96-well plates 
Confluent cells in a 75 cm2 flasks were trypsinised as previously described and 
a cell count conducted. Cells were subsequently resuspended in 10 ml of, 
fresh media to achieve 1x 104 cells/ml and 100 pl of the cell suspension was 
aliquoted into each well of a 96-well plate (Costar, UK). Plates were incubated 
at 37°C, 5% CO2 until confluent. NB Vero cells were seeded at 1x 105 
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2.5.2.8 Culture in 6-well plates 
Cells confluent in a 75 cm2 flasks was trypsinised as previously described and 
resuspended in 25 ml of fresh media. 4 ml of the cell suspension was 
aliquoted into each well of a 6-well plate (Costar, UK). Plates were incubated 
at 37°C, 5% CO2 until confluent. 
2.6 Morphological assessment 
Phase contrast microscopy was used to investigate morphological changes in 
response to toxin exposure and micrographs taken using a Kodak 206 camera 
attached to the microscope. 
2.7 Cell viability 
Cell viability was established using a selection of methods that assessed 
chemical properties and physical characteristics. 
2.7.1 MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) 
assay 
3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrolium bromide, MTT (Sigma) is a 
water soluble tetrazolium salt, yellow in colour used in a colorimetric assay to 
establish cell viability (Mosmann 1983). By dissolving the MTT, 
dehydrogenase enzymes produced in metabolizing cells convert the soluble 
tetrazolium salt to insoluble purple formazan crystals that can be solubilised 
using acid/SDS (5% SDS in 0.01 M HCI) and the absorbance of the converted 
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dye can then be read spectrophotometrically at 570 nm (recommended 
wavelength is 550-600 nm) (Mosmann 1983). 
Stock solution was prepared using MTT powder and distilled water to a 
concentration of 5 mg/ml. The solution was syringe filtered through a 0.2 pm 
filter and stored at 2-8 °C or frozen for use at a later date. 
The stock solution was diluted 1: 10 using specific cell culture medium and 
following the removal of the media covering the cells to be assessed, 500 pl of 
the MTT/DMEM solution was added to each well and incubated at 37°C, 5% 
CO2 for 4 hours. After which, 500 pi of acid SDS lysis buffer was added to 
each well and returned to the incubator overnight. 
Transferring the content of each well into a1 ml eppendorf the cell debris was 
removed by centrifugation at 130,000 rpm for 10 minutes. 100 pl of each 
eppendorf was transferred into a 96-well plate and the absorbance of the 
converted dye was measured spectrophotometrically at 570 nm using a Bench 
Mark Plus microplate spectrophotometer (Biorad, UK). 
2.7.2 Trypan blue exclusion assay 
The trypan blue exclusion assay is simple method used to establish the 
number of viable and non viable cells in a given sample. By mixing the 
sample with an equal volume of trypan blue dye viable cells excluding the dye 
and non-viable cells stained blue (due to a breakdown in their cell membranes 
and increased permeability) can be counted and the percentage of viable cells 
calculated. 
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Cells were harvested by trypsinisation using 0.25% trypsin (Sigma) and 20 PI 
of the cell suspension mixed with an equal volume (20 p1) of 0.08 % trypan 
blue solution (Sigma). 20 pi of the trypan blue stained cell suspension was 
transferred to the edge of the haemocytometer and allowed to spread evenly 
by capillary action. 
Using the 10 x objective of the light microscope the 16 square grid was 
focused on (total area 1 mm3) and the total number of unstained (viable) cells 
and blue (dead) cells counted separately in four (0.1 mm3) squares. 
Calculating the average cells in 0.1 mm3, the total number of cells is equal to 
the average cell number in 0.1 mm3 multiplied by the dilution factor and the 
total volume in one square (10"' cm3). Cell viability was calculated using the 
following equation and reported as percentage cell viability. 
% cell viability = total viable cells (unstained) x 100 
Total cells (stained + unstained) 
2.7.3 DNA and Cell Cycle Analysis using Propidium Iodide and flow 
cytometry 
The propidium iodide (PI) flow cytometric assay (Nicoletti, Migliorati et al. 
1991) was used to investigate DNA/cell fragmentation and cell cycle 
progression. Propidium iodide, a fluorogenic compound, binds 
stoichiometrically to nucleic acids and the fluorescence emitted, measured by 
Fluorescence Activated Cell Sorting (FACS), is directly proportional to the DNA 
content of the cell. All eukaryotic cells progress through a cycle of DNA 
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replication and nuclear/cell division separated by two gap phases (G1 and G2) 
and by using the data compiled from PI cytometric assay and the Cylchred, 
cell cycle analysis program based on algorithms by (Ormerod, Payne et al. 
1987; Watson, Chambers et at. 1987) written by Terry Hoy, analysis of cell 
cycle progression and DNA fragmentation completed. 
2.73.1 Fixing cells 
Cells were harvested by trypsinisation using 0.25% trypsin (Caco-2 and HT29 
cells) or 0.1% trypsin (primary human colonic myofibroblasts). The cells 
(including non-adherent cells removed with the culture media) were pelleted 
by centrifugation at 1000 rpm for five minutes. The pellet was re-suspended 
in 1 ml PBS and pelleted by centrifugation at 1000 rpm for five minutes. This 
washing process was carried out twice. The remaining pellet was resuspended 
in 1 ml of ice cold 70% v/v ethanol and placed on ice. Samples were stored at 
-20 °C and all timepoints stained and analysed together. 
2.7.3.2 Propidium Iodide staining 
FACS tubes containing suspended cells in ethanol were pelleted by 
centrifugation at 1000 rpm for 5 minutes and the pellet resuspended in 1 ml 
of PBA [Phosphate buffered solution with 0.1% BSA (Bovine Serum Albumin, 
Sigma) and sodium azide] and pelleted by centrifugation twice. The pellet 
was finally resuspended in 500 pl of PBA; 5 pl of RNase solution (DNase Free, 
Sigma) added to remove any contaminating RNA and 25 NI of Propidium 
iodide solution (Sigma) placed in each tube. The cells were then incubated for 
20 minutes at 37 °C and placed on ice prior to analysis by flow cytometry. 
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2.7.3.3 Flow Cytometry 
Using the BD Coulter 500, fluorescence emitted and side scatter of PI stained 
cells (488 nm excitation) was measured using the red fluorescent channel 
(>600 nm) and 20,000 events collected. The data was plotted side scatter 
verses fluorescence. Using WinMDi 2.9, the data was converted into a scatter 
plot and a region drawn on the plot to identify single cells and remove cell 
debris. The gated region was subsequently used to produce a histogram. 
2.7.3.4 Analysis of WinMDl histograms using Cylchred 
Raw data files (histograms) prepared using WinMDI were entered into entered 
into Terry Hoy's cell cycle analysis program, Cylchred [written by Terry Hoy 
based on mathematical algorithms (Ormerod, Payne et al. 1987; Watson, 
Chambers et al. 1987), downloaded from 
http: //archive. uwcm. ac. uk/uwcm/hg/hoy/software. html]. Each histogram 
was analyzed and the software provided total number of events and sub G1 
events. In addition, the software provided a percentage value for events in 
each phase of cell cycle following the subtraction of events in the sub-G1 
region. 
The % of sub G1 events was calculated using the following equation: 
(100 / total events) x events in sub Gi 
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2.8 Western Blot analysis using Sodium Dodecyl Sulphate 
- 
Poly- 
acrylamide gel electrophoresis (SDS-PAGE) 
The SDS-PAGE is used to separate proteins based on their size and 
electrophorectic mobility and in this study the technique has been used to 
investigate the presence of intracellular proteins and confirm the homogeneity 
of purified toxin B. The latter of which will be discussed in Chapter 4. The 
SDS-PAGE gel contains two distinct sections; the resolving gel; and the 
stacking gel. The components of the stacking gel remain constant, however 
the percentage resolving gel is dependent on the molecular weight of the 
protein of interest. The intracellular proteins of interest are between 20-25 
kDa and the loading control 0-actin 49 kDa and therefore a 10% resolving gel 
was chosen. Details of component chemicals and solutions needed to prepare 
the gels are provided in Appendix 1. 
2.8.1 The Gel 
A 10% resolving gel was prepared and poured into the assembled apparatus 
(BioRad). A thin layer of iso-propanol was placed onto the resolving gel and 
left for 30 minutes to polymerise. The isopropanoi was removed by washing 
with dH2O and any excess moisture was removed with a small piece of blotting 
paper. The stacking gel was prepared and poured onto the resolving gel layer 
and a comb inserted. The gel was left for 30 minutes to polymerise. When 
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set, the gel was placed into electrophoresis apparatus (BioRad) and the 
reservoirs filled with running buffer. 
2.8.2 Whole cell lysate 
- 
Sample Preparation 
Control and toxin treated cell lysates were prepared by removing the medium, 
washing the cells with warmed PBS and lysing the cells with Cellytic (Sigma); 
25 pl placed into each well and using a cell scraper the content of each well 
was removed and centrifuged for five minutes at 10,000 rpm to remove cell 
debris. The lysate was stored at 
-20°C. The samples were defrosted and 
concentrated using Amicon Ultra 0.5 ml centrifugal filter devices (Millipore) 
and the total protein concentration ascertained using the Bradford Assay. 
Samples were diluted with ice cold PBS to give maximum identical total 
protein concentration. The diluted cell lysates were then mixed 1: 1 with 
Laemelli sample buffer (4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 
0.004% bromphenol blue and 0.125 M Tris HCI, pH approx. 6.8) and placed in 
a block heated to 100 °C for five minutes. When cool, 17 pl of the sample 
was loaded into a well and 5 pl of a full range molecular rainbow marker was 
loaded into the spare well. A constant voltage of 100 V was applied for 100 
minutes. 
2.8.3 Transfer for Western Blot 
After 100 minutes the gel was removed and prepared for transfer onto PVDF 
(Polyvinylidene Diflouride) membrane by soaking in 25 mis of transfer buffer. 
The PVDF membrane was activated by immersion in 100% methanol for 15 
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seconds, followed by a2 minute dH2O wash and a5 minute immersion in 
transfer buffer (see Appendix 1). The gel and membrane were sandwiched 
together, covered with transfer buffer and a variable voltage not exceeding 
0.2 amps (100 V) applied for 50 minutes. 
2.8.4 Membrane processing 
After the proteins are transferred onto the PVDF membrane all remaining 
protein interaction sites were blocked by incubating the membrane in blocking 
buffer (2g skimmed milk powder dissolved in TBS wash buffer, see Appendix 
1) for one hour at room temperature for whole cell lysate membranes and 
overnight at 4°C for ß-actin loading control membranes. The blocking buffer 
was removed and the membranes incubated with their respective primary 
antibodies; 1 hour at room temperature for toxin B membranes and ß-actin 
loading control membranes and overnight at 4°C for whole cell lysate 
membranes specifically Rho A and Rac-1 primary antibodies. 
The membrane was washed with wash buffer and covered with biotinylated 
secondary antibody (containing blocking serum and biotinylated affinity 
purified anti-mouse immunoglobulin) and incubated on a rocking platform at 
room temperature for 30 minutes. The biotinylated secondary antibody binds 
to the primary antibody. 
The preformed avidin/biotinylated horseradish peroxidase macromolecular 
complex was prepared and left to incubate for 30 minutes before use. The 
biotinylated secondary antibody was removed, the membrane washed and the 
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pre-prepared avidin/biotin complex poured over the membrane and left to 
incubate on the rocking platform at room temperature for 30 minutes. 
The membrane was washed and the horseradish peroxidase visualized using 
peroxidase substrate. The peroxidase substrate was poured over the 
membrane and as soon as the colour developed the membrane was rinsed 
with water to end the reaction. When dry the membrane was scanned. 
2.9 Statistical analysis 
Statistical analysis and graphical presentation was performed on GraphPad 
Prism v. 4 (GraphPad Software, Canada) using one way analysis of variance 
(ANOVA) and the students t-test. Statistical significance was reported when 
p=<0.05. 
98 
CHAPTER 3 
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3 Caco-2 cells are more sensitive to toxin A induced cell 
death than HT29 
3.1 Introduction 
Intestinal epithelial cells are believed to be the first host cells that interact 
with luminal C. di>fcile toxins. Responses by the epithelial cells (e. g. loss of 
barrier function due to cell death) may determine the severity of mucosal 
inflammation that develops. Currently, there is little information regarding 
differences between epithelial cell types in their responses to C. difficile 
toxins. It has been reported that areas of mucosa and underlying lamina 
propria from individuals with C. difficile associated disease can appear 
normal despite adjacent areas of ulceration and pseudo-membrane 
formation. Investigation of epithelial response may go some way to 
explain why individuals colonized with toxigenic C. dicile remain 
asymptomatic and others develop fulminant colitis. 
C. difficile toxin A exerts a dramatic effect on mammalian cell physiology, 
altering cell signalling events and ultra-structural maintenance. The first 
and most obvious impact on cell physiology in cells exposed to toxins A 
and B is the `cytopathic response'; loss of structural integrity caused by 
actin reorganisation (Fiorentini, Malorni et al. 1990); opening of tight 
junctions, and; cell rounding. Exposure of cultured human intestinal 
epithelial cell monolayer's to TcdA and TcdB reduced trans-epithelial 
resistance and increased epithelial cell permeability, with flux studies 
identifying that the permeability failing occurred at the intercellular tight 
junction (Hecht, Pothoulakis et at. 1988; Hecht, Koutsouris et al. 1992). 
Alterations in cell surface projections and rearranged microvilli are 
observed in toxin A treated cells (Chang, Lin et at. 1979) and clear 
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actinomorphic changes can be seen using electron microscopy (Fiorentini, 
Malomi et al. 1990). 
These structural and functional alterations are believed to be due to toxin 
induced modifications of the Rho proteins, more specifically the mono- 
glucosylation of Rho, Rac and Cdc42 using UDP-glucose as a co-substrate. 
Nusrat and colleagues found that inactivation of Rho by toxin A led to loss 
of organisation in the perijunctional F-actin ring in T84 colonic cell 
monolayers, resulting in the reduction of TER and an influx of solutes into 
the epithelium (Nusrat, Giry et al. 1995). The substrate targets Rho, Rac 
and Cdc42 also regulate other cellular events outside of the actin 
cytoskeleton (Prepens, Just et al. 1996; Schmidt, Rumenapp et al. 1996; 
Caron and Hall 1998; Brito, Fujji et al. 2002; Hippenstiel, Schmeck et al. 
2002). 
Following the dramatic change in morphology, the second impact of C, 
difficile toxins on the host cell is the 'cytotoxic response', cell death. Cell 
death following toxin A intoxication occurs via apoptosis but our 
understanding of the mechanisms that precede this are still being 
unraveled. Some consider cell death as dependent on Rho inactivation 
with inactivation of Rho in an endothelial cell line resulting in the activation 
of caspase-3 and caspase-9 (Hippenstiel, Schmeck et al. 2002). Whilst 
others argue that apoptosis is independent of Rho glucosylation with toxin 
A inducing the apoptotic pathway in T84 cells via the release of caspase-3, 
-6, -8, -9 and Bid activation (Brito, Fujji et al. 2002) and others reporting 
an accumulation of toxin A at the mitochondria prior to any detectable 
glucosylation of Rho proteins (He, Hagen et al. 2000). Similarly Carneiro 
and colleagues found that toxin A exposed T84 cells induced caspases 6,8 
and 9 prior to caspase 3 activation and induced Bid cleavage using a 
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caspase independent mechanism (Carneiro, Fujii et al. 2006). In non- 
transformed human colonic NCM460 cells exposed to toxin A, apoptosis 
involved p38 activation of p53. The subsequent induction of p21 resulted 
in cytochrome c release and caspase-3 activation (Kim, Kokkotou et at. 
2005). 
To confuse the issue further; others claim that both Rho inactivation and 
caspase independent signalling facilitate apoptosis in cells exposed to C. 
difficile toxin A. It may be that the pathway to apoptosis is also cell 
specific. 
Supporting the cell-specific effect mouse teratocarcinoma cells were more 
sensitive than CHO cells when exposed to TcdA and it was proposed that 
increased expression of TcdA specific carbohydrate receptors may be 
responsible (Tucker, Carrig et al. 1990). Research conducted by Chaves- 
Olarte and co-workers sought to establish why TcdA and TcdB displayed 
different cytotoxic potency despite intoxicating target cells by the same 
mechanism. Using Don and T84 cells, two main differences were 
identified, with differing enzymatic activities highlighted as the main 
determinant and receptor binding difference contributing less (Chaves- 
Olarte, Weidmann et al. 1997). 
A cell specific response to C. difficile toxins have been mentioned 
previously by others however direct comparison of both toxins on multiple 
cell types is poorly documented. We have previously studied the response 
of several intestinal cell types together with primary tissue biopsies and 
whilst not primary objectives of this study a differential response was 
evident with significant differences in toxin A induced cell death. This 
study concluded that epithelial cell death occurred via apoptosis as a result 
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of detachment from the basement membrane. Cells adherent to each 
other survived longer, than single cells, despite basement membrane 
detachment (Mahida, Makh et al. 1996). Also of relevance, we reported a 
dose dependent link to histological severity. Intestinal epithelial cells 
incubated with toxin A express differential levels of TGF-ß and IL8 
depending on the incubated toxin A concentration (Mahida, Makh et al. 
1996). 
The aim of this work is to compare responses to C. difficile toxin A by 
Caco-2 and HT29 human intestinal epithelial cells. 
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3.2 Purification of toxin A 
Toxin A was purified by application of cultured C. difficile (VPI 10463) 
supernatant samples to a bovine thyroglobulin affinity column. Toxin A- 
containing fractions, which demonstrated cytotoxicity in Vero cells and dot 
blot positive, were subsequently subjected to two sequential anion 
exchange chromatographic steps as detailed in Chapter 1,2.1. 
Using the fractions of purified toxin Aa number of assessments were 
carried out to ascertain purity, concentration and cytotoxicity prior to use. 
3.2.1 Protein Concentration 
The protein concentration of the final purified toxin A fractions (Batch 16) 
was calculated to be within the range of 0.04 
- 
1.70 mg/mI (Figure 3-1). 
1.8 
1.6 
1.4 
1.2 
c 
l0 1 ° 
0.8 
c 0.6 
c 0.4 
0.2 
0 
Figure 3-1 Concentration of purified toxin A fractions 
The X axis displays codes for fractions eluted from the Mono-Q column from Batch 16. Toxin 
concentration peaked at fraction All. The Y axis shows concentration of measured sample 
(mg/ml) when measured using Nanodrop at A280 
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Fraction 
3.2.2 Native Polyacrylamide gel electrophoresis (PAGE) 
To check the purity of the purified toxin A and to estimate its molecular 
weight under non-denaturing conditions a Native PAGE gel using a 5% 
resolving gel was performed with fractions, A10, All, A12, A13 and A14 
eluted from Mono-Q column (see Figure 2-3); concentration 0.77 mg/ml; 
1.70 mg/ml; 0.58 mg/ml; 0.31 mg/ml; and 0.17 mg/ml, respectively. A 
high weight molecular weight protein mixture (Amersham Biosciences) was 
used as a marker. 
ftwo 
-- 
. 
"MW g44jjAl4 
Toxin A- 616 kDa 'r'ý 
669 kDa thyroglobulin 
440 kDa ferritin 
232 kDa catalase 
140 kDa lactate dehydrogenase 
Figure 3-2 Native PAGE gel of purified toxin A fractions 
Electrophoresis was performed on five fractions of purified toxin A, on a5% resolving gel. A 
high weight molecular protein mixture (Amersham Biosciences) (M) containing 76 gg of 
thyroglobulin (Mw 669 000 Da), 50 µg of Ferritin (Mw 440 000 Da), 36 µg of Catalase (Mw 
232 000 Da), 48 µg of lactate dehydrogenase (Mw 140 000 Da) and 40 gg of Albumin (Mw 66 
000) was used as a marker. Toxin A exists as a dimer and therefore a single band was seen 
close to the thyroglobulin band at 669 kDa. 
As can be visualised in Figure 3-2 comparison of sample bands against the 
high molecular weight protein marker shows a single distinct band at 
approximately 600 kDa, corresponding to a dimer of 308 kDa toxin A 
protein. 
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3.2.3 Cytotoxic activity of purified toxin A 
As discussed in Chapter 2 section 2.4.3 the cytotoxic activity of purified 
toxin A is determined using the Vero cell assay and the cytotoxicity titre is 
determined following the incubation of Vero cell monolayers to serial 
dilutions of toxin A for 24 h. At 24 h, the lowest serial dilution to induce 
50% rounding in each fraction was identified (Table 3-1). The 
concentration of purified toxin A that elicited the cytotoxic effect were 
calculated to be within the range of 0.58 
- 
400 pg/ml. 
Table 3-i Cytotoxic activity of purified toxin A fractions 
Lowest 
Concentration Maximal dilution at concentration at Batch Fraction which 50% rounding which 50% (mg/ml) 
visible at 24 hours rounding occurs 
(pg/mi) 
16 A 10 0.77 10'' 0.77 
All 1.70 10'9 1.70 
A12 0.58 10'9 0.58 
A13 0.31 10-1 3.1 
A14 0,17 10"' 17 
A15 0.38 10'' 38 
BI 0.04 10-6 400 
B2 0.04 10-6 400 
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3.3 Intestinal epithelial cell response to C. difficile toxin A 
Early experiments investigated the time- and dose-dependent response of 
intestinal epithelial cells Caco-2 and HT29 to various concentrations of 
purified toxin A. 
Using a previously characterized fraction of toxin A with a known pre- 
frozen concentration of 1.16 mg/ml, the toxin concentration was checked 
for possible degradation during storage using the Nanodrop at 280 nm and 
diluted in cell specific medium to give 1000 ng/ml; 100 ng/ml; 10 ng/ml; 1 
ng/ml and 0.1 ng/ml. Removing the medium from Caco-2 and HT29 cells 
grown to confluence, 1 ml of each diluted concentration was added (in 
triplicate) to the cells and the plates re-incubated at 37°C, 5% CO2. 
Control wells were also prepared, containing media only. Morphological 
assessments using light microscopy were made at 30 minutes, 1 h, 2 h, 4 
h, 6 h, 24 h, 48 h and 72 h as described in Chapter 2. 
3.3.1 Cell cytotoxicity established using MTT assay 
Cell cytotoxicity was measured in Caco-2 and HT29 cells incubated with 
varying concentrations of C. difficile toxin A at 48 h and 72 h using the 
MTT assay as described in Chapter 2, section 2.7.1 
3.3.2 Cell viability using Trypan Blue Exclusion Assay 
Cell viability was measured in Caco-2 and HT29 cells incubated with 
varying concentrations of C. difficile toxin A at 48 h and 72 h using the 
Trypan blue exclusion assay as described in Chapter 2, section 2.7.2. 
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3.3.3 Propidium Iodide staining and cell cycle analysis 
Cell cycle analysis was performed on Caco-2 and HT29 cells incubated with 
100 ng/ml of toxin A for 4,8,24,48 and 72 hours using propidium iodide 
and flow cytometry as described in Chapter 2, section 2.7.3. Toxin- 
exposed cells were compared with cells cultured with control medium, 
seeded at the same time and obtained at the same time points as those 
cultured in the presence of the toxin. 
This experiment was also repeated to investigate the response of HT29 
cells to 10 000 ng/ml toxin A. 
3.3.4 Labelling of Toxin A 
To investigate the uptake of Clostridium difficile toxin A the protein was 
labelled using AlexaFluor488 Protein Labelling kit (Invitrogen) and size 
exclusion purification resin (Bio-Rad) to separate unincorporated due from 
the labelled toxin A. 
3.3.4.1 Preparation of toxin A and conjugate 
With a starting toxin A concentration of 2 mg/ml the Tris buffer was 
removed with three PBS exchanges (mixing 1 ml PBS with 500 NI toxin A 
and centrifuged for 20 minutes at 5000 g). The Alex Fluor488 was 
resuspended in 120 pl of PBS and a1M sodium bicarbonate solution 
prepared. Adding 50 pl of iM sodium bicarbonate solution and 30 pl of 
dissolved AlexaFluor488 to the 500 pi of 2 mg/ml toxin A- the reaction was 
stirred for 1 hour in darkness at room temperature. 
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3.3.4.2 Preparation of size exclusion purification resin 
Bio-Gel P-30 is a porous polyacrylamide bead gel prepared by 
copolymerization of acrylamide and N, N'-methylene-bis-acrylamide. The 
gel is extremely hydrophilic; essentially free of charge allowing for efficient 
filtration of the toxin A sample, and; the narrow distribution of bead 
diameter providing excellent resolution and molecular weight 
discrimination. Using the fine size exclusion resin (BioGel P-30, Bio-Rad) 
designed to separate free dye from proteins with MW >40 kDa, a 10X 
stock elution buffer was prepared (0.1 M potassium phosphate, 1.5 M 
NaCl, 2 mM sodium azide, pH7.2) and a 1X dilution made. The resin 
powder was gradually added to the buffer and gently stirred to ensure 
uniform suspension of beads and allowed to hydrate for 12 hours at room 
temperature. Following hydration half of the supernatant was removed 
and the resin sample degassed for 5-10 minutes with occasional swirling of 
the contents. With the addition of two bed volumes of degassed buffer the 
gel was gently swirled to suspend any fine particles and when 90-95% of 
the gel settled the supernatant containing the fine particles was removed 
by suction. This process was completed 3-4 times until 90% of the fine 
particles were removed. 
3.3.4.3 Preparation of size exclusion purification resin column 
The column was prepared as detailed in Figure 3-3. The elution buffer 
(1X) was prepared from 10X stock elution buffer (0.1 M potassium 
phosphate, 1.5 M NaCl, 2 mM sodium azide, pH7.2) and the resin prepared 
as described on page 109. Gently stirring the resin to ensure homogenous 
suspension the resin was carefully pipetted into the column until the resin 
was approximately 3 cm from the top, allowing excess buffer to drain into 
the column bed. 
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Size exclusion purification resin 
Unincorporated dye 
Labelled toxin A- TcdA488 f_t 
Figure 3-3 Column assembly for toxin labeling 
Image adapted from AlexaFluor488 Protein Labelling Kit instructions (Invitrogen). 
3.3.4.4 Separation of labelled toxin A TcdA488 from incorporated dye 
The reaction mixture was loaded into the column and allowed to enter the 
column resin. The vial containing the mixture was rinsed with 100 pl of 
elution buffer and also applied to the column. With the mixture embedded 
in the resin, elution buffer was slowly added until the labelled protein had 
been eluted. Two bands were viewed travelling through the resin 
representing the separation of labelled toxin from unincorporated dye. 500 
pl fractions were collected until both bands were eluted. The first band 
contained labelled toxin A and all eluted 500 pl samples containing 
fluorescent dye were pooled and concentrated. The protein conjugate 
concentration was established using Bradford assay and the degree of 
labelling (moles of dye per mole of protein) of toxin A with AlexaFluor488 
established taking the absorbance measured at 495 nm and inserting that 
value and the protein concentration into the following equation: 
110 
moles of dye per mole of protein = Abs at 495 nm/71,000 x protein conc. 
The above equation was provided in the kit instruction. Stock solutions 
were prepared using PBS and stored in darkness at 4°C. 
3.3.4.5 Quantification of internalised TcdA488 by flow cytometry 
All samples were stored in darkness prior to analysis. Fluorescent 
Activated Cell Sorting (FACS) analysis was carried out using the Becton 
Dickinson LSRII flow cytometer using the Argon 488 nm laser. Median 
fluorescence intensity was recorded from 10,000 events (excitation 488- 
494 nm, detection 519 nm). See representative scatter plots and 
histogram in Figure 3-4. 
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3.3.5 Internalisation of Tcd488 by intestinal epithelial cells HT29 & Caco-2 
3.3.5.1 Biological activity of labeled and unlabeled toxin A 
In view of the possibility that toxin labelling may affect its biological 
activity, the activity of AlexaFluor488 labelled toxin A (TcdA488) was 
compared with unlabeled toxin A on the cells of interest. Caco-2 and HT29 
cultured in 96 well plates as described in 2.5.2.7 were incubated with 
either unlabeled toxin A or labelled toxin A at 10 000,1 000 and 100 ng/ml 
or control medium and cell viability assessed at 48 hours using the MTT 
assay as previously detailed in section 2.7.1. 
3.3.5.2 Cell culture with TcdA488 and fixing of cells 
Initial experiments investigated the dose dependent uptake of TcdA4' by 
Caco-2 and HT29 cells at 24h. HT29 and Caco-2 cells were seeded in 24 
well plates as previously described and grown to confluence. When 
confluent, media was replaced with either labelled toxin A at 2 000,5 000 
and 10 000 ng/ml or control medium for 24 h. Dilutions were prepared 
using cell specific media. After 24 h the media was removed from all wells 
and cells trypsinized with 200 pl of 0.25% trypsin were pooled and placed 
into labelled eppendorf's. The eppendorf containing the media together 
with any non-adherent cell was pelleted by centrifugation at 1000 rpm for 
5 minutes and 100 pl of 0.25% of trypsin added to the pellet. After 
trypsinisation the cells from the wells were transferred into the respective 
eppendorfs and a further 1.5 ml of warmed media added to wash out 
trypsin. The cells were pelleted at 1000 rpm for 5 minutes and 
resuspended in 400 pi of DMEM (2% FCS)/4% formaldehyde solution for 5 
minutes. The cells were again pelleted at 1000 rpm for 5 minutes and 
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resuspended in 0.5% formaldehyde in labelled FACS tubes. The tubes 
were kept in darkness until fluorescence was measured and median 
fluorescence intensity reported. 
All subsequent experiments were conducted using 5000 ng/mI and 10000 
ng/mI of TcdA488 and median fluorescence intensity recorded in control and 
toxin exposed cells after 1 h, 2 h, 5h and 24 h using the above method. 
3.3.5.3 Visualisation of internalized TcdA488 
To visualize the internalization of TcdA4"8 by HT29 and Caco-2 cytospins of 
cells in control medium and following incubation with 10 000 ng/ml TcdA488 
for 24 h were prepared. In brief, HT29 and Caco-2 cells incubated with 10 
000 ng/ml TcdA488 for 24 h were fixed in formaldehyde and stored at 4 °C. 
Glass slides were labelled and place into the metal holder and blotting 
paper placed on top. Transferring 100 pl of HT29 samples and 250 pl of 
Caco-2 samples into the plastic cup, the cup was then clamped into place 
and placed into cytospin centrifuge (Shandon Cytospin 2). The cells were 
spread onto the glass slides using centrifugal force of 1000 rpm for 8 
minutes and stored in darkness overnight prior to mounting. 
Cells were mounted with a small drop of glycerol and a small glass 
coverslip on top. Excess glycerol was wiped away and the perimeter of the 
slip sealed with clear varnish. TcdA488 uptake was visualised and 
micrographs taken using fluorescent microscope (Nikon Eclipse TE2000-S). 
Fluorescent and phase contrast micrographs were taken and can be viewed 
in Figure 3-12. 
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3.3.6 Rho protein expression 
Investigation of Rho signalling in intestinal epithelial cells was completed 
using whole cell lysates from HT29 and Caco-2 cells in control and toxin A 
treated samples and the Western blot technique using Rho specific 
antibodies for detection. See Chapter 2 section 2.8. The proteins 
investigated included Rac-1, Rho A and Rho B. ß-actin was used as a 
loading control. 
In brief, HT29 and Caco-2 intestinal epithelial cells were incubated with 
1000 ng/ml toxin A or control medium for 0 h, 4 h, 8h and 24 h. A 48 h 
timepoint was also included for HT29 cells but not Caco-2, due to extreme 
loss of viable cells. A Western blot was completed for each protein to be 
investigated, including a loading control. A colour scan was made of each 
Western blot. 
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3.4 Epithelial cell response to C. difficile toxin A 
3.4.1 Dose dependent response in HT29 and Caco-2 cells to toxin A-0.1 
-1 000 ng/ml 
Initial experiments investigated the response of intestinal epithelial cells, 
Caco-2 and HT29 to varying concentrations of C. difficile toxin A ranging 
0.1 ng/ml through to 1 000 ng/ml. Morphological assessments were made 
at 1h- 72 h and viability of cells following exposure to toxin A or control 
media at 48 and 72 hours. 
Subsequent experiments were completed using Caco-2 and HT29 cells and 
C. difficfle toxin A at 100 ng/ml, 1000 ng/ml or 10000 ng/ml. Cellular 
viability and cytotoxic effect was established at 48 and 72 hours post toxin 
exposure and compared against untreated (control) cells. 
3.4.2 Alterations to cell morphological 
Morphological assessment was made using light microscopy as described in 
Chapter 2, and the cells in each well categorized into one of three 
morphological stages; no visible rounding; 50% visible rounding and 100 
% visible rounding. The percentage rounding was ascertained by 
observing the rounded cells in ten random high power fields and taking the 
subjective mean of these ten observations. Attachment and signs of cell 
death will also be noted. Photographic representation of these stages in 
each cell line can be viewed in Figure 3-5. 
Assessments were made at 1 hr, 2 hr, 4 hr, 24 hr, 48 hr and 72 hr post 
toxin A exposure. Cell rounding occurred in a time- and dose-dependent 
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manner occurring marginally earlier, by 1 hr, and at lower concentrations 
in Caco-2 cells (Table 3-2). 
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3.4.3 Investigation of cellular viability using the MTT assay 
Cell viability was established after 48 h and 72 h toxin A exposure using 
the MTT assay as previously described. (Chapter 2, section) 
3.4.3.1 Caco-2 cellular viability 
- 
0.1 ng/ml 
-1 000 ng/ml toxin A 
Caco-2 intestinal epithelial cells exposed to C. difficile toxin A showed a 
reduction in mitochondria) dehydrogenase activity, which reflects cell 
viability, in a time and dose dependent manner. A significant reduction in 
cell viability was seen when Caco-2 cells were exposed to concentrations of 
toxin >_ 100 ng/ml at 48 hours and > 10 ng/ml after 72 hours when 
compared to control (untreated cells), Table 3-3. Cells exposed to 
concentrations < 10 ng/mI presented with some loss of cell viability, 
however not significantly so, even after 72 hour exposure to the toxin 
(Table 3-3). 
3.4.3.2 HT29 cellular viability 
- 
0.1-1 000 ng/ml toxin A 
HT29 intestinal epithelial cells exposed to C. diffcile toxin A showed a 
reduction (not statistically significant) in mitochondrial dehydrogenase 
activity, which reflects cell viability, at 48 hours in a dose dependent 
manner; however by 72 hours mitochondrial dehydrogenase activity 
increased to levels found in control (untreated cells) (Table 3-3). 
No significant difference was noted between 48 and 72 hours or at any 
concentration when compared against control (untreated cells) at either 
time point (Table 3-3 B). 
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Table 3-3 Mitochondrial dehydrogenase activity (MDA) in Caco-2 and HT29 
cells to C. diffficile toxin A (0.1-1000 ng/ml) 
MTT assay for mitochondrial dehydrogenase activity (expressed as OD 570 nm) in (A) Caco-2 
cells and (B) HT29 cells exposed to varying concentrations of toxin A for 48 h and 72 h. Data 
in table presents mean (±SEM) of 3 experiments performed in triplicate. ** = p<0.01 
p<0.05 when compared with control 
A 
Conc. 
Period of exposure (h) 
(ng/ml) 48 72 
Control 0.2217: b 0.0157 0.2733 ± 0.0191 
0.1 0.1860±0.0395 0.1920±0.0185 
1 0.2037 ± 0.0194 0.1700 t 0.0364 
10 0.1807 ± 0.0043 0.1037 ± 0.0362 * 
100 0.0910: 1: 0.0252 * 0.0580 ± 0.0380 
1000 0.0460 ± 0.0180 * 0.0293 ±0.0264 ** 
B 
Conc. 
Period of exposure (h) 
(ng/ml) 48 72 
Control 0.3273 ± 0.0238 0.2983f 0.0104 
0.1 0.3193 ± 0.0295 0.2897 ± 0.0184 
1 0.3147 ± 0.0294 0.3000 ± 0.0063 
10 0.2943 ± 0.0177 0.2937 ± 0.0234 
100 0.2957 ± 0.0463 0.306 ± 0.0180 
1000 0.2907 ± 0.0395 0.3117 ±0.0130 
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3.4.3.3 Comparison of viability in cells exposed to C difficile toxin A 
With a significant difference in cellular response observed in Caco-2 cells 
exposed to toxin A >100 ng/ml from 48 hours onwards, future 
experiments were completed to compare the response of Caco-2 and HT29 
cells to 100 and 1 000 ng/ml toxin A. 
Caco-2 and HT29 cells were grown to confluence and incubated with either 
100 ng/ml, 1 000 ng/ml toxin A or control media. Morphological changes 
were noted and found to be similar to that reported in Table 3-2. Cell 
cytotoxicity was measured using the MTT assay as previously described. 
Cell viability was assessed using the Trypan Blue Exclusion assay, see 
2.7.2; together with Propidium Iodide analysis by flow cytometry of DNA 
content, see 2.7.3. 
3.4.3.4 Significant loss of mitochondrial dehydrogenase activity 
Supporting earlier results, cell cytotoxicity as measured using the MTT 
assay (n=7) established a highly significant (p= <0.0001) loss of 
mitochondrial dehydrogenase activity in Caco-2 cells incubated with >_100 
ng/ml purified toxin A from 48 h when compared with control (untreated) 
cells (Table 3-4 and Figure 3-6 A). In contrast, and supporting initial 
experiments the mitochondrial dehydrogenase activity in toxin treated 
HT29 cells remained similar to control (untreated) cells at concentrations 
: 51000 ng/ml toxin A (Table 3-4 and Figure 3-6 B). 
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Table 3-4 Mitochondrial dehydrogenase activity (MDA) in Caco-2 and HT29 
cells to C. dicile toxin A (100-1000 ng/ml) 
MTT assay for mitochondrial dehydrogenase activity (expressed as OD 570 nm) in Caco-2 and 
HT29 cells exposed to varying concentrations of toxin A for 48 h and 72 h. Data in table 
presents mean (±SEM) of 7 experiments performed in triplicate. *** = p<0.000 I when 
compared with control 
Conc. Period of exposure (h) 
(ng/mI) Caco-2 HT29 
48 72 48 72 
Control 0.3527: L 0.0439 0.3722 f 0.0440 0.4542 t 0.0355 0.4434 ± 0.0527 
100 0.1774 ± 0.0410 0.1274 ± 0.0298 0.4294 ± 0.0513 0.4346 ± 0.0491 
1000 0.1266 ± 0.0333 0.102110,0280 0.4286 ± 0.0512 0.4376 ± 0.0500 
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Figure 3-6 Mitochondrial dehydrogenase activity (MDA) in Caco-2 and 
HT29 to C. difficile toxin A (100-1000 ng/mI) 
MIT assay for mitochondrial dehydrogenase activity (expressed as OD 570 nm) in Caco-2 (A) 
and HT29 (B) cells exposed to varying concentrations of toxin A for 48 h and 72 h. Data in 
figures represent mean (±SEM) of 7 experiments performed in triplicate. ***= p<0.0001 when 
compared with control. 
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3.4.3.5 Resilience of HT29 cells 
Given the apparent resilience of HT29 cells to toxin A induced cell death 
experiments were conducted to measure cell cytotoxicity and establish the 
response of HT29 cells to 10 000 ng/ml of purified toxin A using the MIT 
assay. The experiment was also completed on Caco-2 cells. As previously 
described in section 3.3, cells were cultured and incubated with either toxin 
or control medium and the MIT assay conducted after 48 and 72 h. As 
would be expected, a significant loss in viability was seen in Caco-2 cells 
by 48 h and further reduced by 72 h (see Figure 3-7). HT29 cells however 
would appear to be resilient to concentrations 510 000 ng/ml for up 48 h, 
but at 10000 ng/ml a significant loss in mitochondrial dehydrogenase was 
reported at 72 h. 
3.4.4 Trypan blue exclusion assay provides supportive evidence 
The percentage of viable cells was established after 48 and 72 hour toxin A 
exposure using the Trypan blue exclusion assay (n=3) as previously 
described in Chapter 2, section 2.7.2. 
Analysis of cell viability using Trypan Blue supported earlier findings. The 
percentage of viable cells is low with a great many dead Caco-2 cells seen 
(Figure 3-8 A). This correlates with the large reduction in mitochondrial 
dehydrogenase activity reported earlier in Caco-2 cells (Table 3-3). As 
would be expected the percentage of non stained (viable) HT29 cells was 
high with very few blue stained (dead) HT29 cells observed (Figure 3-8 B). 
This correlates with the small reduction in mitochondrial dehydrogenase 
activity reported earlier in HT29 cells (Table 3-3). 
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Figure 3-7 Mitochondrial Dehydrogenase Activity (MDA) in Caco-2 and 
HT29 cells to C. difcile toxin A (10,000 ng/ml) 
MTT assay for mitochondria] dehydrogenase activity (expressed as OD 570 nm) in Caco-2 (A) 
and HT29 (B) cells exposed to 10 000 ng/ml of toxin A for 48 h and 72 h. Data in figures 
represent mean (+SEM) of 3 experiments performed in triplicate. *= p<0.05 **=p<0.001 when 
compared with control. 
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Figure 3-8 Cell viability assessed using Trypan Exclusion Assay in Caco-2 
and HT29 cells to C. difficile toxin A (0.1-1000 ng/ml) 
Assessment of Caco-2 (A) and HT29 (B) cell viability following exposure to toxin A for 48 h 
or 72 h. Proportions of cells that have not taken up trypan blue are expressed as % viable cells. 
Data in figures represent mean (±SEM) of 3 experiments performed in triplicate. *** _ 
P<0.0001 and ** = p<0.01 n. s. = not significant when compared with control 
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3.4.5 Propidium Iodide staining and measurement using FACS confirm 
cell loss 
As described in Chapter 2,2.7.3, Caco-2 and HT29 cells incubated with 
100 ng/ml toxin A or control media were fixed at 8 h, 24 h, 48 h and 72 h, 
stained with Propidium Iodide and fluorescence emitted assessed by flow 
cytometry. Using WinMDI 2.9 and cell cycle analysis programme Cyclhred 
as described in Chapter 2 section 2.7.3 the number of events in the sub- 
G1 region was ascertained and this number presented as a percentage of 
the total events recorded, comparing the percentage events in the sub-G1 
region in toxin A-treated cells with control (untreated) cells. 
As can be viewed in Figure 3-9 A, an increase in the % Sub-G1 cells is 
evident from 4 hours in toxin A-treated Caco-2 cells when compared with 
control cells, the increase in sub-G1 events becoming more prominent 
from 24 h onwards and significant increase noted at 72 h (mean toxin 
46.76% (±SEM 7.36) vs control 12.32% (±2.81) p<0.05]. In contrast, 
and as would be expected from above findings, the % of sub-G1 events in 
toxin A-exposed HT29 cells was similar to control (untreated) cells until 72 
h, when a significant increase was noted when compared with control cells 
(toxin 23.04% (±5.15) vs control 7.97% (±1.53) p<0.05], see Figure 3-9 
B. 
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Figure 3-9 DNA analysis of Propidium iodide stained Caco-2 and HT29 cells 
incubated with C. difficile toxin A, 100 ng/mI 
Assessment of Caco-2 (A) and HT29 (B) sub GI region of the cell cycle following exposure to 
toxin A for 48 h or 72 h. Percentage of sub-GI events calculated using total events and 
number of events in the sub-GI region when analysed using Cylchred. Data in figures 
represent mean (±SEM) of 3 experiments performed in triplicate. 
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3.4.5.1 Uptake of toxin A (TcdA488) is similar in intestinal epithelial cells 
C. difficile toxins are believed to enter the host cell by receptor mediated 
endocytosis and following internalization the toxins inactivates Rho family 
of small GTPases, which are eukaryote switches that modulate downstream 
signalling. Inactivation of the Rho proteins leads to disruption of the actin 
cytoskeleton, cell rounding and eventual death by apoptosis. It can 
therefore be postulated that Caco-2 and HT29 cell specific sensitivities 
occur as a result of differing abilities of the cells to take up/ internalise 
toxin (which could be due to differences in expression of cell surface 
receptors). Thus, it is possible that increased uptake of toxin A by Caco-2 
cells could explain its greater sensitivity to cell death. 
Purified toxin A was labelled with AlexaFluor488 as described in section 
3.3.4, page 108. Using labelled toxin A (TcdA488) uptake and subsequent 
internalisation was studied by incubating HT29 and Caco-2 cells with 
TcdA488 or control media; fixing the cells with formaldehyde and measuring 
emitted fluorescence as described in section 3.3.4.5 page 111. Cytospins 
were prepared from cells incubated with the labelled toxin and fluorescent 
micrographs taken to confirm the internalisation of the labelled toxin, see 
Figure 3-12 Fluorescent micrographs of internalised TcdA'`w. 
3.4.5.2 Biological activity reduced in TcdA488 
In view of the possibility that toxin labelling may affect Its biological 
activity, the ability of AlexaFluor488 labelled toxin A (TcdA488) to induce cell 
death in Caco-2 and HT29 cells, was compared with unlabelled toxin A (see 
section 3.3.5.1, page 113). 
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As previously demonstrated, at concentrations >1000 ng/mI toxin A (TcdA) 
induced a significant reduction in the mitochondrial dehydrogenase activity 
in Caco-2 cells, but not HT29 cells, see Figure 3-10 A&B. Whilst the 
labelled toxin exerted a similar effect on the Caco-2 cells, a significant 
reduction in mitochondrial dehydrogenase activity was only seen at 10 000 
ng/ml (Figure 3-10 A) suggesting that the labelling process may have 
reduced the biological activity of the toxin. 
In order to have the greatest probability of detecting differences (between 
Caco-2 and HT29 cells) in uptake of TcdA488 it was decided to expose them 
to 5 000 ng/ml and 10 000 ng/ml labelled toxin A for up to 24 h. 
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Figure 3-10 Mitochondrial dehydrogenase activity (MDA) in Caco-2 and 
HT29 cells to C. difficile toxin A and TcdA488 
Assay for mitochondrial dehydrogenase activity (expressed as OD 570 nm) in Caco-2 (A) and 
HT29 (B) cells exposed to either labelled toxin A (TcdA488) or unlabelled toxin A (TcdA) for 
48 h to compare biological activity. Data in figures represent mean (+SEM) of 3 experiments 
performed in triplicate. *** p=0.005 when compared with control 
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3.4.5.3 Internalisation of TcdA488 by Caco-2 and HT29 cells 
Uptake of TcdA488 in HT29 and Caco-2 cells occurred in a time dependent 
manner, as can be observed in the representative histograms detailing the 
mean median fluorescence intensity of three separate experiments, see 
Figure 3-13. Considering the uptake and subsequent internalisation, there 
was no significant difference in medium fluorescence intensity when 
corrected for auto-fluorescence in Caco-2 and HT29 cells incubated with 
identical concentrations of TcdA488 
, 
see Figure 3-11 A&B. With evidence 
to suggest that the toxin is entering the cell and the subsequent median 
fluorescence intensity not differing significantly when the cells are 
compared it can be postulated that the cell-specific sensitivities may not be 
attributable to the amount of toxin entering the cell. Our previous findings 
suggest a significant and marked difference in the responses by the two 
cell types following exposure to C. difficile toxin A. Taken together the 
findings suggest that the disparity in toxin induced cell death in Caco-2 and 
HT29 cells may be due to an intracellular mechanism. 
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Figure 3-11 Median Fluorescence Intensity (MFI) of Caco-2 and HT29 cells 
incubated with TcdA488 
Median fluorescence intensities (MFI's) of Caco-2 and HT29 cells exposed to 5,000 ng/mI (A) 
and 10,000 ng/ml (B) of fluorescently-labelled toxin A for 1,2,5 and 24 h. MFI was 
calculated after subtracting auto-fluorescence in cells cultured in control medium only. Data 
presented as mean (±SEM) of 3 experiments 
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3.4.5.4 Cytospin preparation and fluorescent Microscopy confirmed toxin 
internalization 
Fluorescence emitted by the cells when corrected for auto-fluorescence 
was as a direct result of the labelled toxin being internalized. This can as 
can be visualised in the fluorescent micrographs taken from cytospins 
prepared following incubation with 10pg/ml of TcdA488 for 24 hours (Figure 
3-12, page 136). 
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Phase contrast and corresponding fluorescent micrographs of Caco-2 (A&B. E&F) and HT29 (C&D, G&H) cells cultured for 24 h in the absence or presence of fluorescently-labelled toxin A 
(10,000 ng/ml). After washing and detachment, cytospin preparations of the cells were studied by 
phase contrast and fluorescence microscopy. A greater intensity of fluorescence is visible in cells 
exposed to labelled toxin A, compared to auto-fluorescence displayed by controls cells cultured in 
medium only. 
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Figure 3-12 Fluorescent micrographs of internalised TcdA488 
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Figure 3-13 Representative histograms of Median Fluorescence intensity 
(MDI) of Caco-2 and HT29 cells incubated with TcdA488 
Representative histograms of Caco-2 (a-e) and HT29 cells (f-j) incubated with 10,000 ng/ml of 
labelled C. dilcile toxin A (TcdA488) for Ih (b&g), 2h (c&h), 5h (d&i) and 24 h (e&j) or control 
medium (a&f). MFI 
- 
median fluorescence intensity is presented as mean (+SEM) of 3 
experiments. 
3.4.6 Role of epithelial cell cycle in susceptibility to C. difficile toxin A 
induced cell death 
Studies were undertaken to determine whether certain phases of the cell cycle 
are under- or over-represented at various time points following exposure to C. 
difficile toxin A. For these studies, cell cycle analysis was performed by flow 
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cytometry at 4 h, 8 h, 24 h, 48 h and 72 hours after exposure to toxin A as 
described in Chapter 2, section 2.7.3. Toxin-exposed cells were compared with 
cells cultured with control medium, seeded at the same time and obtained at 
the same time points as those cultured in the presence of the toxin. 
Statistically significant differences were seen in individual phases of the cell 
cycle at different time points, see Figures Sa-e Caco-2; 6a-e HT29. 
Comparison of cell cycle profiles of toxin exposed and control Caco-2 cells, 
Figure 3-14 A and B provide contrasting views up to the 24 h time-point. 
However, a significant difference recorded in the percentage of cells in the 
GO/G1 region at 4h and 24 h was not supported by a significant difference in 
any other cell cycle phase until at 72 ha significant difference was recorded in 
the G2 phase, with a significant reduction in the percentage of toxin exposed 
cells when compared to control cells. 
Considering the profiles of HT29 cells in control and toxin exposed conditions, 
a similar contrasting profile is visible up to 24 h with cells incubated in the 
control medium leaving the GO/G1 phase up to 24 h and the toxin exposed 
cells appearing to stop cycling, with minimal movement evident in the cell 
cycle phases, as can be viewed in Figure 3-15. This is supported by a 
significant increase in the number of toxin exposed HT29 cells in the GO/G1 
region and a significant reduction in the corresponding toxin exposed HT29 
cells in the S-phase when compared against untreated cells. 
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Figure 3-14 Whole cell cycle analysis of Caco-2 cells Incubated with C. difficile 
toxin A (100 ng/ml) 
Using PI stained Caco-2 cells incubated with 100 ng/ml of C. docile toxin A (A) or control 
medium (B) for 4 h, 8 h, 24 h, 48 h and 72 h, the cells were sorted using FACS and the resulting 
scatterplot gated to remove debris. Using only the gated events the percentage of cells in each 
phase of the cell cycle was calculated using Cyclhred. Data presented as % (± SEM) of cells in 
GO/G1, S and G2 phase n=3. This data reflects viable cells only and does not reflect the cells lost 
to cell death 
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Figure 3-15 Individual phase cell cycle analysis of Caco-2 cells incubated with 
C. difficile toxin A (100 ng/mI) 
Percentage of Caco-2 cells in GO/GI (A) S-phase (B) and G2 (C), comparison of toxin treated and 
control cells at 4,8.24,48 and 72 h. Data presented as %f SEM n=3 *=p=<0.05 PI stained cells 
were sorted using FACS and the resulting scatterplot gated to remove debris. Using only the gated 
events the percentage of cells in each phase of the cell cycle was calculated using Cyclhred. This 
data reflects viable cells only and does not reflect the cells lost to cell death 
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Figure 3-16 Whole cell cycle analysis of HT29 cells incubated with C. dif idle 
toxin A (100 ng/mI) 
Using PI stained HT29 cells incubated with 100 ng/ml of C. docile toxin A (A) or control 
medium (B) for 4 h, 8 h, 24 h, 48 h and 72 h, the cells were sorted using FACS and the resulting 
scatterplot gated to remove debris. Using only the gated events the percentage of cells in each 
phase of the cell cycle was calculated using Cyclhred. Data presented as % (± SEM) of cells in 
GO/Gl, S and G2 phase n=3. This data reflects viable cells only and does not reflect the cells lost 
to cell death 
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Figure 3-17 Individual phase cell cycle analysis of HT29 incubated with C. 
difficiie toxin A (100 ng/mI) 
Percentage of HT29 cells in GO/G1 (A) S-phase (B) and G2 (C), comparison of toxin treated and 
control cells at 4,8,24,48 and 72 h. Data presented as %± SEM n=3 **=p=<0.01 PI stained cells 
were sorted using FACS and the resulting scatterplot gated to remove debris. Using only the gated 
events the percentage of cells in each phase of the cell cycle was calculated using Cyclhred. This 
data reflects viable cells only and does not reflect the cells lost to cell death 
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3.4.7 Substrate specificity in toxin A exposed intestinal epithelial cells 
Rho, Rac-1 and Cdc42 are the intracellular targets for C. difcile toxins and 
utilizing UDP-glucose as the co-substrate the toxins are capable of maintaining 
these key molecular proteins in an inactive state. The mechanisms that lead 
to their inactivation have been covered in detail in Chapter 1. 
Using whole cell lysates prepared from HT29 and Caco-2 cells incubated with 
either toxin A or control medium Western Blot analysis was completed using 
protein specific antibodies to ascertain the expression of Rac-1 and Rho A, see 
Chapter 2, section 2.8 for a complete description of methods used. 
As discussed in Chapter 1 toxins released by the bacterium C. diff dle 
glucosylate, therein inactivating the protein and disrupting downstream 
signalling. This is believed to be irreversible modification. The Rac-1 
(MAB3735, Mouse IgG, Millipore) detects only the non-glucosylated (active) 
protein, whereas Rho A (26C4: sc-418 Mouse IgG Santa Cruz Biotechnology 
Inc. ) and Rho B (2098 Rabbit IgG, Cell Signalling Technology) detects 
endogenous levels of total protein (glucosylated and non-glucosylated). It has 
been reported however, that glucosylated Rho A is promptly degraded by the 
intracellular proteasome (Genth, Huelsenbeck et al. 2006) and therefore it is 
presumed that the signal being identified from the Rho A antibody is non- 
glucosylated (active) Rho A. 
As can be seen in Figure 3-18, a reduction in non-glucosylated Rac-1 
expression can be observed from as early as 3 hrs in both cell types when 
143 
'ýýs 
. 
compared to the control (untreated) lysate at 0 h. This loss continued 
through to 48 h. 
Total RhoA (glucosylated and non-glucosylated) expression in toxin treated 
Caco-2 cells remained consistent when compared to the control (untreated) 
cell lysate at 0 h. The consistent expression of Rho A in toxin treated Caco-2 
cells was still evident after 24 h. In contrast, a slight reduction in Rho A 
expression in toxin treated HT29 cells was evident at 3h and further 
reductions were noted at 8 h, 24 h and 48 h when compared to control 
(untreated) cell lysate at 0 h. 
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Figure 3-18 Expression of Rac-1, RhoA and beta-actin in control and C. difficile 
toxin A exposed Caco-2 (A) and HT29 (B) cells 
Intestinal epithelial cell monolayers were cultured in medium only (0 h) or in the presence of 1,000 
ng/ml toxin A for 3 h, 8 h, 24 h and 48 h (in HT29 cells only). Lysates of cells were 
electrophoresed on SDS-PAGE gels and following transfer onto PVDF membranes, 
immunostaining was performed using antibodies specific for RhoA, beta-actin or non-glucosylated 
form of Racl. Equal loading of the lanes is illustrated by beta-actin-immunoreactive bands of 
similar size. The figures are representative of five experiments. 
145 
3.5 Discussion 
3.5.1 Purification and Characterisation of C. difficile toxin A 
C. difficile toxin A was purified by bovine thyroglobulin affinity 
chromatography followed by two sequential anion exchange chromatography 
steps on DEAE Sepharose FF and Mono Q. Homogeneity of the toxin was 
confirmed by the presence of a single band on native polyacrylamide gel 
electrophoresis (PAGE) and dot blot using the specific PCG4 antibody. The 
cytotoxic activity was determined using Vero cells assay as described 
previously. This method of purification produces consistent yields of pure 
toxin ranging from 0.06 mg/ml-2.33 mg/ml. 
As has already been discussed, toxin A exerts a dramatic effect on mammalian 
cell morphology. Perhaps the most important of these alterations and 
considered the hallmark of intoxication is the rounding of cells. Cell rounding 
occurs in response to the toxin entering the target cell and subsequently 
inactivating Rho, Rac and Cdc42, small GTPases pivotal in ultra-structure 
maintenance and downstream signalling. 
This chapter looked at the response of two human intestinal epithelial cell 
lines exposed to varying concentrations of toxin A. Caco-2 cells (colonic 
epithelial adenocarcinoma cell line), phenotypically similar to mature 
enterocytes (Sambuy, De Angelis et al. 2005) and HT29 cells (colonic 
epithelial adenocarcinoma cell line) were cultured to confluence and exposed 
to a range of the toxin A concentrations (10000 
- 
0.1 ng/ml). 
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Visible cell rounding was first noted just 1 hour after Caco-2 cells were 
exposed to >_1000 ng/ml of toxin A. Cell rounding in HT29 was also visible 1 
hour after exposure, although only at the highest of concentrations; 10,000 
ng/ml. A similar pattern of responses was noted throughout the experiment 
suggesting that cell rounding occurred in a time- and dose- dependent 
manner with no major difference in morphological change observed in Caco-2 
and HT29 cells. 
Another important observation made during this study involved the integrity 
of the cell monolayers. The integrity of both monolayers were observed at 
given time-points and whilst the Caco-2 monolayers appeared disrupted within 
the first 24 hours, particularly at concentrations 2_100 ng/ml, HT29 
monolayers remained intact throughout, even after 72 hour exposure at the 
highest concentrations. These observations will be discussed in more detail 
alongside cellular viability. 
To establish cell viability and cytotoxicity of a given entity on the host It has 
been suggested that multiple methods be employed, each of which 
considering a different mechanism or feature of cell death (Galluzzi, Aaronson 
et al. 2009). With this in mind the cellular viability of Caco-2 and HT29 cells 
to C. difficile toxin A was investigated using the MTT assay; trypan blue 
exclusion assay; propidium iodide staining of DNA content and visual 
inspection using light microscopy. 
Metabolic activity was investigated using the MTT assay and the ability of 
metabolizing cells to cleave the soluble tetrazolium salt and thereby producing 
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insoluble purple formazan crystals that when solubilised could be quantified 
spectrophometrically 
. 
Caco-2 cell monolayers treated with a range of toxin A concentrations resulted 
in a time and dose dependent reduction in mitochondrial dehydrogenase 
activity. Mitochondrial dehydrogenase activity is reported to be a direct 
reflection of cellular viability (Mosmann 1983). These findings mirror 
observations reported previously (Mahida, Makh et al. 1996) and have also 
been reported in studies considering the effects of C. difficile toxin A on cells 
within the lamina propria (Mahida, Galvin et al. 1998). 
Mitochondrial dehydrogenase activity was significantly reduced in toxin treated 
Caco-2 cells (0.1774 ±0.0418 and 0.1266 ±0.0333), 100 ng/ml and 1000 
ng/ml respectively (mean f SEM p=<0.001) after 48 hours when compared 
with untreated control cells (0.3527 ±0.0439). By 72 hours, a further 
reduction was observed at concentrations 
_100ng/ml (0.1274 ±0.0298 and 
0.1021 ±0.0280) 100 ng/ml and 1000 ng/ml respectively, when compared 
with control (untreated) cells (0.3722 ±0.0440) (mean ±SEM p=<0.01). 
In contrast, only a very small reduction in cell viability was observed in HT29 
monolayers at 48 hours and 72 hours using <_1000 ng/ml cell viability. 
Investigations using 10,000 ng/ml confirmed my previous findings with 
mitochondrial dehydrogenase activity in Caco-2 cells significantly reduced 
when treated with toxin A and HT29 cells showing no significant reduction. 
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The dramatic reduction observed in Caco-2 cells and the minimal effect of 
toxin A observed in HT29 cells was supported by the use of an additional 
viability assay. Using the trypan blue exclusion assay, the percentage of 
viable cells was calculated, as previously discussed. The trypan blue assay 
supported my earlier findings and suggests that the MTT results were an 
accurate reflection of cell viability. 
The MTT assay and trypan blue exclusion assay were further supported by cell 
cycle analysis of cells exposed to toxin A. Using propidium iodide staining the 
DNA content in cells was measured using FACS and the percentage events in 
the sub-G1 region established. A time dependent increase in the % sub G1 
events was evident in Caco-2 cells becoming statistically significant by 72 h 
(p<0.05). Of interest, a significant increase in % sub G1 events was also 
reported in HT29 cells when compared with control (untreated) cells (p<0.05). 
To summarize, Clostridium difficile toxin A exerts a cell specific effect, in which 
Caco-2 display greater susceptibility than HT29 cells. 
These early findings raised a number of questions and perhaps the most 
pertinent at this stage are; i) Why are Caco-2 cells more sensitive to toxin A 
and/or why are HT29 cells more resilient?; and ii) are the mechanisms that 
result in cell death and cell rounding temporally distinct in these cell lines? 
The sensitivities of Caco-2 have been commented upon previously; Mahida 
and colleagues found that Caco-2 cells were more sensitive than T84 
(epithelial cell line) cells, detaching earlier and presenting an early decline in 
mitochondrial dehydrogenase (Mahida, Makh et al. 1996). In this same study, 
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Mahida proposed the following sequence of events resulting from the 
intoxication of confluent epithelial cell lines with C. di>fci/e toxin A; cell 
rounding, detachment of the monolayer from the matrix coating (pseudo 
basement membrane) and subsequently death by apoptosis (Mahida, Makh et 
al. 1996). This sequence of events has been developed over the past 11 
years however the pathway to apoptosis induced by C. difficile toxin A and the 
reasons for the specific sensitivities to C. difficile toxins still remains largely 
undefined. 
The toxin enters the target cell by receptor mediated endocytosis and a 
possible explanation for the differential rounding patterns and cell viability 
seen in the two cell lines may be explained by the ability of the target cell to 
internalize the toxin. Tucker and colleagues reported cells expressing large 
volumes of the tri-saccharide receptor were more susceptible to the cytopathic 
effects of toxin A (Tucker, Carrig et al. 1990). 
Using fluorescently labelled toxin A, internalisation of the toxin by HT29 and 
Caco-2 was investigated. Labelling the toxin reduced some of the original 
bloactivity and therefore higher concentrations were used to maximise the 
response. Studying the response of Caco-2 and HT29 to 5,000 ng/ml and 
10,000 ng/ml of TcdA488, cells were exposed for various periods of time. The 
successful internalisation of the labelled toxin was shown in cytospin 
preparations and extracellular labelled toxin excluded as a possible effect on 
our results. Toxin uptake was dose and time dependent in both cell types, 
with no obvious saturation evident at the concentrations and timescales used. 
Comparison of the two cell types failed to establish a significant difference in 
150 
the amount of toxin being internalised and can therefore not be used to 
explain the cell specific differences attributed to toxin A. 
The cell rounding caused by the inactivation of Rho, Rac and Cdc42; the 
subsequent detachment from the basement membrane and cell death are 
suggested to be temporally distinct events. However, a number of studies 
have looked at the pathways to apoptosis induced by C. difficile toxin A, some 
argue that the inactivation of Rho results in the activation of caspases and 
thus induces apoptosis (Hippenstiel, Schmeck et al. 2002); some argue that 
apoptosis is independent of this activation and have identified a caspase 
independent mechanism (Carneiro, Fujii et al. 2006) and to confuse the issue 
further; others claim that both Rho inactivation and caspase independent 
signalling facilitate apoptosis in cells exposed to C. difficile toxin A. It may be 
that the pathway to apoptosis is also cell specific. 
Caco-2 cells rounded slightly earlier than HT29 cells, but a significant disparity 
has been found in the ability of toxin A to induce cell death in Caco-2 cells but 
not in HT29 cells. As we have shown no difference in the amount of toxin 
being taken into the cell then intracellular processing may provide the 
explanation. The early loss of monolayer integrity observed In Caco-2 cells 
would support the early loss of the regulatory switch, Rho. What remains to 
be ascertained is whether the dramatic decrease in cell viability was the result 
of the cell rounding and detachment from the basement membrane or 
mediated by other independent signalling mechanisms i. e. caspases. 
Once inside the target cell, toxin A exerts it effect by inactivating a number of 
small GTPases, namely Rho, Rac-1 and Cdc42. These proteins are key 
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molecular switches that regulate various different pathways and functions 
within the cell. A number of studies have suggested that substrate specificity 
may be cell specific. A recent study has shown that inactivation of Rho A (but 
not Rac-1) is required to induce cell death in response to C. difficile toxin B in 
basophilic leukaemia cells (Huelsenbeck, Dreger et al. 2007). It is possible 
therefore that toxin A induces greater inactivation of Rho A in Caco-2 cells 
than HT29 cell. Other studies, (Fritz and Kaina 2001) and (Liu, Cemiglia et al. 
2001) suggest that RhoB, which is negatively regulated by RhoA, is the main 
regulator of cell death. 
I therefore postulate that the target substrates for C. diff%i/e toxin A in Caco-2 
and HT29 cells may be different. My initial plan was to investigate the 
expression of RhoA, RhoB and Rac-1 in toxin exposed cells but after months of 
optimisation, investigation of Rho B was abandoned due undetectable RhoB 
concentration levels in the cell types under investigation. The RhoB antibody 
was shown to be active, and specific binding to RhoB expressed in control 
lysates (mouse brain) was shown using Western Blot analysis. Analysis of 
Rho expression was therefore limited to Rac-1 and RhoA. 
As would be expected and in line with cell rounding a reduction in non- 
glucosylated Rac-1 was apparent in both cell types from 3 hr and continued to 
reduce to 72 h. The similarity in cell rounding; loss of non-glucosylated Rac-1 
in response to C. difcile toxin A is in stark contrast to the viability of Caco-2 
and HT29 cells. This disparity would suggest that Rac-1 is associated with 
morphological changes that result in cell rounding but not cell death. The 
expression of RhoA in Caco-2 cells remained consistent throughout with no 
reduction in expression. In contrast, expression of RhoA in HT29 cells is 
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shown to reduce slightly from 3 hr and this reduction continues through to 72 
h. These findings further support a cell specific response but contradict our 
earlier suggestion that RhoA may regulate cell death, if this was so we would 
have expected a reduction in Rho A expression in Caco-2 cells but not in HT29 
cells. 
Rho proteins are linked with many biochemical and biological functions within 
the host cell; one of which being the cell cycle and more specifically G1 
progression and mitosis (Jaffe and Hall 2005). A recent study (Nottrott, 
Schoentaube et at. 2007) suggests that cells in GO/G1 phase of cell cycle may 
be more sensitive to toxin A-induced cell death. Using propidium iodide 
staining we investigated the cell cycle phases in toxin exposed and control 
cells using a dedicated cell cycle programme, Cyclhred to elicit any cell specific 
sensitivities. Whole cycle profiles show an increase in GO/G1 cells In Caco-2 
cells until 48 hrs (a significant increase being reported at 4 and 24 h) and this 
appears mirrored by a decrease in S-phase cells. This would suggest that 
GO/Gi cells may not be progressing into S-phase or not leaving GO/G1. As 
would be expected a decrease in S phase cells would indicate a progression 
through to G2 and this is shown by an increase in G2. From 24 h onwards a 
steady decline in G2 cells is reported. However by 48 h the events In the 
GO/G1 region are declining and S-phase events are increasing 
- 
suggesting 
that progression previously delayed or halted is now occurring. As would be 
expected Caco-2 whole cycle profiles from control cells show a progression 
from GO/G1 into S, with a decrease in GO/Gi and an increase in S phase 
events and as the S-phase decreases an increase in G2 is noted. Of interest 
however is, despite the simultaneous increase in S-phase events a significant 
reduction in G2 events in toxin exposed cells is reported and suggests that the 
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cells may not be progressing through S-phase or are not passing the G2 
checkpoint by 72 h. It is therefore possible that Caco-2 cells are more 
sensitive in the GO-GI phase evidenced by their lack of progression into S- 
phase. This would not however be true in HT29 dells incubated with toxin A; 
these cells also appear to remain in GO/G1 phase when compared with control 
profiles. A very small decrease in GO/G1 events is seen between 4-8 hours 
and this is correlated by an increase in S-phase events however there would 
appear to be limited movement of GO/G1 into S-phase events from 8 h. By 
24 ha significant difference in the percentage of GO/G1 and S-phase events is 
recorded, with a significant increase in GO/G1 cells and a significant decrease 
in S-phase cells when compared with control. 
Whilst a significant difference is not evident at all time-points, cell cycle 
progression is fluid and whilst progression may be delayed in toxin treated 
cells the control cells will be proliferating as normal and progressing through 
all stages of the cell cycle. 
To summarize, this chapter has described the response of two intestinal 
epithelial cell types to varying concentration of purified toxin A. In doing so, it 
has been established that Caco-2 cells are more sensitive to toxin induced cell 
death. Investigations to elucidate the reasons for this cell specific sensitivity 
initially considered a possible difference in the uptake of the toxin Into the cell. 
The incubation of cells with identical concentrations of fluorescently labelled 
toxin A for various time points failed to provide a explanation. Both cells 
internalised the toxin at a similar rate with no significant difference evident. 
Looking for an intracellular explanation, expression of RhoA and Rac-1, two of 
the key GTPases inactivated in target cells were investigated. Using whole cell 
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lysates from cells incubated with either toxin A or control medium Western 
Blot analysis established a time dependent loss of non-glucosylated Rac-1 in 
both cell types. RhoA expression in Caco-2 cells remained constant following 
incubation with toxin A, however a slight time dependent loss of RhoA 
occurred in HT29 cells incubated with toxin A. The cell cycle is regulated by 
Rho proteins and consideration of cell cycle progression was also investigated 
with some interesting findings. 
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CHAPTER 4 
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4 Establish methodology for purification of toxin B 
4.1 Introduction 
Toxin B is designated a cytotoxin (Tucker, Carrig et al. 1990) and whilst the 
molecular weight has been reported to range from 50-300 kDa, DNA sequence 
determination shows the molecular mass to be 270 (kDa) (Barroso, Wang et 
al. 1990; von Eichel-Streiber, Laufenberg-Feldmann et al. 1990). The amino 
acid sequence of the toxins A and B shows some 63% homology (von Eichel- 
Streiber, Laufenberg-Feldmann et al. 1990; von Eichel-Streiber, Laufenberg- 
Feldmann et al. 1992). Despite this similarity, significant differences are 
evident. 
Having successfully purified C. difficle toxin A and after completing 
experiments on both intestinal epithelial cells and primary intestinal 
myofibroblasts and establishing some very interesting responses, my interest 
naturally turned to the possible response of these cells to C. difficile toxin B. 
Would I observe a similar cell specific response? Whilst C. difficile toxin B can 
be purchased as a lyophilized powder, it is expensive and given the variability 
in cytotoxic activity noted by others (Banno, Kobayashi et al. 1984; Mitchell, 
Laughon et al. 1987) it may not reflect the same biological activity as in-house 
toxin B purified from the reference strain used in the toxin A purification. In 
addition, in-house purification of toxin B would provide a stronger starting 
platform for comparative studies of responses to toxin A and B. The in-house 
purification of toxin B has proven difficult due to the close homology and 
elution patterns of toxins A and B and as observed by others the persistence 
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of a contaminating protein that would appear to form a complex with the toxin 
B protein (Meador and Tweten 1988). 
Aim: To successfully purify Clostridium difficile toxin B at sufficient yield and 
biological activity to permit investigations into epithelial cell and myofibroblast 
response to toxin B, comparative and combined (A+B) investigations. 
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4.2 Material and Methods 
Using the most recent protocol held within the Institute, outlined in the flow 
diagram in Figure 4-1, several runs were completed to establish techniques 
and highlight problem areas. Using this protocol, Clostridium difcile toxin B is 
purified by bovine thyroglobulin affinity chromatography followed by 
ammonium sulphate precipitation and two sequential anion exchange 
chromatography steps on ready prepared DEAE Sepharose FF and Mono-Q. 
Homogeneity of the toxin is established on SDS polyacrylamide gel 
electrophoresis (PAGE) and dot blot using the specific monoclonal antibody for 
toxin B. Cytotoxic activity was determined using the Vero cell assay. 
Supernatant sample of 
anaerobically cultured 
Clostridium difficile 
Bovine thyroglobulin 
affinity chromatography 
Ammonium sulphate 
precipitation 
DEAE-FF-Sepharose 
anion exchange 
chromatography 
Mono-Q anion 
exchange 
chromatography 
Characterisation and 
storage 
Figure 4-1 Flow diagram of current C. diffidle toxin B purification protocol 
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4.2.1 Bacterial Culture 
4.2.1.1 Bacterial strains 
Clostridium difficile, VPI 10463 (Toxinotype 0), a widely used reference strain 
was chosen for this study as it expresses the genes tcdA and tcdB and 
produces active forms of toxin A and toxin B proteins. 
4.2.2 Recovery, growth and harvesting of bacteria 
As described under `Toxin A purification', Chapter 2,2.2 Clostridium difficile 
spores were retrieved from long-term storage; vegetative bacteria destroyed 
and resultant solution streaked onto blood agar plates and incubated 
anaerobically. Colonies isolated on blood agar were added to brain heart 
infusion broth, incubated anaerobically at 37°C for two days and the purity of 
the culture was checked by re-streaking the culture onto blood agar and the 
subsequent identification of pure C. difficile colonies. Five flasks were 
prepared and 5 ml of the bacterial harvest was added to each flask and 
incubated anaerobically at 37°C for 3-4 days. The contents of the dialysis 
tubing were centrifuged and the bacterial pellet removed. The remaining 
supernatant was syringe filtered (0.2 pm filter used) and to prevent protein 
degradation, the serine protease inhibitor, 4-(2-Aminoethyl) benzenesulfonyl 
fluoride hydrochloride (AEBSF, Sigma) was added and the supernatant 
samples stored at 4°C. Another five flasks were prepared as above and all the 
supernatant pooled prior to application to the bovine thyroglobulin column. 
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4.2.3 Protein purification chromatography 
4.2.3.1 Bovine thyroglobulin affinity chromatography column 
Using the specific binding to the carbohydrate sequence Galol-3Galß1- 
4GIcNAc found on bovine thyroglobulin, C. difcile toxin A is selected for and 
removed from the supernatant using repeated applications to the column. 
The column was prepared as described in Chapter 2, page 73. 
As described on pages 2.3.1, the column was washed with TBS and the 
filtered supernatant applied to column overnight at 4 °C. Unbound 
supernatant was washed from the column with TBS at 4°C and the column 
then transferred to 37°C and allowed to warm for an hour. The toxin A bound 
to thyroglobulin was eluted with warm TBS and the column washed with acidic 
buffer and basic buffer. The process was repeated to remove as much toxin A 
from the supernatant sample as possible. The column was finally washed and 
stored. 
4.2.4 Protein Precipitation using Ammonium Sulphate 
The addition of salt, (<0.15M) termed `salting in' increases the solubility of 
globular proteins and at higher concentrations salt solubility of the protein 
usually decreases leading to precipitation, termed `salting out' (Green 1955). 
This theory was applied for the selective precipitation of proteins. Using the 
toxin A depleted C. difficile supernatant previously stored at 4°C, 471g/L of 
ammonium sulphate was added to achieve 70% saturation and the solution 
stirred at room temperature for 30 minutes. The solution was subsequently 
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centrifuged at 5000 rpm for 30 minutes and the precipitate collected. The 
pelleted precipitate was re-suspended in 50mM Tris buffer (pH 7.4) and 
113.9g/L of ammonium sulphate was added to achieve 20% saturation. The 
solution was stirred at room temperature for 30 minutes and centrifuged at 
5000 rpm for 30 minutes. The supernatant was kept and 160.9g/L of 
ammonium sulphate added to obtain 50% saturation. The solution was stirred 
at room temperature for 30 minutes and subsequently centrifuged at 5000 
rpm for 30 minutes. The supernatant was discarded and the pellet re- 
suspended in 25 ml 50 mM Tris buffer (pH 7.4). To remove excess salt, the 
protein/Tris solution was dialysed against 50mM Tris buffer overnight at 4°C. 
4.2.5 Anion-exchange chromatography 
Anion exchange chromatography uses the positively charged beads inside the 
column to bind the negatively charged protein of choice. This ionic interaction 
is subsequently broken and the protein is eluted using a NaCl gradient, see 
Figure 2-2. 
Using AKTA PK900 Purifier (GE Healthcare) two sequential anion exchange 
chromatography runs were completed using DEAE-Q-Sepharose (Amersham 
Biosciences, Uppsala, Sweden) and Mono Q columns (Amersham Biosciences). 
The protocol for the purification of toxin B using the DEAE-Q-Sepharose 
column is identical to that for toxin A, with a linear salt gradient being used to 
elute the proteins. The Mono-Q protocol however, employs a linear 0-1 M salt 
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gradient for the purification of toxin A and a stepped 0-1 M gradient in the 
toxin B purification protocol. 
The presence of toxin B and remaining contaminating toxin A in the eluted 
fractions can be confirmed by the specific binding of mouse PCG-4 monoclonal 
antibody to C. difcile toxin A and binding of specific Mab monoclonal antibody 
to toxin B using Vectastain Universal Elite ABC kit (Vector) and VIP Substrate 
kit for peroxidase (Vector). Two identical membranes were prepared, one to 
identify toxin A contamination and the other to confirm the presence of toxin 
B. The method employed was identical to that previously described on page 
79 except the toxin A membrane was incubated with PCG-4 (125 pg/ml 
diluted 1: 10) and the toxin B membrane incubated with anti-toxin B antibody 
(1 mg/ml diluted 1: 1000). The toxin B fractions were pooled and dialysed 
against 20 mM Tris buffer overnight at 4°C. 
The pooled fractions were syringe filtered using a 0.2 pm filter and degassed 
using helium. The sample was injected into the super loop and this time 
passed through a Mono-Q (quaternary amine, a strong anionic exchanger) 
column and fractions eluted using`O-1M NaCI gradient. After immuno- 
histochemical analysis using Dot blot as described previously, toxin B 
containing fractions were pooled and concentrated using centrifugal filter 
devices (Millipore) with a 100kDa molecular weight cut-off (MWCO) as 
described in section 4.2.6.1 page 164 to achieve maximum concentration. 
Characterisation of the toxin B was then performed as previously described for 
toxin A purification. In addition western blot analysis was completed to 
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confirm the homogeneity of the protein sample. Results from an early 
representative run are shown in section 4.3.1. 
4.2.6 Protein characterisation 
Total protein concentration was established using the Bradford Assay. 
Cytotoxicity was assessed using the Vero assay as detailed in Chapter 2, 
2.4.3. 
4.2.6.1 Ultrafiltration and concentration 
To reduce the volume and concentrate the samples from 15 ml to 1 ml the 
samples were filtered and concentrated using a 100 kDa molecular weight cut- 
off filter, (Vivaspin 15, Millipore) as per the manufacturer's instruction. The 
retentate was held in the filter and removed using a fine needle and syringe. 
Smaller volume, 500 uI ultra filtration, (Amicon, Millipore) devices were also 
used and the retentate recovered by reversing the filter device into a clean 
eppendorf and pulsing to retrieve concentrated sample. 
4.2.7 SDS PAGE gel and Western Blot 
An SDS-PAGE gel and Western Blot analysis was used to ascertain 
homogeneity of purified samples. A detailed description of the materials and 
methods can be found in Chapter 2,2.8. 
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4.2.8 Native PAGE gel and Coomassie/Silver Staining 
A Native PAGE gel was used to establish homogeneity of purified samples. A 
detailed description of the materials and methods can be found in Chapter 2, 
2.4.4. 
4.2.9 Purified toxin B- Storage 
Aliquots of purified toxin were stored at 4°C and 
-80°C in the presence or 
absence of 20% glycerol and the cytotoxicity checked prior to use. 
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4.3 Results 
4.3.1 Purification of Clostridium difficile toxin B using old protocol 
Toxin B was purified by bovine thyroglobulin affinity chromatography and 
ammonium sulphate precipitation followed by two sequential anion exchange 
chromatography steps on DEAE Sepharose FF and Mono-Q as outlined earlier. 
Results from a representative run are given below. 
4.3.1.1 DEAE anion exchange chromatography 
Figure 4-2 profiles the application of crude supernatant to the DEAE column, 
the NaCl gradient applied and the resulting elution of protein. Arrows detail 
toxin positive fractions identified following a confirmatory dot blot. 
Comparison of Figure 4-2, the elution profile from the DEAE column and 
Figure 4-3, dot blot give clear evidence of an elution overlap of toxin A and B. 
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Figure 4-2 DEAE-Sepharose anion-exchange chromatography profile of C. 
diffidle toxin A purification 
Whole profile (top) and enlarged inset (bottom). X axis displays mAU values measured at 280 nm; 
Y axis details volume passing through the column and fractions. The peak represents purified 
protein eluted between fraction B10 and F2. Toxin A was found in eluted fraction C5-E9. Toxin 
B was found in eluted fractions D8-F1. The linear line crossing the peak represents the 0-1.0 M 
NaCl gradient used to elute the bound protein. 
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Figure 4-3 Dot blot of fractions eluted from the DEAE-Sepharose column 
Application of fractions Bl2-F2 to nitrocellulose membrane together with positive and negative 
controls were incubated with either specific PCG-4 for toxin A membrane (A) or Mab monoclonal 
for the toxin B membrane (B). Fractions C5 
- 
E9 (A) were confirmed to be toxin A when 
compared with positive control and fractions D8-F2 (B) were confirmed to be toxin B when 
compared with positive control. Fractions D8-E9 contains toxins A and B when referenced against 
positive controls. 
Toxin B positive fractions D11-F2 were pooled and dialysed overnight. 
4.3.1.2 Mono-Q anion exchange chromatography 
Dialysed fractions D11-F2 were applied to the Mono-Q column and fractions 
eluted using a stepped NaCl gradient 0-0.7 M with a 15 ml plateau at 0.7M 
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increasing 0.7-1 M. Several peaks eluted from the column as can be 
visualised in Figure 4-4. Confirmatory dot blots were completed, see Figure 
4-5, to establish the presence/absence of toxins A and B in the sample. As 
with the DEAE dot blots two identical dot blots were prepared and processed 
using either specific PCG-4 for toxin A (A) or Mab toxin B (B) to ascertain 
toxin B positive/toxin A negative fractions. Fractions B3-E6 expressed a trace 
of toxin A when referenced against the control. Looking at the Anti B dot blot, 
Fractions B11-F12 contains toxin B. From these results it would appear that 
fractions B11-E6 contain both toxin A and toxin B and E7-F12 is toxin B 
positive/toxin A negative. 
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Figure 4-4 Mono-Q anion exchange chromatography of C. difcile toxin A 
purification. 
Whole profile (top) and enlarged insets (bottom). X axis displays mAU values measured at 280 
nm; Y axis details volume passing through the column and fractions. Two peaks eluted from the 
column, the first eluting at fractions A6-D14, the other eluting in fractions D15-E11. The stepped 
line crossing the peak represents the NaCl gradient (0-0.7M with a 15 ml plateau and 0.7-1. OM) 
used to elute the bound protein. Immunohistochemistry of fractions found fractions B3-E6 to 
contain toxin A and fractions BII 
-F 12 to contain toxin B. 
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Figure 4-5 Dot blot of fractions eluted from the Mono-Q column 
Application of fractions A5-F12 to nitrocellulose membrane together with positive and negative 
controls were incubated with either specific PCG-4 for toxin A membrane (A) or Mab toxin B for 
the toxin B membrane (B). Fractions B3 
- 
E6 (A) were confirmed to be toxin A when compared 
with positive control and fractions B11-F 12 (B) were confirmed to be toxin B when compared with 
positive control. The obvious overlap may represent some cross reactivity but essentially the 
fractions also contain toxin A. 
4.3.1.3 Concentration and filtration 
Toxin B containing fractions eluted from the Mono-Q column were pooled and 
concentrated as described in the methods, page 164. Total protein 
concentration was established using the Bradford Assay and bovine albumin 
standards, as 107.2 pg/ml. A Native PAGE gel stained with Coomassie blue 
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revealed a very faint band above 250 kDa. Western Blot analysis using 
specific Mab toxin B was completed, no visible banding was evident. 
Identifying low protein concentration as a factor further centrifugal 
concentration of protein was completed, this however resulted in a lower 
protein concentration 65 pg/ml, possibly due to protein degradation. Another 
Native PAGE gel stained with Coomassie blue revealed very faint above 250 
kDa when compared against marker and a smaller molecular weight band 
between 70 and 50 kDa. Western blot analysis using specific Mab toxin B 
revealed no visible banding. Amino acid sequence analysis of the bands found 
in the Coomassie stained NATIVE gel was completed to ascertain if the 
proteins in the gel represented the protein of interest and a fragment of the 
protein of interest. The excised bands were not the protein of interest or a 
fragment. 
Three runs were completed using the above protocol. Two variations were 
introduced during these three runs. The first was to increase the volume of 
bacterial supernatant used; with 5 flasks being used in run 1; 10 flasks in runs 
2 and 3. The second variation was to pool toxin B positive / toxin A negative 
fractions in runs 1 and 2; in run 3 all toxin B positive fractions were pooled, to 
avoid any loss of toxin B and increase the final yield. The production of toxin 
B by the bacteria is far less than toxin A production. 
As can be observed in the above results, a number of issues were identified 
following the purification of toxin B using the above protocol. 
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" Toxin A was still present in the supernatant despite two runs through 
the bovine thyroglobulin column. 
" The close elution and therefore contamination of toxin B fractions with 
toxin A at the DEAE Sepharose stage 
" 
Poor final yield 
- 
too small/too weak for characterisation to be 
completed 
The current protocol takes three weeks from bacterial culture to purified 
protein sample. Reducing this time would limit protein degradation and loss of 
biological activity. The current protocol allowed toxins A and B to be eluted in 
the same peak resulting in either a reduced amount of toxin B because some 
of the fractions contained toxin A or a higher concentration of B which was 
contaminated with toxin A. The Issues outlined above have been added to the 
protocol flow chart, see Figure 4-6. 
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Figure 4-6 Flow diagram identifying problem areas in the current protocol 
used for toxin B purification. 
Current protocol issues highlighted in red.. 
4.3.2 Separation of toxin A and toxin B using revised protocol 
Investigation of elution patterns established that toxins A and B eluted in the 
same peak but eluted at different concentrations of NaCl. Toxin A eluted first 
at an average concentration of 12.5 mS/cm for approximately 75 mis and 
toxin B eluted at an average concentration of 29 mS/cm, some 34 mis after 
toxin A for an average of 46 mis. 
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Identifying a common elution pattern in the earlier runs using the DEAE 
column and the subsequent comparison of these results against the literature, 
a paper by Pothoulakis and colleagues (Pothoulakis, Barone et al. 1986), our 
DEAE column protocol was adjusted to introduce a step in the salt gradient 
and an intermediary wash of the column. The gradient ran 0-0.3 M NaCl 
followed by a 150ml wash at 0.3 M NaCl and then increased from 0.3-1.0 M 
NaCl (Figure 4-7). In addition to the change to our protocol, Buffer A 
currently used in the DEAE purification of toxin B was changed from 20 mM 
Tris buffer to 50 mM Tris buffer, in line with the buffer used by Pothoulakis et 
al (! bid). 
To increase the final yield' it was decided to grow more bacterial supernatant 
and therefore three batches of flasks (5 off), giving a total of 15 flasks, were 
prepared. This extended the purification time by one week, with AEBSF 
inhibitor added to batch 2 and 1 and stored for one or two week at 4°C, 
respectively. 
Using a larger volume of supernatant, the sample was prepared as previously 
described and subsequently applied to the DEAE-FF column and the sample 
eluted using the revised protocol and 50 mM Tris buffer. The eluted fractions 
were applied to dot blot and comparison of the elution profile (Figure 4-7) with 
the toxin A and toxin B dot blots (Figure 4-8) confirmed the two separate 
peaks of protein eluted from the column were toxin A positive - toxin B 
negative in the first peak and toxin B positive 
- 
toxin A negative in the second 
peak. Toxin A was found in fractions D4-H10 and toxin B was found in 
fractions J7-L13. 
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Toxin A Toxin B 
........................... _.................. Figure 4-7 Revised DEAE protocol highlighting stepped gradient and wash 
segment 
Whole profile (top) and enlarged insets (bottom) showing the elution of protein measured at A28° 
(Y axis) into designated fractions (X axis). The peaks represent purified protein. Toxin A was 
found in eluted fraction D4-H10 (Inset 1) and Toxin B was found in eluted fractions J7-L13 (Inset 
2). The linear line crossing the peak represents the revised protocol with stepped NaCl gradient at 
0.3 M, intermediary 150 ml wash and return to linear gradient 0.30 to 1.0 M NaCI to elute the 
bound protein. 
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Figure 4-8 Dot blot of fractions eluted from the DEAE-Sepharose column 
Application of fractions Al-L13 to nitrocellulose membrane together with positive and negative 
controls were incubated with either specific PCG-4 for toxin A membrane (A) or Mab toxin B for 
the toxin B membrane (B). Fractions D4 
- 
H10 (A) were confirmed to be toxin A when compared 
with positive control and fractions J7-L13 (B) were confirmed to be toxin B when compared with 
positive control. 
The revised DEAE protocol was used in all future purifications. With the toxins 
successfully separated, toxin B positive 
- 
toxin A negative fractions were 
pooled, dialysed overnight and applied to Mono-Q column as previously 
described. The Mono-Q elution profile can be viewed in Figure 4-9. Dot blot 
analysis of eluted fractions identified toxin B in C12-D7 and E1-F4 (Figure 
4-10). 
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Figure 4-9 Mono-Q anion-exchange chromatography profile of C. difficile toxin 
B purification 
X axis displays mAU values measured at 280 nm; Y axis details volume passing through the 
column and fractions. Two peaks eluted from the column, the first eluting at fractions All-DiI, 
and the other peak eluting in fractions El-F4. The stepped line crossing the peak represents the 
NaCl gradient (0-0.7M with a 15 ml plateau and 0.7-1. OM) used to elute the bound protein. 
Fractions C12-D7 and E1-F4 were confirmed to be toxin B when compared with positive control. 
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The presence of toxin B was confirmed by immuno-histochemistry in fractions 
C12-D7 and E1-F4. Toxin A was not traced. 
Figure 4-10 Dot blot of fractions eluted from the Mono-Q column 
Application of fractions B5-D7 and E1-F4 to nitrocellulose membrane together with positive and 
negative controls were incubated with either specific PCG-4 for toxin A membrane (A) or Mab 
toxin B for the toxin B membrane (B). Fractions C12- D7 and El- F4 (B) were confirmed to be 
toxin B when compared with positive control. Toxin A was not found when compared with 
positive control. 
Utilising the increased yield and the revised DEAE protocol we had successfully 
managed to produce enough toxin B positive/toxin A negative sample to allow 
characterization, see revised flow chart (Figure 4-11). 
4.3.3 Protein characterization 
- 
concentration and cytotoxicity 
Characterisation of toxin B positive fractions established protein concentration 
ranging 4- 52 ug/mI (pooled concentration 32 ug/ml) and cytoxicity (50 % 
rounding at 24 hours) ranging 10-2- 10-4. Pooled fractions were concentrated 
as previously described into two 1 ml aliquots and protein concentration 
established as 239 and 200 ug/ml and cytoxicity on Vero cells (50% rounding 
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at 24 hours) at 10-8. These samples were run on Native PAGE gel and stained 
with Coomassie Blue and Silver. 
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in DEAE purification 
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Mono-Q anion 
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storage 
Characterisation 
establish 50 kDa 
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Figure 4-11 Flow diagram identifying problem areas and areas optimized. 
Current protocol issues highlighted in red and optimization highlighted using blue text. 
4.3.4 Homogeneity 
Silver and Coomassie stained Native PAGE gels identified two bands, see 
Figure 4-12. As was expected identical bands were found in both samples. 
Proteomic analysis established the two bands using mass spectrometry to be 
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an enolase, mass 46 kDa and a heat shock protein, mass 58 kDa. Further 
proteomic investigation found that whilst toxin B was not present in the gel 
toxin B was present at the gel interface and had not migrated through the gel. 
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Figure 4-12 Native PAGE gel of purified C. difflicile toxin B 
Native PAGE gel stained with A) Coomassie Blue or B) Silver staining. Identical bands found in 
sample 1 and 2, highlighted inside the yellow box, the first band appearing just above the 140kDa 
marker and the second below the 140 kDa marker. 
Western blot analysis using specific Mab toxin B identified a number of 
positive bands and using the specific PCG-4 antibody confirmed the absence of 
toxin A, see Figure 4-13. 
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Figure 4-13 Western blot analysis of purified C. difficile toxin B 
Western blot analysis of toxin B samples 1 and 2 incubated with A) PCG-4 specific antibody for 
toxin A and B) Mab toxin B antibody specific for toxin B. The membranes confirm the absence of 
toxin A and the presence of a number of toxin B immuno-reactive bands confirming the presence 
of toxin B. Full Weight Rainbow Molecular Marker (GE Life Sciences RPN800E) Marker colour 
reference (M); Blue 
- 
225 kDa, Red 
- 
150 kDa, Green 
- 
102 kDa, Yellow 
- 
76 kDa, Purple 
- 
52 
kDa, Blue 
- 
38 kDa, Orange 
- 
31 kDa. 
The simultaneous completion of Coomassie stained SDS-PAGE and Western 
blot found a number of bands present in the Coomassie stained gel which 
were also evident in the Western blot incubated with Mab toxin B, see Figure 
4-14, but as was expected a number of contaminating bands were identified 
on the Coomassie stained SDS-PAGE that were not evident on the western 
blot incubated with toxin B specific antibody. These results confirm the 
contaminating proteins highlighted in the proteomics report. 
182 
225 
150 
L-- j 
L.. 4 
76 
6 52 
38 
31 
AB 
Figure 4-14 SDS PAGE gel of purified C. difcile toxin B 
7.5% SDS-PAGE gel stained with Coomassie blue (A) and the simultaneous transfer of proteins for 
Western Blot analysis using specific Mab for toxin B (B). Full Weight Rainbow Molecular Marker 
(GE Life Sciences RPN800E) Colour reference; Blue 
- 
225 kDa, Red 
- 
150 kDa, Green 
- 
102 kDa, 
Yellow 
- 
76 kDa, Purple 
- 
52 kDa, Blue 
- 
38 kDa, Orange 
- 
31 kDa. 
With the separation of toxin A and the increased yield allowing 
characterisation our focus moved to the other contaminating proteins eluting 
with the toxin B. 
4.3.5 Removal of contaminating proteins 
Starting with a fresh batch of bacterial supernatant I used the revised DEAE 
method, see Figure 4-7. Fractions eluted from the column formed two clear 
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peaks and comparing the elution profile and dot blot the second peak was 
identified as containing the protein of interest, toxin B. Taking a sample of 
each fraction we sought to establish if the contaminants co-elute, elute at the 
beginning; middle or end of our chosen peak. This was established by running 
the samples on a 7.5% SDS-PAGE and staining with Silver, the scanned gel 
can be observed in Figure 4-16 and the strength of the contaminating band 
corresponds with the increase in protein eluted. It would therefore appear 
that the contaminants appear to elute with the toxin. 
Until recently the application of pooled fractions were dialysed against 20mM 
Tris, applied to the Mono-Q column and then the proteins eluted using a 0- 
0.5M NaCl gradient with a 40 ml continuum at 0.5M followed by a second 
gradient on 0.5-1M NaCl, see 
which provides an elution profile from the Mono-Q. This protocol successfully 
eluted toxin B from the column, however analysis of homogeneity confirmed 
the co-elution and toxin B together with the contaminants, see Figure 4-14. 
Taking a sample from the beginning, middle and end of each peak; three 
peaks in total; giving nine samples it was established that the contaminant 
was found in the first two peaks. The eluted fractions were cytotoxic when 
applied to Vero cells and toxin B positive when reference against a positive 
control on a dot blot. The fractions were concentrated up using concentrator 
columns with a 100 kDa molecular weight cut-off. The contaminant was not 
removed with this filter therefore it would appear that either the contaminant 
forms a complex with toxin B or that it may form a homo-oligomer. 
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Figure 4-15 DEAE Sepharose anion exchange chromatograpny profile 
Whole profile (top) and enlarged insets (bottom) X axis displays mAU values measured at 280 nm; 
Y axis details volume passing through the column and fractions. The peaks represent purified 
protein. Toxin A was found in eluted fractions C7-F8 and toxin B was found in eluted fractions 
J3-K3. The linear line crossing the peaks represents the revised protocol with stepped NaCl 
gradient at 0.3M, intermediary 150 ml wash and return to a linear gradient 0.3-1.0 M to elute the 
bound protein. 
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Figure 4-16 SDS-PAGE gel of C. difFcile toxin B containing fractions eluted 
from the DEAE-Sepharose column 
Fractions were denatured with 2-mercaptoethanol and run on SDS-PAGE and Silver stained. As 
previously viewed the contaminant is between 52-76 kDa in size and elutes throughout the toxin B 
positive peak with the band strength corresponding with the peak in. M (Full Weight Rainbow 
Molecular Marker (GE Life Sciences RPN800E)). 
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Figure 4-17 SDS-PAGE gel of fractions containing C. difficile toxin B and 
contaminant eluted from the Mono-Q column 
Fractions denatured with 2-mercaptoethanol, run on 7.5% SDS-PAGE and Silver stained. As 
previously viewed the contaminant is between 52-76 kDa in size. The fractions analysed were 
taken from the beginning, middle and end of the three peaks eluted from the Mono-Q. The 
contaminant can be observed in the first two peaks but not the third. M (Full Weight Rainbow 
Molecular Marker (GE Life Sciences RPN800E)) 
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To identify whether this complex could be successfully reduced to two 
separate proteins the solution containing toxin B and the contaminant was 
incubated with either 2-mercaptoethanol, DTT or PBS at room temperature for 
1 hour. Following the incubation the solution was concentrated using the 100 
MWCO filters, run on an SDS-PAGE and silver stained, see Figure 4-18. 
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Figure 4-18 SDS-PAGE gel of contaminant removal from toxin B positive 
fractions 
Comparison of immuno-histochemistry and the earlier SDS-PAGE fractions CI1-D11 were pooled 
and following a1 hr incubation with PBS (I and 2); DTT (3) or 2-mercaptoethanol (4), samples 2. 
3 and 4 were concentrated using 100 MWCO filters and ran on a SDS-PAGE. The gel was stained 
with silver and scanned. M (Full Weight Rainbow Molecular Marker (GE Life Sciences 
RPN800E)). 
The addition of reducing agents DTT (1 mmol/litre) or 2-Mercaptoethanol (5% 
v/v) for 1 hour prior to concentrating did not denature the contaminant and 
was not removed using the 100 MWCO filter, see Figure 4-18. 
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Having established a solution to the separation of toxins A and B, it was now 
important to resolve the issue of contamination. Further review of the 
literature identified a possible solution. The contaminating proteins have been 
reported previously. Meador and Tweten found that two contaminating 
proteins were eluted with toxin B, the first which was only occasionally eluted 
was a 45kDa protein and the other a 50 kDa protein that regularly 
contaminated toxin B purification attempts (Meador and Tweten 1988). 
Establishing that the 50 kDa protein was neither cytotoxic nor a fragment of 
toxin B, Meador and Tweten successfully managed to remove both of these 
contaminants and maintain the cytotoxicity of the purified toxin B. Instead of 
using a Tris based buffer, Meador and Tweten combined Tris and Calcium 
chloride and used this buffer solution to dialyse the toxin solution prior to the 
Mono-Q purification and as a buffer throughout the application and elution of 
the proteins from the Mono-Q column. In addition to the alteration made to 
the buffer, the gradient used was slightly different and the flow rate was also 
reduced. 
In line with the method used by Meador and Tweten, toxin B positive fractions 
from our revised DEAE method were dialysed against 10 mM Tris 50 mM CaCI 
buffer pH 8, our current stepped gradient removed and the flow rate reduced 
to 0.5 ml/min, see Figure 4-20. Figure 4-19 updates the protocol flow 
diagram with the current stage of toxin B optimization. 
188 
Supernatant sample of 
anaerobically cultured 
Clostridium difficile 
Bovine thyroglobulin 
affinity chromatography 
Ammonium sulphate 
precipitation 
DEAE-FF-Sepharose 
anion exchange 
chromatography 
Mono-Q anion 
exchange 
chromatography 
Characterisation and 
sto rage 
Toxin A and toxin B 
elution separated 
with introduction of 
150 ml wash segment 
in DEAE purification 
protocol. 
Toxin yield higher but 
contaminating 
proteins eluting with 
toxin B 
Toxin B purified. 
improve yield? 
Elution buffer 
changed to include 
Calcium chloride 
- 
stepped NaCI gradient 
changed to linear and 
flow rate reduced to 
separate toxin B from 
contaminants 
Figure 4-19 Flow diagram identifying problem areas and areas optimized. 
Current protocol issues highlighted in red and optimization highlighted using blue text. 
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Figure 4-20 Revised Mono-Q protocol highlighting the linear salt gradient 
Whole profile (top) and enlarged inset (bottom). Showing the elution of protein measured at A28° (Y axis) into designated fractions (X axis) of the revised protocol which removed the step at 0.7 M 
and reduced the flow rate to 0.5 ml/min. Two peaks eluted from the column, the peak I eluting at 
fractions B9-B15, and peak 2 eluting in fractions C8-C12. The line crossing the peak represents the 
NaCl gradient (0-1.0 M) used to elute the bound protein. 
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Two peaks eluted from the Mono-Q and fractions from each peak were pooled, 
concentrated and the proposed contaminant (peak 1) and toxin B (peak 2) 
samples were run on SDS-PAGE and silver stained. 
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Figure 4-21 SDS-PAGE gel of pooled fractions eluted using the revised Mono-Q 
protocol 
Pooled fractions from peak I and peak 2 derived from the Mono-Q column (Figure 4-20). 1) Toxin 
B estimated at 250 kDa 2) unknown contaminant 3) unknown contaminant 4) other contaminants. 
M (Full Weight Rainbow Molecular Marker (GE Life Sciences RPN800E)) 
As can be viewed from the scanned image of the SDS-PAGE Figure 4-21, peak 
1 clearly contains a high concentration of the contaminant and a selection of 
other contaminants. It does however also contain toxin B. Looking at peak 2, 
this peak contains toxin B, it may still contain traces of the contaminant. 
Cytotoxicity of the fractions prior to pooling confirmed the above with 
cytotoxicity being recorded in fractions taken from the first peak. The second 
191 
M Peak 1 Peak 2M 
peak was also cytotoxic 
- 
but a higher cytotoxic effect was noted. Cytotoxicity 
was reduced in fractions pooled to make peak 2 and failed to be increased in 
fractions pooled into peak 1. This would suggest that activity is being lost as 
a result of degradation of toxin B and/or through the process of concentration. 
Peak 1 was also run on Native PAGE to ascertain size of the contaminant. 
From the scanned image and the proposed positioning of the molecular 
marker, the contaminant would appear to be around between 140 and 232 
kDa in size and may represent a homo-oligomer. 
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Figure 4-22 Native PAGE gel of contaminant (pooled peak 1 fractions) eluted 
from the Mono-Q column using the revised protocol. 
A high weight molecular protein mixture (Amersham Biosciences) (M) containing 76 µg of 
thyroglobulin (Mw 669 000 Da), 50 µg of Ferritin (Mw 440 000 Da), 36 µg of Catalase (Mw 232 
000 Da), 48 pg of lactate dehydrogenase (Mw 140 000 Da) and 40 µg of Albumin (Mw 66 000) 
was used as a marker and comparison of the contaminant against the known molecular weights 
seen the contaminant is between 140-232 kDa. 
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To increase overall yield and prevent loss of biological activity it was decided 
to withdraw the thyroglobulin step and proceed immediately to ammonium 
sulphate precipitation. In addition, five more flasks were purchased and 10 
flasks could be harvested in one week, limiting protein degradation and loss of 
cytotoxic activity. Using the revised protocol as detailed in Figure 4-23 
Clostridium difficile toxin B was successfully purified. 
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Figure 4-23 Flow diagram of final optimized protocol for purification of C. 
difficile toxin B. 
Optimization highlighted using blue text. 
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4.4 Stability and cytotoxic activity of Clostridium difficile toxin B 
The successful purification of Clostridium diffcile toxin B has enabled 
experiments investigating the response of intestinal epithelial cells types and 
primary colonic myofibroblasts to be conducted. Toxin B is reported to 
particularly susceptible to degradation and early loss of biological activity 
(Meador and Tweten 1988) with storage at 
-80°C in 20% glycerol reported as 
the best method of storage. Investigating biological activity in a batch of 
purified toxin B using the Vero assay as described previously, the cytotoxic 
activity of toxin B stored at 4°C in Tris buffer and an identical sample stored in 
20% glycerol in 20 pl aliquots at 
-80°C was assessed. 
The cytotoxic activity of the purified toxin stored at 4°C In Tris buffer was 
assessed on a weekly basis for the first four weeks and then fortnightly 
thereafter; the total period of assessment was 12 weeks. The cytotoxicity of 
this batch was assessed upon purification with a cytotoxicity titre 100 % 
rounding at 10-24. The cytotoxic activity remained at 10-24 for 1 month after 
which a gradual reduction 
. 
in activity was recorded. After two months of 
storage at 4°C the cytotoxic activity was 10"14 and by the third month 
cytotoxic activity had fallen to 10"4 
Due to the shortage of toxin B; analysis of the frozen samples was only 
completed twice, the cytotoxic activity being established prior to freezing and 
checked after one week. 
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The remaining purified toxin B from this batch was used in experiments 
investigating the intestinal epithelial cell response to toxin B and as discussed 
in Chapter 5, the cytoxicity of this batch of toxin B stored at 
-80°C had lost 
considerable biological activity, with the pre-frozen titre established at a 
concentration of 10"24 and the defrosted toxin B sample at 10"5 when the 
cytotoxicity was checked. 
My characterization of purified toxin B supports early findings which highlight 
the instability of the purified toxin, however my findings suggest the purified 
toxin can be stored for at least eight weeks before a reduction in biological 
activity is observed. Unless otherwise stated, all toxin B experiments were 
conducted with purified toxin stored at 4°C in Tris buffer and the cytotoxic 
activity established using Vero cells as discussed previously prior to 
application. 
4.5 Discussion 
In contrast to toxin A purification, which has been successfully purified within 
the institute over many years, toxin B purification has proven more difficult. 
The initial aim of my protocol was to see if toxin B could be purified after 
depletion of toxin A via the thyroglobulin column. Whilst the thyroglobulin 
column removed most of the toxin A, a considerable amount of toxin A was 
still found in supernatant samples even after two consecutive applications to 
the column and ammonium sulphate precipitation. This was supported by a 
confirmatory dot blot of fractions eluted from the DEAF column Indicating 
strong Immunoreactivity to the PCG-4 antibody. The inclusion of a stepped 
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salt gradient with an extended wash segment resulted in the successful 
separation of toxin A and toxin B. With other modifications to the protocol, 
namely the change to the buffer used and a reduction in the flow rate used 
during the elution of toxin from the Mono-Q column, toxin B has been purified 
with only minor contamination. Removal of the thyroglobulin column and an 
increase in starting supernatant has ensured a greater yield and the reduction 
in purification time has resulted in greater cytoxicity activity in purified toxin 
B. 
The successful purification of toxin B has allowed studies on Caco-2 and HT29 
cells to be carried out and comparative studies of the responses to toxin A, B 
and A+B by primary colonic myofibroblasts. 
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CHAPTER 5 
197 
5 Caco-2 cells are more sensitive to toxin B-induced cell 
death than HT29 cells 
5.1 Introduction 
The primary target of luminal C. difficile toxins is believed to be the 
intestinal epithelial cells and as discussed in the introduction to Chapter 3 
the response of epithelial cells may determine the severity of mucosal 
inflammation. Following on from my toxin A investigations on intestinal 
epithelial cells my interest naturally turned to epithelial cell response to 
toxin B. 
Our understanding of the role of toxin B in the pathogenesis of Clostridium 
difficile associated disease (CDAD) has become clearer over the last thirty 
years. With early claims suggesting the bacteria only produced one 
cytotoxin, early animal experiments suggested only toxin A mediated C. 
difficile associated diarrhoea and enterocolitis whilst others argued that 
toxin B was unable to elicit disease in the absence of toxin A. In 1995 
Reigler reported that the human colon was 10 times more sensitive to 
toxin B than A and may therefore be more important In C. difficile 
pathogenesis (Riegler, Sedivy et al. 1995). It was In 2003, after the 
isolation of toxin A-negative toxin B-positive toxigenic strains, that toxin B 
was considered as a major virulence factor in CDAD (Johnson, Sambol et 
al. 2003; Komatsu, Kato et al. 2003; Rupnik, Kato et at. 2003). This belief 
was supported by Savidge and colleagues who by generating a chimeric 
animal model using human intestinal xenografts found that toxin B caused 
similar pathophysiological response to that observed with toxin A (Savidge, 
Pan et al. 2003). What is clear today is toxin B is a powerful cytotoxin 
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which is significantly more potent than the enterotoxic activity of toxin A. 
Investigation of epithelial response to toxin B will complement my 
research, comparing my observations of epithelial cell responses with the 
response of these cell types to toxin B. 
Utilising a similar mechanism to toxin A, toxin B secreted by toxigenic 
Clostridium difficile into the lumen preferentially binds to receptors located 
on the basolateral surface of the host cell (Stubbe, Berdoz et al. 2000). 
The toxin is then internalised by receptor mediated endocytosis and 
following acidification the catalytic domain is transiocated into the cytosol 
whereby it inactivates small GTPases, Rho, Rac and CDC-42 (Just, Fritz et 
al. 1994; Just, Selzer et al. 1995). The inactivation of these key molecular 
switches alters cell signalling and ultra structural maintenance leading to 
dramatic changes in cell physiology (Just and Gerhard 2004; Jaffe and Hall 
2005). 
Early research reported dramatic phenotypic alterations in non-intestinal 
epithelial cells exposed to C. difficile toxin B which appeared to occur as a 
secondary response to the toxin induced actin re-organisation (Mitchell, 
Laughon et al. 1987; Fiorentini, Fabbri et al. 1998). Interested in the 
response of intestinal epithelial cells to toxin B, Hecht cultured T84 cells 
reported a similar response in T84 cells to that reported in non-intestinal 
epithelial cells. T84 cells rounded and barrier function was reduced due to 
a toxin induced alteration at the tight junction but cell death was not 
reported. (Hecht 1992). 
Looking to further investigate the cellular response to toxin B, Chaves 
Olarte investigated the response of Don and T84 cells to toxins A and B 
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(Chaves-Olarte, Weidmann et al. 1997) and reported toxin B to be 1,000 
times more potent than toxin A and microinjection of toxins A and B 
established that this difference was due to greater enzymatic activity of 
toxin B and to a lesser extent, toxin binding. Supporting these findings 
Ciesla et al found a significant catalytic difference when comparing UDP- 
glucose hydrolysis in toxin B and toxin A exposed cells (Ciesla and Bobak 
1998). 
Comparing the morphological changes induced by toxins A and B in a 
selection of cultured cells, Donta et al reported toxin B as more active than 
toxin A and of particular interest, they also reported no significant 
difference in the cellular sensitivities across the cell types to toxin B 
(Donta, Sullivan et al. 1982). In contrast, a greater variation in cellular 
response was reported in toxin A exposed cells (Donta, Sullivan et al. 
1982). Of particular interest, a similar comparative study conducted by 
Fiorentini et al suggested the origin and proliferative rate of the target cell 
may also contribute to the toxin B induced response (Fiorentini, Fabbri et 
al. 1998). Using IEC-6, Int407, HT29 and A431, Fiorentini revealed toxin B 
to be a time and dose dependent inducer of apoptosis. Comparative 
research using rabbit ileal loops and cultured cells established some 
contrasting and competing evidence. Whilst toxin A and B produce an 
additive effect on cultured cells, exposure of rabbit ileal loops to A and B 
worked in synergy to cause disease only at high doses (Florentini, Fabbri et 
al. 1998). 
The aim of this work is to compare responses to C. difflcile toxin B by 
Caco-2 and HT29 human intestinal epithelial cells. 
200 
5.2 Materials and methods 
5.2.1 Purification of toxin B 
Toxin B was purified using the revised protocol as outlines in Chapter 4. In 
brief, toxin B was by ammonium sulphate precipitation of cultured C. 
difficile (VPI 10463) supernatant samples followed by two sequential anion 
exchange chromatographic steps as detailed in Chapter 4,4.3. Protein 
concentration and cytotoxic activity were established prior to use. 
As highlighted in Chapter 4, purified toxin B is extremely fragile with 
degradation and loss of biological activity observed within one week of 
purification. It has therefore been essential to assess cytotoxic activity 
and protein concentration prior to commencing any experiments. Section 
5.4.1 of this Chapter will highlight the importance of establishing protein 
concentration and biological activity of toxin B before experimentation. 
5.2.2 Early experiments 
Having already investigated the response of intestinal epithelial cells to C. 
difficile toxin A and establishing a cell specific response in which Caco-2 
cells are more sensitive to toxin A-induced cell death, I was interested to 
see if this sensitivity was also apparent when the cells were exposed to 
toxin B. Intestinal epithelial cells, Caco-2 and HT29 were grown to 70% 
confluence in 24-well plates and using similar toxin B concentrations to 
those used in early toxin A experiments, morphological assessments were 
made at 1,2,3,24,48 and 72 hours. Cell viability was assessed using the 
MTT assay at 72 hours. 
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5.2.2.1 Effect of seeding densities on epithelial cell response 
Caco-2 and HT29 cells were seeded at 4.5 x 105,9.0 x 104 and 2x 104 and 
grown for 24 hours. At 24 hours, the media was replaced with 1000 ng/ml 
toxin B in DMEM supplemented for either Caco-2 or HT29 cells and 
morphological assessments made at 1 h, 2 h, 4h and 24 h. 
5.2.2.2 Intestinal epithelial cell and Vero cell response compared 
As previously discussed the African Green Monkey (Vero) cell response Is 
the gold standard cell type used to establish the cytotoxicity of C. difficile 
toxins. Using, Caco-2, HT29 and Vero cells seeded in 96 well plates 
cellular responses were recorded at 24 h and 48 h. Toxin B was taken 
from two separate batches and serial dilutions were prepared with either a 
starting concentration of 10,000 ng/ml or 1,000 ng/ml in the less 
concentrated batch samples. Morphological assessments were made at 24 
h and 48 h. Cytotoxicity was recorded as lowest possible concentration to 
induce 50% rounding at 24 h and 48 h. 
The findings from these experiments were used to structure future work 
using C. difficile toxin B. 
5.3 Epithelial cell response to Clostridium difficile toxin B 
Caco-2 and HT29 cells were seeded, grown to 40% confluence and 
exposed to serial dilutions of toxin B ranging from 1 000 ng/ml through 10 
ng/ml, prepared using a previously characterized fraction of toxin B with a 
known concentration of 0.73 mg/ml and a pre-experimental cytotoxicity 
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titre of at least 10"16 at 24 hours. Cells were incubated with toxin B for 72 
h. Morphological assessments were made hourly from 1h to 72 h. 
5.3.1 Cell cytotoxicity established using MTT assay 
Cell cytotoxicity was measured in Caco-2 and HT29 cells incubated with 
varying concentrations of C. di G/e toxin B at 48 h and 72 h using the 
MTT assay as described in Chapter 2, section 2.7.1. 
5.3.2 Propidium Iodide staining and cell cycle analysis 
Cell cycle analysis was performed on Caco-2 and HT29 cells incubated with 
1000 ng/ml of toxin B for 8,24,48 and 72 hours using propidium iodide 
and flow cytometry as described in Chapter 2, section 2.7.3. Toxin- 
exposed cells were compared with cells cultured with control medium, 
seeded at the same time and obtained at the same time points as those 
cultured in the presence of the toxin. 
5.3.3 Rho protein expression 
Investigation of Rho signalling in intestinal epithelial cells was completed 
using whole cell lysates from HT29 and Caco-2 cells in control and toxin B 
treated samples and the western blot technique using Rho specific 
antibodies for detection. See Chapter 2 section 2.8. The proteins 
investigated included Rac-1, RhoA. ß-actin was used as a loading control. 
HT29 and Caco-2 intestinal epithelial cells were incubated with 1,000 
ng/mi toxin B or control medium for 0 h, 3 h, 8 h, and 24 h. A western 
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blot was completed for each protein to be investigated, including a loading 
control. A colour scan was made of each western blot. 
5.4 Results Intestinal epithelial cell response to C. difficile toxin B 
5.4.1 Initial experiments identified low biological activity in toxin B 
Early experiments investigated the morphological changes and cell viability 
of intestinal epithelial cells to Clostridium diffcile toxin B. Using a toxin 
sample with a pre-frozen cytotoxicity of titre of 10-24, serial dilutions were 
performed as previously described and applied to sub-confluent epithelial 
cells, Caco-2 and HT29. Morphological assessments were made at 1,2,3, 
24,48 and 72 hours. With only minimal rounding after 24 hours at the 
highest concentrations, cytotoxic activity of this thawed batch of toxin B 
was rechecked in Vero cells. The thawed sample had lost considerable 
biological activity and the new titre was 10"5. It was not until 48 hours 
that 50 % rounding was visible at 1000 ng/ml and at 72 hours rounding 
had risen to 100% and 50% at the two highest concentrations 1000 ng/ml 
and 100 ng/ml, respectively. Given the limited biological activity seen, it 
was decided to only complete the cell viability assay at 72 h. As can be 
viewed in Figure 5-1 A, a small (not statistically significant) dose 
dependent reduction of cell viability measured using the MTT assay was 
apparent in Caco-2 cells exposed to toxin B. HT29 cells provided an 
inconclusive picture with lower concentrations displaying a reduction but 
the highest concentration giving an Increase in mitochondrial 
dehydrogenase activity and hence cell viability. It is worth noting that the 
reduction or increase in mitochondrial dehydrogenase activity Is not 
statistically significant, see Figure 5-1 B. Comparison of mitochondrial 
dehydrogenase activity in untreated control and toxin treated cells at 1000 
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ng/mI for 72 hours (Figure 5-2) confirmed a small (non-significant) 
reduction in cell viability of Caco-2 cells exposed to 1000 ng/ml for 72 
hours and a small (non-significant) increase in cell viability of HT29 cells 
exposed to the same concentration for 72 hours. 
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Figure 5-1 Mitochondrial dehydrogenase activity (MDA) in Caco-2 and 
HT29 cells to C. difci/e toxin B (1-1000 ng/ml) 
MTT assay for mitochondrial dehydrogenase activity (expressed as OD 570 nm) in (A) Caco-2 
cells and (B) HT29 cells exposed to varying concentrations of toxin B for 72 h. Data in figures 
represent mean (fSEM) of 3 experiments performed in triplicate. 
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Figure 5-2 Mitochondrial dehydrogenase activity (MDA) in Caco-2 and 
HT29 cells to C. difficile toxin B (1000 ng/ml) 
MTT assay for mitochondrial dehydrogenase activity (expressed as OD 570 nm) in Caco-2 (A) 
and HT29 (B) cells exposed to 1000 ng/ml of toxin B for 72 h. Data in bars represent mean 
(±SEM) of 3 experiments performed in triplicate. 
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5.4.2 Seeding density and % confluence on epithelial cell response. 
Establishing loss of biological activity as the primary reason for the 
response observed, the relationship between seeding density and 
morphological response following toxin B exposure was investigated. 
Caco-2 and HT29 cells were seeded at three densities, grown for 24 h and 
then incubated with 1000 ng/ml of toxin B. Caco-2 and HT29 cells were 
observed at 1 h, 2 h, 4h and 24 h and percentage rounding, to the 
nearest 10% recorded. As can be viewed in Table 5-1, using these seeding 
densities and subsequent cell monolayer confluence no difference was 
observed using 1000 ng/ml of toxin B for each cell type. As would be 
expected a small difference was noted when the cells were compared 
against each other with Caco-2 cells rounding earlier and rounding 
percentage increasing to a higher rate. 
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5.4.3 Cytotoxic comparison of Caco-2 and HT29 cells to C. difficile toxin B 
Subsequent experiments investigated the response of intestinal epithelial 
cells, Caco-2 and HT29, to varying concentrations of C. difficile toxin B 
ranging 10 ng/ml through to 1 000 ng/ml. A new batch of purified toxin B 
was used and the cytotoxicity established prior to starting the experiment 
as 10"16 (lowest dilution to induce 50% rounding at 24 h). Morphological 
changes were assessed from 1h- 72 h and cellular viability/cytotoxic 
effect established at 24,48 and 72 h. 
5.4.3.1 Alterations to cell morphological 
Morphological assessment was made using light microscopy and the cells 
in each well categorized into one of three morphological stages; no visible 
rounding; 50% visible rounding and 100 % visible rounding. Detailed 
phase contrast micrographs of toxin treated and control HT29 and Caco-2 
cells can be observed in Figure 5-3, Figure 5-4, Figure 5-5, Figure 5-6, 
Figure 5-7, Figure 5-8 and Figure 5-9. Cell rounding occurred in a time- 
and dose-dependent manner with 50% and 100% rounding observed in 
Caco-2 cells after 1h incubation with 100 ng/ml and 1000 ng/ml, 
respectively. Rounding in HT29 was first observed at 2h to 1000 ng/ml, 
see Table 5-2. As observed with C. difcile toxin A, an Increase in non- 
adherent Caco-2 cells was observed from 24 h (Figure 5-7) to 1000 ng/mi 
and by 72 h (Figure 5-9) most cells appeared to be floating with 
morphological characteristics of non-viable cells. In contrast to the 
observed adherence of HT29 cells incubated with C. difficile toxin A, cell 
incubated with 1000 ng/ml toxin B appeared to be losing adherence with 
some cells observed floating at 48 h (Figure 5-8) and 72 h (Figure 5-9). 
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with C. difficile toxin B for 1h 
Intestinal epithelial cells Caco-2 and HT29 grown to 40% confluence were incubated with 
purified toxin B (10-1000 ng/ml) or control medium. 
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Figure 5-3 Phase contrast micrographs of Caco-2 and HT29 cells incubated 
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Figure 5-4 Phase contrast micrographs of Caco-2 and HT29 cells incubated 
with C. difficile toxin B for 2h 
Intestinal epithelial cells Caco-2 and HT29 grown to 40% confluence were incubated with 
purified toxin B (10-1000 ng/ml) or control medium. 
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Figure 5-5 Phase contrast micrographs of Caco-2 and HT29 cells incubated 
with C. difficile toxin B for 4h 
Intestinal epithelial cells Caco-2 and HT29 grown to 40% confluence were incubated with 
purified toxin B (10-1000 ng/ml) or control medium. 
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Figure 5-6 Phase contrast micrographs of Caco-2 and HT29 cells incubated 
with C. difficile toxin B for 8h 
Intestinal epithelial cells Caco-2 and HT29 grown to 40% confluence were incubated with 
purified toxin B (10-1000 ng/ml) or control medium. 
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Figure 5-7 Phase contrast micrographs of Caco-2 and HT29 cells incubated 
with C. difficile toxin B for 24 h 
Intestinal epithelial cells Caco-2 and HT29 grown to 40% confluence were incubated with 
purified toxin B (10-1000 ng/ml) or control medium. 
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Figure 5-8 Phase contrast micrographs of Caco-2 and HT29 cells incubated 
with C. difrfcile toxin B for 48 h 
Intestinal epithelial cells Caco-2 and HT29 grown to 40% confluence were incubated with 
purified toxin B (10-1000 ng/ml) or control medium. 
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Figure 5-9 Phase contrast micrographs of Caco-2 and HT29 cells incubated 
with C. difficile toxin B for 72 h 
Intestinal epithelial cells Caco-2 and HT29 grown to 40% confluence were incubated with 
purified toxin B (10-1000 ng/ml) or control medium. 
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5.4.4 Investigation of cellular viability using the MTT assay 
Cell viability was established after 24 h, 48 h and 72 h (Chapter 2,2.7.1). 
5.4.4.1 Caco-2 cellular viability 
- 
10 ng/ml 
-1000 ng/ml toxin B 
Caco-2 intestinal epithelial cells exposed to C. difficile toxin B showed a 
reduction in mitochondrial dehydrogenase activity, which reflects cell viability, 
in a time and dose dependent manner. A significant reduction in cell viability 
was seen when Caco-2 cells were exposed to concentrations of toxin 21000 
ng/ml at 48 hours, at 72 hrs highly significant reduction in cell viability was 
observed when compared to control (untreated cells) (Table 5-3). Of interest, 
although a dose dependent response was observed at the later time points, 
cellular viability in Caco-2 cells remained fairly consistent at 24 hours with 
minimal reduction in cell viability when the concentration of toxin B was 
increased, see Figure 5-10 A. Cells exposed to concentrations <1000 ng/ml 
presented with some loss of cell viability, however not significantly so, even 
after 72 hour exposure to the toxin (Table 5-3 A). 
5.4.4.2 HT29 cellular viability 
- 
10 to 1 000 ng/ml toxin B 
HT29 intestinal epithelial cells exposed to C. difficile toxin B showed a small 
reduction in mitochondrial dehydrogenase activity reflecting a time dependent 
loss of cell viability by 72 hours, see Table 5-3. No significant difference was 
noted at 24 h 48 h or 72 h at any concentration when compared against 
control (untreated cells), see Table 5-3 B. Observing Figure 5-10 B, a dose 
dependent response was not observed as viability remained largely constant 
across all three concentrations investigated. 
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Table 5-3 Mitochondrial dehydrogenase activity (MDA) in Caco-2 and HT29 
cells to C. difcile toxin B (10-1000 ng/ml) 
MTT assay for mitochondrial dehydrogenase activity (expressed as OD 570 nm) in (A) Caco-2 
cells and (B) HT29 cells exposed to varying concentrations of toxin B for 24 h, 48 h and 72 h. 
Data in table presents mean (±SEM) of 3 experiments performed in triplicate. ** = p<0.01 
p<0.05 when compared with control (Cytotoxicity of toxin B on Vero cells 10'16) 
A 
Conc. Period of exposure (h) 
(ng/ml) 24 48 72 
Control 0.4613 ± 0.0198 0.4450 ± 0.0092 0.4187 t 0.0171 
10 0.4623 ± 0.0196 0.4597 ± 0.0035 0.4227 t 0.0073 
100 0.4537±0.0191 0.4350±0.0158 0.3817±0.0189 
1000 0.4693 ± 0.0 174 0.3880 ± 0.0074 ** 0.2633 ± 0.0209 
B 
Conc. Period of exposure (h) 
(ng/ml) 24 48 72 
Control 0.4927 ± 0.0030 0.4730 ± 0.0116 0.4753 t 0.0092 
10 0.4933 ± 0.0134 0.4840 ± 0.0059 0.4693 f 0.0 159 
100 0.4783 ± 0.0128 0.4680 ±0.0100 0.4490 f 0.0030 
1000 0.4943 ± 0.0113 0.4943 ± 0.0030 0.4653 ± 0.0104 
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Figure 5-10 Mitochondrial dehydrogenase activity (MDA) in Caco-2 and HT29 
cells to C. difficile toxin B (10-1000 ng/ml) 
MTT assay for mitochondrial dehydrogenase activity (expressed as OD 570 nm) in Caco-2 (A) 
and HT29 (B) cells exposed to varying concentrations of toxin B for 24 h, 48 h and 72 h. Data in 
bars represent mean (±SEM) of 3 experiments performed in triplicate. *= p<0.05 **= p<0.01 when 
compared with control. 
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5.4.5 Analysis of PI stained DNA by FACS confirm cell loss 
Caco-2 and HT29 cells incubated with 100 ng/ml toxin B or control media 
were fixed at 8 h, 24 h, 48 h and 72 h, stained with Propidium Iodide and 
fluorescence emitted assessed by flow cytometry. Using WinMDI 2.9 and cell 
cycle analysis programme Cyclhred as described in Chapter 2 the number of 
events in the sub-G1 region was ascertained and this number presented as a 
percentage of the total events recorded, comparing the percentage events in 
the sub-G1 region in toxin B-treated cells with control (untreated) cells. 
As can be viewed in Figure 5-11 A, an increase in the % Sub-G1 cells is 
evident from 8 hours in toxin treated Caco-2 cells when compared with control 
cells and a time dependent increase observed up to 72 hour. A significant 
increase in the % sub-G1 events is first observed at 8h [mean toxin 13.44% 
(±SEM 2.38) vs control 3.77% (±0.52) p=<0.05], however despite the 
obvious increase in % sub G1 events through to 72 h, the increase was not 
statistically significant when compared with control (untreated cells) at 24h 
and 48 h but statistical significance was observed at 72 h [toxin 22.03 
(±6.53) vs control 3.37% (±0.20) p<0.05], see Table 5-4. The absence of 
statistical significance at 
-24 h and 48 h may be explained by the range of 
results (24 h% sub G1 events 8%-23% & 48 h% sub G1 events 5% 
- 
38 %] 
in toxin B exposed Caco-2 cells. By comparison a small (non-significant) time 
dependent increase in percentage of sub-G1 events in toxin B exposed HT29 
cells is noted when compared with control (untreated) cells, see Figure 5-11 
B. 
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Table 5-4 Sub-G1 events in toxin treated Caco-2 and HT29 cells 
Percentage of sub-G1 events in toxin treated (100 ng/ml toxin B [Batch J2C, cytotoxic activity on 
Vero cells x10"88]) and control (untreated cells at 8,24,48, and 72 h. Percentage calculated using 
total events and number of events in the sub-GI region when analysed using Cyclhred. Data in 
figures represent mean (±SEM) of 3 experiments performed in triplicate. * p<0.05 when compared 
with control 
Caco-2 HT29 
Control 100 ng/ml Control 100 ng/ml (untreated) toxin B (untreated) toxin B 
8 3.765±0.5189 13.440t2.376* 3.125±1.068 4.661±2.420 
24 3.821±0.3928 14.150±4.836 4.324±1.973 6.718±4.631 
48 4.183 ± 0.2575 21.920 ± 9.550 5.221 ± 1.785 8.864 ± 3.930 
ä 
72 3.374 ± 0.2019 22.030 ± 6.531 * 5.369 ± 2.000 9.993 ± 4.047 
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Figure 5-11 Percentage of sub-G1 events in Caco-2 and HT29 cells incubated 
with C. difficile toxin B (100 ng/mI) 
Assessment of Caco-2 (A) and HT29 (B) events in the sub-G1 region of the cell cycle following 
exposure to 100 ng/ml toxin B (J2C, cytotoxic activity on Vejo celis x10-88) at 8,24.48 and 72 h. 
Percentage of sub-G1 events calculated using total events and number of events in the sub-G1 
region when analysed using Cyclhred. Data in figures represent mean (±SEM) of 3 experiments 
performed in triplicate. 
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5.4.6 Role of epithelial cell cycle in susceptibility to C. difficile toxin B 
induced cell death 
Studies were undertaken to determine whether certain phases of the cell cycle 
are under- or over-represented at various time points following exposure to C. 
dff /die toxin B. For these studies, cell cycle analysis was performed by flow 
cytometry at 8 h, 24 h, 48 h and 72 h after exposure to toxin B as described 
in Chapter 2, page 94. Toxin-exposed cells were compared with cells cultured 
with control medium, seeded at the same time and obtained at the same time 
points as those cultured in the presence of the toxin. Statistically significant 
differences were seen in individual phases of the cell cycle at different time 
points, see Figure 5-12 & Figure 5-13 for Caco-2 analysis and Figure 5-14 & 
Figure 5-15 for HT29 cell analysis. 
Comparing whole cell cycle profiles in toxin treated and control (untreated) 
Caco-2 cells a notable difference can be observed. Studying Figure 5-12, the 
profile produced using control cells (A) show a smooth parallel progression 
through each phase of the cell cycle. In stark contrast the cell phases in toxin 
B exposed Caco-2 cells change dramatically (B). Considering each phase of 
the cycle a significant decrease in the % of cells in the GO/G1 region (Figure 
5-13 A) of the cycle was evident at 48 h (mean toxin 27.10% (±SEM 2.83) vs 
control 44.17% (±5.62) p<0.05] and 72 h [toxin 26.23 (±2.83) vs control 
46.40% (±5.13) p<0.05] when compared with untreated GO/G1 events. Also 
of interest the % S-phase cells (Figure 5-13 B) in toxin treated cells was 
significantly lower at 8 hour [toxin 26.13% (±5.50) vs control 46.17 (±4.84) 
p<0.05], by 48 hours the % of cells in S-phase was similar to control cells. 
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Mirroring the S-phase response in toxin exposed Caco-2 cells the % toxin 
treated cells in the G2 region (Figure 5-13 C) was significantly higher than 
control at 8h [toxin 48.3% (±6.38) vs control 15.6% (±1.56) p<0.05] and 72 
h [toxin 47.3% (±8.00) vs control 16.07% (±2.18) p<0.05]. 
Whole cell cycle profiles of toxin treated and control (untreated) HT29 cells 
appear similar upon initial inspection (Figure 5-14 A& B), however an overall 
decrease in HT29 cells in the GO/G1 region can be observed and this reduction 
becomes significant 72 h exposure [toxin 59.60% (±0.69) vs control 77.267 
(±3.19) p<0.05]; (Figure 5-15 A). The % of cells in the S-phase of the cell 
cycle remains similar in toxin treated and control cells (Figure 5-15 B). Of 
particular interest the % of toxin B exposed HT29 cells in the G2-phase of the 
cell cycle increased at 8h and remained higher than control cells through to 
72 h (Figure 5-15 C), statistical significance was observed at 8h [toxin 
26.17% (±3.04) vs control 9.1% (±1.03) p<0.05] and 72 h [toxin 22.23 % 
(±4.06) vs control 6.67% (±1.64) p<0.05] when compared with control 
(untreated cells). 
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Figure 5-12 Whole cell cycle analysis of Caco-2 cells incubated with C. difficile 
toxin B (100 ng/mI) 
Using PI stained Caco-2 cells incubated with 100 ng/ml of C. diffcile toxin B (J2C, cytotoxic 
activity on Vero cells x10-88) (A) or control medium (B) for 4 h, 8 h, 24 h, 48 h and 72 h, the cells 
were sorted using FACS and the resulting scatterplot gated to remove debris. Using only the gated 
events the percentage of cells in each phase of the cell cycle was calculated using Cyclhred. Data 
presented as % (f SEM) of cells in GO/G1, S and G2 phase n=3. This data reflects viable cells 
only and does not reflect the cells lost to cell death 
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Figure 5-13 Individual phase cell cycle analysis of Caco-2 cells incubated with 
C. difficile toxin B (100 ng/ml) 
Percentage of Caco-2 cells in GO/GI (A) S-phase (B) and G2 (C). comparison of toxin treated and 
control cells at 8 h, 24 h, 48 h and 72 h. Toxin B from J2C, cytotoxic activity on Vero cells x10-88. 
Data presented as %± SEM n=3 *=p=<0.05 PI stained cells were sorted using FACS and the 
resulting scatterplot gated to remove debris. Using only the gated events the percentage of cells in 
each phase of the cell cycle was calculated using Cyclhred. This data reflects viable cells only and 
does not reflect the cells lost to cell death 
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Figure 5-14 Whole cell cycle analysis of HT29 cells incubated with C. difficile 
toxin B (100 ng/ml) 
Using PI stained HT29 cells incubated with 100 ng/ml of C. drffrcile toxin B (from J2C, cytotoxic 
activity on Vero cells x10-88) (A) or control medium (B) for 4 h, 8 h, 24 h, 48 h and 72 h, the cells 
were sorted using FACS and the resulting scatterplot gated to remove debris. Using only the gated 
events the percentage of cells in each phase of the cell cycle was calculated using Cyclhred. Data 
presented as % (f SEM) of cells in GO/G1, S and G2 phase n=3. This data reflects viable cells 
only and does not reflect the cells lost to cell death 
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Figure 5-15 Individual phase cell cycle analysis of HT29 cells incubated with 
C. difficile toxin B (100 ng/ml) 
Percentage of HT29 cells in GO/GI (A) S-phase (B) and G2 (C), comparison of toxin treated and 
control cells at 4,8,24,48 and 72 h. Toxin B from J2C. cytotoxic activity on Vero cells x10-88 
Data presented as %± SEM n=3 *=p=<0.05 PI stained cells were sorted using FACS and the 
resulting scatterplot gated to remove debris. Using only the gated events the percentage of cells in 
each phase of the cell cycle was calculated using Cyclhred. This data reflects viable cells only and 
does not reflect the cells lost to cell death 
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5.4.7 Substrate specificity in toxin B intestinal epithelial cells 
Rho, Rac-1 and Cdc42 are the intracellular targets for C. difcile toxins and 
utilizing UDP-glucose as the co-substrate the toxins are capable of maintaining 
these key molecular proteins in an inactive state. The mechanisms that lead 
to their inactivation have been covered in detail in Chapter 1. 
Using whole cell lysates prepared from HT29 and Caco-2 cells incubated with 
either toxin B or control medium, Western Blot analysis was completed using 
protein specific antibodies to ascertain the expression of Rac-1 and Rho A, see 
Chapter 2, section 2.8 for a complete description of methods used. 
As discussed in Chapter 1 toxins released by the bacterium C. dHif/cile 
glucosylate, therein inactivating the protein and disrupting downstream 
signalling. This is believed to be an irreversible modification. The Rac-1 
(MAB3735, Mouse IgG, Millipore) detects only the non-glucosylated (active) 
protein, whereas Rho A (26C4: sc-418 Mouse IgG Santa Cruz Biotechnology 
Inc. ) detects endogenous levels of total protein (glucosylated and non- 
glucosylated). It has been reported however, that glucosylated Rho A Is 
promptly degraded by the intracellular proteasome (tenth, Huelsenbeck et al. 
2006) and therefore it is presumed that the signal being identified from the 
Rho A antibody is non-glucosylated (active) Rho A. As can be seen in, a 
reduction in non-glucosylated Rac-1 expression can be observed from as early 
as 3 hrs in both cell types when compared to the control (untreated) lysate at 
0 h. This loss continued through to 24 h. 
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Total RhoA (glucosylated and non-glucosylated) expression in toxin treated 
Caco-2 cells remained consistent when compared to the control (untreated) 
cell lysate at 0 h. The consistent expression of Rho A in toxin treated Caco-2 
cells was still evident after 24 h. In contrast, a reduction in Rho A expression 
in toxin treated HT29 cells was evident at 3h and further reductions were 
noted at 8 h, 24 h when compared to control (untreated) cell lysate at 0 h. 
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Figure 5-16 Expression of Rac-1, RhoA and beta-actin in control and C. difficile 
toxin B exposed Caco-2 (A) and HT29 (B) cells 
Intestinal epithelial cell monolayers were cultured in medium only (0 h) or in the presence of 1,000 
ng/ml toxin B for 3 h, 8h and 24 h. Lysates of cells were electrophoresed on SDS-PAGE gels and 
following transfer onto PVDF membranes, immunostaining was performed using antibodies 
specific for RhoA, beta-actin or non-glucosylated form of Racl. Equal loading of the lanes is 
illustrated by beta-actin-immunoreactive bands of similar size. The figures are representative of 
five experiments. 
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5.5 Discussion 
This chapter looked at the response of two human intestinal epithelial cell 
lines exposed to varying concentrations of toxin B. Caco-2 cells (colonic 
epithelial adenocarcinoma cell line), phenotypically similar to mature 
enterocytes (Sambuy, De Angelis et al. 2005) and HT29 cells (colonic 
epithelial adenocarcinoma cell line) were cultured to confluence and exposed 
to a range of the toxin B concentrations (1000 
- 
10 ng/ml). 
Visible cell rounding was first noted just 1 hour after Caco-2 cells were 
exposed to 1000 ng/ml of toxin B. Rounding in HT29 cells was visible 2 hour 
after exposure also at the highest concentration used. A similar pattern of 
responses was noted throughout the experiment suggesting that cell rounding 
occurred in a time- and dose- dependent manner, with Caco-2 rounding only 
marginally earlier to lower concentrations when compared with the cell 
rounding in HT29 cells. 
Whilst loss of monolayer integrity was reported in Chapter 3 when Caco-2 
cells were exposed to toxin A, toxin B exposed cells were only grown to sub- 
confluence prior to exposure and therefore the effect of toxin B on monolayer 
integrity cannot be discussed. As briefly highlighted, the early experiments 
using toxin B were conducted using near confluent monolayers of Caco-2 and 
HT29, and the basolateral location of toxin B receptors may have contributed 
to the lack of response observed in these experiments. It is worth noting 
that attachment of cells to the pseudo basement membrane (culture plate) 
was effected in Caco-2 cells incubated with toxin B. Toxin B exposed Caco-2 
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cells detached from the basement membrane by 48 h and the majority of 
HT29 cells were still attached even after 72 h exposure to 1000 ng/ml toxin B. 
Cellular viability of Caco-2 and HT29 cells to C. difficile toxin B was 
investigated using the MIT assay and propidium iodide staining of DNA 
content and visual inspection using light microscopy. 
Caco-2 cell monolayers treated with a range of toxin B concentrations resulted 
in a time and dose dependent reduction in mitochondrial dehydrogenase 
activity after 24 h. Of particular interest is the mitochondrial dehydrogenase 
activity of Caco-2 cells exposed to varying concentrations of toxin B during the 
first 24 h-a very small reduction is visible in cells exposed to 100 ng/ml, 
however mitochondrial dehydrogenase activity of cells exposed to 10 ng/ml 
and 1000 ng/ml was similar to that in control (untreated cells). 
Mitochondrial dehydrogenase activity was significantly reduced in Caco-2 cells 
(0.3880 ±0.0074) exposed to 1 000 ng/ml toxin A (mean ± SEM p=<0.001) 
after 48 hours when compared with untreated control cells (0.4450 ±0.0092). 
By 72 hours, a further reduction was observed at 1 000 ng/ml (0.1274 
±0.0298) when compared with control (untreated) cells (0.4187 ±0.0171) 
(mean ±SEM p=<0.01). 
In contrast, only a very small reduction in cell viability was observed in HT29 
monolayers exposed to 51000 ng/mI for 72 hours. 
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The MTT assay was supported by DNA fragmentation assessed by flow 
cytometry (Nicoletti, Migliorati et al. 1991) to toxin B. Using propidium iodide 
staining the DNA content in cells was measured using FACS and the 
percentage events in the sub-G1 region established. A time dependent 
increase in the % events in the sub-G1 region was evident in Caco-2 cells with 
over 22% of all events being in the sub-G1 region at 72 h when exposed to 
100 ng/ml toxin B. The difference in response to toxin B may be explained by 
the two different batches of toxin B; early experiments were completed using 
a batch of toxin with a cytotoxicity titre of 10-16 and the PI experiments 
completed using a batch with a titre of 10-88. This was lower than the % of 
cells in the sub-G1 region of toxin A exposed cells and this may partly be 
explained by the lower concentration of toxin used (100 ng/ml toxin Bv 1000 
ng/mt toxin A). To a lesser extent, a time dependent increase in the % sub G1 
events was seen in HT29 cells when compared with control (untreated) cells. 
Similar to the responses observed in toxin A exposed Caco-2 and HT29 cells 
- 
a cell specific effect is evident with Caco-2 cells displaying a greater 
susceptibility to toxin B induced cell death than HT29 cells. This supports 
earlier work completed by Fiorentini who suggested the origin and proliferative 
rate of the target cell may contribute to toxin B induced cell death (Fiorentini, 
Fabbri et al. 1998). Contradicting this Donta et al reported insignificant 
cellular sensitivities across cell types to toxin B (Donta, Sullivan et al. 1982). 
The differences across studies may be explained by differing cytotoxicity of 
toxins used. 
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Raising similar questions to those considered in Chapter 3 my interest will 
centre on the obvious disparity in cellular responses to C. diffici/e toxin B. 
Comparison of the cell specific response to toxin A and toxin B will be 
discussed in Chapter 7. 
As discussed in some detail in the introduction, C. difficile toxins enter the 
host cell by receptor mediated endocytosis. Toxin B binds to unknown 
receptor believed to be located on the basolateral surface of the host cell. 
Having established similar internalisation of toxin A into our host cells; the 
fragility and volume of purified toxin B did not make labelling a realistic option 
and therefore direct assessment of toxin B internalisation was not 
investigated. It may therefore be possible that the disparity seen in Caco-2 
cells may be explained by a greater number of toxin B receptors and more 
toxin B entering the target cell, however the inactivation of the intracellular 
protein and loss of Rac-1 was largely similar, suggesting similar uptake. 
Supporting our findings, cell rounding caused by the inactivation of Rho, Rac 
and Cdc42; and cell death have been suggested to be temporally distinct 
events. I have reported similarities in cell rounding to toxin B exposure but 
significantly different cellular viability in Caco-2 and HT29 cells. Studying the 
response of Hela and MCF cells to toxin B, Qa'Dan and colleagues found two 
distinct pathways to cell death; a caspase independent and; caspase 
dependent pathway to apoptosis (Qa'Dan, Ramsey et al. 2002). Using a 
caspase inhibitor delayed cell death but the cells still rounded, similarly 
insertion of the enzymatic region of toxin B into cells failed to stimulate 
caspase 3 yet the cells rounded and progressed to cell death. This would 
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suggest that caspase independent apoptosis occurred as a result of substrate 
inactivation (Qa'Dan, Ramsey et al. 2002). 
Caco-2 cells rounded slightly earlier than HT29 cells, but a significant disparity 
has been found in the ability of toxin B to induce cell death in Caco-2 cells but 
not in HT29 cells. As I have been unable to investigate toxin internalisation 
our attention has turned to intracellular processing for a possible explanation. 
The early loss of monolayer integrity observed in Caco-2 cells would support 
the early loss of the regulatory switch, Rho. What remains to be ascertained 
is whether the dramatic decrease in cell viability was the result of the cell 
rounding and detachment from the basement membrane or mediated by other 
independent signalling mechanisms i. e. caspases. 
Once inside the target cell, toxin B exerts it effect by inactivating a number of 
small GTPases, namely Rho, Rac-1 and Cdc42. A number of studies have 
suggested that substrate specificity may be cell specific. A recent study has 
shown that inactivation of RhoA (but not Rac-1) is required to induce cell 
death in response to C. difcile toxin B in basophilic leukaemia cells 
(Huelsenbeck, Dreger et al. 2007). It is possible therefore that toxin B 
induces greater inactivation of Rho A in Caco-2 cells than HT29 cell. Other 
studies, (Fritz and Kaina 2001) and (Liu, Cerniglia et al. 2001) suggest that 
RhoB, which is negatively regulated by RhoA, is the main regulator of cell 
death. 
As discussed in Chapter 4, substrate specificity is suggested to be cell specific 
and I therefore postulate the target substrates for C. difficile toxin B in Caco-2 
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and HT29 cells may be different. Investigating the expression of Rac1 and in 
line with cell rounding, a reduction in non-glucosylated Rac-1 was apparent in 
both cell types from 3 hr, suggesting a similar level of internalization of toxin 
B. This reduction continued through 24 h. The expression of Rho A in Caco-2 
cells remained consistent throughout with no reduction in expression. In 
contrast, expression of Rho A in HT29 cells is shown to reduce from 8 hr and 
this reduction continues through to 24 h. These findings further support a cell 
specific response but contradicts the findings of others, suggesting Rho A may 
regulate cell death (Huelsenbeck, Dreger et al. 2007), if RhoA regulated cell 
death a reduction in Rho A expression in Caco-2 cells would have been 
observed. Huelsenbeck and colleagues investigated the response in a 
different cell type and therefore the substrate specificity argued by my 
findings is supported. 
Rho proteins are linked with many biochemical and biological functions within 
the host cell; one of which being the cell cycle and more specifically G1 
progression and mitosis (Jaffe and Hall 2005). Using propidium iodide 
staining I investigated the cell cycle phases in toxin exposed and control cells 
using a dedicated cell cycle programme; Cyclhred, to elicit any cell specific 
sensitivities. Whole cycle profiles showed a small increase In the percentage 
of GO/G1 cells in toxin exposed Caco-2 cells to 24 h followed by a decrease 
through to 72 hours. A small increase in S-phase cells is noted from 8-24 h 
followed by a moderate increase to 48 h and a decrease to 72 h. The G2 
phase mirrored the S-phase profile, decreasing rapidly to between 24 and 48 
h and increasing again through to 72 h. This shows that cells are progressing 
from S-phase into G2-phase successfully. With a gradual reduction in G2 cells 
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through to 48 h we would also expect an increase in GO/G1 events, the 
absence of this indicates that cells are failing to pass the G2 checkpoint and 
undergo mitosis. 
If we consider specifically the stages of the cell cycle and compare toxin and 
control cells we can see an overall decrease in the percentage of toxin 
exposed cells in the GO/G1 region, becoming significant after 48 and 72 h. 
The S-phase also saw an overall reduction in the percentage of toxin exposed 
cells through to 48 h, being significant at 8 h. However between 24 and 48 h, 
the percentage of toxin B exposed cells in the S-phase increases to match the 
percentage of control cells in S-phase. A decrease in both control and toxin 
treated cells in S-phase is seen through to 72 h. Mirroring the S-phase 
pattern in toxin B exposed Caco-2 cells; the percentage of G2 cells is greater 
when compared with control (untreated) cells in the G2-phase throughout 8- 
72 h, a significant difference being noted at 8 and 72 h. This mirroring would 
suggest that cells are successfully entering G2 but the rapid decline in GO/G1 
events would suggest that Caco-2 cells are more sensitive to toxin B induced 
cell death in GO/G1 or perhaps the cells do not enter GO/G1; failing to pass 
the M1 checkpoint due to poor spindle alignment and undergoing programmed 
cell death. 
Whole cycle profiles of HT29 cells look remarkably similar with the percentage 
of GO/G1 events remaining constant throughout 8-72 h. Running almost 
parallel to the GO/G1 profile the S-phase and G2-phase profiles do not change 
dramatically with a small increase in the percentage of G2 events. To get a 
better understanding of what is happening with the HT29 cells incubated with 
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toxin B comparison of each stage of the cell cycle is needed. A reduction in 
the percentage of cells in the GO/G1 region is observed throughout, becoming 
significantly different at 72 h. Interestingly S-phase profiles appear very 
similar in control and treated HT29 cells. In contrast the percentage of toxin 
treated cells in the G2 region is lower than control cells, being significantly 
different at 8 and 72 h. With a consistent reduction in GO/G1 events and 
increase in G2 events it would appear that cells are progressing through the 
cycle and arresting in G2. These finding were also reported by others, 
however they also reported that HT29 cells underwent cell death in response 
to toxin exposure (Nottrott, Schoentaube et al. 2007). The use of 
recombinant toxin may explain the notable differences in cell death (Nottrott, 
Schoentaube et al. 2007). 
Whilst a significant difference is not evident at all time-points, cell cycle 
progression is fluid and whilst progression may be delayed in toxin treated 
cells the control cells will be proliferating as normal and rotating through all 
stages of the cell cycle. 
To summarize, this chapter has described the response of two intestinal 
epithelial cell types to varying concentration of purified toxin B. In doing so, it 
has been established that Caco-2 cells are more sensitive to toxin induced cell 
death. Investigation to elucidate the reasons for this cell specific sensitivity 
initially considered a possible difference in the uptake of the toxin into the cell 
but as discussed previously biological fragility of toxin B did not permit this to 
be investigated. Looking for an explanation intracellularly, expression of Rho 
A and Rac-1, two of the key GTPases inactivated in target cells was 
240 
investigated. Using whole cell lysates from cells incubated with either toxin B 
or control medium Western Blot analysis established a time dependent loss of 
non-glucosylated Rac-1 in both cell types. Rho A expression in Caco-2 cells 
remained constant following incubation with toxin B, however a time 
dependent loss of occurred in HT29 cells incubated with toxin B. The cell cycle 
is regulated by Rho proteins and consideration of cell cycle progression was 
also investigated with some supporting evidence. 
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CHAPTER 6 
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6 Primary colonic myofibroblast response to C. difficile 
toxins 
6.1 Introduction 
Intestinal myofibroblasts represent a distinct sub-population of cells that 
are located below the intestinal epithelium, separated by a porous 
basement membrane (Powell, Mifflin et al. 1999). The intestinal 
myofibroblast has characteristics of both the smooth muscle cell and the 
fibroblast, strongly expressing alpha-smooth muscle actin and vimenten 
respectively. Myofibroblasts play an important role in the maintenance of 
normal mucosal functions and in inflammation, repair and fibrosis (Powell, 
Mifflin et al. 1999). 
Fundamental processes rely on a complex network of cell to cell, cell to 
extracellular matrix and chemical messenger interactions and the intestinal 
myofibroblast regulate a number of fundamental interactions in the 
gastrointestinal tract (Powell, Mifflin et al. 1999; Powell, Mifflin et al. 
1999). 
The cells play an important role in organogenesis of the intestine (Simon- 
Assmann, Kedinger et al. 1995) by secreting soluble mediators and growth 
factors the myofibroblasts promote epithelial growth, proliferation and 
differentiation (McKaig, Makh et al. 1999). Myofibroblasts are also 
responsible for contraction to release fluid from the gastric glands 
(Synnerstad, Ekblad et al. 1998) and motility in the intestinal villa (Joyce, 
Haire et al. 1987). In addition, myofibroblasts regulate epithelial functions 
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such as electrolyte transport and barrier function (Beltinger, McKaig et al. 
1999). 
The myofibroblast is also a key facilitator of the repair and inflammatory 
processes when the intestine is damaged or attacked by a pathogen or 
toxic agent (Powell, Mifflin et al. 1999). 
Damage and loss of epithelial cells lining the intestinal tract triggers a 
repair process called restitution (Silen and Ito 1985; Podolsky 1997). This 
mechanism is promoted by Prostaglandin COX-1 and COX-2 activation and 
growth factors released from myofibroblasts (Blikslager, Roberts et al. 
1997). The residual epithelial cells either side of the denuded space move 
along the basement membrane, forming new tight junctions and restoring 
the luminal barrier (McKaig, Makh et al. 1999). If the damage or assault 
penetrates the basement membrane, a complex ordered repair process is 
activated (Wallace and Granger 1996). The early release of chemical 
signals activates the myofibroblasts leading to cell motility and contraction 
to reduce the wound area (Moore, Carlson et at. 1989). The subsequent 
release of matrix proteins and growth factors induce a chain of events 
starting with angiogenesis and tissue remodelling followed by epithelial cell 
proliferation and differentiation (Wallace and Granger 1996). After 
granulation and scar formation myofibroblasts undergo apoptosis 
(Desmouliere, Redard et al. 1995). Whilst matrix molecules produced by 
myofibroblasts assist in wound healing unregulated production of the 
molecules results in tissue fibrosis (Border and Noble 1994; Kovacs and 
DiPietro 1994). 
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Myofibroblasts are avid producers of chemokines and cytokines and play a 
major role in the inflammatory response being able to accentuate or 
diminish an inflammatory reaction (Fiocchi 1997; Roberts, Nadler et al. 
1997; Strong, Pizarro et al. 1998). Through the expression adhesion 
molecules on their cell surface, myofibroblasts invite other cells of the 
immune system to join them to facilitate a pooled inflammatory response 
(Saada, Pinchuk et al. 2006). 
Given my interest in the mucosal cell response to C. diffici/e toxins I have 
investigated the response of intestinal epithelial cells to toxins A and B and 
following the disruption of the epithelial cell barrier the toxins would 
encounter cells of the lamina propria. It has previously been shown that 
myofibroblasts provide protection to intestinal epithelial monolayers 
against loss of barrier function in response to low concentrations of toxin 
A, via TGF-beta secretion (Johal, Solomon et al. 2004) and of particular 
interest, the responses by primary intestinal myofibroblasts to C. difflcile 
toxins remain to be characterized. 
The aim of this work is to investigate and compare responses to C. 
difficlle toxins A and B by primary human colonic myofibroblasts. 
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6.2 Materials and methods 
6.2.1 Purification, preparation and application of toxin A and B 
Toxin A was purified as detailed in Chapter 2. Toxin B was purified by 
ammonium sulphate precipitation of cultured C. di> cile (VPI 10463) 
supernatant samples followed by two sequential anion exchange 
chromatographic steps as detailed in Chapter 4. 
Using previously characterized fractions of toxin A and toxin B, protein 
concentration and cytotoxicity was investigated again prior to use as 
described previously. 
Purified toxin was subsequently diluted using warm DMEM, supplemented 
for use with myofibroblasts, Caco-2 or HT29 cells. The existing media 
covering the confluent cell monolayers was gently aspirated and discarded 
and the medium containing varying concentrations of toxin A, toxin B or 
toxin A+B was placed onto the cells in each well and the plates re- 
incubated at 37°C, 5% CO2. Each concentration was completed in 
triplicate with control wells. 
6.2.2 Primary colonic myofibroblast response to C. difficile toxin A-a 
comparison using intestinal epithelial cells, HT29 and Caco-2 
Early experiments investigated the responses of myofibroblasts (derived 
from histologically normal colonic mucosal samples) to C. dlfficile toxin A 
alongside identical experiments using intestinal epithelial cell lines 
- 
HT29 
and Caco-2. Whilst myofibroblasts are a primary cell type with features of 
smooth muscle/fibroblasts like cells and a distinctive phenotype, Caco-2 
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and HT29 are carcinoma derived intestinal epithelial cells, it was 
considered that the responses provided by the cell lines would provide a 
'real time' benchmark of sensitivity to C. difficile toxin A and in the absence 
of primary epithelial cells; provide a direct comparison of mucosal cell 
responses to C. dicile toxin A. 
Intestinal myofibroblasts, Caco-2 and HT29 cells were seeded in 24 well 
plates, grown to confluence and exposed to either 100 ng/ml or 1000 
ng/ml of toxin A (cytotoxicity titre 50% rounding at 10"94 on Vero cells at 
24 h) or control medium. Morphological assessments were made by phase 
contrast light microscopy and micrographs taken at 1,2,3,24,48 and 72 
h. Cell viability was assessed using the MTT assay. Two plates for each 
cell type were prepared; the first plate was incubated with toxin for 48 hrs; 
and the second for 72 hrs. 
6.2.3 Morphological changes over the time-course 
Morphology of cells incubated with toxin A (cytotoxicity titre 50% rounding 
at 10-94 on Vero cells at 24 h) were investigated as described in the 
Chapter 2, at various time points (1 h through to 72 h) and micrographs 
taken. Morphological changes were described as percentage rounding and 
specific signs of apoptosis, necrosis noted. 
6.2.4 Cell cytotoxicity 
Cell cytotoxicity was assessed at 48 h and 72 h using the MTT assay as 
described in Chapter 2, section 2.4.3. 
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6.2.5 Propidium Iodide staining and cell cycle analysis 
Establishing that cell numbers were insufficient using 3 wells of a 24 well 
plate per treatment and time-point subsequent cell cycle experiments were 
completed using 2 wells of a6 well plate. Cell cycle analysis was 
performed on myofibroblasts incubated with either 1000 ng/ml of toxin A 
(cytotoxicity titre 50% rounding at 10-14 at 24 h) or control medium for 8, 
24,48 and 72 hours using propidium iodide and flow cytometry as 
described in Chapter 2, section 2.7.3. Toxin-exposed cells were compared 
with cells cultured with control medium, seeded at the same time and 
obtained at the same time points as those cultured in the presence of the 
toxin. 
6.2.6 Rho protein expression 
Investigation of Rho signalling in intestinal myofibroblasts was completed 
using whole cell lysates from cells in control and toxin A treated samples 
and the western blot technique using Rho specific antibodies for detection. 
The proteins investigated included Rac-1, RhoA and ß-actin was used as a 
loading control. The Rac-1 (MAB3735, Mouse IgG, Millipore) detects only 
the non-glucosylated (active) protein, whereas Rho A (26C4: sc-418 Mouse 
IgG Santa Cruz Biotechnology Inc. ) detects endogenous levels of total 
protein (glucosylated and non-glucosylated). It has been reported 
however, that glucosylated Rho A is promptly degraded by the intracellular 
proteasome (Genth, Huelsenbeck et al. 2006) and therefore it is presumed 
that the signal being identified from the Rho A antibody is non-glucosylated 
(active) RhoA. 
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Myofibroblasts were incubated with 1 000 ng/ml toxin A (cytotoxicity titre 
50% rounding at 10"94 at 24 h) or control medium for 4h and 24 h. A 
Western blot was completed for each protein to be investigated, including a 
loading control. A colour scan was made of each western blot. 
6.2.7 Smooth muscle actin expression in toxin A exposed myofibroblasts 
To investigate the expression and distribution of smooth muscle actin in 
myofibroblasts incubated with 1000 ng/ml toxin A (cytotoxicity titre 50% 
rounding at 10-14 at 24 h) or control medium. Myofibroblasts were cultured 
on glass coverslips placed into a 24 well plate and grown to confluence as 
previously described. Upon confluence the cells were exposed to toxin A 
for 3,6,24 and 48 hours or control medium. After each time point the 
toxin was removed and the glass coverslip gently removed from the well 
and fixed in acetone for 1 minute. The coverslip was allowed to dry before 
being placed into a fresh 24 well plate, wrapped in foil and stored at 
-20 
°C. The plate was removed from the freezer and the coverslips incubated 
with monoclonal anti-a smooth muscle actin (Clone 1A4, Sigma) in TBS 
p. H. 7.5 (1: 500) for 1 h. The primary antibody was removed and the 
coverslips washed five times with TBS p. H. 7.5; covered with biotinylated 
secondary antibody (containing blocking serum and biotinylated affinity 
purified anti-mouse immunoglobulin) and incubated at room temperature 
for 30 minutes. The biotinylated secondary antibody binds to the primary 
antibody, monoclonal anti-a smooth muscle actin. 
The preformed avidin/biotinylated horseradish peroxidase macromolecular 
complex was prepared and left to incubate for 30 minutes before use. The 
biotinylated secondary antibody was washed off and the pre-prepared 
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avidin/biotin complex pipetted into each well, covering the coverslips. The 
coversiips were left to incubate at room temperature for 30 minutes. 
The coverslips were washed a further five times to remove the 
avidin/biotin complex. The horseradish peroxidase was visualized using 
peroxidase substrate (VIP Substrate Kit, Vector), when prepared the 
peroxidase substrate was pipetted onto the slips. Leaving the membrane 
to develop for two minutes, the peroxidise substrate was removed and the 
coverslips washed with water to remove the peroxidise and end the 
reaction. 
The cover-slips were counterstained using Gill's Hematoxylin, in brief, water 
covering coverslips was removed and enough Gill's Hematoxylin was put 
into each well to immerse the coverslips. The counter stain was removed 
after 1 minute and any excess removed by washing with water. The glass 
coverslips were gently removed from the plate and each coverslip was 
passed through a graded series of ethanol solutions and finally zylene. The 
coverslips were then mounted onto glass slides with DPX mountant and left 
to dry overnight before inspection. 
The slides were visualised for immuno-stained cells using phase contrast 
microscopy and micrographs taken at various magnifications. 
6.2.8 Recovery of intestinal myofibroblasts pre-exposed to toxin A 
Given the apparent resilience of myofibroblasts to Clostrfdlum difficile toxin 
A and their paracrine functioning in the lamina propria studies were 
designed to see if myofibroblasts could recover from toxin A exposure. 
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Reviewing earlier observations 100% rounding could be achieved after 3 
hours to 1000 ng/mI and therefore myofibroblasts grown to confluence in 6 
well plates were pre-exposed to toxin A 1000 ng/ml (cytoxicity titre of 
50% rounding at 24 h on Vero cells 10"94) for 3 h, 24 h and 48 h followed 
by washing and culture in medium only. The medium was replaced three 
times a week. The cells were observed at 3 hours and then once a week 
using phase contrast microscopy for signs of recovery and micrographs 
taken. 
6.3 Intestinal Myofibroblast response to C. difficile toxin B 
Following the successful purification of Clostridium difficile toxin B 
investigations to ascertain the myofibroblast response to this toxin were 
commenced. Toxin B was re-characterised prior to use as described in 
section 6.2.1 page 246. 
Intestinal myofibroblasts were exposed to either 10 ng/ml, 100 ng/ml or 
1000 ng/ml of toxin B or control medium; morphological assessments 
made and cell cytotoxicity assessed using the MTT assay as outlined in 
section 6.2.2 pages 246 to 247. 
6.3.1 Cell cytotoxicity 
Cell cytotoxicity, following the incubation of myofibroblasts with 10 ng/ml, 
100 ng/ml or 1000 ng/ml toxin B or control medium (cytotoxicity titre 50% 
rounding at 10"47 at 24 h), was assessed at 24 h, 48 h, and 72 h using the 
MIT assay (measuring mitochondria) dehydrogenase activity in 
metabolising cells). 
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6.3.2 Propidium Iodide staining and cell cycle analysis 
Cell cycle analysis was performed on myofibroblasts incubated with either 
1000 ng/ml of toxin B (cytotoxicity titre 50% rounding at 10"94 at 24 h) or 
control medium for 8,24,48 and 72 hours using propidium iodide and flow 
cytometry. Toxin-exposed cells were compared with cells cultured with 
control medium, seeded at the same time and obtained at the same time 
points as those cultured in the presence of the toxin. 
6.3.3 Rho protein expression 
Investigation of Rho signalling in intestinal myofibroblasts was completed 
using whole cell lysates prepared from cells in control and toxin B 
(cytotoxicity titre 50% rounding at 10"14 at 24 h) treated samples and the 
Western blot technique using Rho specific antibodies for detection. The 
proteins investigated included non-glucosylated Rac-1 and total 
(glucosylated and non-glucosylated) Rho A. ß-actin was used as a loading 
control. 
Myofibroblasts were incubated with 1 000 ng/ml toxin B or control medium 
for 4h and 24 h. A western blot was completed for each protein to be 
investigated and a colour scan was made of each western blot. 
6.3.4 Smooth muscle actin expression in toxin B exposed myofibroblasts 
The expression and distribution of smooth muscle actin in myofibroblasts 
was re-investigated using confluent cells incubated with 1000 ng/mi toxin 
B (cytotoxicity titre 50% rounding at 10"54 at 24 h) for 3 h, 6 h, 24 h and 
48 h; or control medium. The methods for which are identical to those 
252 
used in toxin A investigation of smooth muscle actin and is described in 
section 6.2.7 page 249. 
6.3.5 Hoechst 33812 staining of toxin B exposed myofibroblasts 
To investigate signs of apoptosis in toxin B exposed myofibroblasts, cells 
were grown on glass coverslips to confluence and incubated with either 
1000 ng/ml or 100 ng/ml toxin B (cytotoxicity titre 50% rounding at 10-94 
at 24 h) or control medium for 48 h and 72 h. At the given time-points the 
toxin/media was removed and the coverslips fixed In 100 % acetone by 
immersing the slips in the acetone for 1 minute. The excess acetone was 
gently blotted and the slips allowed to dry before storing in a fresh 24 well 
plate covered with foil at 
-20°C. 
The plate was removed from the freezer and the glass coverslips stained 
with Hoechst stain (1: 10 Hoechst 33812 and PBS, (Sigma)) for 15 minutes 
at room temperature. The stain was removed and the coverslips washed 
three times using PBS. The coverslips were gently removed from the plate 
and mounted onto glass slides using a 1: 1 glycerol: PBS solution. The 
slides were observed immediately using the fluorescent microscope (Nikon 
Eclipse TE2000-S). Fluorescent and corresponding phase contrast 
micrographs were taken. 
6.3.6 Recovery of intestinal myofibroblasts to C. difficile toxin B 
After observing recovery in intestinal myofibroblasts to C. difflcile toxin A, 
identical experiments were conducted using toxin B. With similar time 
course changes in myofibroblast morphology to toxins A and B, pre- 
exposure with toxin B was kept to 3 hours using 1000 ng/ml toxin B. As 
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before, myofibroblasts grown to confluence in 6 well plates were pre- 
exposed to toxin B 1000 ng/ml (cytotoxicity titre 50% rounding at 10"" at 
24 h) for 3 h, 24 h and 48 h followed by washing and culture in medium 
only. The medium was replaced three times a week. The cells were 
observed at 3 hours and then once a week using phase contrast 
microscopy for signs of recovery and micrographs taken. 
6.3.7 Comparative response to C. difficile toxins A and B 
Observing a difference in the response elicited by intestinal myofibroblasts 
to toxins A and B, I wanted to ensure that our observations were not as a 
result of the toxins being studied separately and the possible effect of 
using different myofibroblast isolates in our observed response. With this 
in mind, cell cytoxicity (MTT) and morphological assessments were 
repeated using identical myofibroblast isolates seeded at the same time 
and toxin A and toxin B experiments run simultaneously. 
It has been reported that toxin B is more cytotoxic than toxin A (Riegler, 
Sedivy et al. 1995). With this in mind one might expect myofibroblasts to 
be more sensitive to toxin B, however having already established that toxin 
B was in fact no more cytotoxic than A on intestinal epithelial cell type, 
HT29, further investigations were completed to compare the cytotoxicity of 
toxins A&B on myofibroblasts. As outlined in Chapter 2, the 'gold 
standard cytoxicity assay' for C. difficile toxins is the African Green Monkey 
(Vero) cell bioassay. In brief, Vero cells seeded in a 96 well plates were 
cultured for 24 hours and serial dilutions of toxins A&B 10"1 through 10-95 
prepared and applied to the Vero cells. After 24 hours the assay Is read 
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and the lowest serial dilution to induce 50% rounding at 24 hours 
recorded. 
With the titre for each toxin established, three serial dilutions, 10-3,10"5 
and 10"' were prepared as described in 6.2.1 page 246 for each toxin and 
applied simultaneously to confluent myofibroblasts and Vero cells. 
Morphological assessments were made by light microscopy and 
micrographs taken at 1,2,3,24,48 and 72 h and a comparison of 
cytotoxicity of toxins A&B ascertained. 
6.3.7.1 Morphological changes over the time-course 
Morphology of cells incubated with toxin B (cytotoxicity titre 50% rounding 
at 10-57 at 24 h) were investigated as described in the Chapter 1- Material 
and methods at various time points (1 h through to 72 h) and micrographs 
taken. Morphological changes were described as percentage rounding and 
specific signs of apoptosis, necrosis noted. 
6.3.8 Scanning Electron Microscopy 
To obtain an in-depth picture of the morphological changes Induced by C. 
difficile toxins, myofibroblasts were grown on Thermanox cover-slips 
placed into the wells of a 24 well culture plate. The cells were grown to 
confluence as previously described and incubated with 1000 ng/ml of toxin 
A (cytotoxicity titre 50% rounding at 10"94 at 24 h), toxin B (cytotoxicity 
titre 50% rounding at 10-47 at 24 h) or control medium for 24 hours. 
Following the 24 h period the media/toxin was removed and the wells 
gently washed with warmed PBS. The cells were then fixed with 3% 
gluteraldehyde by gently pippetting 500 pl of the solution into each well 
- 
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submerging the Thermanox slide. The plates were stored at 4 °C until 
processing. 
Removing the plates from storage the slides were washed three times with 
0.1 M Phosphate / Cacodylate buffer and post fixed in 1% osmium 
tetroxide for 30 minutes in the fume cupboard. The slides were washed 5 
x1 minute using distilled water and then dehydrated using a graded series 
of ethanol solutions (2 x 15 min using 50% ethanol; 2x 15 min using 70% 
ethanol; 2x 15 min using 90% ethanol; and finally 3x 20 min using 100% 
ethanol). The remaining traces of ethanol evaporated and 
Hexamethyldisilazane was added to each well to cover the slip. The slides 
were incubated with the Hexamethyldisilazane for 2x 15 minutes and 
slips/wells left to dry overnight in the fume hood. 
The following morning the dry slides were carefully removed and mounted 
onto aluminium stubs using sticky carbon tabs and placed in the dessicator 
until coating. The samples were coated with gold using the Sputter 
Coater and viewed on the scanning electron microscope (JEOL 840). 
6.3.9 Small G Protein Activation Assay (RhoA 
- 
colorimetric) 
- 
G-LISATM 
The RhoA G-LISATM (Cytoskeleton Inc, USA) is an enzyme linked 
immunosorbent assay (ELISA) based activation assay that measures RhoA 
activity in cells. RhoA Is a small GTPase that acts as a molecular switch by 
cycling from a GDP bound (inactive) to a GTP (active) form, Its function 
has been described previously. C. difficile toxins A and B inactivate this 
key molecular switch by keeping the protein in its inactive form. Using 
the Rhotekin 
- 
RBD (Rho binding domain) protein, which only binds to the 
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active (GTP bound) form of RhoA, the G-LISA is able to measure the level 
of GTP-loaded RhoA (active form) in cells. The kit provides all the 
necessary reagents and the only additional product sourced was the 
ultrapure water (Sigma Ltd, Poole, UK) used to reconstitute the reagents. 
All reagents were reconstituted and stored according to the manufacturers 
guidelines. 
Three different myofibroblast isolates were revived, grown to 90% 
confluence, split as previously described and 20,000 cells per well seeded 
into 3 off 6 well plates. The cells were grown to 70% confluence over 
three days and the media changed the day after seeding. To investigate 
the inactivation of RhoA, four different conditions were prepared; 
incubation with toxin A; incubation with toxin B; serum starved 
(inactivates cellular RhoA); and control. The serum starved condition was 
achieved by washing the cells in serum (FCS) free medium, incubating the 
cells in fresh medium containing 0.5% serum (FCS) overnight and at the 
start on the experiment replacing the medium for serum free. Toxin A and 
toxin B were diluted to 1000 ng/ml using DMEM supplemented with 10% 
FCS, 0.1% NEAA and PSG and applied to cells for 4 h. The medium was 
also replaced on the control wells. 
After 4 h, all medium was removed; the wells washed with ice cold PBS 
and the cell culture plates placed on ice. The cells were lysed using 100 pl 
ice cold lysis buffer and a cell scraper, the same 100 pl of buffer was 
transferred across wells of the same condition to achieve a higher protein 
concentration and placed Into ice cold eppendorfs. Samples were 
subsequently centrifuged at 4°C for 2 minutes at 5000g and the lysate 
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removed, placed into clean ice-cold eppendorfs, snap frozen and stored at 
-80 °C. 20pl of each lysate was left on ice to establish protein 
concentration. Protein concentration was ascertained using the Precision 
Red protein assay (supplied with the kit). In brief, 10 pl of each sample 
and a blank (lysis buffer) was placed into a 96 well plate (induplicate) and 
300 pl Precision Red added to each well. After 1 minute the absorbance 
was read at 600 nm using the plate reader (BioRad). After subtracting the 
blank absorbance value, the reading was multiplied by 3.75 as per the 
instructions. The value calculated was the protein concentration. Protein 
concentrations ranged from 1.2 
- 
1.6 mg/ml. 
The frozen samples were defrosted and diluted to 1 mg/ml using ice cold 
lysis buffer and placed on ice. With the assay preparation and lysate 
collection complete the G-LISA was carried out according to manual 
supplied with the kit. Each sample was measured in duplicate and a RhoA 
positive control, supplied with the kit was also used. The level of active 
RhoA is measured with absorbance set at 490 nm and the samples 
compared against the positive control. 
6.4 Results 
6.4.1 Primary colonic myofibroblast response to C. difficile toxin A- 
benchmarking against intestinal epithelial cell responses. 
Preliminary experiments investigated the response of Intestinal 
myohbroblasts to C. difficile toxin A at two concentrations, 100 and 1000 
ng/ml. These concentrations have been to shown to cause cell rounding in 
both HT29 and Caco-2 cells and induce cell death in Caco-2 cells. Using 
the two intestinal epithelial cell types and the myofibroblasts, simultaneous 
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experiments were set up and the morphological response and cell viability 
in response to toxin A recorded. Morphological changes were assessed 
from 1h- 72 h using light microscopy and the cells in each well 
categorized into one of three morphological stages; no visible rounding; 
50% visible rounding and 100 % visible rounding. Tabular confirmation of 
rounding can be found in Table 6-1 and representative micrographs of 
myofibroblasts at each of these stages can be viewed in Figure 6-1. 
Cellular viability was established at 48 and 72 hours post toxin exposure. 
6.4.1.1 Dose and time dependent change in cell morphology 
As was previously observed in Caco-2 and HT29 cells a time and dose 
dependent response was recorded, this response also being recorded in the 
intestinal myofibroblasts with 50% rounding visible after just 3 hours, see 
Table 6-1. Of particular interest, myofibroblasts incubated with toxin A 
appear to initially transform into a stellate shape before rounding, see 
Figure 6-1 c and a small number of these cells can still be viewed even 
after 48 h, image d. 
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Figure 6-1 Phase contrast micrographs of primary colonic myofibroblasts 
to C. difficile toxin A 
Representative images taken from three experiments using different patient isolates. Cells 
incubated with either control medium (f) or 1000 ng/ml toxin A from 1 hour through 72 hour 
(a-e). Arrow indicate cells in stellate form. 
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6.4.1.2 Investigation of cellular viability using the MTT assay 
Cell viability was established after 48 and 72 hour toxin A exposure using the 
MTT assay. 
As previously reported in Chapter 3, Caco-2 intestinal epithelial cells exposed 
to C. difficile toxin A showed a significant reduction in mitochondrial 
dehydrogenase activity (Figure 6-2 A), which reflects cell viability, in a time 
and dose dependent manner. Mitochondrial dehydrogenase activity in HT29 
cells remained largely similar with no reduction observed even at the highest 
concentration, see Figure 6-2 B. 
Using the intestinal epithelial cell types as a benchmark for sensitivity the 
myofibroblast would appear to be as resilient as HT29 cells to 51000 ng/ml 
toxin A, (see Figure 6-2 B and C) with no reduction in mitochondrial 
dehydrogenase activity in myofibroblasts exposed to 100 ng/ml and 1000 
ng/ml toxin A at 48 and 72 h. 
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Figure 6-2 Mitochondrial dehydrogenase activity (MDA) in Caco-2, HT29 and 
primary colonic myofibroblasts to C. difficile toxin A (100- 1000 ng/ml) 
MTT assay for mitochondrial dehydrogenase activity (expressed as OD 570 nm) in (A) Caco-2 
cells (B) HT29 cells (C) Myofibroblasts exposed to 100 and 1000 ng/ml toxin A for 48 h and 72 h. 
Data in figures represent mean (±SEM) of 4 experiments performed in triplicate. ** = p<0.01 when 
compared with control 
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Time (h) 
control 100 ng/ml M 1000 ng/ml 
Time (h) 
control 100 ng/ml 1000 ng/ml 
Table 6-2 Mitochondrial dehydrogenase activity (MDA) in Caco-2, HT29 and 
primary colonic myofibroblasts to C. dl lcile toi in A (100-1000 ng/mI) 
MTT assay for mitochondrial dehydrogenase activity (expressed as OD 570 nm) in (A) Caco-2 
cells, (B) HT29 cells and (C) Myofibroblasts exposed to varying concentrations of toxin B for 48 h 
and 72 h. Data in table presents mean (±SEM) of 4 experiments performed in triplicate. ** _ 
p<0.01 when compared with control 
A 
Conc. 
Period of exposure (h) 
(ng/ml) 48 72 
Control 0.4405 ± 0.0253 0.4538 ± 0.0381 
100 0.2648 ± 0.0082 ** 0.1795 ± 0.0168 * 
1000 0.1965 ± 0.0057 ** 0.1568 ± 0.0091 * 
B 
Conc. 
Period of exposure (h) 
(ng/ml) 48 72 
Control 0.5230 ± 0.0127 0.5468 t 0.0365 
100 0.5298: h 0.0175 0.5310 f 0.0325 
1000 0.5320: b 0.0076 0.5320: h 0.0416 
C 
Conc. 
Period of exposure (h) 
(ng/ml) 48 72 
Control 0.2570 ± 0.0419 0.2423 f 0.0230 
100 0.2518: 1: 0.0405 0.2313 f 0.0241 
1000 0.2560* 0.0437 0.2328 t 0.0264 
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6.4.1.3 Propidium Iodide staining and assessment of DNA fragmentation by 
flow cytometry 
As described in section 6.2.5 page 248, Myofibroblasts incubated with toxin A 
or control media were fixed at 8,24,48 and 72 h; stained with Propidium 
Iodide, and; fluorescence emitted measured by fluorescent activated cell 
sorting (n=3). Using WinMDI 2.9 and cell cycle analysis programme Cyclhred 
as described in Chapter 2, page 94 the number of events in the sub-G1 region 
was ascertained and a percentage of events in the sub-G1 region calculated 
against total events and presented as % of sub-G1 events in toxin treated 
cells against control (untreated) cells (Table 6-3). 
As can be viewed in Figure 6-3, a small time dependent increase in the 
percentage of cells in the sub-G1 region can be observed, peaking at 72 h 
[mean toxin 4.2 (±SEM 0.936) vs control 0.807 (f 0.030) p<0.05], a 
significant increase was observed when compared against control. 
Representative DNA profiles of toxin and control cells indicate the majority of 
cells displayed DNA profiles of viable cells, see Figure 6-4. 
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Table 6-3 DNA analysis of Propidium iodide stained myofibroblasts incubated 
with C. difficile toxin A, 100 ng/mI 
Percentage of sub-G1 events in toxin treated (1000 ng/ml toxin A) and control (untreated cells at 8, 
24,48, and 72 h. Percentage calculated using total events and number of events in the sub-G1 
region when analysed using Cyclhred. Data in figures represent mean (±SEM) of 3 experiments 
performed in triplicate. n. s. = not significant. 
% of sub-G1 events in myofibroblasts 
Control (untreated) 1000 ng/ml toxin A p 
8 2.313±0.902 0.885 ± 0.135 n. s. 
24 2.114±0.808 1.385±0.131 n. s. 
48 0.576±0.165 2.140±0.210 n. s. 
"v 0 
72 0.807±0.030 4.216±0.936 0.0219 
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Figure 6-3 DNA analysis of Propidium iodide stained primary colonic 
myofibroblasts incubated with C. difficile toxin A, 1000 ng/mI 
Assessment of myofibroblast sub GI region of the cell cycle following exposure to 1000 ng/ml 
toxin A at 8,24,48 and 72 h. Percentage of sub-G1 events calculated using total events and 
number of events in the sub-GI region when analysed using Cyclhred. Data in figures represent 
mean (+SEM) of 3 experiments performed in triplicate. * p<0.05 
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Figure 6-4 Representative DNA fluorescent profiles of propidium iodide 
stained myofibroblasts incubated with C. difficile toxin A (1000 ng/ml) 
Cells cultured in the absence or presence of toxin A (1000 ng/ml. cytotoxicity titre 50% rounding 
at 10-14 at 24 h) for 8.24,48 and 72 h. Histograms represent data from all events produced using 
raw FACS data and WinMDl 2.9 scatterplots gated for single cells excluding cell debris at given 
timepoints. The sectioned part of the histogram shows events in the sub-GI region and the other 
two peaks represent cells in the GO/G I and G2 regions. respectively. The S phase events are found 
between the two peaks. Data for events in the sub-G I region represent means of three experiments 
performed in triplicate. 
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6.4.1.4 Myofibroblast response to increasing concentration of toxin A 
In Chapter 3, it was established that HT29 cells were resilient to 
concentrations of toxin A 
_<10 000 ng/ml, with minimal loss of viability. 
Having observed a similar response in myofibroblasts at 1000 ng/ml, 
propidium iodide staining and determination of cell loss was repeated using a 
ten-fold increase, 10 000 ng/ml of toxin A (cytotoxicity titre 50% rounding at 
10"18 at 24 h). Repeating this experiment with three different myofibroblast 
isolates, the representative DNA profiles, in Figure 6-5, show no loss of cell 
viability with a similar % sub G1 events in control and toxin treated 
histograms. The DNA profiles of toxin exposed cells are indicative of normal 
viable cells. 
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Figure 6-5 Representative DNA fluorescent profiles of propidium iodide 
stained myofibroblasts incubated with C. difficile toxin A (10000 ng/ml) 
Cells cultured in the absence or presence of toxin A (10000 ng/ml. cytotoxicity titre 50% rounding 
at 10-18 at 24 h) for 8.24,48 and 72 h. Histograms represent data from all events produced using 
raw FACS data and WinMDI 2.9 scatterplots gated for single cells excluding cell debris at given 
timepoints. The sectioned part of the histogram shows events in the sub-GI region and the other 
two peaks represent cells in the GO/GI and G2 regions. respectively. The S phase events are found 
between the two peaks. Data for events in the sub-G I region represent means of three experiments 
performed in triplicate. 
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6.4.1.5 Cell cycle response in toxin A exposed intestinal Myofibroblasts 
Providing confirmatory evidence of sustained viability in toxin A exposed 
myofibroblasts, the investigation of cell cycle progression was investigated 
to ascertain if phases of the cell cycle are under- or over-represented at 
various time points following exposure to C. difficile toxin A. For these 
studies, cell cycle analysis was performed by flow cytometry at 8,24,48 
and 72 hours after exposure to toxin A as described in 6.2.5 page 248. 
Toxin-exposed cells were compared with cells cultured with control 
medium, seeded at the same time and obtained at the same time points as 
those cultured in the presence of the toxin. 
Comparing whole cell cycle profile in toxin treated and control (untreated), 
Figure 6-6 A and B, a striking but not significant difference appears to 
occur between 8 and 24 h. Looking at the control (untreated) profile the 
GO/G1 and S phase contours remain apart throughout, however in toxin 
treated cells the GO/G1 and S phase contours clearly overlap at 24 hours. 
Some small observed differences can be reported when toxin exposed cells 
are compared with control (untreated cells), the percentage of toxin 
treated cells in GO/G1 was lower than control until 48 hour where the toxin 
and control cells were very similar and remained so through to 72 hours. 
Mirroring the apparent reduction in toxin exposed myofibroblasts in GO/G1 
phase, a higher percentage of toxin exposed cells in S-phase is observed. 
The percentages of cells in G2 phase remain similar throughout. Whilst 
small observations have been made no statistical significance was seen in 
individual phases of the cell cycle at any given time point, see Figure 6-7 
A-C. 
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Figure 6-6 Whole cell cycle analysis of myofibroblasts incubated with C. 
difficile toxin A (1000 ng/ml) 
Using PI stained myofibroblasts incubated with 1000 ng/ml of C. difficile toxin A (B17, 
cytotoxic activity on Vero cells x10-14) (A) or control medium (B) for 4 h, 8 h, 24 h, 48 h and 
72 h, the cells were sorted using FACS and the resulting scatterplot gated to remove debris. 
Using only the gated events the percentage of cells in each phase of the cell cycle was 
calculated using Cyclhred. Data presented as % (± SEM) of cells in GO/G1, S and G2 phase 
n=3. This data reflects viable cells only and does not reflect the cells lost to cell death 
271 
1 
ö 
1 
N 
e 
A 
75 
N 
50 
0 
B 
50 
0 
C 100-1 
(4) 
d 
v 
w 0 
\° 0 
0 
0 12 24 36 48 60 72 
Time (h) 
Toxin A Control 
Figure 6-7 Individual phase cell cycle analysis of myofibroblasts incubated 
with C. difficile toxin A (1000 ng/ml) 
Percentage of myofibroblasts in GO/Gl (A) S-phase (B) and G2 (C), comparison of toxin 
treated and control cells at 8 h, 24 h, 48 h and 72 h. Toxin A from BI 7, cytotoxic activity on 
Vero cells x10-14 Data presented as %f SEM n=3 *=p=<0.05 PI stained cells were sorted 
using FACS and the resulting scatterplot gated to remove debris. Using only the gated events 
the percentage of cells in each phase of the cell cycle was calculated using Cyclhred. This data 
reflects viable cells only and does not reflect the cells lost to cell death 
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6.4.1.6 Substrate specificity in toxin A exposed primary colonic 
myofibroblasts. 
Rho, Rac-1 and Cdc42 are the intracellular targets for C. difficile toxins and 
utilizing UDP-glucose as the co-substrate the toxins are capable of 
maintaining these key molecular proteins in an inactive state. The 
mechanisms that lead to their inactivation have been covered in detail in 
Chapter 1. 
Using whole cell lysates prepared from myofibroblasts incubated with 
either toxin A (cytotoxicity titre 50% rounding at 10-94 at 24 h) or control 
medium Western Blot analysis was completed using protein specific 
antibodies to ascertain the expression of non-glucosylated Rac-1 and total 
(non-glucosylated and glucosylated) Rho A, see Chapter 2 for a complete 
description of methods used. 
As' can be seen in Figure 6-8, a reduction in non-glucosylated Rac-1 
expression can be observed from as early as 4 hrs when compared to the 
control (untreated) lysate at 0 h. This loss continued through to 24 h. 
Total Rho A expression in toxin treated myofibroblasts remained constant 
when compared to the control (untreated) cell lysate at 0 h. The 
consistent expression of Rho A in toxin treated myofibroblasts was still 
evident after 24 h. 
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Figure 6-8 Expression of Rac-1, RhoA and beta-actin in control and C. 
difficile toxin A exposed primary colonic myofibroblasts 
Myofibroblast monolayers were cultured in medium only (0 h) or in the presence of 1,000 
ng/ml toxin A (cytotoxicity titre on Vero cells 50% rounding at 10"4 at 24 h) for 4h and 24 h. 
Lysates of myofibroblasts were electrophoresed on SDS-PAGE gels and following transfer 
onto PVDF membranes, immunostaining was performed using antibodies specific for RhoA, 
beta-actin or non-glucosylated form of Racl. Equal loading of the lanes is illustrated by beta- 
actin-immunoreactive bands of similar size. The figures are representative of three experiments 
using myofibroblasts isolated from colonic mucosal samples from three donors. 
6.4.1.7 Smooth Muscle Actin distribution in toxin A exposed myofibroblasts 
Immunohistochemical studies showed that the processes in toxin A 
exposed myofibroblasts were strongly immunoreactive for alpha-smooth 
muscle actin and the persistence of these immunoreactive processes was 
still evident at 72 h. Longitudinally arranged, a-smooth muscle actin- 
immunoreactive, bundles of microfilaments are seen in myofibroblasts 
cultured in control medium (Figure 6-9 A& B). In myofibroblasts exposed 
to C. difficile toxin A (Figure 6-9 C-L), the cell cytoplasm surrounding the 
nucleus and the cell processes (identified with arrows in Figure 6-9 F) are 
immunoreactive for a-smooth muscle actin. In addition, upon microscopic 
inspection of the toxin A exposed myofibroblasts, the integrity of the cell 
membrane remained intact throughout. 
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Figure 6-9 Alpha smooth muscle actin expression by C. difficile toxin A 
exposed myofibroblasts 
Alpha- smooth muscle actin expression (3-72 h). Immunocytochemical studies were 
undertaken in monolayers of isolated normal human colonic myofibroblasts that had been 
cultured in medium only (A & B) or in the presence of 1,000 ng/ml toxin A (C-L). Low x10 
(A-K) and High x40 and x100 (B-L) power images are shown at various time points; 3h (C & 
D), 6h (E & F), 24 h (G & H), 48 h (I & J) and 72 h (K & L). Arrows point to 
immunoreactive processes extending from the cell. 
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6.4.1.8 Recovery of Myofibroblasts exposed to C. difficile toxin A 
In studies undertaken using 
- 
myofibroblasts isolated from 8 different 
donors, morphological recovery of the cells was studied after 3h pre- 
exposure to 1000 ng/ml and 10000 ng/ml toxin A followed by washing and 
culture in medium only. While cultured in medium, signs of recovery were 
observed between 2-4 weeks in myofibroblast isolates pre-exposed to 
toxin A (cytotoxicity titre on Vero cells 50% rounding at 10-14 at 24 h) for 3 
h (see Figure 6-10). Myofibroblasts returned to normal morphology with 
the monolayers becoming fully confluent between 4 and 9 weeks. In 
addition, following trypsinisation and re-culture (passage in 1: 3 split ratio), 
the toxin A-pre-exposed myofibroblasts proliferated to confluence. 
Subsequent recovery experiments increased the pre-exposure time to 
include 24 and 48 h to 10000 ng/ml and 1000 ng/ml toxin A. The colonic 
myofibroblasts pre-exposed to toxin A (cytotoxicity titre on Vero cells 50% 
rounding at 10"18 at 24 h) for 3 h, 24 h and 48 h all showed signs of 
recovery in a dose and time dependent manner. 
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Figure 6-10 Phase contrast micrographs of recovery in myofibroblasts pre- 
exposed to C. difficile toxin A (1000-10000 ng/mI) for 3h 
Recovery in myofibroblasts following pre-exposure to 10000 ng/ml (images la-6b) and 1000 
ng/ml (images 7a-llb). Image (A) represents low (x10) and image (B) high (x40) power 
micrographs of control (untreated) cells. Image I a-b and 7a-b pre-exposure after 3 hr; 2a-b and 
8a-b I week later; 3a-b and 9a-b 2 weeks later; 4a-b and IOa-b 3 weeks later; 5a-b and I la-b 4 
weeks; 6a-b 5 weeks 
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6.4.2 The changing morphology of myofibroblasts to C. difficile toxins 
shown in scanning electron micrographs. 
Scanning electron micrographs of control and C. difcile toxin exposed 
myofibroblasts provide detailed evidence of the dramatic change in 
myofibroblast morphology. Myofibroblasts maintained in control medium 
spread to occupy a large surface area. By contrast cells incubated with 
toxin A or B change from flat cells to those with a stellate appearance and 
myofibroblast size reduced (Figure 6-11 A& D). The numerous processes 
of varying thickness can be viewed using phase contrast microscopy but 
additionally the scanning electron microscopy has identified distinct 
globular structures seen either close to the cell body or at a distance 
associated with processes (marked with arrows in Figure 6-11 B, C, and F). 
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Figure 6-11 Scanning electron micrographs of C. difticile toxin A or toxin B exposed primary colonic myofibroblasts 
Micrographs of myofibroblasts incubated with (' /f/icde toxin A (A-C) or toxin B (D-F) 1000 ng/ml or control medium (G-H) for 24 It Arrows point to distinct globular 
structures seen either close to the cell body or associated at a distance to processes (further characterization of globular structures needed) 
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6.4.3 Results 
- 
Primary colonic myofibroblast response to C. difficile 
toxin B 
With the myofibroblast response to toxin A established experiments to 
investigate the response of intestinal myofibroblasts to C. difficile toxin B 
were completed. Given the reported increase in cytotoxicity of toxin B 
three concentrations were studied, 10,100 and 1000 ng/ml and in addition 
to cell viability being studied at 48 and 72 hours, a 24 hour time point was 
included. These concentrations have been to shown to cause cell rounding 
in both HT29 and Caco-2 cells and induce cell death in Caco-2 cells. 
Myofibroblasts were grown to confluence and the morphological response 
and cell viability in response to toxin B exposure recorded. Morphological 
changes were assessed from 1h- 72 h using phase contrast microscopy 
and the cells in each well categorized into percentage cell rounding. 
Tabular confirmation of rounding can be found in and representative 
micrographs of myofibroblasts at each of these stages can be viewed In 
Figure 6-12. Cellular viability was established at 24,48 and 72 hours post 
toxin exposure. 
6.4.3.1 Dose and time dependent change in cell morphology 
A time and dose dependent response was recorded in the intestinal 
myofibroblasts exposed to toxin B (cytoxicity titre on Vero cells at 24 h 10- 
47), with 50% rounding visible after just 1 hour at 1000 ng/ml, see Table 
6-1. As observed in toxin A exposed myofibroblasts, toxin B exposure 
causes an transformation into a stellate shape, see Figure 6-12, image c. 
By 3 hours the majority of cells were rounded (exposed to 100 or 1000 
ng/ml) with only a few cells still in a stellate form. By 24 hours 100% 
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rounding was evident and the majority of cells appeared to be fragmented 
or floating in cells exposed to >_100 ng/ml toxin B 
a b 
1 hr x20 3 hr x20 
24 hr x20 
e f 
control x20 
Figure 6-12 Phase contrast micrographs of myofibroblasts exposed to C. 
difficile toxin B (1000 ng/ml) 
Phase contrast micrographs of primary intestinal myofibroblasts exposed to C. difrcile toxin 
B. Representative image taken from three experiments using different patient isolates. Cells 
incubated with either control medium (f) or 1000 ng/ml toxin B (cytotoxicity titre on Vero 
cells at 24 h 10-47) from Ih through to 72 h (a-e). 
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Table 6-4 Cell rounding in primary colonic myofibroblasts to C. difficile toxin B 
Percentage cell rounding in cells in response to 10 ng'ml 100 ng ml and 1000 ng/ml of toxin B Morphological changes to the cells 'acre studied by phase contrast 
miamurp} and the percentage of rounded cells ascertained by counting the rounded cells in ten random high power fields and taking the mean of these ten observations and 
--Tornnnc the salve to the nearest 10%. 
Duration of toxin B exposure 
Toxin B 
(n9/-I) 
1h 2 hours 3 hours 8 hours 24 hours 48 hours 72 hours 
0 
- - - 
60 100 100 100 
00 
- 
- 
80 100 100 100 100 
000 70 90 100 100 100 100 100 
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6.4.3.2 Investigation of cellular viability using the MTT assay 
Having observed a consistent response to toxins A and B in intestinal epithelial 
cells, with a significant reduction of cell viability in toxin exposed Caco-2 cells 
and resilience in HT29 cells to both toxins the results for toxin B exposed 
myofibroblasts were of particular interest. The myofibroblast responses to C. 
difficile toxin B resulted in a time and dose dependent loss of mitochondrial 
dehydrogenase activity, see Figure 6-13. At 10 ng/ml, a small loss was 
apparent but not statistically significant, see Table 6-5. 
In stark contrast to the responses reported in toxin A exposed myofibroblasts 
(Figure 6-2 page 263), mitochondrial dehydrogenase activity as a measure of 
cell viability in myofibroblasts was significantly reduced following exposure to 
100 ng/ml and 1000 ng/ml as early as 24 hour when compared against 
control (untreated cells) [100 ng/ml mean 0.2001 (±SEM 0.0144) vs control 
0.3941 (±0.0105) p= <0.05; 1000 ng/ml 0.1774 (±0.0065) vs control 0.3941 
(±0.0105) p= <0.01] and a continued loss seen through 48 hour [100 ng/mi 
0.1834 (±0.0382) vs control 0.4078 (±0.0037) p=<0.05; 1000 ng/ml 0.1719 
(f 0.0295) vs control 0.4078 (±0.0037) p=<0.05] and 72 hours [100 ng/ml 
0.1437 (±0.0170) vs control 0.3117 (±0.0177) p=<0.01; 1000 ng/ml 0.1411 
(±0.0201) vs control 0.3117 (±0.0177) p=<0.05]. 
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Figure 6-13 Mitochondrial dehydrogenase activity (MDA) in myofibroblasts 
exposed to C. difficile toxin B (10-1000 ng/mI) 
MTT assay for mitochondrial dehydrogenase activity (expressed as OD 570 nm) in myofibroblasts 
exposed to 10.100 and 1000 ng/ml toxin B (cytotoxicity on Vero cells at 24 h l0-47) for 24.48 and 
72 h. Data in figures represent mean (±SEM) of 3 experiments performed in triplicate. *°p<0.05 
** = p<0.01 when compared with control 
Table 6-5 Mitochondrial dehydrogenase activity (MDA) in myofibroblasts 
exposed to C. difficile toxin B (10-1000 ng/mI) 
MTT assay for mitochondrial dehydrogenase activity (expressed as OD 570 nm) in myotibroblasts 
exposed to varying concentrations of toxin B for 24.48 h and 72 h. Data in table presents mean (±SEM) of 3 experiments performed in triplicate. *=p<0.05 ** = p<0.01 when compared with 
control 
Conc. 
Period of exposure (h) 
(ng/ml) 24 48 72 
Control 0.3941 ± 0.0105 0.4078 ± 0.0037 0.3117 ± 0.0177 
10 0.3771 f 0.0109 0.3760 f 0.0121 0.3286 f 0.0075 
100 0.2001 f 0.0144 * 0.1834 ± 0.0382 * 0.1437 f 0.0170 ** 
1000 0.1774 f 0.0065 ** 0.1719 ± 0.0295 * 0.1411 f 0.0201 
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6.4.3.3 PI staining and measurement using FACS confirm cell loss 
As described in section 2.7.3, Myofibroblasts were incubated with toxin B 
(cytotoxicity titre on Vero cells at 24 h 10"94) or control media were fixed at 8 
, 
24,48 and 72 h; stained with Propidium Iodide, and; fluorescence emitted 
measured by fluorescent activated cell sorting (n=3). Using WinMDI 2.9 and 
cell cycle analysis programme Cyclhred as described in Chapter 
, 
the number 
of events in the sub-G1 region was ascertained and this number presented as 
a percentage of the total events recorded, comparing the percentage events in 
the sub-G1 region in toxin A-treated cells with control (untreated) cells. 
As can be viewed in Figure 6-14 a time dependent increase in the percentage 
of cells in the sub-G1 region is observed in toxin treated cells, becoming 
statistically significant at 72 hours [1000 ng/ml 35.150 (±1.310) vs control 
0.800 (±0.019) p=<0.01]. Although not statistically significant 13% of the 
total events were sub-G1 events at 48 hours, see Table 6-6. Supporting the 
MTT data, representative DNA profiles of toxin B exposed myofibroblasts 
clearly show DNA fragmentation due to apoptotic death at 48 hour and 72 
hour, see Figure 6-15. 
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Table 6-6 DNA analysis of Propidium iodide stained primary colonic 
myofibroblasts incubated with C. difficile toxin B (1000 ng/mI) 
Percentage of sub-GI events in toxin treated (1000 ng/ml toxin B) and control (untreated cells at 8. 
24,48. and 72 h. Percentage calculated using total events and number of events in the sub-GI 
region when analysed using Cyclhred. Data in figures represent mean (±SEM) of 3 experiments 
performed in triplicate. n. s. = not significant. 
% of sub-GI events in myofibroblasts 
Control (untreated) 1000 ng/mI toxin B p 
8 1.126 f 0.146 1.291 f 0.0626 n. s. 
24 1.436 f 0.041 2.298 f 0.243 n. s. 
48 1.168+0.215 13.380±3.815 n. s. 0 
72 0.800 f 0.019 35.150 ± 1.310 0.0015 
40 ** 
Cl, 
30 
d 
20 
10 
IS, 
0 
Figure 6-14 DNA analysis of Propidium iodide stained primary colonic 
myofibroblasts incubated with C. difficile toxin B, 1000 ng/mI 
Assessment of myofibroblast sub GI region of the cell cycle following exposure to 1000 ng/mI 
toxin B (cytotoxicity titre on Vero cells at 24 h 10-94) at 8.24.48 and 72 h. Percentage of sub-GI 
events calculated using total events and number of events in the sub-G I region when analysed 
using Cyclhred. Data in figures represent mean (±SEM) of 3 experiments performed in triplicate. 
** p<0.0I 
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Figure 6-15 Representative DNA profiles of propidium iodide labelled 
myofibroblasts exposed to C. difficile toxin B 
Cells cultured in the absence or presence of toxin B (1000 ng/ml. cytotoxicit) titre 50% rounding 
at 10-94 at 24 h) for 8.24,48 and 72 h. Histograms represent data from all events produced using 
raw FACS data and WinMDl 2.9 scatterplots gated for single cells excluding cell debris at given 
timepoints. The sectioned part of the histogram shows event, ire the sub-GI region and the other 
two peaks represent cells in the GO/G 1 and G2 regions. respectively. The S phase events are found 
between the two peaks. Data fier events in the sub-6 I region represent means of three experiments 
performed in triplicate 
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6.4.3.4 Cell cycle response in toxin B exposed intestinal myofibroblasts 
An increase in the % events in the sub-G1 region of the cell cycle following 
exposure of myofibroblasts to C. di>fcile toxin B from 48 hours supported my 
earlier finding that toxin B reduced cell viability and induced cell death. As 
commented upon previously, studies by others has suggested that cells in 
certain phases of the cell cycle are more susceptible to toxin-induced cell 
death and to this end cell cycle progression was investigated to ascertain if 
phases of the cell cycle are under- or over-represented at various time points 
following exposure to C. difcile toxin B. For these studies, cell cycle analysis 
was performed by flow cytometry at 8,24,48 and 72 hours after exposure to 
toxin B as described in Chapter 2, page 94. Toxin-exposed cells were 
compared with cells cultured with control medium, seeded at the same time 
and obtained at the same time points as those cultured in the presence of the 
toxin. 
Studying the individual Figure 6-17 and whole cycle graphs Figure 6-16 of 
toxin treated and control (untreated) myofibroblasts the percentage of cells in 
each phase at any given time point are largely similar with no identifiable 
differences. 
288 
A 
N 
a, 
w 0 
\° 0 
100 
75 
U) 
50 
1 
25 
0 
B 
Figure 6-16 Cell cycle analysis of myofibroblasts incubated with C. difficile 
toxin B 
Using PI stained m, olibroblasts incubated with 1000 ng/ml of C. difcile toxin 13 (J2C. cvtotoxic 
activity on Vero cells z 10 `'a) (A) or control medium (B) for 4 h. 8 h. 24 h, 48 h and 72 h. the cells 
were sorted using FACS and the resulting scatterplot gated to remove debris. Using only the gated 
events the percentage of cells in each phase of the cell cycle was calculated using Cyclhred. Data 
presented as % (± SEM) of cells in GO/GI. S and G2 phase n=3. This data reflects viable cells 
only and does not reflect the cells lost to cell death 
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Figure 6-17 Individual phase cell cycle analysis of myofibroblasts 
incubated with C. difficile toxin B (1000 ng/ml) 
Percentage of myofibroblasts in GO/Gl (A) S-phase (B) and G2 (C), comparison of toxin 
treated and control cells at 8 h, 24 h, 48 h and 72 h. Toxin B from J2C, cytotoxic activity on 
Vero cells x10-94 Data presented as %± SEM n=3 *=p=<0.05 PI stained cells were sorted 
using FACS and the resulting scatterplot gated to remove debris. Using only the gated events 
the percentage of cells in each phase of the cell cycle was calculated using Cyclhred. This data 
reflects viable cells only and does not reflect the cells lost to cell death 
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6.4.3.5 Substrate specificity in toxin B exposed primary colonic 
myofibroblasts. 
Rho, Rac-1 and Cdc42 are the intracellular targets for C. difficile toxins and 
by utilizing UDP-glucose as a co-substrate the toxins are capable of 
maintaining these key molecular proteins in an inactive state. The 
mechanisms that lead to their inactivation have been covered in detail in 
Chapter 1. 
Using whole cell lysates prepared from myofibroblasts incubated with 
either toxin B (cytotoxicity titre on Vero cells at 24 h 10-54) or control 
medium Western Blot analysis was completed using protein specific 
antibodies to ascertain the expression of Rac-1 and Rho A, see Chapter 2 
for a complete description of methods used. 
As can be seen in Figure 6-18, a reduction in non-glucosylated Rac-1 
expression can be observed from as early as 4 hrs when compared to the 
control (untreated) lysate at 0 h. This loss continued through to 24 h. 
Rho A expression in toxin treated myofibroblasts remained consistent when 
compared to the control (untreated) cell lysate at 0 h. The consistent 
expression of Rho A in toxin treated myofibroblasts was still evident after 
24 h. 
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Figure 6-18 Expression of Racl, RhoA and beta actin in control and C. 
diffici/e toxin B exposed myofibroblasts. 
Monolayers of isolated normal human colonic myofibroblasts were cultured in medium only (0 
h) or in the presence of 1,000 ng/ml toxin B (cytotoxicity titre on Vero cells at 24 h 10-S4) for 4 
h and 24 h. Lysates of myofibroblasts were electrophoresed on SDS-PAGE gels and following 
transfer onto PVDF membranes, immunostaining was performed using antibodies specific for 
RhoA, beta-action or non-glucosylated form of Racl. Equal loading of the lanes is illustrated 
by beta-actin-immunoreactive bands of similar size. The figures are representative of three 
experiments using myofibroblasts isolated from colonic mucosal samples from three donors. 
6.4.3.6 Smooth Muscle Actin distribution in toxin B exposed myofibroblasts 
Immunohistochemical studies showed longitudinally arranged, a-smooth 
muscle actin-immunoreactive, bundles of microfilaments in myofibroblasts 
cultured in control medium (A & B). The processes in toxin B exposed 
myofibroblasts were strongly immunoreactive for alpha-smooth muscle 
actin at 3h and 6h (C-F) and the persistence of these immunoreactive 
processes was evident at 24 h (G & H). By 48 h and 72 h and as observed 
by phase contrast microscopy (Figure 6-19) the majority of myofibroblasts 
exposed to toxin B (at concentration of 1000 ng/ml) had lost processes 
and variable immunoreactivity for a-smooth muscle actin was observed at 
48 hours (I & J). At 72 hours many toxin B exposed cells appeared to 
have lost the integrity of their cell membranes, showing either negative or 
weakly positive immunoreactivity for a-smooth muscle actin and appearing 
non-viable (K & Q. 
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Figure 6-19 Alpha-smooth muscle actin expression by control and C. 
difficile toxin B exposed myofibroblasts (1000 ng/ml) 
Immunocytochemical studies were undertaken in monolayers of isolated normal human 
colonic myofibroblasts that had been cultured in medium only (A & B) or in the presence of 
1,000 ng/ml toxin B (cytotoxicity on Vero cells at 24 h 10-54) (C-L). Low x40 (A-K) and High 
x100 (B-L) power images are shown at various time points; 3h (C & D), 6h (E & F), 24 h (G 
& H), 48 h (I & J) and 72 h (K & L). 
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6.4.3.7 Hoechst staining of toxin B exposed myofibroblasts 
To investigate signs of apoptosis in toxin B exposed myofibroblasts were 
fixed, stained with Hoechst 33342 and mounted onto to glass slides. The 
slides were observed immediately using the fluorescent microscope (Nikon 
Eclipse TE2000-S). Fluorescent and corresponding phase contrast 
micrographs were taken, see Figure 6-20. Fluorescent microscopy of 
myofibroblasts after staining with Hoechst 33342 in control cells (A & B) 
and cells exposed to C. difficile toxin B (cytotoxicity on Vero cells at 24 h 
10"94), 100 ng/ml (C & D) and 1000 ng/ml (E & F). Toxin B induced 
morphological changes typical of apoptosis; cells with nuclear chromatin 
fragmentation and/or condensation are indicated by the arrow and the 
arrow-head, respectively. 
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Figure 6-20 Hoechst 33342 staining of control and C. difficile toxin B 
exposed myofibroblasts (100 
-1000 ng/mI) 
Phase contrast and fluorescent micrographs of control (A & B) and 100 ng/ml and 1000 ng/ml 
toxin B exposed myofibroblasts (Cytotoxicity titre on Vero cells at 24 h 10"94), (C & D) and (E 
& F) at 72 h, respectively. Cells with chromatin fragmentation and/or condensation are 
indicated by the arrow and the arrowhead, respectively. 
6.4.3.8 Recovery of Myofibroblasts exposed to C. difficile toxin B 
Conducting similar experiments to those completed using toxin A, intestinal 
myofibroblasts were grown to confluence in 6 well plates and pre-exposed 
to toxin B 1000 ng/ml for 3 hours followed by washing and culture in 
medium only. 100 % rounding was recorded in toxin treated wells at 3 
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hours. The medium was replaced three times a week. The cells were 
observed at 3 hours and then once a week using phase contrast 
microscopy. Whilst toxin A pre-exposed cells returned to a normal 
morphology and returned to a confluent monolayer, toxin B exposed cells 
failed to recover despite removal of toxin, washing and regular 
replacement of fresh media for nine weeks. 
6.4.4 Comparative response of primary colonic myofibroblasts to C. 
difficile toxins 
Having established a toxin specific response in the primary intestinal 
myofibroblast in the isolates studied I wanted to ensure that the response 
being observed was not as direct result of toxins being studied separately 
using different isolates or as a result of increased cytotoxicity of toxin B. 
Prior to completing simultaneous experiments the cytotoxicity titre of both 
toxin A and B was established and identical serial dilutions applied to 
myofibroblasts and Vero cells and the morphological response recorded. 
6.4.4.1 Comparative cytotoxicity of C. difficile toxins A and B 
The cytotoxicity of C. difficile toxin A&B was established using the bio- 
assay as 419 x 10"94 pg/ml and 750 x 10"94 pg/ml to induce 50% cell 
rounding after 24 hours, respectively. Toxins were subsequently diluted to 
give three different concentrations; 10"3,10"5 and 10"' and the toxins 
applied to confluent myofibroblasts and Vero cells. Morphological changes 
were recorded as no-visible rounding, 50% rounding or 100% rounding 
(see Table 6-7) and micrographs taken (Figure 6-21). As observed 
previously a time and dose dependent response can be observed in both 
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myofibroblasts and Vero cells. At 10-5 and 10-7, cell rounding occurred 
considerably later, in most condition the first signs of rounding did not 
occur until 24 hour. A largely similar response was observed in Vero cells 
exposed to 10-3 toxin A or B, toxin A achieving 100% cell rounding in 2 
hours (Figure 6-21 A) and toxin B by 4 hour (Figure 6-21 K). The 
myofibroblast morphological response to toxins A and B was identical with 
cells 50% rounded by 3 hours and 100% by 4 hours (Figure 6-21 bb and 
jj; cc and kk). 
Table 6-7 Comparison of cell rounding in myofibroblasts and Vero cells to 
C. difficile toxin B 
Cell rounding; 100% (+) 50% (+/-) in Myofibroblasts and Vero cells in response to 419 x l0-' 
µg/ml; 419 x 10-5 µg/ml; 419 x l0-' µg/ml toxin A and 750 x 10"3; 750 x 10"5; 750 x 10-' toxin 
B. 
Vero cells Myofibroblasts 
Duration of 
exposure Toxin A Toxin B Toxin A Toxin B 
1o' o5 1o 10, 105 10 103 105 1o7 103 105 1o7 
2h + 
- - - 
- - - 
- - - 
3h + 
- 
+/- 
- 
+/- 
- - 
+/ 
- - 
4h + 
- - 
+ 
- - 
+ 
- 
- 
+ 
- - 
6h + 
- 
- 
+ 
- 
- 
+ 
- - 
+ 
- 
- 
24 h + 
- - 
+ +/- 
- 
+ 
- - 
+ +/- 
- 
30 h + + 
- 
+ + 
- 
+ +/- 
- 
+ + 
- 
48 h + + + + + 
- 
+ + +/- + + +/- 
72h + + + + + + + + + + + + 
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Figure 6-21 Phase contrast micrographs of myofibroblasts and Vero cells 
to C. difficile toxins A or B 
Myofibroblasts (aa-pp) and African Green Monkey (Vero) cells (A-P) exposed to C difficile 
toxin A ((419 x l0-' ig ml) A-H & aa-hh) and toxin B (750 x 10' µg/ml) I-P & ii-pp) for 2 
hour through 72 hour. 
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6.4.4.2 Comparative viability of myofibroblasts to C, difficile toxins A& B 
To investigate the comparative viability of toxin exposed myofibroblasts 
simultaneous experiments were conducted investigating the response of 
four isolates to toxins A and B. Toxin A protein concentration measured as 
419 pg/ml with cytotoxicity titre on Vero cells at 24 h of 10'94 and toxin B 
protein concentration measured as 750 pg/ml with cytotoxicity titre on 
Vero cells at 24 h of 10-94. All isolates were cultured at the same time; 
seeded at similar densities; toxins applied and viability established after 24 
h, 48 h and 72 h using the MTT assay. 
As previously reported intestinal myofibroblasts incubated with C. difficile 
toxin A&B 510,000 ng/ml round in a time and dose dependent manner. 
Cell viability, measured using the MTT assay and the conversion of 
tetrazolium salts to a formazan product by mitochondrial dehydrogenase 
released from viable cells, was not reduced in toxin A exposed cells at 
concentration 510,000 ng/ml when compared against control (untreated) 
cells after 72 hours (Figure 6-22 A), [mean toxin 0.4858 (±SEM 0.0434) vs 
control 0.5359 (±0.0103). In contrast and supporting the results outlined 
in section 6.3.1 page 251, a loss in cellular viability can be observed at 24 
hour to 1000 ng/ml toxin B [toxin 0.3913 (±0.0535) vs control 0.5772 
(±0.0314) p=<0.01] and further reduced at 10,000 ng/ml [toxin 0.4054 
(±0.0436) vs control 0.5772 (±0.0314) p=<0.01]. This loss increased at 
48 hour to >_1000 ng/ml [1000 toxin 0.3239 (±0.0172) vs control 0.5623 
(±0.0299) p=<0.01]; (10,000 toxin 0.3714 (±0.0359) vs control 0.5623 
(±0.0299) p=<0.001). The loss in cell viability of myofibroblasts 
incubated with toxin B continued to increase through to 72 hours with a 
highly significant loss reported in all cells incubated with 1000 ng/ml [toxin 
0.2043 (±0.0191) vs control 0.0535 (±0.0103) p=<0.001] and 10,000 
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ng/ml [toxin 0.2206 (±0.0126) vs control 0.0535 (±0.0103) p=<0.001), 
(see Figure 6-22 B). No loss of viability was seen in myofibroblasts 
incubated with 100 ng/mI toxin B even after 72 hour (toxin 0.4388 
(±0.0631) vs control 0.0535 (±0.0103)] (Figure 6-22 B). 
Comparison of cell viability in C. diffcile toxin A and toxin B exposed 
myofibroblasts found a significant difference when mean absorbance of 
formazan product was compared (Table 6-8). The difference between 
toxin A and toxin B exposed cells can be viewed as early as 24 hours when 
myofibroblasts are incubated with 2_1000 ng/ml of toxin (Figure 6-23 B& 
C). The difference observed is statistically significant with cell viability 
being lower in toxin B exposed cells than in toxin A cells, [1000 toxin A 
0.5854 (f 0.0311) vs toxin B 0.3913 (10.5350) p<0.05; 10000 toxin A 
0.6060 (*0.0443) vs toxin B 0.4054 (t 0.0436) p<0.05. By 48 hours, the 
difference was highly significant following exposure to 1000 ng/ml for 48 
hours [toxin A 0.5838 (±0.0304) vs toxin B 0.3239 (±0.0172) p<0.001] 
and at 10,000 ng/ml [toxin A 0.5925 (f 0.0337) vs toxin B 0.3714 (f 
0.0359) p<0.011 and this difference was also observed at 72 hours 
following exposure to 1,000 ng/ml [toxin A 0.4783 (f 0.0296) vs toxin B 
0.2043 (±0.0191) p<0.001] and at 10,000 ng/ml [toxin A 0.4858 
(±0.0434) vs toxin B 0.2206 (f 0.0126) p<0.01]. 
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Figure 6-22 Mitochondrial dehydrogenase activity (MDA) in myofibroblasts 
incubated with C. difficile toxin A or toxin B 
MTT assay for mitochondrial dehydrogenase activity (expressed as OD 570 nm) in 
Myofibroblasts exposed to 100,1000 and 10000 ng/ml toxin A (A) or toxin B (B) for 24,48 
and 72 h. Data in figures represent mean (±SEM) of 3 experiments performed in triplicate. 
**=p<0.01 *** = p<0.00I when compared with control 
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Table 6-8 Mitochondrial dehydrogenase activity in myofibroblasts 
incubated with either C. difficile toxin A or toxin B 
MTT assay for mitochondria] dehydrogenase activity (expressed as OD 570 nm) in 
Myofibroblasts exposed to varying concentrations of toxins A&B for 24,48 h and 72 h. Data 
in table presents mean (±SEM) of 3 experiments performed in triplicate. **=p<0.01 *** 
_ 
p<0.001 when toxin A treated and toxin B treated cells are compared. 
24 h 
Conc. 
(ng/ml) Toxin A Toxin B P 
100 0.6015 ± 0.0432 0.5769 ± 0.0432 n. s. 
1000 0.5854 ± 0.0311 0.3913 ± 0.5350 0.0201 
10000 0.6060 ± 0.0443 0.4054 ± 0.0436 0.0180 
48 h 
Conc. 
(ng/mI) Toxin A Toxin B p 
100 0.5537 ± 0.0340 0.5340 ± 0.3852 n. s. 
1000 0.5838 ± 0.0304 0.3239 ± 0.0172 0.0003 
10000 0.5925 ± 0.0337 0.3714 ± 0.0359 0.0041 
72 h 
Conc. 
(ng/ml) Toxin A Toxin B P 
100 0.4984 ± 0.0485 0.4388 ± 0.0631 n. s. 
1000 0.4783 ± 0.0296 0.2043 ± 0.0191 0.0002 
10000 0.4858 ± 0.0434 0.2206 ± 0.0126 0.0011 
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Figure 6-23 Comparison of mitochondrial dehydrogenase activity (MDA) in 
myofibroblasts exposed to C. difficile toxin A or toxin B 
MTT assay for mitochondrial dehydrogenase activity (expressed as OD 570 nm) in 
Myofibroblasts exposed to 100 (A), 1000 (B) and 10000 (C) ngiml toxin A or toxin B for 24. 
48 and 72 h. Data in figures represent mean (±SEM) of 3 experiments performed in triplicate. 
*=p<0.05 **=p<0.01 *** = p<0.001 when toxin A treated and toxin B treated cells are 
compared. 
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Looking at the dose response in toxin B exposed myofibroblasts a 
significant difference is noted at all time points between 100 and 1000 
ng/ml toxin B [24 h 0.5769 (±0.0432) vs 0.3913 (±0.0535) p<0.05; 48 h 
0.5340 (± 0.0385) vs 0.3239 (± 0.0172) p<0.01; 72 h 0.4388 (±0.631) 
vs 0.2043 (± 0.0191) p<0.05], see Figure 6-24. However reviewing the 
response between 1000 and 10,000 ng/ml we see no significant difference 
at any time point; in fact the mean values are largely similar. 
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Figure 6-24 Mitochondrial dehydrogenase activity in myofibroblasts 
incubated with C. difficile toxin B- dose comparison 
MTT assay for mitochondrial dehydrogenase activity (expressed as OD 570 nm) in 
Myofibroblasts exposed to toxin B for 24,48 and 72 h. Data in figures represent mean (±SEM) 
of 3 experiments performed in triplicate. *=p<0.05 **=p<0.01 *** = p<0.001 when 
absorbance values for 100 ng/ml, 1000 ng/mI and 10000 ng/ml are compared. 
If we investigate the time response to C. difficile toxins A&B we can see 
that absorbance values of formazan product reduce in a time dependent 
manner. Of particular interest, a notable pattern in the reduction of cell 
viability occurs at 1000 ng/ml and 10,000 ng/ml of toxin, see Table 6-8. 
In all concentrations only a moderate loss is seen at 24 hours however 
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between 24 and 48 hours a marked reduction is observed in both toxin A& 
B becoming statistical significant between 48 and 72 hours in response to 
1000 ng/ml toxin A and B [48 h 0.3239 (±0.0172) vs 72h 0.2043 (f 
0.0191) p<0.01] and 10000 ng/ml toxin B [48 h 0.3714 (±0.0359) vs 72 
h 0.2206 (±0.0126) p<0.01]. Cell viability in control (untreated) cells 
remained constant throughout the experimental time course with no 
significant loss. 
6.4.5 Investigation of RhoA activity in C. difficile toxin A and toxin B 
exposed myofibroblasts 
Previous experiments have focused on the expression of RhoA in toxin 
exposed cells with the understanding the inactive form (GDP-bound) was 
rapidly degraded within the cell and therefore by producing a western blot 
from toxin exposed cell lysates and a RhoA specific antibody, any RhoA 
expression observed on the membrane would be from the active form (GTP 
bound) RhoA. Using the G-LISA TM (Cytoskeleton) RhoA activity in toxin 
exposed myofibroblasts was investigated. As can be observed in Figure 
6-25 a highly significant reduction in active RhoA is observed at 4h in 
myofibroblasts exposed to 1 pg/ml toxin A or toxin B when compared with 
control. These findings contradict earlier findings and strongly suggest 
that the inactivated RhoA in myofibroblasts is not rapidly degraded and the 
banding observed on the Western blot may in fact be the inactive form of 
RhoA. However, the findings are still largely similar when toxin A and 
toxin B RhoA activity/inactivity is compared. 
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Figure 6-25 Levels of active, GTP-bound RhoA in C. difficile toxin-exposed 
myofibroblasts 
Lysates were obtained from monolayers of normal human colonic myofibroblasts cultured for 
4 It in medium only or in the presence of I µg/ml toxin A or I pg/ml toxin B. GTP-bound 
RhoA levels were quantified using an ELISA-based assay. Experiments were performed in 
duplicate, and the bars represent mean (SEM) absorbance values for 3 different cultures of 
myofibroblasts isolated from colonic mucosal samples obtained from 3 donors. The p value 
was <0.01 for the control versus toxin A or toxin B. 
6.4.6 Comparative response to C. difficile toxins A, B or A+B 
Having established that toxin A and B elicit differential effects on intestinal 
myofibroblasts I was interested to see if an additive effect could be 
induced by exposing cells to a combination of toxin A and B. 
A series of experiments were conducted using three different isolates and 
cells exposed to either toxin A, toxin B or a combination of A+B at 100 
ng/mI and 1000 ng/ml for 24,48 and 72 hours. Combination A+B was 
prepared using 200 ng/ml and 2000 ng/ml of each and diluting 1: 2 with 
the other toxin solution. Toxin A protein concentration measured as 3.17 
mg/ml with cytotoxicity titre on Vero cells at 24 h of 10-95 and toxin B 
protein concentration measured as 271 pg/ml with cytotoxicity titre on 
Vero cells at 24 h of 10-25. 
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Control Toxin A Toxin B 
Upon initial analysis of the raw data dose and time dependent loss of cell 
viability is observed in toxin B exposed myofibroblasts (Table 6-9) with a 
significant loss to 100 ng/mI at 24 h when compared with control cells 
[mean 0.2796 (±SEM 0.01485) vs 0.3318 (± 0.00743) p<0.01]. This loss 
increased and at 72 ha highly significant loss is seen at 100 ng/ml [0.2168 
(f 0.01240) vs 0.2896 (± 0.01240) p<0.0001], see Figure 6-26 (a). At 
24 h, cell viability in toxin A exposed myofibroblasts remained largely 
similar to that in control cells even at 10000 ng/ml [0.3056 (± 0.01038) vs 
0.3147 (± 0.08702)]. In contrast to my previous findings, a loss In cell 
viability was observed at 48 h in myofibroblast exposed to 1000 ng/ml 
toxin A [0.2906 (± 0.00594) vs 0.3219 (± 0.00524) p<0.01] with a 
greater loss at 10000 ng/ml, [0.2544 (± 0.00300) vs 0.3219 (± 0.00524) 
p<0.0001], see Figure 6-26 B. This reduction continued through 72 h with 
a significant reduction seen at 100 ng/ml [0.2536 (± 0.00676) vs 0.2992 
(t 0.01437) p<0.05], 1000 ng/ml [0.2436 (t 0.00597) vs 0.2992 (f 
0.01437) p<0.01] and at 10000 ng/ml (0.2067 (f 0.00627) vs 0.2992 (f 
0.01437) p<0.0001]. Reviewing the raw data for myofibroblasts exposed 
to toxin A+B, a time and dependent loss of cell viability is observed (see 
Table 6-9) with a significant loss noted at 24 h to 100 ng/ml [0.3526 (± 
0.003884) vs 0.3908 (± 0.01269) p<0.05]. Of Interest however, whilst a 
loss continued to be reported at 100 ng/ml, this loss was no longer 
significant and appeared to be decreasing with time, at 48 h [0.3044 (± 
0.00689) vs 0.3457 (± 0.02017)] and by 72 h [0.2637 (f 0.00399) vs 
0.2701 (± 0.01953)]. At 1000 ng/ml A+B a highly significant loss was 
seen at 24 h [0.2602 (± 0.00530) vs 0.3908 (f 0.01269) p<0.0001] 
decreasing to [0.1955 (± 0.00234) vs 0.3457 (±0.02017) p<0.0001] at 48 
h and at 72 h [0.01719 (f 0.00627) vs 0.2701 (±0.01953) p<0.0001], 
see Figure 6-26 A-C. 
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Table 6-9 Mitochondrial dehydrogenase activity (MDA) in myofibroblasts 
exposed to C. difficile toxin A, toxin B or toxin A+B 
MTT assay for mitochondrial dehydrogenase activity (expressed as OD 570 nm) in 
Myofibroblasts exposed to 100 ng/ml and 1000 ng/ml of toxin A, toxin B or toxin A+B for 24, 
48 h and 72 h. Data in table presents mean (±SEM) of 3 experiments performed in triplicate. 
* p<0.05 **p<0.01 ***p<0.001 when toxin treated cells are compared with control (untreated) 
cells. 
Conc. 
24 h 
(ng/ml) Toxin A Toxin B Toxin A+B 
Control 0.3147 ± 0.08702 0.3318 ± 0.00743 0.3908 ± 0.01269 
100 0.3216 ± 0.00966 0.2796 t 0.01485 0.3526 t 0.003884 
1000 0.3213 ± 0.00839 0.2404 f 0.00431 *** 0.2602 t 0.00530 *** 
Conc. 
48 h 
(ng/ml) Toxin A Toxin B Toxin A+B 
Control 0.3219 ± 0.00524 0.3310 ± 0.00754 0.3457 ± 0.02017 
100 0.3050 ± 0.00615 0.2574 ± 0.01392 ** 0.3044 ± 0.00689 
1000 0.2906 ± 0.00594 ** 0.1986 ± 0.00389 *** 0.1955 ± 0.00234 *** 
Conc. 
72 h 
(ng/mI) Toxin A Toxin B Toxin A+B 
Control 0.2992 ± 0.01437 0.2896 ±0.01240 0.2701 ± 0.01953 
100 0.2536 ± 0.00676 * 0.2168 ± 0.01240 *** 0.2637 ± 0.00399 
1000 0.2436 ± 0.00597 ** 0.1649 ± 0.00398 *** 0.1719 ± 0.00627 *** 
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Figure 6-26 Mitochondrial dehydrogenase activity in myofibroblasts 
incubated with C. difficile toxin A, toxin B or toxins A+B 
MTT assay for mitochondrial dehydrogenase activity (expressed as O. D. 570 nm) in 
Myofibroblasts exposed to 100 ng/ml and 1000 ng/ml toxin A, toxin B or toxin A+B for 24 h 
(A), 48 h (B) and 72 h (C). Data in figures represent mean (+SEM) of 3 experiments 
performed in triplicate. p values * <0.05, ** <0.01, *** <0.001 when compared with control 
myofibroblasts. 
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Comparison of toxin's A, B and A+B was completed after O. D values of 
toxin treated cells were normalised against control cells and the data 
presented as a percentage of viable cells. All control (untreated) values 
were termed 100% viable and the toxin treated cells calculated as a 
percentage of control cells and subsequently reported as mean percentage 
viable (±SEM). 
Supporting my earlier findings, at 24 ha significant difference was 
observed when the percentage viable toxin A and toxin B treated 
myofibroblasts were compared. A significant reduction was seen using 100 
ng/ml [(A) 102.60 (± 3.42) vs (B) 84.32 (± 4.32) p<0.01] and a highly 
significant difference at 1000 ng/ml [(A) 100 (+4.03) vs (B) 72.65 (f 
1.53) p<0.0001]. This significant difference was repeated at 48 h, see 
Table 6-10. By 72 h, the percentage of viable cells was no longer 
significantly different in myofibroblasts treated to 100 ng/ml toxin A and 
toxin B but a highly significant difference was reported to 1000 ng/ml toxin 
A and toxin B, see Table 6-10. 
As would be expected a significant loss in the percentage of viable cells 
was noted when toxin A treated cells were compared against toxin A+B, 
(Figure 6-27). At 24 h, a significant difference was reported between 100 
ng/ml toxin A and toxin A+B [(A) 102.60 (f 3.42) vs (A+B) 91.20 (+ 
3.920) p<0.05] increasing to [(A) 100.00 (t 4.03) vs 67.38 (± 3.25) 
p<0.0001]. This loss is clearly presented in Figure 6-27 A. A similar 
difference in toxin A and toxin A+B percentages was seen at 48 h. By 72 
h, a significant difference is no longer seen between myofibroblasts 
exposed to 100 ng/ml toxin A and 100 ng/ml toxin A+B and at 1000 
ng/ml, a highly significant was reported at 24 and 48 h but the difference 
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at 72 h has been reduced with significance at p<0.05 [(A) 82.99 (f 4.391) 
vs (A+B) 66.25 (f 4.58)], see Figure 6-27 C. 
6.4.6.1 Comparison of response to toxin B and toxin A+B 
At 100 ng/ml, the percentage viable cells in toxin A+B was consistently 
higher than the percentage of viable cells following exposure to toxin B, 
see Table 6-10 and by 72 h this difference [(B) 75.76 (±5.83) vs (A+B) 
101.10 (±6.17)] had become statistically significant, p<0.01, see Figure 
6-27 C. 
Reviewing the time dependent response, analysis of the percentage of 
viable cells in toxin exposed myofibroblasts suggests that cells incubated 
with toxin A were more susceptible between 48 and 72 h to 100 ng/ml and 
1000 ng/ml (Figure 6-28 A) [48 h 0.3050 (± 0.00615) vs 72h 0.2536 (f 
0.00676) p<0.0001; 48h 0.2906 (±0.00594) vs 72 h 0.2436 (±0.00597) 
p<0.0001]. In response to toxin B, a small reduction in mitochondrial 
dehydrogenase activity was noted between 24 and 48 h to 100 ng/ml, 
between 48-72 h this reduction became statistically significant [48 h 
0.2574 (±0.01392) vs 72 h 0.1649 (f 0.00398) p<0.05. In response to 
1000 ng/ml a highly significant loss was observed between 24 and 48 h 
[24 h 0.2404 (± 0.00431) vs 48 h 0.1986 (± 0.00389) p<0.0001] and this 
statistically significant loss was also reported between 48 h and 72 h. 
Of particular interest, a highly significant reduction in mitochondrial 
dehydrogenase in toxin A+B exposed myofibroblasts was observed 
between 24 h and 48 h to both 100 ng/mI and 1000 ng/mi (p<0.0001), 
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see Figure 6-28 C and this reduction continued through 48 h and 72 h to 
100 ng/mI (p<0.0001) and 1000 ng/mI (p<0.0001). 
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Table 6-10 Comparison of percentage viable cells in myofibroblasts 
Incubated with C. difficiie toxin A, toxin B or toxin A+B 
MTT assay for mitochondrial dehydrogenase activity in myofibroblasts exposed to 100 ng/ml 
and 1000 ng/ml toxin A, toxin B and toxin A+B for 24 h, 48 h and 72 h.. Data in table 
represent mean (±SEM) of 3 experiments performed in triplicate. Raw O. D. values have been 
normalised against control (untreated) myofibroblasts and expressed as a percentage of control 
cells. p values * p<0.05 ** p<0.01 *** p<0.001 
24 h 
Conc. 
(ng/ml) 
Toxin A Toxin B p 
100 102.60 f 3.42 84.32 ± 
. 
4.32 0.0043 
1000 100.00 t 4.03 72.65 ± 1.53 <0.0001 
Conc. 
(ng/ml) 
Toxin A Toxin A+B p 
100 102.60 ± 3.42 91.20 t 3.920 0.0434 
1000 100.00 ± 4.03 67.38 t 3.25 <0.0001 
Conc. 
(nglml) 
Toxin B Toxin A+B p 
100 84.32 ±A32 91.20 f 3.920 0.255 
1000 72.65 ± 1.53 67.38 f 3.25 0.162 
48 hrs 
Conc. 
(ng/ml) 
Toxin A Toxin B p 
100 94.82 ± 1.69 78.06 t 4.59 0.0035 
1000 90.31 ± 1.49 60.23 f 1.807 <0.0001 
Conc. 
(ng/ml) 
Toxin A Toxin A+B p 
100 94.82 ± 1.69 89.77 ± 3.84 0.246 
1000 90.31 ± 1.49 58.26 ± 3.73 <0.0001 
Conc. 
(ng/ml) 
Toxin B Toxin A+B p 
100 78.06 ± 4.59 89.77 ± 3.84 0.068 
1000 60.23 + 1.807 58.26 ± 3.73 0.641 
72 hrs 
Conc. 
(n9lml) 
Toxin A Toxin B p 
100 86.50 f 4.91 75.76± 5.83 0.178 
1000 82.99± 4.391 57.31 ± 2.33 <0.0001 
Conc. 
(ng/ml) 
Toxin A Toxin A+B p 
100 86.50 t 4.91 101.10 f 6.17 0.083 
1000 82.99 t 4.391 66.25 t 4.58 0.018 
Conc. 
(ng/ml) 
Toxin B Toxin A+B p 
100 75.76± 5.83 101.10±6.17 0.009 
1000 57.31 ± 2.33 66.25 ± 4.58 0.101 
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Figure 6-27 Comparison of percentage viable cells in myofibroblasts 
incubated with C. difficile toxin A, toxin B or toxin A+B 
MTT assay for mitochondrial dehydrogenase activity in myofibroblasts exposed to 100 nglml 
and 1000 ng/ml toxin A, toxin B and toxin A+B for 24 h (A), 48 h (B) and 72 h (C). (A) 
represents data from all time points. Data in figures represent mean (±SEM) of 3 experiments performed in triplicate. Raw O. D. values have been normalised against control (untreated) 
myofibroblasts and expressed as a percentage of control cells. p values * p<0.05 ** p<0.01 
*** p<0.001. 
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Figure 6-28 Mitochondrial dehydrogenase activity (MDA) in myofibroblasts 
incubated with toxin A, toxin B or toxin A+B - comparison of duration 
MTT assay for mitochondrial dehydrogenase activity (expressed as O. D. 570 nm) in 
myofibroblasts exposed to 100 ng/ml and 1000 ng/ml of toxin A (A), toxin B (B) and toxin 
A+B (C). Data in figures represent mean (±SEM) of 3 experiments in triplicate. * p<0.05, 
**p<0.01 and ***p<0.001 when period of exposure is compared 24 h- 48 h and 48 h- 72 h. 
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Investigating the dose response in toxin A, toxin B and toxin A+B exposed 
myofibroblasts and the increased loss of viability when toxin concentration 
is increased, this series of experiments suggest that no significant 
difference in loss is observed in myofibroblasts exposed to 100 ng/ml and 
1000 ng/ml toxin A at 24 h through 72 h. In contrast both toxin B and 
toxin A+B exposed myofibroblasts saw a significant reduction in cell 
viability when the toxin concentration was increased and this significant 
reduction in response to dose continued through 72 h. 
6.5 Discussion 
Initial experiments studied the response of myofibroblasts to C. dif/die 
toxin A using intestinal epithelial cells, Caco-2 and HT29 as a benchmark to 
previously observed responses. Myofibroblasts rounded in a time and dose 
dependent manner, rounding slower than HT29 and Caco-2 cells in which 
50% of the cells were rounded after 1 h; whereas 50% rounding was 
observed in myofibroblasts after 3h with cells initially taking a stellate 
form before rounding. The stellate form is characteristic of the stellate 
myofibroblast as described by (Powell, Mifflin et al. 1999), however the 
significance of this form needs further investigation. This stellate form was 
still seen in some cells after 48 h exposure. Using the MTT assay to 
investigate cell viability in myofibroblasts, Caco-2 and HT29 cells incubated 
with toxin A, the response by HT29 and Caco-2 cells was as previously 
discussed in Chapter 3. A significant reduction in Caco-2 cell viability was 
observed and HT29 cells appeared resilient to C. difficile toxin A. This Is in 
stark contrast to the loss of viability in HT29 cells reported by others, 
however this may be explained in part by their use of recombinant toxin A 
(Nottrott, Schoentaube et al. 2007). Benchmarking the myofibroblast 
response to toxin A, it would appear to be as resilient to toxin A induced 
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cell death as the intestinal epithelial cell, HT29. Supporting the MTT data, 
DNA analysis using propidium iodide staining and flow cytometry 
established normal DNA profiles in cells incubated with 1000 ng/ml toxin A 
for 
_<72h. A ten-fold increase in toxin A concentration to 10000 ng/ml also 
produced DNA profiles representative of normal viable cells and no 
difference in the percentage of sub-G1 events was noted when control and 
toxin treated profiles were compared. It has been reported by others that 
under- or over-representation of cell cycle phases contribute to the 
observed response in the host cell (Fiorentini and Thelestam 1991; 
Nottrott, Schoentaube et al. 2007). Cell cycle analysis compiled using 
Terry Hoy's Cyclhred programme found small differences in the 
percentages of cells between 8 and 24 hours in toxin treated and control 
cells but no significant difference was observed at individual time points. 
Having observed a similar response in intestinal epithelial cells to C. 
difficile toxins A and B, despite claims that toxin B is significantly more 
cytotoxic (Chaves-Olarte, Weidmann et al. 1997). I was keen to 
investigate the response of myofibroblasts to toxin B. Conducting similar 
experiments to those conducted with toxin A it became apparent that a 
differential response to C. difcile toxins occurred in myofibroblasts. 
Morphological experiments provided the earliest evidence of a differential 
response. Cell rounding occurred earlier with 50% rounding being 
observed at 1 hour following exposure to 1000 ng/ml toxin B and by 24 h 
the majority of cells appeared fragmented, with signs of surface blebbing 
and the cells were no longer adherent to 2: 100 ng/ml. The observed 
morphological changes were supported by a series of experiments looking 
at cell viability. Using the MTT assay, a significant reduction in cellular 
viability was seen at 24 h to 2100 ng/ml (100 ng/ml p<0.05; 1000 ng/ml 
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p<0.01) and this significant loss continued through to 72 h. DNA analysis 
of propidium iodide stained cells measured using flow cytometry confirmed 
a time dependent loss in cell viability with the percentage of events in the 
sub-G1 region becoming statistically significant at 72 h to 1000 ng/ml toxin 
B (p<0.01). Confirming apoptosis, Hoechst staining of myofibroblasts 
incubated with 1000 ng/ml toxin B for 24 h displayed chromatin 
fragmentation and/or condensation. Cell cycle analysis of control and toxin 
treated myofibroblasts were largely similar with no identifiable differences 
when compared. 
With a differential response to C. diffcile toxins A and B identified further 
experiments were conducted to investigate the comparative response of 
the toxins. Studying the toxins together using the same patient isolates 
would ensure the response being observed was as a direct result of the 
toxins and not primary cell variability. To counteract the argument that 
toxin B is more cytotoxic and therefore a different response is expected a 
series of experiments were conducted investigating the cytotoxicity of C. 
difficile toxin A and toxin B. The gold standard cell type (Vero cells) was 
used to ascertain cytotoxicity (Donta, Sullivan et al. 1982) in C. difficile 
toxins and both toxin were subsequently diluted to achieve identical serial 
dilutions. The diluted toxins were simultaneously applied to confluent Vero 
cells and myofibroblasts. All cells rounded in a dose and time dependent 
manner and both toxins induced similar responses in myofibroblasts with 
largely similar rounding schedules. These same toxin samples were used 
in the comparative experiments of toxin A and toxin B. 
C. difficile toxin A and toxin B was applied to four different myofibroblast 
isolates, time course changes in cell morphology noted and cell viability 
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established after 24 h, 48 h, and 48 h using the MIT assay. Confirming 
our earlier findings where the toxins were studied in isolation of each 
other, cell viability was not reduced in myofibroblasts exposed to 510000 
ng/ml toxin A when compared against control (untreated) cells after 72 h. 
In contrast and supporting the results outlined in section 6.4.3.2 page 283, 
a loss in myofibroblast viability was observed as early as 24 h to 51000 
ng/ml (p<0.01) and continued through 72 h. Given the disparity in 
responses to C. difficile toxins and as would be expected comparison of cell 
viability is significantly different when absorbance values for toxin A and 
toxin B exposed myofibroblasts are compared. Whilst a time and dose 
dependent response was noted when morphological changes were 
reported, if we consider loss of viability only a small reduction was 
observed in myofibroblasts exposed to 100 ng/ml toxin B and this loss did 
not reach statistical significance even after 72 h exposure. In addition, if 
we look at the difference in loss between myofibroblasts incubated with 
100 ng/ml and 1000 ng/ml toxin B, a significant difference can be viewed 
at all time points, however the loss of viability between 1000 ng/ml and 
10000 ng/ml is minimal. This may suggest saturation of the myofibroblast 
with toxin and/or a reduction in the ability to process the toxin. Although 
toxin internalisation is believed to occur within minutes of exposure 
(Henriques, Florin et al. 1987), in our experiments some loss was observed 
at 24 h and continued through 48 h in toxin A and B, however the greatest 
loss in cell viability was observed between 48 and 72 h in both toxin A and 
toxin B exposed cells. Whilst statistical significance was not evident In 
toxin A exposed myofibroblasts when compared against control, some loss 
was observed and this loss was greatest between 48 and 72 h. This loss 
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could not be explained by extended culture conditions as only a small non- 
significant loss was reported in control cells. 
To investigate the disparity observed in toxin exposed myofibroblasts, Rho 
expression in toxin treated myofibroblasts was studied. Clostridium 
difficile toxins target small intracellular proteins (Just, Selzer et al. 1995), 
and by inactivating these proteins messaging within the cell are disrupted 
(Jank, Giesemann et al. 2007). The changes to cell morphology observed 
when myofibroblasts are incubated with C. difficile toxins are likely to be 
due to inactivation of these proteins. Using specific antibodies for non- 
glucosylated Rac-1 and total RhoA both toxins induced loss of non- 
glucosylated Rac-1 over a similar time period implying uptake of toxins A 
and B is similar in myofibroblasts. Analysis of RhoA expression in 
myofibroblasts using Western blot and specific RhoA antibody remained 
constant, with no change in total levels of RhoA levels in myofibroblasts 
exposed to both toxins A or B and may therefore not responsible for the 
observed differences. However, subsequent experiments investigating the 
activity of RhoA by G-USATM showed a significant reduction in active RhoA 
when toxin A and toxin B exposed cells were compared with control. This 
would therefore suggest that the signal being observed using Western blot 
analysis was in fact inactive (GDP bound) RhoA and challenges the findings 
of others that inactive RhoA is degraded intracellularly (Dillon, Rubin et al. 
1995; Genth, Huelsenbeck et al. 2006). Our intention was to also 
investigate RhoB expression but despite sourcing mouse brain lysate 
(positive control) and achieving a good signal, a signal from myofibroblast 
lysate could not be achieved. 
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Myofibroblasts consistently responded to toxins A and B by change in 
morphology to stellate shaped cells. Scanning electron micrographs of 
control and C. difcile toxin-exposed myofibroblasts highlight the changing 
morphology from a monolayer of `flat' cells cultured in control medium and 
the stellate form of toxin A and B exposed cells with numerous processes. 
In myofibroblasts exposed to either toxin, distinct globular structures are 
present either close to the cell body or at a distance, associated with a 
process. These same distinct globular structures are seen in transmission 
electron micrographs of toxin exposed myofibroblasts. 
Reorganisation of the actin cytoskeleton and subsequent cell rounding are 
early cytopathic responses to C. difficile toxins. Myofibroblasts strongly 
express smooth muscle actin and to further elucidate the differences 
observed between toxin A and B on intestinal myofibroblasts, 
immunocytochemical studies investigating alpha smooth muscle actin 
provided some interesting results. Myofibroblasts in control medium 
displayed longitudinally arranged alpha-smooth muscle actin 
- 
immunoreactive bundles of microfilaments. In myofibroblasts exposed to 
C. difficile toxin A or toxin B for 6 h, the immuno-reactive longitudinally 
arranged bundles were no longer visible and the cell cytoplasm 
surrounding the nucleus together with cell processes were immuno- 
reactive for alpha smooth muscle actin. The main cell bodies and 
processes of toxin A exposed cells remained strongly immuno-reactive for 
alpha smooth muscle actin. By contrast, at 48 h toxin B exposed cells 
displayed variable immuno-reactivity and lacked processes and after 72 h 
cells were either negative or weakly positive for alpha smooth muscle actin 
and appeared non-viable. 
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The consistent expression of alpha smooth muscle actin, combined with 
the apparent resilience of myofibroblasts to C. difficile toxin A and the 
unique attributes of the intestinal myofibroblast a series of experiments 
were conducted to see if the cells could recover from pre-exposure to C. 
difficile toxin A. In studies undertaken with myofibroblasts isolated from 
different donors, morphological recovery of the cells was studied after 3h 
pre-exposure to toxin A. While in cultured medium, the myofibroblast 
morphology gradually reverted to normal. Subsequently, the cells were 
also able to proliferate after passage. Later studies extending the period of 
exposure confirmed these finding with intestinal myofibroblasts pre- 
exposed to C. difficile toxin A <_ 10000 ng/ml for 48 h can recover. This 
remarkable characteristic of the myofibroblasts may have important 
implications for mucosal tissue repair and regeneration in patients with 
colitis due to C. dif /cite infection. Myofibroblasts pre-exposed to C. difficile 
toxin B failed to recover. 
Most strains of C. difcile produce both toxin A and toxin B and therefore 
whilst it is important to elicit the response of each toxin, do the toxins 
work synergistically to exert a greater effect. Conducting a series of 
experiments Investigating the combined effect of toxin A+B, 
myofibroblasts isolated from three different patients were incubated with 
either toxin A, toxin B or toxin A+B. Morphological changes were noted 
and cell viability established at 24 h, 48 h and 72 h. Myofibroblasts 
incubated with toxin A+B rounded at a similar rate to that observed in cells 
incubated with either toxin A or toxin B. Supporting my previous finding a 
significant loss was observed in toxin B exposed myofibroblasts at 24 h, 
however this loss was observed at a lower concentration, 100 ng/ml 
(p<0.01) and continued through 72 h. In contrast to my earlier finding 
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(no significant reduction in toxin A exposed myofibroblasts using 10000 
ng/ml for 72h), when toxin A exposed myofibroblasts were compared with 
control (untreated) cells a significant loss in cell viability was observed at 
48 h to 1000 ng/ml (p<0.01) and a highly significant loss reported at 48 h 
to 10000 ng/ml toxin A (p<0.0001). The differences observed in the 
myofibroblast mitochondrial dehydrogenase activity in response to toxin A 
may be explained in part by the inter-individual variability. 
Myofibroblasts incubated with toxin A+B showed a significant loss of 
viability at 24 h to 100 ng/ml (p<0.05). Of particular interest, whilst a loss 
continued to be reported at 100 ng/ml at 48 h and 72 h the loss was 
decreasing with time. It should be considered therefore, that at 100 
ng/ml, toxin A protects the myofibroblast against loss of mitochondrial 
dehydrogenase activity due to toxin B. At the higher concentrations of 
toxin A+B, cell viability continued to reduce through 72 h. Comparison of 
viability in toxin A, toxin B and toxin A+B exposed myofibroblast found a 
significant difference between toxin A and toxin B treated cells as 
previously reported. As expected, comparing cellular viability in toxin A 
and toxin A+B exposed myofibroblasts provided similar results, toxin B Is a 
more potent cytotoxin in intestinal myofibroblasts. A significant 
difference in cell viability was observed when myofibroblasts exposed to 
1000 ng/ml of either toxin A or toxin A+B are compared (p<0.0001). 
Supporting my earlier question; myofibroblasts incubated with 100 ng/ml 
of toxin A+B appeared to reducing their loss of viability over time when 
compared to the viability of toxin A exposed myofibroblasts, the significant 
difference between toxin A and toxin A+B observed at 24 and 48 h was not 
seen at 72 h. Further supporting the potential protective role of toxin A; 
comparison of cell viability in toxin B and toxin A+B exposed 
myofibroblasts provides crucial evidence. No significant difference in cell 
323 
viability was found when 1000 ng/ml toxin B and toxin A+B exposed 
myofibroblasts were compared. Of particular interest, a gradual increase 
in cell viability is observed in toxin A+B exposed myofibroblasts when 
compared with toxin B exposed myofibroblasts and this increase in cell 
viability becomes statistically significant by 72 h to 100 ng/ml of toxin 
A+B. 
Investigating the time and dose response of toxins on myofibroblasts, a 
greater reduction in cell viability is observed to toxin A between 48 and 72 
h, with no dose dependent difference. Loss of cell viability in toxin B 
exposed myofibroblasts was greatest between 48 and 72 h to 100 ng/ml 
toxin B; at 1000 ng/ml a consistent significant loss in cell viability is 
observed from 24 through 72h. By contrast, cell viability in cells 
incubated with toxin A+B also provide a consistent loss in cell viability, 
however this is observed at 100 ng/ml and 1000 ng/ml. These findings 
would suggest that toxin A+B does not have a cytotoxic additive effect but 
the combination may exert a quicker host cell response. A fuller 
discussion, incorporating key discussion points from this chapter and 
others can be found at Chapter 7. 
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CHAPTER 7 
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7 Discussion 
Revisiting the initials aims of this research, my general discussion can be split 
into three distinct sections; 1) the successful optimization of C. difficile toxin B 
purification to allow 
- 
2) studies investigating the intestinal epithelial response 
to C. difficule toxin A and toxin B; and 3) studies investigating the response of 
primary colonic myofibroblasts to toxin A, toxin B and toxin A+B. 
The protocol for C. difcile toxin B has been successfully optimized as outlined 
in Chapter 4. The purified toxin has been shown to be active and 
characterization has established a protein concentration ranging 250 pg/ml 
- 
2.0 mg/ml and cytotoxicity (established using Vero cells) as ranging from 10"4 
to 10"94. The protein can also be stored at 4°C in Tris buffer for a number of 
weeks before cytotoxicity is reduced. Given the wide range of cytotoxic 
activity in toxin B samples, groups of experiments were conducted using toxin 
purified from just one batch and the titre re-checked prior to use. The 
cytotoxic activity of toxin used in each group of experiments is noted in each 
chapter. 
As discussed in the introduction to Chapter 3, intestinal epithelial cell types, 
Caco-2 and HT29 were used to investigate the response of epithelial cells to C. 
difficile toxins in the absence of primary cells. Whilst others have investigated 
the response of different cell types to C. difficile toxins, my research used 
these distinct epithelial types to investigate the comparative response to C. 
difficile toxins and the subsequent investigation of these responses is novel. I 
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have established a cell specific response to C. difffcile toxin A and B, where 
Caco-2 cells are significantly more sensitive to toxin A and toxin B-induced cell 
death. Investigating the reasons for this dramatic disparity I have shown that 
by labeling toxin A with a fluorogenic dye no significant difference In toxin 
internalization is seen when the two cell types are compared. This is 
supported by a loss of Racl (associated with internalization and the 
subsequent rounding of cells) in both cell types at 4h and the similar 
morphological time course of cell rounding in both cell types. Whilst labeling 
of toxin B was not completed and the uptake not Investigated directly, a 
similar loss of non-giucosylated Rac1 was observed in both cell types to toxin 
B and cell rounding was largely similar. As commented on in the discussion to 
Chapters 3 and 5, the dramatic differential response to the C. diffiG/e toxins 
cannot be explained by the Internalization and subsequent Inactivation of Rac1 
by either toxin. Considering another intracellular target of the toxins, 
expression of RhoA was also investigated In Caco-2 and HT29 cells exposed to 
toxins A or B. Expression of RhoA in Caco-2 cells exposed to toxins A or B 
remained constant, however RhoA expression in HT29 cells reduced In a time 
dependent manner following exposure to C. difficile toxins. These findings are 
in contrast to those of others who have linked the loss of RhoA in response to 
C. difficile toxins with cell death (Huelsenbeck, Dreger et al. 2007). This 
difference may be explained In part by the use of rat basophilic leukemia cells 
(RBL). RhoA plays a major role In regulation and localization of stress fibres 
and the formation of perijunctional rings at the apical side of epithelial cells 
(Ridley and Hall 1992) and as discussed in Chapter 1 is also linked with cell 
cycle progression by interacting with a diverse range of effector proteins (Jaffe 
and Hall 2005). Cell cycle analysis of viable cells following exposure to C. 
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difficile toxins suggests that toxin B exposed Caco-2 cells are failing to pass 
the M1 checkpoint; similarly a large proportion of toxin A exposed Caco-2 cells 
appear not be progressing into S phase, this may be explained in part by cells 
being arrested at the restriction point in Gi; the small proportion of cells 
progressing through to S-phase having already passed the point of no return, 
`restriction point' (Blagosklonny and Pardee 2002) prior to toxin exposure. It 
is therefore possible that toxin A exposed cells are more sensitive in GO/Gi, 
this has been reported by others (Nottrott, Schoentaube et al. 2007). In 
contrast, a considerable number of HT29 cells appear to undergo cell cycle 
arrest in GO/G1. RhoA has been specifically linked to G1 progression and 
mitosis (Jaffe and Hall 2005), inactivation of RhoA has been shown to block 
G1 progression whilst microinjection of active RhoA restores senescent cells to 
the cycle (Olson, Ashworth et al. 1995). Comparing these findings with the 
results of this study, it would be expected that toxin exposed Caco-2 cells 
would be undergoing cell death in GO/G1 as a result of RhoA inactivation, 
however RhoA inactivation was not observed. It has also been reported that 
active Cdc42 (Yasuda, Oceguera-Yanez et al. 2004), another possible target 
for C. difficile toxins is linked with mitotic arrest and It is therefore possible 
that toxin B is activating Cdc42 In Caco-2 cells, arresting cells in M phase. 
Unfortunately Cdc42, as a possible substrate, in Caco-2 cells was not 
investigated. The disparity observed in the two cells line Is therefore not 
explained by the constant expression of RhoA in Caco-2 and a gradual 
reduction in RhoA expression In HT29 cells. It has been shown that 
inactivation of Rac-1 and Cdc42 can induce G1 cell cycle arrest however as 
with RhoA the mechanism is cell-type specific and the pathways complicated 
(Coleman, Marshall et al. 2004). Further studies are needed to elucidate the 
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possible role of RhoA, Cdc42 In C. difficile toxin induced cell death in Caco-2 
cells. Later experiments investigating RhoA expression in myofibroblasts 
exposed to C. difficile toxin A and B used the G-LISATM to differentiate 
between total RhoA expression and active RhoA. The G-LISA TM results 
contrast and enhance those of the western blot with no active RhoA present In 
toxin exposed myofibroblasts and therefore confirmation of active RhoA in 
Caco-2 and HT29 suggested with the G-LISATM. 
The individual characteristics of these two intestinal epithelial cell lines should 
not be overlooked when looking for a possible explanation of the differential 
responses of Clostridium difficile toxins. Caco-2 cells are derived from a 
colorectal adenocarcinoma in a 72 year old male and HT29 cells derived from 
a colorectal adenocarcinoma in a 44 year old female. Perhaps the most 
notable difference between the two cell lines is the ability of Caco-2 cells to 
upon confluence differentiate from colonocyte to an enterocyte phenotype. It 
is suggested that the timing and degree of transition may cause confusion 
when Interpreting experiments using Caco-2 cells as a model of small 
intestinal function (Engle, Goetz et al. 1998) and therefore the degree of 
transition may reflect the absorptive abilities of the cells (Hilgendorf, Spahn- 
Langguth et al. 2000). In contrast, differentiation of HT29 cells is apparently 
similar to that observed during embryonic development of the intestine (Le 
Bivic, Hirn et at. 1988) and whilst C. difflcile has been isolated in neonates, 
they remain asymptomatic (Willey and Bartlett 1979). This may explain the 
resilience observed in HT29 cells. Another possible explanation may be 
potential expression of P-glycoprotein in Caco-2 cells and not in HT29 cells 
(Hilgendorf, Spahn-Langguth et al. 2000). This cell membrane associated 
329 
protein leads to higher secretion rates and consequently lower permeabilities 
in the absorptive direction (Faassen, Vogel et al. 2003), however whether this 
protein plays a role in toxin mediated cell death is still to be Investigated. it 
has been suggested that CYP3A is very weakly expressed in Caco-2 cells, 
however it has reported by others that levels of CYP3A are not different when 
the two cells lines are compared (Gervot 1996) 
The heightened response of the Caco-2 to toxin B may be explained by the 
lower seeding density of cells prior to toxin exposure and it Is postulated that 
the near confluent monolayers used in toxin A exposed experiments may have 
been expressing proteins of the differentiated enterocyte (Stlerum, Gaspart et 
al. 2003). It has been suggested that Caco-2 differentiation results in the 
formation of dense intercellular junctional complexes presenting a unique 
paracellular as well as transcellular barrier (Le Ferrec 2001). The absence of 
this monolayer in toxin B exposed Caco-2 cells would therefore increase basal 
toxin B receptor availability. 
Intestinal myofibroblasts represent a distinct subpopulation of cells located 
immediately below the single monolayer of epithelial cells. Primary colonic 
epithelial cells are highly susceptible to C. dlfcile toxin-induced cell death 
(Riegler, Sedivy et at. 1995; Mahida, Makh et al. 1996). The loss of epithelial 
cells in vivo would be expected to expose myofibroblasts to C. difficile toxins. 
The concentration of toxins A and B used were based upon the maximal 
concentration of toxin A observed in stool samples analysed previously 
(Solomon, Webb et al. 2005) and the comparative experiments performed as 
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part of this study which showed similar cytotoxic activities of toxins on 
myofibroblasts. By using monolayers of myofibroblasts isolated from normal 
colonic mucosal samples from different donors, we showed that the cells 
consistently responded to toxins A and B by a change In morphology to 
stellate cells. Moreover, scanning electron microscopy showed small globular 
structures in cells incubated with the toxins, and further studies are required 
to characterize the nature of these structures. The cell body and processes in 
toxin-exposed myoflbroblasts were strongly immunoreactive for alpha-smooth 
muscle actin. Although morphological studies and MTT assays suggested that 
a proportion of colonic myofibroblasts remained viable after 72 h of incubation 
with toxin B, all cells eventually underwent cell death, even after short (3 h) 
pre-exposure periods. However, it should also be noted that at low 
concentrations, the presence of toxin A provided protection against a toxin B- 
induced loss of viability. Such exposure of myofibroblasts to both toxins is 
likely to occur in the colonic mucosa in vivo. 
In contrast to responses to toxin B, a majority of the toxin A-exposed 
myofibroblasts remained viable, even when exposed to a high (10 pg/ml) 
concentration of the toxin for up to 72 h. It is worth discussing at this point 
the obvious discrepancy in absorbance values of myofibroblast experiments, 
this can be explained in part by the variability of myofibroblast isolates and it 
may also reflect the use of two different supplies of MTT. Interestingly, after 
pre-exposure (for 3h to 48 h) to high concentrations (1 and 10 pg/ml) of 
toxin A (followed by washing and culture in medium only), the myofibroblast 
morphology gradually reverted to normal. Subsequently, the cells were also 
able to proliferate after passage. This remarkable characteristic of the 
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myofibroblasts may have important implications for mucosal tissue repair and 
regeneration in patients with colitis due to C. diffcile infection. Our previous 
studies showed that following 3h of pre-exposure to <0.01 pg/ml toxin A, the 
T84 carcinoma-derived colonic epithelial cell line was able to recover its 
barrier function during subsequent culture in medium. However, this was not 
the case if the initial pre-exposure was to >0.01 pg/ml toxin A (Johal, Solomon 
et al. 2004). Moreover, there was a significant loss of viability in T84 and 
Caco-2 cell monolayers exposed to >0.1 pg/ml toxin A (unpublished 
observations in studies performed using the same batch of toxin as that used 
in the current series of experiments, together with our previous studies 
(Mahida, Makh et al. 1996)). Thus, primary human colonic myofibroblasts not 
only are much more resistant to cell death than carcinoma derived epithelial 
cell lines but also are able to recover after pre-exposure to high 
concentrations of toxin A. Primary human colonic epithelial cells are more 
sensitive to toxin A-induced cell death than Caco-2 and T84 carcinoma derived 
epithelial cell lines (Mahida, Makh et al. 1996). Indeed, our previous studies 
have shown that among the normal human colonic mucosal cells, epithelial 
cells and macrophages (and also monocytes) are more sensitive than 
lymphocytes to toxin A-induced cell death (Mahida, Makh et al. 1996; Mahlda, 
Galvin et al. 1998; Solomon, Webb et al. 2005). Although direct comparisons 
have not been made, our current studies suggest that colonic myofibroblasts 
may be more resistant to toxin A-induced cell death than the colonic lamina 
propria lymphocytes. After exposure to 1 pg/ml toxin A, a large proportion of 
colonic lamina propria T cells underwent programmed cell death, mainly from 
72 h onwards (Mahida, Galvin et al. 1998). In contrast, most of the colonic 
myofbrobiasts incubated with 10 pg/ml toxin A were viable at 72 h. Reasons 
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for the differences in susceptibility of colonic mucosal cells to toxin A-induced 
cell death remain to be determined. One possibility is that specific cell types 
bind and internalize different amounts of toxin A. However, since there is 
rapid cell rounding and glucosylation of Racl (see below), a significant amount 
of toxin A Is likely to be Internalized by the myofibroblasts. The persistence of 
stellate morphology and adherence to the culture dish are other distinct 
features of toxin A-exposed myofibroblasts compared with epithelial cells. 
Since similar appearances were not seen with toxin A-exposed NIH 3T3 cells 
(unpublished observations), the stellate morphology of myofibroblasts could 
be due to the persistence of alpha-smooth muscle actin. It Is likely that the 
changes in the morphology of myofibrobiasts Incubated with toxin A or B are 
due to inactivation (following glucosylation) of the Rho subfamily of GTPases, 
which are major intracellular targets of the toxins (Barbieri, Riese et al. 2002; 
Jank, Glesemann et al. 2007). Both toxins induced a loss of the 
nonglucosylated form of Racl In colonic myofibroblasts over similar periods 
(within 4 h). Together with largely similar rates of cell rounding, these studies 
imply that the uptake of both toxins is similar In myofibroblasts and that the 
greater sensitivity to cell death In response to toxin B Is unlikely to be 
mediated via Rac1. Previous studies using rat basophilic leukemia (RBL) cells 
also suggested that glucosylation/inactivation of Raci is responsible for cell 
rounding (cytopathic effect) but not for cell death (cytotoxicity) (Huelsenbeck, 
Dreger et al. 2007). Studies of other cell types have shown that inactivation 
of RhoA is required for cell death (Moorman, Bobak et al. 1996; Bobak, 
Moorman et al. 1997; Hippenstiel, Schmeck et at. 2002). However, following 
4h of exposure to C. dlicl% toxin A or B, there was a marked reduction in 
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levels of active, GTP-bound RhoA, implying toxin-induced RhoA inactivation in 
the colonic myofibroblasts. In contrast, total levels of RhoA did not change in 
myofibroblasts exposed to either toxin A or B for 24 h. This is in contrast to 
the case for RBL cells, where high concentrations of toxin B (which led to cell 
death) induced a loss of RhoA (Huelsenbeck, Dreger et al. 2007). Such a loss 
may be due to the fact that glucosylated RhoA Is degraded more efficiently by 
the proteasome than the nonmodified form (Dillon, Rubin et al. 1995; Genth, 
Huelsenbeck et al. 2006), and further studies are required to determine why 
total levels of RhoA do not change in toxin exposed myofibroblasts. Since 
there were marked reductions In levels of active, GTP-bound RhoA in response 
to both toxins, other factors are likely to be involved in the induction of cell 
death In myofibroblasts cultured with toxin B. In addition to functions in the 
cytoskeleton and cell adhesion, Rho proteins have been found to regulate a 
wide range of cellular activities, such as cell polarity, endocytosis, vesicle 
trafficking, and differentiation (Burridge and Wennerberg 2004). Peptide 
regulatory factors such as platelet-derived growth factor (PDGF) and 
epidermal growth factor (EGF) stimulate Rac, leading to Rho activation (Ridley 
and Hall 1992; Ridley, Paterson et al. 1992). Inactivation of Rac and other 
members of the Rho subfamily may therefore have a significant impact on the 
normal functions of colonic myofibroblasts, which include regulation of 
epithelial barrier function (Beltinger, McKaig et al. 1999; ]ohal, Solomon et al. 
2004) and repair of epithelial wounds (created by loss of injured epithelial 
cells). For the latter, myofibroblasts have been shown, via their contractile 
properties, to reduce the size of the wound (Moore, Carlson et al. 1989) and 
to also enhance restitution (McKaig, Makh et al. 1999), a process by which 
epithelial cells at the wound edge migrate to cover the mucosal defect. Such 
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protective responses by the myofibroblasts may explain, at least in part, the 
focal nature of mucosal inflammation in C. difficile associated colitis. However, 
once cells are exposed to high concentrations of C. difficile toxins, impairment 
of myofibroblast functions may lead to severe inflammation, as seen in 
pseudomembranous colitis. The concentrations of C. difficile toxins used in our 
studies are likely to be representative of those seen in vivo. Thus, we have 
previously shown that although the median stool concentration of toxin A in 
patients with C. difficile infection was 4.3 ng/ml, the levels ranged from 0.6 
ng/ml to 19 pg/ml (Solomon, Webb et al. 2005). 
7.1 Future Work 
This research is novel and at the time of writing the response of primary 
colonic myofibroblasts, a distinct subset of cells located In the lamina propria, 
to C. difficile toxins had not been reported on. My research provides an 
opening for future research. My most interesting finding; the recovery of 
colonic myofibroblasts pre-exposed to toxin A and the protective factor that 
toxin A appears to exert when toxins A and B are studied together. 
Given that we have previously shown that secretion of TGF-beta by 
myofibroblasts has a protective function, this area should be Investigated in 
more detail. Perhaps myofibroblasts release more TGF-beta in response to 
toxin A than toxin B and this may explain why the cells recover and also when 
cells are cultured In toxins A+B a significant difference In cell viability is 
observed when compared to cells cultured with toxin B alone. 
335 
In addition to the work on myofibroblasts, I think further Investigation of RhoA 
expression in epithelial types exposed to toxin A and B may broaden our 
knowledge of both the pathogenesis of C. difficile disease but also widen our 
knowledge of the toxins as glucosyltransferases. 
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APPENDIX 1 
SOLUTIONS 
Vero cell and HT29 cell culture 
Dulbecco's Modified Eagle Medium 
Supplemented with 10% FCS 
(Gibco, UK); 100 ng/ml penicillin (Brittania Pharmaceuticals Ltd., 
Poole, UK); 100 ng/ml streptomycin 
(Sigma Ltd., Poole, UK); 50 ng/mI 
gentamycin (Roussel Laboratories, 
Uxbridge, UK); 200 mM L-giutamine 
(Sigma Ltd., Poole, UK). 
0.25% trypsin 
5 mis of 10 x trypsin solution 
(Gibco, UK), in versine (0.02% 
EDTA in PBS pH7.2) 
Freezing media 5 mis of DMSO (Sigma Ltd., UK) 
made up to 50 mis with FCS 
Caco-2 cell culture 
Dulbecco's Modified Eagle Medium 
Supplemented with 10% FCS 
(Gibco, UK); 100 ng/ml penicillin 
(Brittania Pharmaceuticals Ltd., 
Poole, UK); 100 ng/ml streptomycin (Sigma Ltd., Poole, UK); 50 ng/ml 
gentamycin (Roussel Laboratories, 
Uxbridge, UK); 200 mM L-glutamine 
(Sigma Ltd., Poole, UK) and 50 pl 
holotransferrin (Sigma Ltd., Poole, 
UK). 
Trypsin and freezing media as Vero cell. 
t4, yofibroblast isolation and cell culture 
Dulbecco's Modified Eagle Medium 
Supplemented with 10% FCS (Gibco, UK); 100 ng/ml penicillin 
(Brittania Pharmaceuticals Ltd., 
Poole, UK); 100 ng/ml streptomycin (Sigma Ltd., Poole, UK); 50 ng/mi 
gentamycin (Roussel Laboratories, 
Uxbridge, UK); 200 mM L-glutamine 
(Sigma Ltd., Poole, UK) and 1% 
non-essential amino acids (Sigma 
Ltd., Poole, UK). 
0.1% trypsin 
2 mis of 10 x trypsin solution (Gibco, UK), in versine (0.02% 
EDTA in PBS pH7.2) 
Freezing media as above 
Roswell Park Memorial Institute (RPMI 1640) 
Supplemented with 10% FCS (Gibco, UK); 100 ng/ml penicillin; 
100 pg/ml streptomycin; 50 pg/ml 
gentamycin (all from Sigma Ltd., 
Poole, UK). 
Hanks Balanced Salt Solution (HBSS) w/o Ca2+ and Mg2+ (xl) 
110 ml 10x HBSS w/o Ca2+ and 
Mg2+ (Sigma Ltd., Poole, UK) to 1L 
sterile distilled water. Adjust to pH 
7-8 with 1M sterile NaOH. Add 5 ml 
Penicillin/Streptomycin (100 pg/ml) 
and 2.5 ml Gentamycin (50 pg/mi) 
(Sigma Ltd., Poole, UK) 
DTT/HBSS solution (10 mM DIT) 
DTT/HBSS solution (1 mM DTT) 
EDTA (100 mM) 
EDTA/HBSS solution (10 mM EDTA) 
EDTA/HBSS solution (1 mM EDTA) 
0.077 g Dithiotreitol (DTT) powder 
(Sigma Ltd., Poole, UK) in 50 ml 1x 
HBSS solution. Filter and store at 
4°C. 
5 ml 10 mM DTT solution in 45 ml 1 
x HBSS solution. Mix and store at 
room temperature. 
1.86 g Ethylenediaminetetracetic 
acid (EDTA) (Sigma Ltd., Poole, UK) 
in 50 ml sterile distilled water. Filter 
and store at 4°C. 
5 ml 100 mM EDTA solution in 45 ml 
1x HBSS solution. Adjust to pH 7-8 
with sterile NaOH. Store at 4°C. 
5 ml 10 mM EDTA solution in 45 ml 
1x HBSS solution. 
2 
Purification of C. difflcie toxins 
BHI broth (500 mis) 
18.5 g BHI powder (Oxoid, UK); 2.5 
g Yeast extract (Oxold, UK); 0.25 g 
Cysteine hydrochloride (Sigma Ltd., 
Poole, UK); 0.15 g Sodium 
formaldehyde sulphoxylate (Fisher 
Chemicals, UK); 500 mis distilled 
water. 
Solutions for Thyroalobulln column 
Acidic buffer (0.1 M glycine, 0.5 M NaCl pH 2.0) 
3.75 g glycine (BDH, UK); 14.61 g 
NaCl (Sigma Ltd., Poole, UK) in 500 
mis distilled water, adjusted to pH 
2.0 with 1M HCI. Degas with helium 
Basic buffer (0.1 M glycine, 0.5 M NaCI pH 10.0) 
3.75 g glycine (BDH, UK); 14.61 g 
NaCl (Sigma Ltd., Poole, UK) in 500 
mis distilled water, adjusted to pH 
10.0 with 1M NaOH. Degas with 
helium 
Tris Buffered Saline (0.15 M NaCI, 0.05 M Tris pH 7.0) 
4.38 g NaCl (Sigma Ltd., Poole, 
UK); 3.0275 Trizma base (Sigma., 
Poole, UK) in 500 mis distilled water 
adjusted to pH 7 with 1M HCI. 
Degas with helium 
Storage solution 0.02 % sodium azide (Sigma Ltd., 
Poole, UK) In Tris Buffered Saline 
(as above, 10-20 mis) 
Toxin A Durification DEAE-FF Seoharose and Mono-O column solutions 
Buffer A (20 mM Tris, pH 7.5) 
1.211 g Trizma base (Sigma Ltd., 
Poole, UK) In 500 mis distilled 
water, adjusted to pH 7.5 with 1M 
HCI. Filter and degas with helium. 
Buffer B (20 mM Tris, 1M NaCl, pH 7.5) 
1.211 g Trizma base (Sigma Ltd., 
Poole, UK); 29.22 g NaCl (Sigma 
Ltd., Poole, UK) in 500 mis distilled 
water, adjusted to pH 7.5 with 1M 
HCI. Filter and degas with helium. 
3 
Dialysis Buffer (20 mM Tris, pH 7) 
12.11 g Trizma base (Sigma Ltd., 
Poole, UK) in 5L distilled water 
adjusted to pH 7 with 1M HCl 
Toxin B purification DEAE-FF Seoharose and Mono-O column solutions 
Tris solution for resuspension and dialysis (50 mM Tris, pH 7.4) 
6.055 g Trlzma base (Sigma Ltd., 
Poole, UK) per Titre of distilled 
water, adjusted to pH 7.4 using 1M 
HCI 
Buffer A (50 mM Tris, pH 7.5) 
Buffer B (50 mM Tris, pH 7.5) 
3.0275 g Trlzma base (Sigma Ltd., 
Poole, UK) in 500 mis distilled 
water, adjusted to pH 7.5 with 1M 
HCI. Filter and degas with helium. 
3.0275 g Trizma base (Sigma Ltd., 
Poole, UK); 29.22 g NaCl (Sigma 
Ltd., Poole, UK) in 500 mis distilled 
water, adjusted to pH 7.5 with 1M 
HCI. Filter and degas with helium. 
Cali viability and cvtoxicity assay solutions 
MTT (3-(4,5 dimethylthiazol-2,5-diphenyitetrazolium bromide) 
Stock solution 
- 
dissolve MTT In PBS 
w/o Ca 2+ and Mg2+ (Sigma Ltd., 
Poole, UK) to 5 mg/ml. Filter and 
store at 4°C. 
Acid SDS (5% in 0.01 M HCl) 
Dissolve 5g sodium 
dodecylsuiphate (SDS) in 100 ml 
0.01 M HCI. 
Prooidium Iodide staining of DNA 
- 
solutions 
PBA (Phosphate Buffered Saline with 0.1% Bovine Serum Albumin and 
sodium azide) 
Dissolve 0.1 g Bovine Serum 
Albumin (Sigma Ltd., Poole, UK) and 
0.1 g sodium azide In PBS w/o Ca 2+ 
and Mg24 (Sigma Ltd., Poole, UK). 
Store at 4°C. 
4 
Dot Blot solutions 
Wash Buffer (100 mM Tris; 150 mM NaCI; 0.1% tween-20 pH 7.5) 
6.05 g Trizma base, 4.38 g NaCl and 
500 NI tween-20 (all from Sigma 
Ltd., Poole, UK) in 500 mi distilled 
water. Adjust to pH 7.5 using 1M 
HCI 
Blocking Buffer (100 mM Tris; 150 mM NaCI; 0.1% tween-20,5% 
skimmed milk powder pH 7.5) 
1g skimmed milk powder (Sigma 
Ltd., Poole, UK) in 20 ml wash 
buffer. 
Native PAGE solutions 
Resolving Buffer 4x (1.5 M Tris, pH 8.8) 
91 g Trizma base (Sigma Ltd., 
Poole, UK) in 500 ml distilled water. 
Adjust to pH 8.8 using 1M HCi. 
Running Buffer 5x (125 mM Tris, 0.96 M glycine) 
7.55 g Trizma base and 36 g glycine (both from Sigma Ltd., Poole, UK) in 
500 ml distilled water. Dilute to 1x 
with distilled water. 
Native PAGE Gel 
3.35 ml 30% acrylamlde/bis 
acrylamide 
5.0 ml 4x Tris resolving buffer 
11.54 ml distilled water 
200 pi 10% (w/v) ammonium 
persulphate 
20 pl TEMED 
SDS PAGE Gel solution 
Resolver 4x Trls-Cl/SDS pH 8.8 (1.5 M Tris with 0.4 % SDS) 
91 g Trizma base (Sigma Ltd, Poole, 
UK) dissolved in 500 ml distilled 
water adjust to pH 8.8 with 1M HCI; 
add 20 ml 10% SDS solution. Store 
at 4°C 
Stacking Buffer 4x Tris-CI/SDS pH 6.8 (0.5 M Tris with 0.4 % SDS) 
6.05 g Trlzma base (Sigma Ltd, 
Poole, UK) dissolved in 100 ml 
distilled water adjust to pH 6.8 with 
1M HCI; add 4 ml 10 % SDS 
solution. Store at 4 °C. 
5 
Running Buffer 5x Tris-Cl/Glycine/SDS (0.1 M Tris, 0.96 M Glycine 
with 0.5 % SDS) 
15.1 g Trizma base and 72 g Glyclne (both from Sigma Ltd, Poole, UK) 
dissolved in 1L distilled water. 50 
ml 10 % SDS. Store at 4 °C. 
7.5 % acrylamide SDS resolving gel (resolving range 36-94 kDa) 
3.75 ml 30% acrylamide/bis 
acrylamide (Sigma Ltd, Poole, UK), 
3.75 ml 4x Tris-CI/SDS (pH 8.8), 
7.50 ml distilled water, 50 pl 10 % (w/v) ammonium persulfate and 10 
pI TEMED (Sigma Ltd, Poole, UK). 
10 % acrylamide SDS resolving gel (resolving range 16-68 kDa) 
5.00 ml 30% acrylamide/bis 
acrylamide (Sigma Ltd, Poole, UK), 
3.75 ml 4x TrIs-CI/SDS (pH 8.8), 
6.25 ml distilled water, 50 pl 10 % (w/v) ammonium persulfate and 10 
pl TEMED (Sigma Ltd, Poole, UK). 
Stacking gel 
0.65 ml 30% acrylamide/bis 
acrylamide (Sigma Ltd, Poole, UK), 
1.25 ml 4x Tris-CI/SDS (pH 6.8), 
3.05 ml distilled water, 25 pl 10 % (w/v) ammonium persulfate and 5 
pI. TEMED (Sigma Ltd, Poole, UK). 
Western Blot 
Transfer Buffer (48 mM Tris; 39 mM Glycine) 
Dissolve 3.1 g Trizma base and 14.4 
g Glycine in 500 ml distilled water. 
Add 200 ml methanol and adjust 
volume to 1L using distilled water 
6 
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Colonic inflammation in Clostridium d(/icile infection is mediated by released toxins A and B. We investigated 
responses to C. (jicile toxins A and B by isolated primary human colonic myofibroblasts, which represent a 
distinct subpopulation of mucosal cells that are normally located below the intestinal epithelium. Following 
incubation with either purified toxin A or B, there was a change in myofibroblast morphology to stellate cells 
with processes that were immunoreactive for alpha-smooth muscle actin. Most of the myofibroblasts remained 
viable, with persistence of stellate morphology, despite exposure to high concentrations (up to 10 pg/ml) of 
toxin A for 72 h. In contrast, a majority of the toxin B-exposed myoiibroblasts lost their processes prior to cell 
death over 24 to 72 It. At low concentrations, toxin A provided protection against toxin B-induced cell death. 
Within 4 h, myofibroblasts exposed to either toxin A or toxin B lost expression of the nonglucosylated form of 
Racl, and there was also a loss of the active form of RhoA. Despite preexposure to high concentrations of toxin 
A for 3 h, colonic myotibroblasts were able to recover their morphology and proliferative capacity during 
prolonged culture in medium. However, toxin B-preexposed myofibroblasts were not able to recover. In 
conclusion, primary human colonic mucosal myofibroblasts are resistant to toxin A (but not toxin B)-Induced 
cell death. Responses by colonic myofibroblasts may play an important role in mucosal protection, repair, and 
regeneration in colitis due to C. difcile infection. 
Clostridium dificile induces colonic inflammation via two 
released toxins, A and B, and histologically, the colonic disease 
is often characterized by focal areas of epithelial ulceration 
and inflammatory exudates (38,46). The first host cells that the 
toxins interact with in the colon are likely to be surface epi- 
thelial cells, which normally provide an essential barrier 
against luminal microorganisms and their products. In intact 
monolayers of carcinoma-derived intestinal epithelial cell lines 
in vitro, apically applied toxin A induces injury and loss of 
barrier function (43,45). Other early responses by intestinal 
epithelial cells exposed to toxin A include changes in the cy- 
toskeleton (10,15) and secretion of cytokines, such as trans- 
forming growth factor beta (TGF-p) (20) and interleukin-8 (5, 
13,26), before the cells undergo programmed cell death (6, 
26). Our previous studies have shown that primary human 
intestinal epithelial cells, monocytes, and intestinal macro- 
phages are more sensitive than lymphocytes to C. dif icile toxin 
A-induced cell death (25,26,42). 
In the intestinal mucosa, myofibroblasts represent a distinct 
subpopulation of cells that are located below the intestinal 
epithelium, separated by a porous basement membrane (37). 
Intestinal myofibroblasts have morphological and other fea- 
tures of smooth muscle cells and fibroblasts, as illustrated by 
strong expression of alpha-smooth muscle actin (a character- 
istic of smooth muscle cells) and vimentin (also expressed by 
fibroblasts). In addition to controlling the deposition of extra- 
cellular matrix (24,29), intestinal myofibroblasts may regulate 
epithelial functions, such as electrolyte transport (3), restitu- 
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tion (28), and barrier function (3), and also functions of stem 
cells (18). In view of their capacity to secrete a number of 
cytokines and to interact with other cell populations (36), in- 
testinal myofibroblasts are also believed to be key players in 
inflammatory responses in the intestine (1,9,12,22). They 
have been shown to provide protection to intestinal epithelial 
monolayers against loss of barrier function in response to low 
concentrations of toxin A, via secretion of TGF-ß (20). Fol- 
lowing injury and loss of toxin-exposed epithelial cells in vivo, 
myoflbroblasts, which are capable of migrating onto the sur- 
face of the basement membrane (24), would be expected to be 
exposed to C. di Jlcile toxins. However, responses of primary 
human intestinal myofibroblasts to C. dfjicile toxins remain to 
be characterized. 
A majority of the biological effects of C. dif eile toxins A and 
B are believed to be mediated via the ability of their N termini 
to glucosylate and inactivate Rho GTPases such as RhoA, 
-B, 
and C. Racl-3, RhoG, and Cdc42 (2,19). Rho GTPases are 
key regulators of the actin cytoskeleton and influence many 
cellular processes, such as cell polarity, migration, vesicle traf- 
ficking, and cytokinesis (7,14). 
The aims of our studies were to characterize responses of 
primary human colonic myofibroblasts (isolated from healthy 
large intestinal mucosal samples) to purified C. difcile toxins 
A and B. 
MATERIALS AND METHODS 
Purification of toxins A and B. Toxin A was purified as previously described 
(21). C. difficile VP! strain 10463 was cultured anaerobically in brain heart 
infusion broth (Oxoid. United Kingdom) in dialysis culture flasks. After centrif- 
ugation, supernatant samples were loaded onto a bovine thyroglobulin affinity 
column, and eluted toxin A-containing fractions were then applied to Q Sephar- 
ose FF and Mono 0 columns (GE Healthcare, Sweden). During the purification 
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steps, toxin A-containing fractions were identified by dot blot analysis using the 
anti-toxin A antibody PCG-4 (23). 
The purification protocol for toxin B was adapted from previous studies (30, 
35,44). A broth culture of C. difiicie VPI strain 10463 was centrifuged to remove 
bacteria from the toxin-containing supernatant. The latter was made 70% satu- 
rated by the addition of solid ammonium sulfate. After I h, the precipitate was 
collected by centrifugation and resuspended in 50 mM Tris-HCI buffer (pH 7.4). 
The process of ammonium sulfate precipitation was repeated to make the solu- 
tion 50% saturated. Following centrifugation, the pellet was resuspended in 50 
mM Tris-HA buffer (pH 7.4) and then dialyzed for 24 h in 50 mM Tris-HCI 
buffer (pH 7.4). The dialyzed sample was applied to a DEAE-Sepharose column 
(GE Healthcare, Sweden) and eluted initially with a linear NaCI gradient in 50 
mM Tris-HCI buffer (0.05 to 0.25 M NaCI), followed by 150 ml of 50 mM 
Tris-HCI buffer (pH 7A) containing 0.3 M NaCI. Subsequent elution was with a 
second linear gradient of NaCl (0.3 to I M) in 50 mM Tris-HCI buffer (pH 7.4). 
Toxin B-containing fractions were identified by dot blot analysis using anti-toxin 
B antibody (Biodesign International), and pooled fractions were dialyzed for 
24 h against 10 mM Tris-HC% buffer (pH 8.0) containing 50 mM CaC12 before 
application to a Mono Q anion-exchange column (GE Healthcare, Sweden). 
Purified toxin B was eluted from the Mono 0 column by use of a linear NaCl 
gradient (0 to I M) in 10 mM Tris-HCI buffer (pH 8.0) containing 50 mM CaC12. 
Isolation and culture of human colonic myotibroblasts. Fresh, histologically 
normal colonic mucosal samples (>5 cm from cancer, with tissue surplus to 
clinical requirements) were obtained (after informed consent) from operation 
resection specimens. The median age of tissue donors was 69 years (range, 47 to 
87 yrs; 6 females and 12 males). Ethical committee approval was provided by the 
Nottingham Research Ethics Committee (REC Q1020310). 
Intestinal myofibroblasts were isolated and established in pure culture as 
previously described (24). In brief, surface epithelial cells were detached from 
mucosal samples by three sequential treatments with I mmol EDTA, and the 
tissue samples, denuded of epithelial cells, were cultured (at 37°C and 5% C02) 
in 10% fetal calf serum (FCS)-RPMI (Gibco-[nitrogen, United Kingdom). 
During culture of mucosal samples devoid of epithelial cells, myofibroblasts 
migrate out of the subepithelial regions of the lamina propria via basement 
membrane pores to establish colonies in tissue culture dishes (24). After removal 
of the tissue samples, the myofibroblasts proliferate to establish monolayers that 
can be maintained over many passages. Our previous studies have shown that the 
isolated intestinal myofibroblasts retain their phenotype and functional charac- 
teristics over many passages (18,24,27). 
Isolated colonic myofibroblasts, which expressed alpha-smooth muscle actin 
and vimentin (but not desmin), were studied at passages 3 to 7 and were 
maintained in culture in Dulbecco's modified Eagle's medium (Sigma) supple- 
mented with 10% FCS and 1% nonessential amino acids (Gibco-Invitrogen, 
United Kingdom). Monolayers of the cells were exposed to various concentra- 
tions (0 to 10 µglml) of purified C. dificile toxin A or B for various intervals (3 
h to 72 h). In some experiments, morphological recovery of myofibroblasts was 
studied after preexposure to toxin A or B (at a concentration of 1 µg/ml or 10 
µg/ml) for 3 It to 48 h. 
Morphological changes to the cells were studied by phase-contrast microscopy 
(changes assessed in 10 random high-power fields) and scanning electron mi- 
croscopy. The nuclear morphologies of control and toxin-exposed myofibroblasts 
were studied by fluorescence microscopy after staining with Hoechst 33342 dye 
(42). Immunohistochemical studies were undertaken using monoclonal antibod- 
ies to alpha-smooth muscle actin, desmin, and vimentin (all from Sigma). Effects 
on cell viability were investigated using an assay for mitochondrial dehydroge- 
nase activity. Changes to myofibroblast DNA were studied by flow cytometry 
following propidium iodide staining. 
Immunohistochendstry. Control and toxin-exposed myafibroblasts cultured on 
glass coverslips were fixed in acetone, and immunohistochemical studies were 
undertaken using a Vectastain ABC peroxidase kit as previously described (24). 
In brief, the cells were incubated with antibodies to alpha-smooth muscle actin, 
desmin, and vimentin (all from Sigma) for 30 min, and after being washed, the 
myofibroblasts were exposed to biotinylated horse anti-mouse antibody, followed 
by avidin-biotinylated horseradish peroxidase complex. Peroxidase activity was 
developed with diaminobenzidine, followed by nuclear staining using hematox- 
ylin. Controls included use of buffer instead of primary antibody and an irrele. 
vant primary antibody (anti-cytokeratin). 
Assay for rnilochondrlal debydrogenase. Metabolism by mitochondrial dehy- 
drogenase of the yellow tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-Biphenyl 
tetrazolium bromide (MIT) to the purple formazan reaction product can be 
quantified spectrophotometrically and can be used as an assay for cell prolifer- 
ation or cell death (33). MTT assays were undertaken as previously described 
(26). In brief, cells (40 x 10' applied per well) were grown to confluence in 
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96-well tissue culture plates (Nunc), and the assays were performed in triplicate. 
After exposure of cells to toxin A or B (or control medium) for various periods, 
MTT (Sigma Chemical, St. Louis, MO) was added to each well (to a final 
concentration of 0.5 mg(ml), and incubation was continued for 4 h. The cells were 
then incubated overnight in solubilization solution (50% sodium dodecyl sulfate 
in 0.1 mmol/liter HCI). The spectrophotomettic absorbance of the samples was 
subsequently measured with a microliter enzyme-linked immunosorbent may 
(ELISA) plate reader using a 570-nm filter. 
Propidlum Iodide staining and flow cytometry. Propidium iodide staining was 
performed as previously described (25,34). Control and toxin-exposed myofi- 
broblasts were detached using 0.1%0 (wttvol) trypain-0.2% (wttvol) EDTA. Fol- 
lowing centrifugation (400 Xg for 10 min), the myofibroblasts were fixed and 
permeabilized with ice-cold 70% ethanol for 60 min. After being washed with 
phosphate-buffered saline (PBS), the cells were incubated with propidium iodide (100 µg/ml; Sigma) at room temperature in the dark for 15 min. Fluorescence 
emission of propidium iodide was analyzed with a Beckman Coulter Altra flow 
cytometer (Beckman Coulter) at 617 nm after excitation with a blue laser at 488 
nm. Events that fell within the marked hypodiploid region (apoptotic events) 
were enumerated by the statistics function of WinMDI V2.8 software, and the 
results are expressed as percentages of total events. 
Western blot analysis. Lysates of control and toxin A- or toxin B-exposed 
myofibroblasts were separated by SDS"polyacrylamide gel electrophoresis on a 
12.5% acrylamide resolving gel (using Bio-Rad Protean 11 slab gel electropho- 
resis equipment). After transfer to polyvinylidene difluoride membranes, immu- 
nostaining was performed using a Vectastain Elite ABC kit (Vector Laborato- 
ries) and antibodies to beta-actin (Abeam Ple, United Kingdom), the 
nonglucosylated form of Racl (11) (clone 102; BD Transduction Laboratories), 
and RhoA (clone 2604. Santa Cruz Biotechnology Inc. ) (RhoA detection was 
not affected by glucosylation). 
Assessment of changes In RhoA. Changes in levels of the active, GTP-bound 
form of RhoA in myofibroblasts were studied using an EUSA-based Rho acti- 
vation assay (RhoA G-LISA activation assay; Cytoskeleton Inc. ). Lysates (in 
buffer containing protease inhibitor) were obtained from monolayers of Isolated 
colonic myofibroblasts that had been exposed for 4h to control medium (Dul- 
becco's modified Eagle's medium supplemented with 10% FCS and 1% nones- 
sential amino acids), I µglml toxin A, or I sg/ml toxin B. The lysates were 
applied to wells coated with Rho-GTP-binding protein. In this assay, active, 
GTP-bound RhoA in cell lysates binds to the wells, while inactive, GDP-bound 
Rho is removed during washing steps. The bound active RhoA was detected 
using a RhoA-specific antibody, followed by a secondary antibody conjugated to 
horseradish peroxidase. The spectrophotometric absorbance was subsequently 
measured using a 490-nm filter. 
Statistical analysis. Data are expressed as means with standard errors of the 
means (SEM) and were analyzed by one-way analysis of variance and an un- 
paired r test. 
RESULTS 
Morphological changes in myoflbroblasts exposed to C. dif- 
fici e toxins. Morphological responses to different concentra- 
tions (0.1,1, and 10 µg/ml) of purified toxins A and B were 
studied by phase-contrast microscopy. Monolayers of isolated 
intestinal myofibroblasts maintained in control medium spread 
to occupy a large surface area. In the presence of the highest 
concentration (10 pg/ml) of either toxin, approximately 50% of 
cells were rounded (with visible processes) at 2 h, and all cells 
were rounded at 4 h. When cells were exposed to lower con- 
centrations of the toxins (1 and 0.1 µg/ml), myofibroblast cell 
rounding occurred a few hours later in toxin A-exposed cells 
than in those cultured with toxin B. 
Myofibroblasts exposed to toxin A changed in morphology 
from flat cells to those with a stellate appearance. Over 72 h, 
the cell cytoplasm around the nucleus appeared to decrease 
further in size, with maintenance of prominent processes. Mor- 
phological changes in toxin B-exposed myo lbroblasts were 
initially similar to those in toxin A-exposed cells, but at later 
time points (48 to 72 h), a majority of the myofibroblasts lost 
their processes and many appeared nonviable (Fig. IE and J). 
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FIG. 1. Images (phase-contrast microscopy) of control and C dif- 
ficile toxin-exposed myofibroblasts. Monolayers of isolated normal hu- 
man colonic myofibroblasts were cultured in medium only (A and F) or 
in the presence of 10 µg/ml toxin A (B, D, G, and I) or toxin B (C, 11, 
E, and J) for 2h(B, C, G, and 11)or 72h(D, E, I, and J). Low (Ato 
E)- and high (F to J)-power images (similar magnifications were used 
for panels A to E and for panels F to J) are shown. For cells cultured 
in medium only (A and F), confluent monolayers of "flat" cells are 
seen, whereas those exposed to toxin A for 2 It (B and G) or to toxin 
B for 2h (C and H) appear stellate, with numerous processes. Myo- 
fibroblasts exposed to toxin A for 72 h (D and I) contracted further 
than those exposed to toxin A for 2h (B and G). Cells cultured with 
toxin B for 2h (C and H) appear morphologically similar to those 
exposed to toxin A for the same period (B and G). In contrast to 
myotibroblasts exposed to toxin A for 72 h (D and I), most cells (except 
two) cultured with toxin B for the same period (E and J) have lost their 
processes, and many appear nonviable. 
However, some toxin B-exposed myofibroblasts remained via- 
ble at 72 h, with persistence of processes (Fig. IJ). 
Scanning electron microscopy of myolibroblasts exposed to 
toxin A or toxin B (1 µg/ml) for 24 h showed that in addition 
to numerous processes of various thicknesses, distinct globular 
structures were seen either close to the cell body or at a 
distance and were associated with processes (Fig. 2). 
Immunohistochemical studies (at 6h in response to 1 µg/ml 
toxin A) showed that the processes in both toxin A- and toxin 
FIG. 2. Scanning electron micrug 
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toxin-exposed myulibroblasts. Monolaycrs of isolated normal human 
colonic myofibroblasts were cultured in medium only (A and I)) or in 
the presence of I µg/ml toxin A (B and E) or toxin B (C and F) for 
24 h. Myofibroblasts cultured in medium only (A and D) are seen as 
confluent monolayers of "flat" cells, whereas those exposed to toxin A 
(B and E) or toxin B (C and F) appear stellate, with numerous pro- 
cesses. In myolibroblasts exposed to either toxin, distinct globular 
structures (arrows) are present either close to the cell body or at a 
distance and are associated with a process. Ban, 10 µm. 
B-exposed myofibroblasts were strongly immunoreactive for 
alpha-smooth muscle actin (Fig. 3). At 48 h and 72 h, and as 
observed by phase-contrast microscopy (see above), a majority 
of the myofibroblasts exposed to toxin B (1 µg/ml) had lost 
processes (Fig. 3), but in toxin A-exposed (I µg/ml toxin) cells, 
there was persistence of processes that were immunoreactive 
for alpha-smooth muscle actin. At 72 h, many toxin B-exposed 
cells appeared to have lost the integrity of their cell mem- 
branes, but this did not occur in toxin A-exposed cells. 
Recovery following exposure to toxin A. In studies under- 
taken using myofibroblasts isolated from 8 different donors 
(cells from 3 to 5 donors were used for each experimental 
condition), morphological recovery of the cells was studied by 
phase-contrast microscopy after preexposure to toxin A for 3 h, 
24 h, or 48 h. Following 3h of preexposurc to toxin A (cells 
were incubated with 1 and 10 µg/ml toxin A for 3 h, followed 
by washing and culture in medium only), the colonic myofihro- 
blasts returned to their normal morphology over 28 to 63 clays, 
with the monolayers becoming fully confluent. Following 
trypsinization and reculture (passage at a 1: 3 split ratio), the 
3-h toxin A-preexposed myofibroblasts proliferated to conflu- 
ence. Following preexposure to 1 µg/ml toxin A for 24 h or 
48 h, myolibroblast recovery was slower, but all the cells 
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difficile toxin-exposed myofihrohlasts. lmmunocytocheinical studies 
were undertaken with monolayers of 
isolated normal human colonic 
mvotibroblasts that had been cultured in medium only (A, B, K, and L) 
or in the presence of I µg/ml toxin A for 6h (C and D) or 72 h (G and 
H). Myolibroblasts exposed to toxin B (1 µg/ml) for 6h (E and F) 
and 72 h (I and J) are also shown. Low-power (A, C, E, G, 1, K, and 
L) and high-power (B, D, F, 11, and J) images are shown. Longitudi- 
nally arranged, alpha-smooth muscle actin-immunoreactive bundles of 
microfilament are seen in myofibroblasts cultured in control medium 
(A and B). In myofibroblasts exposed to C. dif/ieile toxin A for 6h (C 
and D) or 72 h (G and H) or to toxin B for 6h (E and F), the cell 
cytoplasm surrounding the nucleus and the cell processes (arrows) are 
immunoreactive for alpha-smooth muscle actin. In contrast, cells ex- 
posed to toxin B for 72 h (I and J) have lost their processes and show 
only weak alpha-smooth muscle actin immunoreactivity, and many 
appear nonviable. Myofibroblasts cultured in medium only were also 
used as an immunocytochemistry control (K; buffer was used instead of 
primary antibody) and to show a lack of dcsmin immunoreactivity (L). 
INFHC 
. 
IMMUN. 
showed normal morphology after culture in medium for 28 
days. 
In contrast to the case with toxin A, none of the myofibro- 
blast monolayers preexposed (for 3 h, 24 h, or 48 h) to toxin B 
(at I µg/ml) showed any signs of recovery. Thus, after culture 
in medium for 28 days, no viable myofibroblasts were seen in 
toxin B-preexposed monolayers. 
MTT assays of myofibroblasts exposed to C. dijicile toxins. 
MTT assays were undertaken to assess changes in myofibro- 
blast viability in response to toxin A or B. In order to assess the 
ability of the assay to detect maximal loss of cell viability, 
monolayers of primary colonic myofibroblasts were cultured in 
medium for 24 h, in the absence or presence of 0.1% Triton 
X-100. Compared to the control, there was an 81.3% reduction 
in the mean absorbance value for the formazan reaction prod- 
ucts of myofibroblasts exposed to Triton X-100 (0.353 [0.017] 
versus 0.066 [0.004]; P<0.0001). 
In studies conducted for up to 72 h, mitochondrial dehydro- 
genase activities of myofibroblasts exposed to 0.1,1, and 10 
µg/ml toxin A did not differ from those of cells cultured in 
control medium (Fig. 4a). In contrast, myolibroblasts exposed 
to toxin B (especially those exposed to i and 10 µg/ml of the 
toxin) showed a significant loss of mitochondrial enzyme ac- 
tivity (Fig. 4b). Moreover, the mean (SEM) absorbance values 
of the formazan reaction products of myofibroblasts exposed 
to 1 µg/ml and 10 µg/ml toxin B at 24 h (0.391 [0.028] and 0.405 
[0.024], respectively), 48 h (0.323 [0.013] and 0.371 [0.021], 
respectively), and 72 h (0.204 [0.012] and 0.221 [0.007], respec- 
tively) were largely similar. This suggests that while the major- 
ity of myofibroblasts are susceptible to toxin B (at concentra- 
tions of -1 µg/ml), a proportion remain viable despite 
exposure to the highest concentration (10 p. g/ml) of toxin B for 
up to 72 h. 
In the presence of toxin A at a concentration of 0.1 µg/ml, 
myofibroblasts were protected against the effects of toxin B 
applied at the same concentration (absorhance value for myo- 
fibroblasts [expressed as % of value for control cells) after 
exposure to toxin B only for 72 h, 75.76% [5.83%]; that for cells 
after exposure to both toxins A and B for 72 h, 101.10%% [6.17%]; P<0.01 [n 
= 3]). When toxin B was present at a 
concentration of I p. g/ml, absorbance values of myofibroblasts 
exposed to toxin B alone (for 72 h) were not significantly different from those of cells incubated with both toxins A and B (57.31% [2.330/b] versus 66.25% [4.58%]). 
DNA fluorescence profiles of myofibroblasts exposed to C. di icile toxins. Events in the hypodiploid region of cellular DNA profiles reflect DNA fragmentation due to apoptotic cell death (25,34). In myofibrohlasts (isolated from 3 donors) 
exposed to I p. g/ml toxin B, there was a time-dependent in- 
crease in the proportion of events in the hypodiploid region (control versus toxin B-exposed cells at 8 h, 1.131/'0 [0.14%] 
versus 1.29% [0.06%]; at 24 h, 1.44% [0.041%) versus 2.30% [0.24%] [P < 0.03]; at 48 h, 1.17% 10.21%] versus 13.38% [3.81%] [P < 0.04]; and at 72 h, 0.80% [0.019%] versus 35.15% [1.31%] [P < 0.0001]) (Fig. Sal. In contrast, myofibrohlasts 
exposed to 1 i. g/ml toxin A showed only small (but statistically 
significant) increases in hypodiploid events at 48 h (for control 
versus toxin A-exposed cells, 0.58% [0.16%] versus 2.14% 
[0.29%]; P<0.01) and 72 h (for control versus toxin A-ex- 
posed cells, 0.81% [0.029%] versus 4.22% [0.94%] P<0.03) 
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Rho activation assay showed marked reductions in levels of 
active, GTP-bound RhoA in lysates of myofibroblasts exposed 
to either toxin A or toxin B (Fig. 8). 
DISCUSSION 
M24 
M48 h 
®72h 
FIG. 4. Mitochondrial dehydrogenase activities of control and C. 
difficile toxin-exposed myofibroblasts. MIT assays were undertaken 
with monolayers of isolated normal human colonic myolibroblasts that 
had been cultured in medium only (0 Ixg/ml toxin) or in the presence 
of various concentrations (0.1 to 10 µg/ml) of toxin A (a) or toxin B (b) 
for various intervals (24 to 72 h). Bars in figures represent mean 
(SEM) absorbance values for 4 different cultures of myofibroblasts 
(isolated from colonic mucosal cells obtained from 4 donors) in ex- 
periments undertaken in triplicate. (a) Responses to toxin A. For each 
period of culture, there were no significant differences between myo- 
fibroblasts incubated with control medium (0 i. g/mI toxin A) and those 
exposed to the three different concentrations of toxin A. (b) Responses 
to toxin B. Compared to myofibroblasts cultured in control medium (0 
µg/ml) for the relevant periods, there were significant reductions in 
mitochondrial dehydrogenase activity in cells exposed to 0.1 µg/ml 
toxin B for 72 h and to I and 10 µg/ml toxin B for 24 h, 48 h, and 72 h. 
+, P < 0.02; ", P <0.0{X)1. 
(Fig. 56). DNA fluorescence profiles of myofibroblasts exposed 
to 10 µg/ml toxin A showed that the majority of the cells 
showed normal DNA profiles (Fig. 5c) that would be expected 
for viable cells. 
Hoechst-stained cells. In myofibroblast monolayers exposed 
to toxin B, Hoechst staining confirmed significant levels of 
apoptosis, as demonstrated by nuclear condensation (due to 
dense chromatin) and nuclear fragmentation (Fig. 6). 
Racl and RhoA expression in myofibroblasts exposed to C. 
difficile toxins. Western blot analysis using a specific antibody 
(11) showed loss of the nonglucosylated form of Racl from 4h 
onwards in myolibroblasts cultured with either toxin A or toxin 
B (Fig. 7a and b). This implies glucosylation of intracellular 
Racl by both toxins. 
In a Western blot analysis conducted over 24 h, levels of 
expression of RhoA protein (whose detection by the antibody 
used was not altered by glucosylation) did not change in myo- 
fibroblasts exposed to either toxin. However, an ELISA-based 
Intestinal myofibroblasts represent a distinct subpopulation 
of cells located immediately below the single monolayer of 
epithelial cells. Primary colonic epithelial cells are highly sus- 
ceptible to C. difficile toxin-induced cell death (26,41). The loss 
of epithelial cells in vivo would be expected to expose myofi- 
broblasts to C. difficile toxins. By using monolayers of myofi- 
broblasts isolated from colonic mucosal samples from different 
donors, we showed that the cells consistently responded to 
toxins A and B by a change in morphology to stellate cells. 
Moreover, scanning electron microscopy showed small globu- 
lar structures in cells incubated with the toxins, and further 
studies are required to characterize the nature of these struc- 
tures. The cell body and processes in toxin-exposed myofibro- 
blasts were strongly immunoreactive for alpha-smooth muscle 
actin. Although morphological studies and MTT assays sug- 
gested that a proportion of colonic myofibroblasts remained 
viable after 72 h of incubation with toxin B, all cells eventually 
underwent cell death, even after short (3 h) preexposure peri- 
ods. However, it should also be noted that at low concentra- 
tions, the presence of toxin A provided protection against a 
toxin B-induced loss of viability. Such exposure of myofibro- 
blasts to both toxins is likely to occur in the colonic mucosa 
in vivo. 
In contrast to responses to toxin B, a majority of the toxin 
A-exposed myofibroblasts remained viable, even when exposed 
to a high (10 µg/ml) concentration of the toxin for up to 72 h. 
Interestingly, after preexposure (for 3h to 48 h) to high con- 
centrations (1 and 10 µg/ml) of toxin A (followed by washing 
and culture in medium only), the myolibroblast morphology 
gradually reverted to normal. Subsequently, the cells were also 
able to proliferate after passage. This remarkable characteris- 
tic of the myofibroblasts may have important implications for 
mucosal tissue repair and regeneration in patients with colitis 
due to C. di, (Jicile infection. Our previous studies showed that 
following 3h of preexposure to <0.01 µg/ml toxin A, the T84 
carcinoma-derived colonic epithelial cell line was able to re- 
cover its barrier function during subsequent culture in me- 
dium. However, this was not the case if the initial preexposure 
was to 2! 0.01 µg/ml toxin A (20). Moreover, there was a sig- 
nificant loss of viability in T84 and Caco-2 cell monolayers 
exposed to ? 0.1 µg/ml toxin A (unpublished observations in 
studies performed using the same batch of toxin as that used in 
the current series of experiments, together with our previous 
studies [26]). Thus, primary human colonic myofibroblasts not 
only are much more resistant to cell death than these carcino- 
ma-derived epithelial cell lines but also are able to recover 
after preexposure to high concentrations of toxin A. 
Primary human colonic epithelial cells are more sensitive to 
toxin A-induced cell death than Caco-2 and T84 carcinoma- 
derived epithelial cell lines (26). Indeed, our previous studies 
have shown that among the normal human colonic mucosal 
cells, epithelial cells and macrophages (and also monocytes) 
are more sensitive than lymphocytes to toxin A-induced cell 
death (25,26,42). Although direct comparisons have not been 
0.0 0.1 1.0 10.0 
Conc. toxin A (&g/ml) 
0.0 0.1 1.0 10.0 
Conc. toxin B (µyml) 
1628 MULLAN ET AL. 
11 h + 6h 
'1 control ý ý 
*) toxin B ý' 
, 
, 
! 
1ý 
,., ' 
111 
24 h 24 h 
control In B 
415h 8 n 
nt rol 
ic 
i nB 
jox 
72h " 
itr0Y 
1i 72h 
e toxin B 
, 
. 
(A) 
INFECf. IMMUN. 
t gh 
ý' OOntrol 
2 
t 8h 
toxin A ý , ý, 
Ih 
c ontrol 
,rIh toxin A 
.- 
24h 
control 
# 24h 
toxin A 1 
* 
c24h ontrol rr 
24h * 
toxin A 
tw 4oontrol 
t 
'i`ý 48 h 
toxin A 
48h 
control 
* 4G h 
In A 
t 
,r 72h 
control 
72h 
toxin A w 
72h 
iI control 
* 72h 
toxin A 
fib) ýcý 
FIG. S. Representative DNA fluorescence profiles of propidium iodide-labeled preparations of control and C. difficile toxin-exposed myoli- 
broblasts. Monolayers of isolated normal human colonic myofibroblasts were cultured in medium only (control) or in the presence of I µg/ml toxin 
B (a), I p. g/ml toxin A (b), or 10 µg/ml toxin A (c) for various intervals (8 to 72 h). Following permeahilization, detached myofibroblasts were 
incubated with propidium iodide and DNA fluorescence analyzed by flow cytometry. Events within the hypodiploid region (') reflect DNA 
fragmentation due to apoptotie cell death. In contrast to myofibroblasts exposed to 1 µg/ml (h) and 10 µg/ml (c) toxin A, cells cultured with 1 jig/ml 
toxin B (a) showed a time-dependent increase in events in the hypodiploid (sub-Gi) region. 
made, our current studies suggest that colonic myofibroblasts 
may he more resistant to toxin A-induced cell death than the 
colonic lamina propria lymphocytes. After exposure to 1 µg/ml 
toxin A, a large proportion of colonic lamina propria T cells 
underwent programmed cell death, mainly from 72 h onwards 
(25), In contrast, most of the colonic myofibroblasts incubated 
with 10 µg/ml toxin A were viable at 72 h. Reasons for the 
differences in susceptibility of colonic mucosal cells to toxin 
A-induced cell death remain to be determined. One possibility 
that specific cell types bind and internalize different amounts is 
of toxin A. However, since there is rapid cell rounding and 
glucosylation of Rac I (see below), a significant amount of toxin 
A is likely to be internalized by the myofibroblasts. 
The persistence of stellate morphology and adherence to the 
culture dish are other distinct features of toxin A-exposed 
myofibroblasts compared with epithelial cells. Since similar 
appearances were not seen with toxin A-exposed NIH 3T3 cells 
(a) 
(b) 
Oh 4h 24h 
Rac1 
40ý Oft RhoA 
irc ýy ai 
FIG. 6. Hoechst 33342 staining of control (, A and 13) myolihrohlasts 
and those exposed to toxin B (I µg/ml) for 72 h (C and D). phase- 
contrast (A and C) and fluorescence (B and D) micrographs are 
shown. (D) Nuclear condensation (arrowhead) and nuclear fragmen- 
tation (arrows) are seen in toxin B-exposed cells. 
ft- Beta-actin 
I IG. 7. Expression ut Rac I, RhoA, and beta-actin in control and C. 
di(Jirile toxin-exposctl mqulibruhLtti. I. ysatcs were obtained from 
monolayers of normal human colonic myofihroblasts cultured in me- 
dium only (0 h) or in the presence of I µg/ml toxin A (a) or I µg/ml 
toxin B (b) for 4h and 24 h. In contrast to the case for RhoA, loss of 
the nonglucosylated form of Racl was seen in myofibroblasts exposed 
to toxin A (a) or toxin B (b) for 4h and 24 h. Equal loading of the lanes 
is illustrated by beta-actin-immunoreactive bands of similar size. The 
figures are representative of three experiments using myofibroblasts 
isolated from colonic mucosal samples from three donors. 
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Control Toxin A Toxin B 
FIG. 8. Levels of active, GTP-bound RhoA in control and C. dif- 
ficile toxin-exposed myolibroblasts. Lysates were obtained from mono- 
layers of normal human colonic myofibroblasts cultured for 4h in 
medium only or in the presence of I p. g/ml toxin A or I p. g/mI toxin B. 
GTP-bound RhoA levels were quantified using an EI. ISA-based assay. 
Experiments were performed in duplicate, and the bars represent 
mean (SFM) absorbance values for 3 different cultures of myofibro- 
blasts isolated from colonic mucosal samples obtained from 3 donors. 
The P value was <0.01 for the control versus toxin A or toxin B. 
(unpublished observations), the stellate morphology of myoti- 
broblasts could be due to the persistence of alpha-smooth 
muscle actin. It is likely that the changes in the morphology of 
myofibroblasts incubated with toxin A or B are due to inacti- 
vation (following glucosylation) of the Rho subfamily of 
GTPases, which are major intracellular targets of the toxins (2, 
19). Both toxins induced a loss of the nonglucosylated form of 
Racl in colonic myotibroblasts over similar periods (within 
4 h). Together with largely similar rates of cell rounding, these 
studies imply that the uptake of both toxins is similar in myo- 
fibroblasts and that the greater sensitivity to cell death in rc- 
sponse to toxin B is unlikely to be mediated via Rae]. Previous 
studies using rat basophilic leukemia (RBL) cells also sug- 
gested that glucosylation/inactivation of Rae I is responsible for 
cell rounding (cytopathic effect) but not for cell death (cyto- 
toxicity) (17). Studies of other cell types have shown that in- 
activation of 
RhoA is required for cell death (4,16,32). How- 
ever, 
following 4h of exposure to C. difficile toxin A or B, there 
was a marked reduction 
in levels of active, GTP-bound RhoA, 
implying toxin-induced RhoA inactivation in the colonic myo- 
libroblasts. In contrast, total levels of RhoA did not change in 
myofibroblasts exposed to either toxin A or B for 24 h. This is 
in contrast to the case for RBL cells, where high concentra- 
tions of toxin B (which led to cell death) induced a loss of 
RhoA (17). Such a loss may be due to the fact that glucosylated 
RhoA is degraded more efficiently by the protcasome than the 
nonmodified form (8,11), and further studies are required to 
determine why total levels of RhoA do not change in toxin- 
exposed myofibroblasts. Since there were marked reductions in 
levels of active, GTP-bound RhoA in response to both toxins, 
other factors are likely to be involved in the induction of cell 
death in myolibroblasts cultured with toxin B. 
In addition to functions in the cytoskeleton and cell adhe- 
sion, Rho proteins have been found to regulate a wide range of 
cellular activities, such as cell polarity, endocytosis, vesicle traf- 
ficking, and differentiation (7). Peptide regulatory factors such 
as platelet-derived growth factor (PDGF) and epidermal 
growth factor (EGF) stimulate Rae, leading to Rho activation 
(39,40). Inactivation of Rae and other members of the Rho 
subfamily may therefore have a significant impact on the nor- 
mal functions of colonic myofibroblasts, which include regula- 
tion of epithelial barrier function (3,20) and repair of epithe- 
lial wounds (created by loss of injured epithelial cells). For the 
latter, myofibroblasts have been shown, via their contractile 
properties, to reduce the size of the wound (31) and to also 
enhance restitution (28), a process by which epithelial cells at 
the wound edge migrate to cover the mucosal defect. Such 
protective responses by the myofibroblasts may explain, at least 
in part, the focal nature of mucosal inflammation in C. diJJicile- 
associated colitis. However, once cells are exposed to high 
concentrations of C. difficile toxins, impairment of myofibro- 
blast functions may lead to severe inflammation, as seen in 
pseudomembranous colitis. The concentrations of C. difficile 
toxins used in our studies are likely to be representative of 
those seen in vivo. Thus, we have previously shown that al- 
though the median stool concentration of toxin A in patients 
with C. difficile infection was 4.3 ng/ml, the levels ranged from 
0.6 ng/ml to 19 µg/ml (42). 
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Editor B. A. McCormick 
ABBREVIATIONS 
ADP Adenosine diphosphate 
AEBSF 4-(2-Aminoethyl) benzenesulfonyl fluoride 
hydrochloride 
AMP Antimicrobial peptide 
API Activating protein 1 
aPKC atypical protein kinase C 
ATCC American Type Culture Collection 
BHI Brain heart infusion broth 
Bp Base pairs 
BSA Bovine serum albumin 
C C-terminal 
CDAD Clostridium difficife associated disease 
CDI Clostridium difficile infection 
CDK cyclin dependent kinase 
CDKI cyclin dependent kinase inhibitor 
CDT CD196 ADP-ribsytransferase toxin 
CHO (cells) Chinese hamster ovary (cells) 
Cip/Kip CDK interacting protein / Kinase inhibitory protein 
COX (-1 or 
-2) Cyclooxygenase (-1 or -2) 
CrD Crohn's Disease 
CROPS Combined repetitive oligopeptides 
DE Downstream effector 
DEAE Diethylaminoethyl 
DMEM Dulbecco's Modified Eagles Medium 
a 
DMSO Dimethylsulphoxide 
DNA Deoxyribonucleic acid 
DPX Distyrene, a plasticizer and xylene mountant 
DTT Dithiothreitol 
DXD (motif) aspartate 
- 
any residue 
- 
aspartate (motif) 
ECM Extracellular matrix 
EGF Epidermal growth factor 
ERK extracellular signal regulator kinase 
FACS Fluorescence activated cell sorting 
F-actin Filamentous actin 
FCS Foetal calf serum 
GAP's GTPase activating proteins 
GDP Guanine diphosphate 
GEF's Guanine nucleotide exchange factors 
G-LISA G protein linked immuno-sorbent assay 
GTP Guanine triphosphate 
GTPase Small monomeric guanine tri-phospate proteins 
HBSS Hanks Buffered Saline Solution 
HMC-1 Human mast cell 
HPA Health Protection Agency 
IBD Irritable bowel syndrome 
IEC Intestinal epithelial cells 
IEL Intraepithelial lymphocyte 
IgG Immunoglobulin G 
IL11 Interleukin 11 
IL8 Interleukin 8 
INK4 Inhibitor of CDK4 
Kb Kilobase 
b 
kDa Kilodaltons 
L Ligand 
LP Lamina propria 
Mab Monoclonal antibody 
MAPK Mitogen-activating protein kinase 
MCP Monocyte chemoattractant protein 
MDA Mitochondrial dehydrogenase activity 
MFI Median fluorescence intensity 
MIP-2 Macrophage inflammatory protein 2 
MMP Matrix metalloproteases 
Mono-Q (Mono) 
- 
quarternary amine 
MTT 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrolium 
bromide 
MW Molecular weight 
MWCO Molecular weight cut-off 
N N terminal 
NAD Nicotinamide adenine dinucleotide 
NAP Nucleasome assembly protein 
NEAA Non essential amino acids 
NK-Kß nuclear factor kappa beta 
NLR Nod-like receptor 
O Oxygen 
OH Hydroxyl group 
PAGE Poly-acrylamide gel electrophoresis 
PaLoc Pathogenicity Locus 
PBA PBS with 1% bovine serum albumin 
PBS Phosphate buffered saline 
PCG-4 Mouse monoclonal antibody to C. difficile toxin A 
C 
PDGF Platelet-derived growth factor 
PI Propidium iodide 
PMC Pseudomembranous colitis 
PP Peyer's Patches 
PSG Pencillin, Streptomycin, Gentamycin 
PVDF Polyvinylidene diflouride 
R Receptor 
RNA Ribonucleic acid 
RPMI Roswell Park Memorial Institute 
S1 Switch 1 
S2 Switch 2 
SDS Sodium dodecyl sulphate 
SEM Standard error of mean 
TBS Tris buffered saline 
TcdA Toxin A 
tcdA Toxin A gene 
TcdA488 Toxin A labelled with AlexaFluor488 
TcdB Toxin B 
tcdB Toxin B gene 
TcsL Clostridium sordellii lethal toxin 
TER Trans-epithelial resistance 
TGF-¢ Transforming growth factor beta 
Thr (35/37) Threonine at position 35 or 37 
TJC Tight junction complex 
TLR Toll-like receptor 
TNFo Tumor necrotisis factor alpha 
UDP Uridine diphosphate 
Zp Zonular occludin 
d 
Gamma 
